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Oesophageal cancer is a common form of cancer in South Africa. The 
predominant subtype is oesophageal squamous cell carcinoma (OSCC) and the 
disease has a very poor prognosis. The aim of this thesis was to investigate the 
genetics of OSCC in the South African Black and Mixed Ancestry populations. 
 
Genetic susceptibility to OSCC was explored initially through case-control 
association studies of 18 variants with strong evidence of association with the 
disease in other populations. Most loci did not show association in the South 
African populations. However, in the Mixed Ancestry population, ALDH2 +82 
A>G (rs886205) and RUNX1 rs2014300 were associated with OSCC (odds ratio 
(OR) = 0.70, 95% confidence interval (CI) = 0.55-0.89, P=0.0038; and OR = 
1.33, 95% CI = 1.09-1.63, P=0.0055, respectively). Further investigation of 
PLCE1 in the Black population found Arg548Leu (rs17417407) to be associated 
with disease (OR = 0.74, 95% CI = 0.60-0.93; P=0.008). These findings suggest 
that there may be substantial differences in the genetic architecture of OSCC in 
African populations. Additionally, genetic susceptibility was explored in the Black 
population using the Immunochip, a genotyping array containing ~200,000 
variants. Although no polymorphisms were significantly associated with OSCC, 
several variants in TGFBR3 showed suggestive evidence of association, which 
was promising as the TGF-β  pathway  has  been  shown  to  have  an  important  role  
in the development of the disease. 
 
In a pilot study to investigate somatic mutations in OSCC, the whole-exomes of 
8 blood-tumour pairs were sequenced, with mutations identified in several 
tumour suppressor genes, including TP53, KL and APC. Sanger sequencing of 
two candidate genes, TP53 and PPM1D, in all available samples, showed that 
60% of tumours contained TP53 mutations, and that 36% of tumours showed 
evidence of loss of heterozygosity at the PPM1D locus, suggesting that it may 
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Cancer is the third leading cause of death world-wide after cardiovascular 
disease and infectious and parasitic diseases (World Health Organization 2008), 
with approximately 12.7 million cases diagnosed and 7.6 million deaths 
occurring world-wide in 2008 (Ferlay et al. 2010.a). In the USA, this was 
estimated to cost $124.6 billion in 2010 (National Cancer Institute 2012). This is 
likely to increase in the future, with more cancers occurring due to an expanding 
and aging population. The need to reduce costs and save lives through 
prevention or early detection is, therefore, essential. Two approaches are vital to 
this: avoidance of known environmental risk factors and the application of 
personalized medicine. The latter would enable cancer treatment to be specific 
to each patient, with their inherited genome and their cancer genome guiding 
treatment. This approach is still a long way from being common practice in the 
clinic, with the genetics of cancer needed to be further explored. This includes 
identifying both genetic variants which affect cancer susceptibility and the 
somatic changes that occur in the tumour.  
 
Certain cancers are better understood than others, with those common in the 
industrialized world, such as breast and colorectal cancer, receiving the most 
funding for research. Oesophageal squamous cell carcinoma is common in the 
developing world with a high incidence in regions of South Africa and Asia. This 
thesis aims to improve our knowledge of both the genetic susceptibility and the 
somatic mutations that occur in oesophageal squamous cell carcinoma in the 








1.1 Oesophageal cancer 
The oesophagus is a muscular tube that connects the pharynx to the stomach, 
moving food through this region of the digestive tract. It is approximately 18-26 
cm in length and has cervical (~6 cm), thoracic (~25 cm) and abdominal (~4 cm) 
parts (Satvinder and Kang 2008). It is usually referred to in terms of thirds: the 
upper, middle and distal thirds. The upper region consists of striated muscle, 
with smooth muscle in the lower section (Kuo and Urma 2006). Oesophageal 
cancer mainly occurs in the middle and lower thirds. 
 
Oesophageal cancer is the eighth most common form of cancer in the world, 
with 482,000 newly diagnosed cases in 2008, accounting for 3.8% of all cancers 
(Ferlay et al. 2010.a). This compares to 1.61 million lung cancer cases, which is 
the cancer with the highest worldwide incidence (12.7% of all cancers). Other 
cancers with high a incidence include breast (10.9% of all cancers), colorectal 
(9.7%), stomach (7.8%) and prostate (7.5%). Oesophageal cancer is the sixth 
most common form of death from cancer, with 407,000 deaths occurring 
worldwide during 2008 (Ferlay et al. 2010.a).  
 
The estimated incidence and mortality rates for oesophageal cancer throughout 
the world in 2008 are shown in Figure 1.1 (Ferlay et al. 2010.a). It is estimated 
that southern Africa has the highest oesophageal cancer age-standardized 
incidence (and mortality) rate in the world, with 22.3 cases per 100,000 in 
males. This is closely followed by males in eastern Asian, with 20.3 cases per 
100,000. At the other end of the spectrum, middle and western Africa have the 
lowest incidence, with approximately 1.5 cases per 100,000 in males. The 
majority of both cases and deaths occur in developing countries, with incidences 
in males of 11.8 cases per 100,000 in less developed regions compared to 6.5 
cases per 100,000 in more industrialized countries. In all regions, the incidence 
is greater in males than females.  
 





Figure 1.1: Oesophageal cancer incidence and mortality rates  
World-wide estimates of age-standardized incidence and mortality rates for oesophageal cancer 
in 2008 (Ferlay et al. 2010.a) 
 
Two main subtypes of oesophageal cancer exist, squamous cell carcinoma and 
adenocarcinoma, which together account for more than 95% of oesophageal 
carcinomas (Layke and Lopez 2006). These subtypes are aetiologically 
unrelated. World-wide, oesophageal squamous cell carcinoma (OSCC) is the 
most predominant form of oesophageal cancer, mainly occurring in developing 
countries (Lam 2000). In the western world, OSCC cases have decreased over 
recent years, and, together with the rise in adenocarcinoma cases, has led to 
adenocarcinoma being the predominant form in these regions (Holmes and 
Vaughan 2007). 




1.1.1 Oesophageal adenocarcinoma 
1.1.1.1 Definition and incidence 
Oesophageal adenocarcinoma develops from glandular epithelial cells and 
predominantly affects the lower third of the oesophagus (Satvinder and Kang 
2008). The disease occurs mainly in western countries where the number of 
cases has increased dramatically over the last four decades and it is now the 
most common form of oesophageal cancer in these regions (reviewed in 
Holmes and Vaughan 2007). Worldwide, the UK has the highest incidence of 
oesophageal adenocarcinoma (Bollschweiler et al. 2001). In the USA, the 
incidence of adenocarcinoma increased from 3.6 cases per million to 25.6 cases 
per million between 1973 and 2006 (Pohl et al. 2010). Incidence rates are 
showing signs of slowing, with an 1.3% annual increase observed from 1996-
2006 compared to 8.2% between 1973 and 1996 (Pohl et al. 2010). In the USA, 
the group most at risk of developing adenocarcinoma is Caucasian males, with 
a male:female ratio of 7:1 and Caucasian:Black ratio of 4:1 (reviewed in Holmes 
and Vaughan 2007). Most males are diagnosed with adenocarcinoma aged 
between 75 and 79, with females slightly older at 80-84 (reviewed in Holmes 
and Vaughan 2007). 
 
1.1.1.2 Environmental risk factors 
The large increase of oesophageal adenocarcinoma cases over a relatively 
short period of time, as described above, suggests that environmental risk 
factors play an important role in the development of the disease. The strongest 
risk factor is gastroesophageal reflux disease (GERD) (reviewed in Reid et al. 
2010). This is where the contents of the stomach (food, liquid or stomach acid) 
moves back into the oesophagus via the lower oesophageal sphincter, which 
normally remains closed preventing it occurring. It is thought that GERD causes 
damage to the oesophageal mucosa (reviewed in Hamilton and Aaltonen 2000). 
Individuals with GERD have a greater than four-fold risk of developing 
oesophageal adenocarcinoma than controls, although less than half of cancer 




patients experience frequent GERD symptoms (Lagergren et al. 1999; Farrow et 
al. 2000; Reid et al. 2010). Gastroesophageal reflux disease is also believed to 
lead   to   the   development   of   Barrett’s   oesophagus,   a   specialized   intestinal  
metaplasia where metaplastic columnar epithelium, which is similar to the 
intestinal cell structure, replaces the normal oesophageal squamous epithelium. 
However,  a  recent  study  showed  that  almost  half  of  Barrett’s  oesophagus  cases  
had no GERD symptoms (Ronkainen et al. 2005; Zagari et al. 2008).  
 
Barrett’s  oesophagus  has  itself  previously been considered the main risk factor 
for adenocarcinoma (Hamilton and Aaltonen 2000). However, a recent review 
by Reid et al. (2010)   has   questioned   this,   as   Barrett’s   oesophagus   rarely  
develops into cancer and the majority (95%) of adenocarcinoma patients do not 
have the condition. Therefore, the relationship between adenocarcinoma, 
Barrett’s  oesophagus  and  GERD  is  still  not  fully understood.  
 
A high body mass index (BMI) is also a known environmental risk factor for 
adenocarcinoma (reviewed by Holmes and Vaughan 2007, and Umar and 
Fleischer 2008). As BMI increases, the risk of developing cancer also increases, 
with one study reporting an odds ratio (OR) of 6.1 (95% confidence interval (CI) 
= 2.7 – 13.6)   for   individuals  with   a  BMI   of   40+   (BMI   ≥   30   is   clinically   obese)  
compared to those with a healthy BMI of 18.5 – 24.9 (Whiteman et al. 2008). It 
is suggested that interactions also occur between obesity and GERD, with 
individuals suffering from both conditions having an even greater risk of 
adenocarcinoma. Compared to people with a healthy BMI and no GERD, the 
following risks were observed: obese people with regular GERD symptoms, OR 
= 16.5 (95% CI = 8.9 – 30.6); obese people with no GERD, OR = 2.2 (95% CI = 
1.1 – 4.3); and people with a healthy BMI with GERD, OR = 5.6 (95% CI = 2.8 – 
11.3) (Whiteman et al. 2008).   
 
Other risk factors also contribute to adenocarcinoma development but to a 
lesser extent than those described above. Smoking is suggested to increase 




risk by 1.5 to 4-fold, with the risk remaining even 30 years after smoking 
cessation (Gammon et al. 1997; Holmes and Vaughan 2007). However, in a 
Swedish population, smoking was not found to be a risk factor (Lagergren et al. 
2000). Diets with nutritional deficiencies, such as those low in fruit and 
vegetable intake and cereal fibre, also show evidence of association with 
adenocarcinoma (reviewed in Pera et al. 2005). Alcohol consumption is not a 
risk factor for adenocarcinoma, in contrast to oesophageal squamous carcinoma  
(reviewed in Holmes and Vaughan 2007).  
 
The use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDS) 
has been shown to have a preventative role in the development of both 
oesophageal  adenocarcinoma  and  Barrett’s  oesophagus  (Anderson et al. 2006; 
Duan et al. 2008; Sadeghi et al. 2008).  
 
1.1.1.3 Genetic susceptibility  
Only a few studies, using mainly relatively small number of cases, have 
examined the association between genetic variants and the development of 
oesophageal adenocarcinoma. These have been candidate gene studies which 
have focused on genes involved in DNA repair, cell cycle control, apoptosis and 
other carcinogenic pathways, but results have been conflicting (reviewed in 
Cheung and Liu 2009). The largest study to date genotyped 1330 SNPs in 354 
genes which were involved in 14 pathways linked to carcinogenesis (Liu et al. 
2010). Variants in CASP7 and CASP9 (both involved in apoptosis) were 
associated with the disease, together with a SNP in PGR (involved in the sex 
hormone signalling pathway) in females only. This study contained 335 cases 
and 319 controls so lacked power to detect variants with a modest effect. 
 
Several studies suggest that gene-environment interactions may affect the risk 
of oesophageal adenocarcinoma. For example, SNPs in angiogenic genes may 
interact with GERD, BMI and smoking to modify disease risk (Zhai et al. 2012), 




and variants in apoptotic genes also show evidence of interaction with GERD 
and smoking (Wu et al. 2011.a). 
 
1.1.2 Oesophageal squamous cell carcinoma (OSCC) 
1.1.2.1 Definition and incidence 
OSCC   is   defined   as   “a   malignant   epithelial   tumour   with   squamous   cell  
differentiation, microscopically characterised by keratinocyte-like cells with 
intercellular   bridges   and/or   keratinisation”   (Hamilton and Aaltonen 2000). It is 
the most the common form of oesophageal cancer, occurring predominantly in 
developing countries. The incidence is variable, with high risk areas identified. 
For  example,  a  large  number  of  cases  are  observed  in  the  ‘Asian  oesophageal  
cancer  belt’  which  begins  in  Turkey  and  passes   through Iraq, Iran, Kazakhstan 
and into Northern China (Mudan and Kang 2007). In the Henan province of 
China, mortality rates in males are greater than 100 per 100,000 people 
(Hamilton and Aaltonen 2000; Mudan and Kang 2007). High risk regions are 
also present in South Africa, particularly the Transkei region (Somdyala et al. 
2003; Somdyala et al. 2010). Western countries tend to have an age-
standardized incidence rate of 1-4 per 100,000 individuals but higher rates are 
observed, such as in certain regions of France (~11 cases per 100,000) (IARC 
2007.a; Melhado 2010).  In the USA, OSCC has a higher incidence in black 
men than Caucasian men, contrasting to that of adenocarcinoma (Cook et al. 
2009).   
 
In low-risk areas, the incidence of oesophageal cancer is higher in males than 
females, but in high-risk regions the ratio is close to unity (Mahboubi et al. 1973; 
Parkin et al. 2005; Islami et al. 2009.a). It is thought that the higher use of 
alcohol and tobacco among males is responsible for the gender imbalance in 
the low-risk regions (Kamangar et al. 2009). The unity observed in high-risk 
regions may indicate that risk factors that have a gender bias are absent, such 
as smoking and alcohol consumption, and that other environmental risk factors 




are involved which may be specific to these regions (Wabinga et al. 2000). 
Alternatively, genetic risk factors may be important. 
 
1.1.2.2 Clinical: Presentation, outcome and treatments  
OSCC mainly occurs in the middle third of the oesophagus (50-60%), with 
around 30% occurring in the lower third, and a smaller proportion (10-20%) in 
the upper third (Lewin and Appelman 1996). In the early stages of OSCC, the 
tumour is known as a superficial or early carcinoma, where the tumour is 
confined to the mucosa or submucosa. Advanced carcinoma occurs when 
tumours spread beyond the submucosa, where they are exophytic, ulcerating or 
infiltrative (Deere 2007).  
 
Oesophageal cancer has a poor prognosis, with a 5-year survival rate of less 
than 10%, which is unchanged over the last three decades (Hendricks and 
Parker 2002). This is probably due to the largely asymptomatic nature of the 
cancer in its early stages, resulting in the majority of new cases being classified 
as advanced disease (stages III and IV). The most common symptoms 
experienced at this stage are dysphagia (difficulty swallowing), odynophagia 
(pain with swallowing), chest and back pain during swallowing, hoarseness, a 
chronic cough and weight loss. At early stages of disease, surgery and 
radiotherapy are potential treatments but as the disease develops into advanced 
stage, palliative care is generally the only option. 
 
1.1.2.3 Environmental risk factors  
World-wide, the main environmental risk factors for developing OSCC are 
alcohol consumption and tobacco use. In the western world, these habits are 
estimated to be responsible for 90% of all cases (Hamilton and Aaltonen 2000). 
However, this estimate is significantly lower in high-risk regions; in the Henan 
province of China, alcohol and tobacco are estimated to account for only 1% of 
cases and in South Africa this figure is 50% (Hamilton and Aaltonen 2000). This 




difference in the contribution of alcohol and tobacco observed between 
developing countries and the western world may be due to the lower number of 
smokers/drinkers in developing regions or the presence of other risk factors that 
have a larger effect. The contribution of other risk factors to OSCC development 
is not fully understood and is discussed below. 
 
1.1.2.3.1 Alcohol 
In 2007,  the  World  Health  Organization’s  International  Agency  for  Research  on  
Cancer (IARC) recognised that ethanol is carcinogenic to humans and that 
alcohol consumption causes an increased risk of upper aerodigestive tract 
cancers, including oesophageal cancer (IARC 2010). The product of ethanol 
oxidation, acetaldehyde, is also carcinogenic to humans (IARC 2010). The exact 
mechanism by which ethanol and acetaldehyde cause an increased risk of 
OSCC is not fully understood. Ethanol is suggested to cause DNA damage and 
has been shown to cause sister chromatid exchange in human cells, while 
acetaldehyde can form DNA adducts which are mutagenic and cause 
chromosomal aberrations (IARC 2010). Alcohol consumption alone accounts for 
more than 60% of OSCC cases in several countries including USA, Japan and 
Taiwan (Lee et al. 2009). Increasing levels of alcohol consumption is correlated 
with a higher risk of developing OSCC (Lee et al. 2005). 
 
1.1.2.3.2 Tobacco 
Cigarettes contain thousands of chemicals, of which more than 60 are 
carcinogens, and to date, 15 have been identified as being carcinogenic to 
humans (IARC 2004.a; U.S. Department of Health and Human Services 2010). 
Following persistent exposure to these carcinogens over a number of years, 
DNA adducts can form in individuals leading to mutations in oncogenes or 
tumour-suppressor genes which affect cell growth and apoptosis pathways 
(reviewed in U.S. Department of Health and Human Services 2010).  
 




The IARC has concluded that tobacco smoking does cause OSCC, which was 
supported by a review of published literature that found an association in 52 out 
of 54 studies (IARC 2004.a). This was observed in several populations, 
including those from China, Japan, Europe and the USA. Smokers are found to 
have an approximately 5-fold increased risk of developing OSCC compared to 
non-smokers, which increases further for heavy smokers (Blot and McLaughlin 
1999). Following smoking cessation, the risk of developing OSCC is reduced, 
with one study observing a 60% decrease in risk after five years (Lee et al. 
2005).   
 
Smokers who also consume alcohol are at an even greater risk of developing 
OSCC, with a multiplicative interaction effect between these environmental 
factors (Lee et al. 2005). An odds ratio of 20.4 was reported for individuals who 
smoke and drink alcohol compared to those who abstain from both activities.  
 
1.1.2.3.3 Diet 
The effect of an individual’s  diet  on  cancer  risk  has  produced  conflicting  results,  
perhaps because it relies on patients keeping an accurate record of food and 
drink consumption. A high intake of fresh fruit and vegetables has been thought 
to decrease the risk of cancer and other diseases, which led to the World Health 
Organization recommending a minimum intake of five portions of these foods a 
day.  However, recently the protective effect of fruit and vegetable consumption 
against cancer risk has been shown to be minimal in a European population 
(Boffetta et al. 2010). For OSCC, results have also been inconsistent; studies in 
China and Uruguay have shown fruit and vegetable consumption to be either 
protective or to have no effect (De Stefani et al. 2003; Li and Yu 2003). 
Consumption of poultry and fish have also been associated with a decreased 
risk of OSCC, whereas an increased risk of disease was observed with a high 
intake of red, stewed and salted meat (De Stefani et al. 2003). Conflicting 
results have been found when analyzing the effect of hot drink consumption with 




OSCC development (Islami et al. 2009.b). In an Iranian population, regularly 
drinking hot (>65°C) tea was associated with an increased risk of developing 
OSCC compared to those who drank tea at less than 65°C (Islami et al. 2009.c). 
This association was also observed in a South American population 
(Castellsague et al. 2000), but not in a Swedish population (Terry et al. 2001).  
 
1.1.2.3.4 Other potential risk factors 
Betal quid chewing is common in Asia where it is chewed with tobacco in most 
countries apart from Taiwan. Studies in the Taiwanese population have allowed 
the effects of betal quid chewing to be observed independently of tobacco 
smoking, and identified the practice as being associated with a 2-3 fold 
increased risk of OSCC (Lee et al. 2005). When combined with alcohol 
consumption and tobacco smoking, an odds ratio of 41.2 (95% CI = 23.6 – 72.0) 
was observed compared to individuals who abstain from all of these practices. 
For people who smoke and drink but do not chew betal quid, an odds ratio of 
20.4 (95% CI = 12.7 – 32.9) was reported (Lee et al. 2005). The IARC 
concluded that using betal quid with tobacco causes OSCC (IARC 2004.b). 
 
The presence of Helicobacter pylori (H. pylori) infection in the stomach has 
shown conflicting evidence of an association with OSCC (reviewed in Kamangar 
et al. 2009). However, three meta-analyses have found no overall association 
(Rokkas et al. 2007; Islami and Kamangar 2008; Zhuo et al. 2008). Similarly, 
association with human papillomavirus (HPV) infection has shown variable 
results which Kamangar et al. (2009) suggest may be due to a number of 
factors including geographic location, inadequate adjustment for other risk 
factors, false-positive results due to experimental error or due to chance. The 
IARC concludes that there is a lack of evidence to support a role for HPV in 
oesophageal cancer development (IARC 2007.b). 
 




BMI has also been associated with OSCC risk, with a lower BMI associated with 
a higher risk of disease, which is in contrast to oesophageal adenocarcinoma 
(Smith et al. 2008).  
 
1.1.2.4 Genetic susceptibility 
A contribution of genetic variants to OSCC susceptibility is supported by the 
existence of individuals who are exposed to environmental risk factors but who 
do not develop the disease, and by others who avoid known risk factors but do 
develop cancer. Additionally, there is evidence that OSCC aggregates in 
families, with family history causing an approximate 2-4 fold increased risk of 
developing the disease (Chang-Claude et al. 1997; Hemminki and Jiang 2002; 
Garavello et al. 2005; Akbari et al. 2006; Wen et al. 2006; Gao et al. 2009; Wu 
et al. 2011.b). These familial cases are thought to develop earlier and have a 
worse prognosis than sporadic cases (Wen et al. 2006; Wen et al. 2009). 
However, whether a family history of disease is due to a shared environment or 
genetics is also an area of contention. In one Chinese population, environmental 
risk factors were estimated to be responsible for the majority of familial cases 
(Wu et al. 2011.b). In another Chinese population, genetic susceptibility is 
considered the most important factor, due to incidences of cancer in non-blood 
relatives not being associated with risk of OSCC (Gao et al. 2009). This is 
supported by a high-risk Iranian population, where 82% of familial cases were 
related by blood, with only 18% by marriage (Ghadirian 1985). Studies in 
monozygotic and dizygotic twins would enable heritability to be estimated, but 
this has not been completed for OSCC. 
 
Genetic association studies in OSCC have predominantly been carried out in 
Asian populations due to the high-risk regions in this area. The majority of 
studies are candidate gene association studies, focusing on genes involved in 
alcohol metabolism, detoxification of carcinogens, DNA repair, apoptosis and 
cell proliferation (reviewed in Lao-Sirieix et al. 2010). However, the results are 




not always consistent, with variations observed in different populations. This 
may be due to genetic risk factors and gene-environmental interactions that are 
specific to each population. Alternatively, studies may be underpowered to 
detect modest effects. OSCC candidate gene studies are discussed further in 
Chapter 3 of this thesis.  
 
Several genome-wide association studies (GWAS) for OSCC have been 
performed in Asian populations. The first, in 2009 in a Japanese population, 
identified associations with ALDH2 Glu504Lys (rs671) on chromosome 12q24 
and ADH1B Arg48His (rs1229984) on chromosome 4q23 (Cui et al. 2009). This 
was followed by three independent studies in Chinese populations which 
reported association of a total of 8 single-nucleotide polymorphisms (SNPs) in 6 
susceptibility loci (Abnet et al. 2010; Wang et al. 2010.a; Wu et al. 2011.c). One 
variant, PLCE1 His1927Arg (rs2274223) on chromosome 10q23, was 
significantly associated in all three studies with an odds ratio of 1.34 in two 
studies and 1.43 in the third. This was the only SNP associated with OSCC in 
the study by Abnet et al. (2010) which used 2,115 cases and 3,302 controls, 
and interestingly, the authors found the same variant to be associated with 
gastric cancer with a similar effect size. In addition to PLCE1 His1927Arg, Wang 
et al. (2010.a) identified an association with C20orf54/SLC52A3 (rs13042395) 
on chromosome 20p13. Wu et al. (2011.c) found associations of six further 
variants with OSCC at four loci: PDE4D (rs10052657) on chromosome 5q12, 
RUNX1 (rs2014300) on chromosome 21q22.3, a variant near UNC5CL 
(rs10484761) on chromosome 6p21.1 and three SNPs at a locus on 12q24 - 
ACAD10 (rs11066015), C12orf51 (rs2074356) and rs11066280.  
 
Further replication studies of PLCE1 and C20orf54 have been carried out in 
Chinese and American populations. In a Chinese population (380 cases and 
380 controls), only the PLCE1 His1927Arg was shown to be associated with 
OSCC (GG vs. AA genotype), with an odds ratio of 1.95 (95% CI = 1.05 – 3.59) 
(Gu et al. 2012). In the US population, a small study of 52 OSCC cases and 211 




controls showed an association between the PLCE1 variant and the disease 
using a dominant model (OR = 0.5, 95% CI = 0.3 – 1.0; P<0.05), although the 
authors acknowledged that they did not correct for multiple testing (3 SNPs in 3 
tumour types were tested) (Palmer et al. 2012). The effect is in the opposite 
direction to that observed in Chinese populations, and increasing the sample 
size in this study would help to confirm whether this is a true association. 
 
During the preparation of this thesis, an additional study by Wu et al. (2012.a) 
was published which followed up a further 169 SNPs that showed a suggestive 
evidence of association with OSCC (10-7 < P< 10-4) in their 2011 GWAS (Wu et 
al. 2011.c). Two replication stages were carried out, totalling ~8,000 of both 
cases and controls. A meta-analysis of the GWAS and the two replication 
stages produced 15 variants which were significantly associated with OSCC at 
the genome-wide significance threshold (P<5 x 10-8). Of these, 8 were in the 
region of the alcohol dehydrogenase (ADH) gene cluster in chromosome 4q23. 
Additionally, a genome-wide gene-environment analysis was performed to study 
the effect of alcohol consumption. This found two variants, in IGFB2 and 
SLC10A2, which were protective in non-drinkers but increased risk in drinkers. 
These variants were not significant when results were not stratified by alcohol 
consumption, suggesting that environmental factors should be taken into 
consideration at an early stage of the analysis. 
 
In a population of European descent, a GWAS has been completed in upper 
aerodigestive tract cancers (UADT), including 437 OSCC cases (McKay et al. 
2011). Of the 5 SNPs that were associated with all UADT cancers, SNPs at 
ADH1B (rs1229984), ADH7 (rs1573496) and ALDH2 (rs4767364) were 
associated with OSCC.    




1.2 Cancer in Africa 
In 2008, it was estimated that ~715,000 new cancer cases and ~542,000 cancer 
deaths occurred in Africa (Ferlay et al. 2010.b). However, cancer incidence and 
mortality in the continent are difficult to estimate due to the lack of cancer 
registries. Only 5 national and 50 local registries, covering 8% of the African 
population, were included in the above estimates (Ferlay et al. 2010.b; Jemal et 
al. 2012). Data quality in these local registries is also known to vary, with only 5 
being of high enough standard for inclusion in other world-wide cancer 
incidence reports (Jemal et al. 2012). However, cancer is seen as a growing 
health problem in Africa, with incidences and deaths expected to almost double 
by 2030, with 1.34 million new cancer cases and 1.02 million cancer deaths 
predicted to occur (Ferlay et al. 2010.b). This is due to both the increase in 
population size over this period and the expected increase in life-expectancy 
resulting from a reduction in death rates from other diseases (IARC 2008).   
 
Another important factor in the increase of new cancer cases in Africa is the 
changing of lifestyle habits, and as African countries develop, inhabitants with 
disposable incomes may adopt a more westernized lifestyle (reviewed in Jemal 
et al. 2012, and Lingwood et al. 2008). This brings its own problems, such as 
tobacco use, excessive alcohol consumption and obesity caused by an 
unhealthy diet and lack of physical activity. All of these contribute to cancer 
development, as well as a plethora of other health issues. Diseases resulting 
from these risk factors are preventable, and, therefore, will cause a burden to 
the health care systems in African countries which are already over-stretched 
due to long-term health problems such as HIV infection and malaria.  
 
The lack of good-quality health care in Africa to diagnose and treat cancer 
patients may ultimately lead to premature death. The vast majority (80%) of new 
cancer patients in Africa are diagnosed when the disease is already at an 
advanced stage when palliative care is generally the only option (Jemal et al. 




2012). This results in a low 5-year survival rate for patients which will not 
improve until the health care system is developed to be able to diagnose cancer 
earlier and to provide adequate treatment.  
 
Currently, African governments and international funding agencies focus on 
communicable diseases which affect a larger number of people and will, 
therefore, have a greater impact, but this leaves little consideration for cancer 
patients. Jemal et al. (2012) highlight the fact that developing countries can 
learn from Western countries to prevent cancer becoming a major problem. For 
example, controlling tobacco use by banning smoking in public places, 
increasing taxes and educating the population regarding health issues 
associated with it may prevent a smoking culture from developing.  
 
1.2.1 Oesophageal cancer in Africa 
1.2.1.1 Incidence 
Oesophageal cancer is ranked as the fourth and seventh most common form of 
cancer in African males and females, respectively (Ferlay et al. 2010.b). 
However, the incidence does vary widely across the continent. Middle and 
western Africa have the lowest rates in the world (~1.5 cases per 100,000 for 
males in both regions in 2008), whereas southern and eastern Africa observe 
some of the highest rates (22.3 cases per 100,000 and 14.9 cases per 100,000, 
respectively for males) (Ferlay et al. 2010.a).  
 
In southern Africa, the disease is the third most common cancer in both males 
and females, with age-adjusted incidence rates in 2008 of 22.3 and 11.7 per 
100,000, respectively (Ferlay et al. 2010.b). Certain regions of South Africa 
have a particularly high incidence, namely the former Transkei region in the 
Eastern Cape province (Somdyala et al. 2010). An increase in the incidence of 
oesophageal cancer was first reported in this area in 1957 by R.J Burrell (Burrell 
1957) and, since then, the incidence has remained consistently high (Somdyala 




et al. 2010). Rates within the Transkei itself also vary, with the south-western 
districts having a higher incidence than north-eastern regions (Somdyala et al. 
2003). In the high-risk regions of the Transkei, age-standardised incidence rates 
reached 102.6 cases per 100,000 in males during 1965-1969 (IARC 2003). 
More recent figures for rural populations in the Eastern Cape Province, where 
the majority are Xhosa-speaking indigenous Black Africans, show incidence 
rates of 32.7 cases per 100,000 in males and 20.2 cases per 100,000 in 
females during 1998-2002 (Somdyala et al. 2010). This places osophageal 
cancer as the most common form of cancer in males and second in females in 
this region, with squamous cell carcinoma being the predominant subtype, 
accounting for 87.6% of oesophageal cancers (Figure 1.2) (Somdyala et al. 
2010).  
 





Figure 1.2: Cancer incidence in the Eastern Cape Province of South Africa  
Cancer incidence in rural populations of the Eastern Cape Province of South Africa, 1998-2002 
(Somdyala et al. 2010). Oesophageal cancer is the most common form of cancer in males and 
third in female. 
 
1.2.1.2 Environmental risk factors 
Along with recording incidences of oesophageal cancer in the Transkei, R.J. 
Burrell began investigating possible environmental risk factors in the 1950s. 
This involved visiting many villages over an area of 16,500 square miles with 
permission from various chiefs (Burrell 1962). Photographs taken from this 
period are shown in Figure 1.3, which show the typical surroundings visited and 
Burrell himself.  






Figure 1.3: R.J Burrell investigating oesophageal cancer in South Africa  
R.J Burrell visited South African villages in the 1960s to investigate risk factors for oesophageal 








Incidences of oesophageal cancer together with factors such as composition of 
land, place of work and diet were recorded which allowed a comparison 
between high and low-risk areas. In 1962, Burrell proposed that factors in 
household gardens were responsible for the high incidences of OSCC, which 
would require further study (Burrell 1962). Indeed, by comparing gardens in 
regions with high cancer incidences to those of low incidences an association 
was found between OSCC and mineral deficiency in garden plants (Burrell et al. 
1966).  
 
In the decades following the studies conducted by Burrell, further environmental 
risk factors have been investigated. The Fusarium species of fungus, which 
produce mycotoxins such as Fumonisin B1 and B2, have been shown to 
contaminate maize, a staple food in the Transkei. The incidence of F. 
verticillioides in corn was found to be higher in the regions of the Transkei with a 
high incidence of OSCC compared to those with a lower cancer rate (Marasas 
et al. 1981). Other studies also support this, together with evidence of higher 
levels of mycotoxins in corn found in high-risk OSCC regions (Marasas et al. 
1988; Sydenham et al. 1990; Rheeder et al. 1992). However, whether the 
fungus and the mycotoxins are causal to OSCC is unknown. The most recent 
IARC monograph in 2002 concluded that Fumonisin B1 is possibly carcinogenic 
to humans (IARC 2002). The studies described above were all completed over 
20 years ago, and it is not known whether this could still be a risk factor in the 
Transkei today. 
 
Human papillomaviruses may also play a role in OSCC development in South 
Africa. Hale et al. (1989) observed HPV infection in 65% (13/20) of OSCC 
tumours, with Matsha et al. (2002) reporting rates of 46% (23/50). However, 
both of these studies failed to include control samples and, hence, the rate may 
represent a high HPV rate in the population.  
 




The effects of alcohol consumption and tobacco smoking, the main risk factors 
for OSCC world-wide, have been investigated in South Africa. Results have 
been conflicting, particularly for alcohol consumption with either an increased 
risk or no effect observed, perhaps due to low sample numbers or to different 
forms of alcohol being consumed. Two of the most recent studies in the Black 
South African population show conflicting results, with Dandara et al. (2006) 
reporting no association with smoking and drinking, compared to Pacella-
Normal et al. (2002) who reported an increased risk in smokers and drinkers. 
The latter study observed odds ratios of 3.8 (95% CI = 2.3-6.1) and 1.8 (1.2-2.8) 
for smoking and drinking, respectively. Aside from a lack of power to detect 
associations, a possible reason for the discrepancy observed is that there are 
regional differences within the country. Individuals in the study by Dandara et al. 
were from the Eastern and Western Cape, whereas the patients in the Pacella-
Norman et al. study resided in greater Johannesburg. In the high-risk region of 
the Transkei in the Eastern Cape, alcohol was also not identified as a risk factor 
(Sammon 1992; Matsha et al. 2006). In these South African populations, 
traditional home-brewed beer was consumed which may have a different 
composition to westernized beer or have a lower alcohol content. This might 
produce a less carcinogenic effect compared to that observed in other 
populations where alcohol is a risk factor. Additionally, in the former Transkei 
region, only 16% of men regularly consumed alcohol and 31% smoked tobacco 
in 2002 (Somdyala et al. 2010), which may have led to a lack of power to detect 
these environmental effects. Alternatively, other environmental or genetic risk 
factors contribute to OSCC development in this region.  
 
1.2.1.3 Genetic susceptibility 
Several candidate gene association studies have been published which focus 
on OSCC in South African populations. The samples in all of these studies 
(including those used in this thesis) come from the same source, with the 
sample size increasing over time.  





In 2005, the first OSCC association study in the South African population was 
published. This found the variant CYP2E1*6 to be associated with OSCC in the 
South African populations (Li et al. 2005). However, this study analyzed the 
Black and Mixed Ancestry populations jointly. It is now believed that the 
populations should be analyzed separately due to our acquired knowledge of 
population structure which shows that the Black and Mixed Ancestry populations 
are genetically different. A combined analysis may lead to false-positive 
associations (and false-negatives) due to population stratification. 
 
A further study reported association of the CYP3A5*3 allele with a reduced risk 
of OSCC in the Mixed Ancestry population (P = 0.025) but this was not 
corrected for the multiple tests performed (Dandara et al. 2005).  
 
Variants in alcohol metabolising genes have also been tested for association 
with OSCC, with the ALDH2 rs671 variant (Glu504Lys) reported to be 
associated with the disease in the Black population (Li et al. 2008). However, 
this was a surprising result since other evidence suggests that this variant is 
specific to Asian populations (Li et al. 2009.a).  
 
Two studies have investigated variants in GST genes for susceptibility to OSCC 
(Li et al. 2010.a; Matejcic et al. 2011). These are plausible candidate genes for 
cancer susceptibility as glutathione S-transferases (GSTs) cause the 
detoxification of toxic compounds, such as environmental carcinogens. The 
association of GST variants with susceptibility to cancer has also been studied 
for many years (Rebbeck 1997). The first study in the South African population 
identified a deletion in GSTT1 (GSTT1*0) and the variant GSTP1 341 C/T 
(Ala114Val) as being associated with OSCC in the Black population (Li et al. 
2010.a). This latter variant was also associated in the Mixed Ancestry 
population, together with a deletion in GSTM1 (GSTM1*0). In contrast, in a 
more recent study by Matejcic et al. (2011), the 54-kb deletion in GSTT1 was 




not associated with OSCC in the Black population. This difference is thought to 
be due to an improved genotyping technique that allowed all three genotypes to 
be determined, rather than only homozygous deletions as in the earlier study, as 
well as an increased sample size.  Also in this study, a 37-kb deletion in 
GSTT2B was significantly associated with OSCC in the Mixed Ancestry 
population (OR = 0.71, 95% CI = 0.57 – 0.90; P = 0.004). 
 
Finally, variants in mismatch repair enzymes have been investigated 
(Vogelsang et al. 2012). Three variants were significantly associated with OSCC 
in the Mixed Ancestry population; MSH3 rs26279, PMS1 rs5742938 and MLH3 
rs28756991. No variants were associated with the disease in the Black 
population.  
 
1.3 Population genetics  
1.3.1 Modern human evolution 
Modern humans are thought to have evolved in Africa about 200,000 years ago. 
Fossil evidence suggests that modern humans originated in East Africa but 
recent genetic studies indicate a southern African origin (Henn et al. 2011). 
Migration out of Africa, to Eurasia and to the Americas, is thought to have 
occurred within the last 40,000 - 80,000 years and 15,000 - 30,000 years, 
respectively, and it is estimated that only around 1,000 - 1,500 founding 
individuals left Africa (Campbell and Tishkoff 2010). 
 
Polymorphisms that arose in African populations prior to migration out of the 
continent account for ~90% of variation seen in all human populations today 
(McClellan and King 2010). The migration of a relatively small number of 
individuals out of Africa led to a reduction in genetic variation in subsequent 
generations of the migrants, known as a population bottleneck. Variation that 
has arisen since then is thought to be due to rapid population growth caused by 
the development of agriculture and urbanisation (McClellan and King 2010), 




which will be influenced by factors specific to a population such as the 
environment and selection pressures. Due to the population bottleneck that 
occurred, African populations are the most genetically diverse in the world 
(Tishkoff and Williams 2002). 
 
1.3.2 Genetic structure of African populations  
The first large-scale study into the variation in African genomes was the 
HapMap project which started in 2002 and aimed to identify genetic 
polymorphisms in multiple human populations of European, Asian and African 
ancestry, including the Yoruba from Ibadan, Nigeria (YRI) (www.hapmap.org). 
On a similar principle, the 1000 Genomes project aims to whole-genome 
sequence 2,500 individuals from 27 global populations, including five from Africa 
(www.1000genomes.org).  
 
Numerous other studies have also focused on determining the structure of 
African populations to reveal insights into the origin of modern humans, 
evolutionary history and adaptation of populations (Tishkoff et al. 2009; de Wit 
et al. 2010; Quintana-Murci et al. 2010; Henn et al. 2011; Lachance et al. 2012; 
Pickrell et al. 2012; Schlebusch et al. 2012). In one study, the hunter-gatherer 
populations (including the Hadza and Sandawe of Tanzania  and  the  ≠Khomani  
Bushmen of South Africa) were found to have the greatest amount of genetic 
diversity in the world and have the lowest linkage disequilibrium levels across 27 
African populations (Henn et al. 2011). From this work, Henn and colleagues 
were able to conclude that modern humans were likely to have originated in 
southern Africa.  
 
In 2010, the first whole genome sequences of African individuals were published 
of a Khoisan hunter gatherer and a Bantu individual (Archbishop Desmond 
Tutu), together with exome sequences from a further three hunter-gatherers, all 
from southern Africa (Schuster et al. 2010). In total, 1.3 million novel variants 




were discovered, and remarkably, the authors found that the hunter-gatherers 
were more genetically distinct from each other than a European and an Asian 
individual.  
 
More recently, Lachance et al. (2012) have sequenced the whole genomes of 5 
individuals from three hunter-gatherer populations; one from Cameroon 
(Pygmies) and two from Tanzania (Khoisan-speaking Hadza and Sandawe). As 
well as identifying novel variants and determining shared ancestry both between 
the hunter-gatherer populations and within other African populations, this 
approach enabled the authors to identify loci that were specific to traits, such as 
height in the Pygmy population.  
 
1.3.3 Population history and genetic structure of the South African 
Xhosa and Mixed Ancestry populations 
The hunter-gatherers populations, known as the San (or Bushmen) and 
Khoikhoi, or collectively as the Khoisan, were the first inhabitants of what is 
nowadays known as South Africa. Bantu-speaking groups originated from 
Cameroon/Nigeria and began to migrate around 1500 BC, spreading both south 
and to the east (Johnson 2004; Bryc et al. 2010). It is the latter group that 
eventually reached South Africa in the third century. Five Bantu-speaking 
groups were known to reside in South Africa, all of which relied on agriculture 
and cattle herding (Johnson 2004). One of these groups, the Nguni, is the origin 
of the Xhosa and Zulu populations, and migration continued through the east of 
South Africa, with the Xhosa settling in what is now the Eastern Cape Province. 
The Xhosa and Zulu languages are influenced by the click-sounding Khoi 
languages, showing that the groups would have interacted. Indeed, four studies 
have analyzed the genetic structure of the Xhosa population, and, although the 
number of other African populations in each study is variable, results show that 
the Xhosa contain Khoisan ancestry (Tishkoff et al. 2009; Bryc et al. 2010; 
Patterson et al. 2010; Schuster et al. 2010). Two of the studies also suggest 




relatedness with the Yoruban population (Patterson et al. 2010; Schuster et al. 
2010). 
 
In 1652, non-African populations began to arrive in the area now known as 
Cape Town due to the opening of a fuelling station by the Dutch East India 
Company to allow their ships to be re-supplied on route to East Asia (reviewed 
in de Wit et al. 2010). This resulted in the settlement of Europeans which was 
followed in 1658 by the importation of slaves from India, Indonesia, Madagascar 
and other African countries. This began the formation of the South African 
Mixed  Ancestry  population,  described  historically  as   the   ‘Coloured’  population.  
With the settlers being mainly male, mixed marriages between white Europeans 
and local Khoi females were initially encouraged (Johnson 2004). Genetic 
studies show 60% of the maternal contribution to the Mixed Ancestry population 
is from the Khoisan, with a negligible contribution from European females 
(Quintana-Murci et al. 2010). Slaves were also encouraged to have children to 
provide more labour, with the white slave owners often fathering the child 
(Johnson 2004). Race-based restrictions first came into force in the 1700s and 
in the twentieth century this extended to the banning of inter-racial marriages 
and forcing population groups to reside in particular areas. These restrictions 
over several centuries established the Mixed Ancestry population. Restrictions 
were not alleviated until the post-apartheid era in 1994.  
 
Four studies have analysed the genetic structure of the Mixed Ancestry 
population, and these support the historical evidence of the formation of the 
population (Tishkoff et al. 2009; de Wit et al. 2010; Patterson et al. 2010; 
Quintana-Murci et al. 2010). The studies do differ slightly in the estimates of the 
amount of each ancestral component, which may be due to sampling of the 
Mixed Ancestry population from different regions or as a result of using different 
world-wide populations in the analysis. De Wit et al. (2010) estimated the 
ancestral components as Khoisan (32-43%), Bantu-speaking Africans (20-36%), 
European (21-28%) and Asian (9-11%), whereas Tishkoff et al. (2009) 




estimated approximately equal levels of Khoisan, Black African, European and 
Indian ancestry with a lower level of East Asian ancestry. Patterson et al. (2010) 
did not quantify the contribution of each component but reported genetic 
contributions from at least the Xhosa, Europeans, South Asians and 
Indonesians. Finally, Quintana-Murci et al. (2010) determined five ancestral 
populations; Khoisan, Bantu, European, Indian and Southeast Asian. 
 
The most recent figures (2011 census) show that South Africa has a population 
of over 50 million people and consists of different population groups as follows: 
79.2% Black Africans, 8.9% Mixed Ancestry, 8.9% white and 2.5% Indian/Asian 
and 0.5% other 
(http://www.statssa.gov.za/Census2011/Products/Census_2011_Census_in_bri
ef.pdf). IsiZulu is the most frequently spoken first language (22.7%), followed by 
isiXhosa (16%), Afrikaans (13.5%) and English (9.6%). The Xhosa mainly reside 
in the Eastern Cape, with over 5 million of the 8 million individuals who speak 
Xhosa as a first language living here, making up 78.8% of the Eastern Cape 
population. The majority of those who speak Afrikaans as a first language 
mainly reside in the Western Cape, making up ~50% of the population in this 
region.  
 
1.3.4 Genetic association studies in African populations 
The genetic structure of African populations is characterised by high levels of 
haplotype diversity and low levels of linkage disequilibrium (LD) (Teo et al. 
2010). This is a disadvantage in the identification of disease associations in 
GWAS since these arrays are currently designed based on European ancestry. 
GWAS arrays may exclude SNPs in complete LD with another variant as no 
additional information is gained from their inclusion. Hence, causal variants may 
not be present on the array, but their effect will still be detected through the 
analysis of a SNP in a high level of LD with it (known as tagging SNPs). In 
African populations with a lower level of LD, tagging SNPs for causal variants 




may not exist and so no association will be detected. Alternatively, a tagging 
SNP may be in moderate LD with the causal variant in African populations but 
due to the weaker effect that would be observed, it may fail to reach the 
genome-wide significance threshold to account for multiple testing (Teo et al. 
2010). Indeed it is noted that it is harder to achieve genome-wide significance in 
African populations compared to European and Asian populations due to the 
lower level of LD (Jallow et al. 2009). To successfully use a GWAS in African 
populations, a larger number of SNPs are likely to be needed to obtain 
significant coverage of their genomes. SNP arrays should also be designed 
based on sequence data from the relevant populations, which for the majority of 
African populations is lacking.  
 
However, there is an advantage to performing association studies in African 
populations as they provide an opportunity to identify causal variants in disease 
susceptibility. Current genome-wide association studies in non-African 
populations are often unable to distinguish the causal variant from tagging 
SNPs. In these populations, the high level of LD may extend over a large region, 
meaning that tagging SNPs may not even be located in the gene containing the 
causal variant. If the regions that show disease associations in non-African 
populations are fine-mapped in African populations, then causal polymorphisms 
could potentially be identified. This is summarized in Figure 1.4 where the 
causal variant is in high LD with a nearby variant in non-African populations, 
potentially leading to this tagging variant being associated with disease. 
  








Figure 1.4: Linkage disequilibrium in African populations  
Due to the population bottleneck that occurred following migration out of Africa, non-African 
populations have a higher level of linkage disequilibrium (LD) than African populations (as 
shown by the shade of the bars: the darker the colour, the higher the level of LD). In African 
populations, a disease causal SNP (A) and a nearby SNP (B) are independent of each other. In 
non-African  populations,   the  high   level  of  LD  between   these  variants  means  SNP  B   ‘tags’   the  
causal SNP and hence will also be associated with disease status. If this region is fine-mapped 
in the African populations, association studies could potentially identify the causal rather than 
the tagging variant. 
 
Promisingly, a proof-of-concept study, where the causal variant (rs334 at the 
haemoglobin S locus) was already known, has shown that lack of significant 
associations in an African GWAS can lead to the identification of the causal 
variant through other approaches (Jallow et al. 2009). This study attempted to 
identify the causal variant for protection against malaria in individuals from The 
Gambia, West Africa. A GWAS, which did not contain rs334, did not identify any 
variants that reached genome-wide significance, with the strongest association 
having P = 3.9 x 10-7. This region, which was also the region known to contain 
the causal variant, was subsequently fine-mapped in a subset of samples and 
the information used to impute the genotypes for an expanded set. This resulted 
in much stronger association signals, with the strongest association being P= 
4.5 x 10-14, which was the causal rs334 SNP. This study highlights the fact that 
current GWAS chips designed for non-African populations are, alone, not 
suitable for association studies in African populations. Indeed Jallow et al. also 
note that genotyping arrays based on the HapMap YRI populations may also not 
be adequate. With our knowledge of the vast degree of genetic variation that is 
present in African populations, genotyping arrays specific to the population of 









interest will be needed. Alternatively, the availability of reference panels for 
specific populations would allow imputation.  
 
An alternative approach to identify disease associations is emerging. Pasaniuc 
et al. (2012) have shown that low-coverage (0.1-0.5x) whole exome sequencing 
data, together with imputation to reference panels, can be used to perform a 
genome-wide association study, producing similar results to using a standard 
GWAS array. This will enable all detected variants to be tested for disease 
association, which would be beneficial in African population studies. 
 
Once the best approach for large-scale hypothesis-free association studies in 
African populations has been determined, it will be important to identify 
susceptibility variants for diseases that are prominent in these countries 
themselves (reviewed in Campbell and Tishkoff 2008). To date, approximately 
14 genome-wide association studies have been completed in African 
populations (excluding African-American) with varying sample numbers 
(Hindorff et al.; accessed 04/04/2013), including analysis of the susceptibility to 
HIV, tuberculosis and malaria (Jallow et al. 2009; Lingappa et al. 2011; Thye et 
al. 2012; Timmann et al. 2012). No studies have yet examined susceptibility to 
cancer. 
 
1.4 Genetic susceptibility to cancer 
1.4.1 Models of susceptibility 
In 1971, Alfred Knudson proposed that cancer can be caused by the acquisition 
of   two   mutations   in   the   same   gene,   later   known   as   the   ‘two-hit   hypothesis’  
(Knudson 1971). Here, Knudson studied retinoblastoma in patients with familial 
and sporadic cancers and found that tumours in familial cases were mostly 
biliateral and multi-focal, whereas sporadic tumours were unilateral and unifocal. 
Statistical analysis of the age distribution of bilateral and unilateral cases 




indicated that they  matched  a   “one-hit”  curve  and   “two-hit”  curve,   respectively.  
He proposed that patients with the familial dominant form of the cancer inherited 
one germline mutation and acquired an additional somatic mutation, whereas in 
sporadic forms of the disease, both mutations occurred somatically. Later, 
experimental studies confirmed the model, showing that germline and/or 
somatic mutations result in two non-functional copies of RB1, a tumour 
suppressor gene (Friend et al. 1986). This two-hit model is relevant to other 
dominant forms of familial cancer which affect tumour suppressor genes, 
including breast cancer caused by mutations in BRCA1 and BRCA2 (Smith et 
al. 1992; Gudmundsson et al. 1995). In most sporadic forms of cancer, more 
than one gene is required to be mutated in order for the disease to develop. The 
two-hit model may still be applicable to result in the loss of function of a tumour 
suppressor gene, but other mutated genes will also contribute to tumourigenesis 
(reviewed in Berger et al. 2011).  
 
In addition to the two-hit model, other mechanisms of action of tumour 
suppressor genes have also been suggested which have been extensively 
reviewed by Berger et al. (2011) and is summarized below (see also Figure 1.5). 
One of these mechanisms is haploinsufficiency, whereby the normal function of 
one copy of a gene is lost through mutation or deletion. The effect on disease 
development may be due to the 50% reduction in gene expression or protein 
activity, or due to the formation of a mutant protein that inhibits the function of 
the normal protein (Berger et al. 2011). Haploinsufficiency together with the two-
hit hypothesis, represent discrete models of loss of tumour suppression, 
whereby either one or two copies of the gene are non-functional. The alternative 
to this is a continuum model of tumour suppression. This suggests that it is the 
change in gene expression or protein expression that is important for tumour 
development, which may vary between 0-100%, with a greater loss causing a 
higher  chance  of  malignancy.  For   some   tumour  suppressor  genes,  a   ‘fail-safe 
mechanism’   may   be   activated   if   complete   loss   of   the   gene   occurs,   whereby 
other mechanisms are activated to prevent the consequences of complete loss 




of the gene. For example, if complete loss of Pten occurs, p53 causes Pten-
loss-induced cellular senescence (PICS). This continuum model may have 
important implications for cancer susceptibility as changes in gene expression 
may be caused by germline polymorphisms in the promoter or regulatory 




Figure 1.5: Models for tumour suppressor genes  
Discrete models of tumour suppressor genes include the two-hit paradigm and 
haploinsufficiency, which result in one or two non-functional copies of the gene. An alternative 
model is a continuum, whereby tumourigenesis is correlated with a reduction in gene expression 
(or  protein  activity)   levels.   ‘Fail-safe  mechanisms’  may  also  be  activated  which  attempt   to  halt  
malignancy by causing cellular senescence. Oncogenes may also comply with this model. 
(Berger et al. 2011) 
 
 
It is thought that cancer susceptibility in the general population is affected by the 
co-inheritance of multiple risk variants, together with the presence of 
environmental risk factors. These germline polymorphisms have a smaller effect 
than the highly penetrant alleles described previously for dominant familial 
cancer, and include rare moderate-risk alleles (minor allele frequency (MAF) 
<2%; OR >2.0) and common low-risk alleles (MAF >10%; OR <1.5) (reviewed in 
Fletcher and Houlston 2010). The types of risk alleles that have been identified 
in breast cancer are shown in Figure 1.6. Common low-risk variants have 
proved hard to detect, requiring extremely large sample numbers. In addition, 




methods used to detect these variants may not identify the causal variant, as 
discussed in the following section.  
 
 
Figure 1.6: Types of susceptibility loci  
Types of breast cancer susceptibility loci based on the relative risk and the risk allele frequency. 
(Varghese and Easton 2010) 
 
1.4.2 Detection of susceptibility loci using association studies 
1.4.2.1 Candidate gene association studies 
Candidate gene studies make use of a prior knowledge of a genes function or 
disease associations to select genes of potential interest for a genetic 
association study. For example, genes involved in apoptosis or DNA repair 
would be good candidates for cancer studies as mis-regulation of these 
pathways could lead to uncontrolled growth or genomic instability in cells. Using 
cases and controls from the same population, the genotype and allele 
frequencies of a selected variant can be determined and analysed to test 
whether there is a significant difference between the two groups. This has led to 
the identification of several disease susceptibility loci. However, the number of 




genes that can be tested for association has been limited by the time-
consuming process of testing one gene at a time. Also, the prior probability of 
selecting a disease-associated gene is low, given the total number of genes in 
the human genome.  
 
1.4.2.2 Genome-wide association studies 
Genome-wide association studies (GWAS) are a hypothesis-free approach, 
enabling case-control association tests of variants across the whole genome. 
The number of SNPs that can be genotyped in a single experiment has 
increased over the years, with current platforms, such as the Illumina 
HumanOmni5-Quad, able to genotype 4.3 million markers per sample. Due to 
the large number of tests carried out, a high level of significance is required to 
declare a disease association, with the consensus significance threshold being 
P<5 x 10-8, based on the Bonferroni correction. In order to have high power to 
detect common variants which contribute a small effect, several thousand cases 
and controls are needed. If variants are rare or low frequency, then tens of 
thousands of samples will be required, which is beyond the scope of many 
disease studies in terms of project funding and acquiring sufficient sample sizes. 
Typically, a GWAS is carried out in an initial set of cases and controls and the 
most promising hits are then selected for replication in an independent set of 
samples. A meta-analysis can be performed to generate a combined p-value for 
association. 
 
The current GWAS genotyping platforms were designed for populations of 
European descent, with the SNPs selected based on frequencies and LD in this 
population. If the platform is not optimized for use in other populations, true 
associations may fail to be detected. For example, as discussed previously (see 
section 1.3.4), African populations are the most genetically diverse in the world 
and have a lower level of LD. A variant found to be associated with a disease in 
a European population GWAS may be tagging the causal SNP which was not 




itself genotyped. The same tagging SNP would not be associated with the 
disease in the African population if it was not in strong LD with the causal SNP. 
Therefore, population-specific GWAS genotyping platforms are needed, which 
will initially require the variants and haplotypes in these populations to be 
identified. The HapMap and 1000 Genome Projects are contributing to our 
knowledge in this area (www.hapmap.org; www.1000genomes.org). 
 
According to the Catalog of Published Genome-Wide Association Studies 
published by the National Institute of Health, a total of 1,554 studies have 
identified 8,972 variants associated with diseases/traits (Hindorff et al.; 
accessed 04/04/2013).  
 
1.4.2.3 Customized genotyping arrays 
Customized genotyping arrays are also available to enable customers to select 
their own SNPs of interest to be included on the chip. For example, the Illumina 
“Infinium  iSelect  HD  Custom  Genotyping  BeadChips”  allows  3,000   - 1,000,000 
SNPs to be selected. Arrays which have been designed in this manner and 
which focus on specific disease areas are the Illumina Immunochip and the 
Metabochip. The Immunochip was developed by a consortium of groups 
researching immune-related   diseases,   including   Crohn’s   disease,   rheumatoid  
arthritis and psoriasis (Cortes and Brown 2011; Trynka et al. 2011). The 
Metabochip is designed for the investigation of 23 traits focusing on metabolic, 
cardiovascular and anthropometric traits (Voight et al. 2012). Both of these 
genotyping platforms contain ~200,000 variants which attempt to replicate 
known regions of associations and those which have previously failed to meet 
the genome-wide significance threshold of P<1 x 10-8. In addition, they are 
designed to allow the fine-mapping of known association regions. Also included 
were SNPs of particular interest to any of the groups involved in the chip design. 
 




Several disease areas have now published their results of Immunochip and 
Metabochip studies including psoriasis, rheumatoid arthritis, celiac disease, 
inflammatory bowel disease and coronary heart disease (Trynka et al. 2011; 
Deloukas et al. 2012; Eyre et al. 2012; Jostins et al. 2012; Tsoi et al. 2012). 
These have genotyped extremely large numbers of samples, for example in 
inflammatory bowel disease, 26,000 cases and 16,000 controls were used 
(Jostins et al. 2012). All studies have identified many additional variants that are 
associated with disease susceptibility.   
 
1.4.2.4 Missing heritability 
Despite using these large-scale genotyping platforms, the cumulative effect of 
susceptibility variants identified through association studies does not always 
match the estimated heritability of the disease calculated from twin studies. This 
has  led  to  the  ‘missing  heritability’  problem  which  involves  all  complex  diseases.  
For example, in a meta-analysis studying the susceptibility to psoriasis using 
>10,000 cases and >22,000 controls, the 39 independent associated variants 
account for 22% of the estimated heritability (Tsoi et al. 2012).  
 
This missing heritability has several potential sources (reviewed in Manolio et al. 
2009). Firstly, studies may still be under-powered to detect common variants 
with small effect sizes and rare variants with moderate or small effect sizes. In 
addition, power may be lost due to genotyping tagging variants instead of causal 
variants. To enable more variants to be tested for association with disease, 
genotypes for additional variants can be imputed using reference panels (e.g. 
from 1000 Genomes project) from the same population. If reference panels are 
not available for a population, whole-exome or whole-genome sequencing may 
be needed, either in the study samples themselves, or in a set of individuals to 
form a new reference panel where imputation can then be performed in the 
study samples. Inclusion of known population-specific variants on GWAS arrays 




may provide additional or stronger disease associations in these populations, if 
imputation is not possible.  
 
In addition to single-nucleotide polymorphisms, other factors may also be 
responsible for the missing heritability. These include structural variants, such 
as insertions, deletions, inversions and translocations, which are currently 
difficult to genotype accurately in large-scale studies; a Wellcome Trust Case 
Control Consortium found very limited evidence of the involvement of structural 
variants in 8 common diseases (Craddock et al. 2010). Other factors which 
might contribute to disease susceptibility are epigenetic changes, and both 
gene-gene and gene-environment interactions. 
 
Alternatively, associations may be diluted by the presence of a wide range of 
phenotypes within the disease classification. Sub-set analysis, such as young-
onset disease or variations in clinical presentation, may identify further 
susceptibility loci specific in these groups. However, this will result in reduced 
sample sizes and potentially a loss of power.  
 
1.5 Somatic mutations in cancer 
1.5.1 Cell division, errors and repair 
Cell division occurs during development and throughout life to replace existing 
cells. Errors may occur in DNA replication due to DNA damage caused by both 
internal and external factors. Internal factors include the production of reactive 
oxygen species as a result of normal cellular metabolism. These can oxidise 
bases leading to mis-pairing during replication, or induce single- and double-
strand breaks (De Bont and van Larebeke 2004). External sources include 
environmental factors known to increase the risk of cancer, such as tobacco 
smoke and ultraviolet radiation. Damage initiated by tobacco smoke is due to 
the formation of DNA adducts as a result of detoxification of the carcinogenic 




compound by enzymes such as cytochrome P450. These DNA adducts bind 
DNA and can cause nucleotides to be mis-read during replication, resulting in 
mutations. Ultraviolet radiation is known to cause the formation of pyrimidine 
dimers which distorts the shape of the DNA helix, affecting both transcription 
and replication.  
 
The majority of DNA damage and replication errors that occur will be repaired 
by   the  cell’s  DNA   repair  mechanisms,  such  as  nucleotide  excision   repair.  The  
errors which escape this process will be retained, with daughter cells inheriting 
them, producing germline or somatic mutations depending on the cell type in 
which they occur.  
 
1.5.2 Somatic mutations 
If a somatic mutation occurs in a gene or region which confers a growth 
advantage to the cell, this can initiate the process of cancer development. 
These mutations occur in genes that play a key role in pathways that are usually 
highly regulated, such as cell growth or apoptosis, and are referred to as driver 
mutations. Driver mutations occur in oncogenes and tumour suppressor genes. 
The former are genes are usually involved in the promotion of cell growth, 
whereby harmful mutations cause them to continually promote growth. 
Mutations in oncogenes are activating mutations which act in a dominant 
manner, requiring only one mutation to lead to a cellular effect. Tumour 
suppressor genes normally function to suppress cell growth or act as caretakers 
of genomic stability. Mutations occur in both copies of the gene in the same cell, 
hence acting in a recessive manner, and lead to inactivation of the protein. Over 
80% of known driver mutations are in oncogenes (Stratton 2011). 
 
Somatic mutations are randomly dispersed throughout the genome, and many 
will occur in regions which have no effect on protein function. If these occur in a 




cell with a driver mutation, they will be co-selected in the clonal evolution of the 
tumour, and are referred to as passenger mutations. 
 
The number of driver mutations present in tumours is known to vary in different 
cancer types (reviewed in Stratton 2011). For example, medullablastomas 
harbour only a few mutations, whereas lung cancers have many more which is 
thought to be due to the continual bombardment of the genome by carcinogenic 
compounds in tobacco smoke. As cancers evolve they will acquire more driver 
mutations in order for them to continue to survive and expand. This is a multi-
step process which results in a neoplastic tumour that has the six hallmarks of 
cancer;;   “self-sufficiency in growth signals, insensitivity to growth-inhibitory 
signals, evasion of programmed cell death, limitless replicative potential, 
sustained   angiogenesis,   and   tissue   invasion   and   metastasis”   (Hanahan and 
Weinberg 2000).  Recently,  “reprogramming  of  energy  metabolism and evading 
immune  destruction”  have  also  been  added  to  this  list   (Hanahan and Weinberg 
2011). To achieve all of these hallmarks, many processes have to be mis-
regulated, which is perhaps why so many genes have been found to be mutated 
in cancer. 
 
To date, 487 genes have been reported to harbour mutations which have been 
implicated in cancer, of which 84% are somatic variants, 8% are germline 
variants, and 8% contain both types (Cancer Gene Census; accessed 17/12/12; 
www.sanger.ac.uk/genetics/CGP/Census/). Many more may exist and the 
challenge is to identify the driver mutations and to distinguish them from the 
passenger mutations. Driver mutations are likely to cause significant changes to 
the structure or expression of a gene and be found in a significant proportion of 
tumours of a particular type. Therefore, genes that are frequently mutated are 
likely to be essential in the development of that particular cancer.  
 




1.5.3 Why do we want to identify somatic mutations? 
The identification of driver somatic mutations could provide enormous amounts 
of information enabling us to understand how cancer develops, and to explain 
the variation occurring between the same type of cancer in different patients, 
enabling re-classification based on mutations present. For example, one of the 
most thorough studies to date has been in breast cancer where the genomes 
and transcriptomes of ~2000 tumours were analysed (Curtis et al. 2012). By 
combining genetic copy number alternations and expression data, samples 
were suggested to cluster into 10 subtypes. This may lead to clinical benefits by 
determining the type of treatment that is most likely to be successful for each 
subtype.  
 
Genetic mutations have been shown to affect treatment success. For example, 
colorectal cancer patients with mutations in KRAS do not to respond to 
cetuximab therapy and have a worse prognosis than those without KRAS 
mutations (Lievre et al. 2006). In addition, the identification of driver mutations 
can also provide a new therapeutic target for drug development. For example, 
targeting the known BRAF V600E mutation in melanoma patients led to tumour 
regression in the majority of treated patients (Flaherty et al. 2010). 
 
1.5.4 Methods to detect somatic mutations 
The principle of detecting somatic mutations involves comparing tumour DNA to 
normal DNA (either blood or normal non-cancerous tissue) from the same 
patient to detect changes that have arisen in the tumour. The first mutations to 
be observed in cancer were large chromosomal translocations that could be 
observed under a microscope. Following this, copy number changes could be 
identified using comparative genome hybridization (CGH) or, more recently, 
array CGH. In addition, SNP genotyping arrays can detect copy number 
alterations together with regions of loss-of-heterozygosity (LOH). The ability to 




study small insertions/deletions and single nucleotide mutations has only been 
possible since the advent of DNA sequencing. Sanger sequencing enabled the 
analysis of candidate cancer genes, and more recently, whole-exome 
sequencing has allowed an unbiased approach to examine all somatic 
mutations occurring within the coding regions of the genome. Whole-genome 
sequencing of cancer patients has also been successful in identifying somatic 
mutations, but this approach requires additional resources, which is discussed 
below.  
 
1.5.4.1 Whole-exome and whole-genome sequencing  
A major advance in discovering somatic mutations has been the development of 
next-generation sequencing, where whole-exomes or whole-genomes can be 
sequenced in a relatively short time period. Whole-exome sequencing has been 
the favoured method to date, with the sequencing only of ~1% of the genome 
(~30Mb) providing numerous advantages. Firstly, sequencing the exome 
enriches for driver mutations by focusing on the coding regions of genes, and is 
quicker and cheaper than sequencing the whole genome. In addition, whole-
genome sequencing produces a very large amount of data which requires more 
computational storage space and experienced bioinformaticians to identify the 
potential driver mutations amongst the thousands of somatic mutations that are 
likely to be present. However, whole-genome sequencing can also detect large-
scale genomic changes, such as deletions and translocations, and mutations in 
regulatory regions outside of the exome. 
 
The whole-genome/exome approach is not always successful in identifying 
driver mutations. Reasons for this include the contamination of tumour tissue 
with surrounding normal tissue. If this occurs, then the mutation will be present 
in a low percentage of the sequencing reads, which may be below the threshold 
for calling a variant. The threshold could be reduced, but this risks an increase 
in false positive mutation calls. 





Another reason for the failure to identify novel driver mutations is that there 
tends to be a selective follow-up of mutations in genes which have already been 
identified as a cancer gene. Therefore, mutations in genes of unknown function 
or with no known link to cancer will be treated with caution and are less likely to 
be included in the next stage of analysis. In order to identify them as driver 
mutations, a large number of cancers will need to be sequenced to determine if 
the genes are mutated in multiple patients. To determine the effect of a variant, 
functional validation may be needed to assess whether processes such as 
growth or apoptosis are affected.  
 
If few or no driver mutations are identified by exome sequencing, then whole-
genome sequencing may unveil other classes of mutations. However, some 
tumour types may have very few mutations. 
 
1.5.5 Large-scale cancer sequencing projects  
Several large-scale projects exist to explore the molecular basis of cancer 
including The Cancer Genome Atlas (TCGA) (http://cancergenome.nih.gov/) 
and the International Cancer Genome Consortium (ICGC) (http://icgc.org/). 
TCGA is a comprehensive effort to sequence and identify somatic changes in 
more than 20 types of cancer, and the ICGC aims to identify not only the 
genomic changes in 50 cancer types but also the transcriptomic and epigenetic 
changes. 
 
The large amount of data that is being produced from whole-genome/exome 
sequencing projects has led to the development of several databases which 
compile the results of published studies for easy access. One of these, The 
Catalogue of Somatic Mutations in Cancer (COSMIC) 
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/), contains all the 
somatic mutations that have been identified in different types of cancer. 




Additionally, The Cancer Gene Census 
(www.sanger.ac.uk/genetics/CGP/Census/) provides a list of genes that have 
been identified as cancer genes, together with the class of mutation and the 
cancer type.  
 
1.5.6 Somatic mutations in oesophageal cancer 
According to the COSMIC database (accessed 04/04/2012), TP53 is the most 
frequently mutated gene in OSCC, with 50% of tumours (933/1884) harbouring 
mutations (Figure 1.7). This is followed by NOTCH1 with 43% (16/37) of 
tumours mutated. One whole-exome sequencing study has been performed in 
OSCC, with 12 matched normal and tumour samples sequenced (Agrawal et al. 
2012). After follow-up of frequently mutated genes in an additional 41 pairs of 
samples, Agrawal et al. identified the following mutation rates: TP53 (62% of 
tumours), NOTCH1 (21%), NOTCH2 (6%), NOTCH3 (8%) and FBXW7 (6%). 
No OSCC samples have been whole-genome sequenced as yet, which may 
provide further insights into the complete mutation profile of this form of cancer. 
Somatic mutations in OSCC are further discussed in Chapter 6 (section 6.1). 
 
 





Figure 1.7: Somatic mutations in OSCC 
COSMIC data for the top 20 genes mutated in 1157 OSCC samples, only including genes that 




The aim of this project is to investigate the genetics of oesophageal squamous 
cell carcinoma (OSCC) in the Black and Mixed Ancestry populations of South 
Africa. Firstly, the genetic susceptibility to OSCC will be studied by performing 
case-control association studies of genes and loci with strong evidence of 
association with OSCC in other populations, and by using the Illumina 
Immunochip genotyping array. The latter approach will also enable the 
population structure of the samples to be investigated. Secondly, somatic 
mutations will be identified by sequencing the whole-exome of OSCC blood-
tumour pairs. 




2 Methods  
2.1 Materials  
2.1.1 Reagents 
Absolute qPCR ROX mix     ABgene   
SureSelect Reagent Kit     Agilent 
Herculase II Fusion DNA Polymerase   Agilent 
SureSelectXT Human All Exon V4 capture Library Agilent 
BigDye® Terminator v3.1 Cycle Sequencing Kit   Applied Biosystems 
Genescan™  500  Liz™  Size  Standard      Applied Biosystems 
Hi-Di Formamide      Applied Biosystems   
Sequencing buffer      Applied Biosystems 
TaqMan SNP assays     Applied Biosystems 
Agencourt AMPure XP kit           Beckman Coulter Genomics 
ExoSAP-IT         GE Healthcare 
TruSeq Cluster Generation Kit    Illumina 
TruSeq Sequening Kit     Illumina 
dNTPs         Invitrogen 
Qubit® dsDNA BR (Broad-Range) Assay  Invitrogen 
Qubit® dsDNA HS (High-Sensitivity) Assay  Invitrogen 
Kaspar v4 High ROX mix     KBioscience 
Kasp by design assay     KBioscience 
Dynabeads MyOne Streptavidin T1   Life Technologies 
2X PCR mastermix      Promega 
GoTaq® Flexi DNA polymerase     Promega  
QIAamp DNA Mini Kit     Qiagen 
Orange G       Sigma-Aldrich 
Reaction buffer      Thermo Scientific 
Magnesium Chloride      Thermo Scientific 
100 bp DNA Ladder      Web Scientific 




Dimethyl sulphoxide (DMSO)    VWR 
 
2.1.2 Solutions 
x 10 x Tris/Borate/EDTA (TBE): 
  Tris-HCL 108g 
Boric Acid 55.6g 
EDTA 9.3g 
Made up to 1 litre with Milli-Q water 
x DNA /RNA Precipitation Solution: 
  75μl  NaOAc   
  1562.5μl  95%  Ethanol   
   362.5μl  Milli-Q water  
x Orange G Loading Buffer: 
Glycerol 30% 
Orange G 0.2% w/v 
x 10x Phosphate Buffered Saline (PBS) pH 7.4: 
80 g NaCl (1.37M) 
2 g KCl (0.03M) 
14.4 g Na2HPO4 (0.01M) or 18g Na2HPO42H2O 
2.4 g KH2PO4 
    Made up to 1 litre with ddH2O 
x Sucrose Triton X-100 lysis Buffer: 
10 ml 1 M Tris-HCl (pH 8)  
5 ml 1M MgCl2                
10 ml Triton X-100 
Made up to 1 litre with ddH2O  
x T20E5: 
       2ml 1 M Tris-HCl (pH 8)  
      1 ml 0.5 M EDTA   
x SDS (10%): 




       Add 10 g of SDS powder to 100 ml of ddH2O 
x Proteinase K solution:  
Add 25 ml of H2O to stock powder (250 mg) to produce 10mg/ml           
x Saturated NaCl: 
Add 40 g NaCl slowly to 100 ml of sterile water until saturated.  
x TE: 
10 mM Tris-HCl pH 8.0 (1ml 1M) 
1 mM EDTA pH8.0 (0.2ml 0.5M) 
             Made up to 100 ml with ddH20. 





This project is in collaboration with the Oesophageal Cancer research group led 
by Professor Iqbal Parker at the University of Cape Town, South Africa. This 
group includes a research nurse who recruits and consents participants and 
obtains blood samples. DNA was extracted from blood in the International 
Centre for Genetic Engineering and Biotechnology (ICGEB) at the University of 
Cape  Town  and  an  aliquot  sent  to  King’s  College  London (KCL). 
 
Ethical approval for this study was obtained from the joint University of Cape 
Town/Groote Schuur Hospital Research Ethics Committee and the University of 
Stellenbosch/Tygerberg Hospital Ethics Committee. 
 
For this study, patients with histologically confirmed primary invasive OSCC 
were recruited between March 2000 and August 2011 at Groote Schuur and 
Tygerberg Hospitals in Cape Town, South Africa. Controls were recruited from 
factories and outpatient clinics in the Western Cape between June 2000 and 
November 2010. Cases and controls were mainly from the South African Black 
and Mixed Ancestry populations, with other ethnicities excluded from the study. 
Over 98% of the Black cases and controls were Xhosa speakers. 
 
Germ-line DNA from blood samples was initially available from 358 OSCC 
patients and 477 controls from the South African Black population, and 201 
OSCC patients and 427 controls from the Mixed Ancestry population. During the 
course of the study, the sample size was expanded to a total of 407 OSCC 
patients and 849 controls from the Black population, and 257 OSCC patients 
and 860 controls from the Mixed Ancestry population.   
 
DNA samples from matched blood-tumour pairs were available from 11 OSCC 
patients. 
 




2.3 DNA extraction 
2.3.1 Blood samples 
DNA was extracted by collaborators at the University of Cape Town using the 
following method. Blood was transferred to sterile polypropylene tubes and 
diluted with 2 volumes of 1X PBS. Tubes were inverted to mix and centrifuged 
at 2200 g for 15 min. The supernatant was discarded and the pellet 
resuspended in 25 ml of Sucrose Triton X-100 lysis buffer and vortexed. Tubes 
were placed on ice for 5 min before centrifuging for 5 min at 2200 g. The 
supernatant was again discarded and the pellet re-suspended in 3 ml of T20E5 
(0.6X the volume of original blood sample). To this, 300 µl 10% SDS was added 
together with 100 µl 10 mg/ml proteinase K. Tubes were inverted to mix and 
incubated overnight at 45ºC. 
 
To each sample, 4 ml of saturated NaCl was added and mixed vigorously for 15 
seconds. Tubes were then centrifuged for 40 min at 2400 g. To precipitate the 
DNA, 1 volume of absolute alcohol (at room temperature) was added and after 
gently agitating the tube, the DNA pellet was removed to an eppendorf tube. 
The pellet was washed in 1 ml of 70% ice-cold alcohol before centrifuging at 
10000 rpm for 5 minutes. The alcohol was removed and the DNA pellet 
dissolved  in  400  μl TE buffer. 
 
2.3.2 Tissue samples 
Tumour biopsy DNA was extracted by collaborators at the University of Cape 
Town using the QIAamp DNA Mini Kit. Briefly, the sample was brought to room 
temperature and then half of the tumour was homogenized in 80 µl of PBS in a 
1.5ml microcentrifuge tube (the other half was used for RNA extraction, not 
used in this project). To each sample, 100 µl Buffer ATL was added followed by 
20 µl Proteinase K. Samples were vortexed and incubated at 56°C, mixing 
occasionally, until the tissue was completely lysed. Then, 200 µl Buffer AL was 




added and tubes pulse-vortexed for 15 sec before being incubated at 70°C for 
10 min. Following this, 200 µl ethanol (96-100%) was added to the sample and 
again mixed by pulse-vortexing for 15 sec. The mixture (including any 
precipitate) was then applied to a QIAmp spin column (in a 2ml collection tube) 
and the tube (with closed cap) centrifuged at 6000 x g (8000 rpm) for 1 min. The 
QIAmp spin column was placed in a clean 2 ml collection tube and the tube 
containing the filtrate was discarded. Then, 500 µl Buffer AW1 was added to the 
QIAmp spin column and centrifuged at 6000 x g (8000 rpm) for 1 min. Again, the 
QIAmp spin column was placed in a clean 2 ml collection tube and the tube 
containing the filtrate discarded. To the QIAmp spin column, 500 µl Buffer AW2 
was added and the tube centrifuged at full speed (20000 x g; 14000 rpm) for 3 
min. The QIAmp spin column was placed in a clean 1.5 ml microcentrifuge tube 
and the collection tube discarded. Then, 200µl Buffer AE or distilled water was 
added to the tube and incubated at room temperature for 1 min. The tube was 
then centrifuged at 6000 x g (8000 rpm) for 1 min. The resulting filtrate 
contained the DNA. In order to obtain a higher yield, the QIAmp spin column 
was placed in a clean 1.5 ml microcentrifuge tube, and again, 200µl Buffer AE 
or distilled water was added to the tube and incubated at room temperature for 1 
min. The tube was centrifuged at 6000 x g (8000 rpm) for 1 min and the DNA 
filtrate was combined with the rest of the DNA. 
 
2.3.3 DNA quantification 
DNA from the initial batches was quantified using Quant-iT™   PicoGreen   ®  
dsDNA   Reagent   Kit   according   to   manufacturer’s   instructions.   The   Picogreen  
reagent is a fluorophore and binds to double stranded DNA. Upon excitation, it 
is emits lights at a specified wavelength which is detected using a Tecan Genios 
Plate Reader.  
  
DNA subsequently collected was quantified using Qubit® dsDNA BR (Broad-
Range)  Assay  according   to  manufacturer’s   instructions,  using  1:200  dilution  of  




DNA in the Qubit working solution. If the concentration was too low to be 
detected by this method, Qubit® dsDNA HS (High-Sensitivity) Assay was used, 
according   to   manufacturer’s   instructions.   These   Qubit   reagents   bind   double  
stranded DNA and a Qubit Fluorometer detects the level of emission after 
excitation of the Qubit fluorophore.  
 
2.4 Candidate gene case-control association studies 
2.4.1 Polymerase chain reaction 
2.4.1.1 Primer design 
Primers were designed using Primer3 software (http://frodo.wi.mit.edu/primer3/) 
and UCSC In-Silico PCR was used to ensure primer pairs were specific to the 
region of interest (http://genome.ucsc.edu/cgi-bin/hgPcr). Primers were 
synthesized by Integrated DNA Technologies (USA). 
 
2.4.1.2 Primer optimization 
Polymerase chain reaction (PCR) conditions were optimized for each primer 
pair following the same standard method described here. Initially a temperature 
gradient was carried out which spanned a 10°C range around the annealing 
temperatures of the primers (typically 55°C – 65°C). The 10 µl PCR reactions 
contained 10 ng DNA, 1X PCR mastermix, 0.4 µM forward primer and 0.4 µM 
reverse primer. PCR was performed on a PTC-0225 DNA Engine (MJ 
Research), as were all other PCRs throughout this project, using the following 
conditions: 
2 min at 92°C 
20 sec at 92°C 
30 sec at 55°C – 65°C          30 cycles 
30 sec* at 72°C  
5 min at 72°C 
Hold at 15°C 
 




* Extension time depended on amplimer length, with every 500 base-pairs 
requiring an additional 30 seconds.  
 
If the PCR product was not successfully amplified (via visualisation under UV 
light, see section 2.4.1.3), an alternative mastermix was made containing 
individual components for the reaction enabling quantities to be adjusted. For 
example, a typical 10 µl mastermix contained 10 ng DNA, 1X reaction buffer, 
1.5mM MgCl2, 0.4 µM forward primer, 0.4 µM reverse primer, 10% DMSO and 
0.625 U GoTaq® Flexi DNA polymerase. If required, the magnesium chloride 
concentration was varied (1mM – 2mM MgCl2) and DMSO removed. 
  
2.4.1.3 Gel electrophoresis 
Gel electrophoresis using DNA stained with ethidium bromide (EtBr) allows for 
visualization and sizing of a PCR product. Briefly, 2% agarose gels were made 
by dissolving 1g agarose in 50ml 1X TBE and, once cool to touch, 2.5 µl EtBr 
(10 mg/ml) was added and swirled to mix. The solution was poured into gel 
tanks with end-plates and combs, and left to cool and solidify for 20 minutes. 
Following removal of end-plates and combs, a running buffer of 50 ml 1X TBE 
containing 2.5 µl EtBr was poured into tank. To each DNA sample, 5 µl Orange 
G loading dye was added before loading into the gel wells. In an adjacent well, 5 
µl 100bp DNA ladder was added to enable the size of the PCR product to be 
determined. A current of 100V was then applied to the gel tanks for an 
appropriate time to allow for resolution of DNA bands. Samples were visualized 
under UV light using a bench top UV transilluminator (UVP). 
 




2.4.2 Genotyping assays 
2.4.2.1 CASP8 insertion/deletion genotyping 
Genotyping of a 6-bp (AGTAAG) insertion/deletion in CASP8 gene (-652 6N del, 
rs3834129) was achieved by determining the size of the PCR products. Primers 
were previously designed (Morgan et al. 2005; Sun et al. 2007), see Table 2.1. 
The  forward  primer  was  fluorescently  labelled  at  the  5’  end  with  6-FAM.   
 
Table 2.1: CASP8 -652 6N del (rs3834129) primers 







CTGCATGCCAGGAGCTAAGT GCCATAGTAATTCTTGCTCTGC 171 & 177 
 
Briefly, the 5 µl PCR reaction contained 1X PCR mastermix, 0.4 µM of each 
primer and 20 ng of DNA. PCR conditions were as previously described (see 
p.70) using an annealing temperature of 62°C and an extension time of 30 
seconds. 
 
The PCR products were diluted 1:20 using Milli-Q H2O and then 1 µl of this was 
added to a 96-well non-skirted plate. To each well, 10 µl of a LIZ loading cocktail 
(containing 9.88 µl HiDi Formamide and 0.12 µl GeneScan 500 LIZ size 
standard) was added. The samples were then heat denatured for 2 minutes at 
95°C on a thermocycler. PCR products were separated by capillary 
electrophoresis on an ABI3730xl DNA Analyzer (Applied Biosystems) and sized 
using GeneMapper software (Applied Biosystems).   
   
2.4.2.2 PLCE1 insertion/deletion genotyping 
The 14bp indel (CCCGGGCTCTGCCT) in the 5’  untranslated  region  of  PLCE1 
exon 1 was amplified and genotyped by size separation of the PCR products 




using 3% agarose gel electrophoresis and visualised with ethidium bromide/UV 
light. Primers used for amplification are shown in Table 2.2.  
 
Table 2.2: PLCE1 14 bp indel primers 
Variant Forward primer Reverse primer Product length (bp) 
PLCE1  
14bp indel GGGAGCGGACTGTGAACG GTGTCCCCGCTACTGTGTGT 217 & 203 
 
The 10 µl PCR reaction contained 1X reaction buffer, 1.5 mM MgCl2, 0.4 µM of 
each forward and reverse primer, 1 U GoTaq® Flexi DNA polymerase, 0.2 mM 
dNTP and 10% DMSO. PCR conditions were as previously described (see p.70) 
using an annealing temperature of 63°C and an extension time of 30 seconds. 
 
2.4.2.3 TaqMan SNP genotyping assays 
TaqMan SNP genotyping assays were designed and synthesized by Applied 
Biosystems. Table 2.3 shows the assay used for each variant genotyped. 
Custom assays were designed by Applied Biosystems after submitting the 
nucleotide sequence for the region of interest together with the alternative allele 
for the polymorphism. Primer and probe sequences for the custom assays are 
shown in the Appendix, Table A.3, but are not available for validated assays. 
 




Table 2.3: TaqMan SNP genotyping assays 
Variant 








ADH1B rs1229984 9   
ALDH2 rs886205 9   
ALDH2 rs671 9   
ADH7 rs1573496 9   
COX-2 rs689466  9  
FAS rs1800682  9  
FAS rs2234767  9  
FASL rs763110  9  
MGMT rs12917  9  
PLCE1 rs2274223  9  
C20orf54 rs13042395  9  
RUNX1 rs2014300  9  
PDE4D rs10052657  9  
Near UNC5CL rs10484761  9  
COX-2 rs20417   9
CASP8 rs1045485   9
ALDH2 rs441   9
 
Reactions  were  carried  out  according  to  manufacturer’s  instructions  but  used  a  
2.5 µl reaction volume with half the recommended amount of the TaqMan assay 
mix  and  with  ABgene’s  Absolute  QPCR  ROX  mix.   Initially, 1µl DNA (20 ng/µl) 
was added to wells in a 96-well semi-skirted low-profile PCR plate (Starlab) and 
dried for 9 minutes at 65°C. A mastermix containing 1.25 µl ROX mix, 0.03125 
µl TaqMan assay mix and 1.21875 µl Milli Q H2O was made per reaction and 
added to wells. PCR was performed using one of the following sets of 
conditions. 
 
For validated and custom TaqMan SNP genotyping assays:    
15 min at 95°C  
15 sec at 92°C 
60 sec at 60°C           
Hold at 15°C  
 
45 cycles 





For TaqMan Drug Metabolism Genotyping Assays:  
15 min at 95°C  
15 sec at 92°C           
90 sec at 60°C             
Hold at 15°C   
 
Fluorescent levels at the PCR end-point were determined using a 7900HT Fast 
Real-Time PCR system (Applied Biosystems) and genotypes assigned using 
SDS 2.2.2 software (Applied Biosystems). 
 
2.4.2.4 KASPar SNP genotyping assays 
The nucleotide sequence for the SNPs of interest and surrounding regions were 
submitted to KBioscience who designed and synthesized KASPar-by-design 
assays. The primer sequences are not made available. Reactions were carried 
out   following   the   ‘KASP  version  4.0  SNP  Genotyping  Manual’   in  4   µl   reaction  
volumes. Initially, 1 µl 20 ng/µl DNA was dried to 96-well semi-skirted low-profile 
PCR plate and then a mastermix containing 0.055 µl SNP assay mix, 2 µl 
KASPar v4.0 High Rox reagent and 2 µl Milli Q H2O was made per reaction and 
added to wells. The following conditions were used for PCR: 
15 min at 94°C  
20 sec at 94°C     
60 sec at 65°C -57°C (dropping 0.8°C per cycle)            
20 sec at 94°C   
60 sec at 57°C           
 
Fluorescent levels at the PCR end-point were determined using a 7900HT Fast 
Real-Time PCR system (Applied Biosystems) and genotypes assigned using 








2.4.3 Sequencing of PLCE1 exons 
2.4.3.1 Amplification of PLCE1 exons 
PCR was carried out in a 10 µl reaction containing 10 ng DNA, 1X PCR 
mastermix, 0.4 µM of each forward and reverse primer for all reactions apart 
from amplification of exon 1. This 10 µl reaction contained 10 ng DNA, 1X 
reaction buffer, 1.5 mM MgCl2, 0.4 µM of each primer, 0.2 mM dNTPs, and 10% 
DMSO. Primers for the amplification of the 34 exons of PLCE1 are shown in 
Appendix, Table A.1, together with the annealing temperature and extension 
time for each primer set. PCR conditions were as previously described (see 
p.70). 
 
2.4.3.2 Sanger sequencing of PLCE1 exons 
The PCR product was cleaned using ExoSAP-IT, where 1 µl PCR product was 
added to 0.25 µl ExoSAP-IT and 5.75 µl Milli Q H2O. This was heated to 37ºC 
for 30 minutes followed by 15 minutes at 80ºC to inactivate the enzymes. 
Forward and/or reverse cycle sequencing was then performed   in   a   5.25   μl  
reaction  volume  using  3.5  µl  of  cleaned  PCR  product  together  with  0.25  μl  of  20  
μM  sequencing  primer  (see  Appendix,  Table A.2)  0.25  μl  of  BigDye  Terminator 
v3.1 and 1.25 µl of sequencing buffer. Reactions were run on a thermocycler 
with the following conditions: 
30 sec at 96ºC 
15 sec at 50ºC         30 Cycles 
1 min at 60ºC 
Hold at 10ºC 
 
Purification of the sequencing product was then carried out to remove 
unincorporated dye terminators by ethanol precipitation. To the sequencing 
product, 20 µl precipitation solution was added and the plate sealed and briefly 
vortexed before incubating at room temperature for 15 mins. The plate was then 
centrifuged at 3000 rpm in a Sorvall Legend RT centrifuge for 30 mins. 




Following this, plates were inverted onto blotting paper and briefly centrifuged 
(400 rpm for 10 seconds). To each well, 100 µl 70% ethanol was then added 
and the plate sealed and briefly vortexed. The plate was centrifuged at 3000 
rpm for 10 mins, and again plates were inverted onto blotting paper and briefly 
centrifuged. The plate was dried at 60ºC for 5 minutes. To each well, 10 µl Hi-Di 
formamide was added and the plate sealed with a grey septa seal before being 
heat denatured at 95 ºC for 2 minutes. Sequencing products were then 
subjected to electrophoresis on a ABI 3730xl DNA sequencer (Applied 
Biosystems) and the results aligned to the human reference genome and 
analyzed using Staden software package. 
 
2.4.4 Statistical analysis 
2.4.4.1 Hardy-Weinberg equilibrium (HWE) 
Hardy-Weinberg equilibrium (HWE) describes the principle that genotype 
frequencies are determined by the allele frequencies in a random mating 
population. Deviations from the expected frequencies can indicate problems 
with the data, such as genotyping errors, or inbreeding and population 
stratification. In disease groups, this can also signify association with the trait. If 
deviations are present in the control group, variants which fail to meet a specific 
threshold should be removed from analysis.  
 
If alleles A and a have frequencies p and q, then under HWE genotypes AA, Aa 
and aa will have frequencies p2, 2pq and q2, respectively. The genotype 
frequencies must also sum to 1, hence: 
p2 + 2pq + q2 = 1 
  
The expected genotype frequency can be calculated based on the experimental 
allele frequencies. The frequencies of the observed (O) and expected (E) 
genotypes can then be tested for a significant difference using a chi squared 
(F2) test with one degree of freedom:  
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HWE chi-squared values were calculated using Microsoft Excel, with these 
values converted to a p-value   using   the   ‘CHIDIST’   function.   P   <0.05   was  
considered as a statistically significant deviation from the HWE for candidate 
gene association tests.  
 
2.4.4.2 Association tests 
Genotype and allele frequencies were calculated for cases and controls. To 
determine if there was a significant difference between these two groups, the 
minor allele frequencies (both allelic and genotypic) were compared using a 
Pearson’s  chi-squared (F2) test, which was performed using a two-by-two table 
(http://www.quantitativeskills.com/sisa/statistics/twoby2.htm). For a single test, a 
threshold of P< 0.05 was used to identify a statistically significant difference.  
 
When multiple testing occurred, the Bonferroni correction was applied. This 
defines the significance level as 0.05/n, where n is the number of tests 
performed. In Chapter 3, the significance threshold was set at P<0.0042 
(0.05/12) for the testing of 12 variants that were polymorphic in the South 
African populations to ensure the overall type I error rate was no more than 5%. 
In Chapter 4, a significance threshold of P<0.01 (0.05/5) was used for the 
association tests of the five SNPs that were identified in the Chinese genome-
wide association studies. This threshold was also applied to the association 
tests of the five additional PLCE1 variants. No additional correction was applied 
for the two populations tested. 
 
2.4.4.3 Odds ratio  
The odds of an event occurring is a ratio of the probability that an event occurs 
to the probability that it does not. The odds ratio (OR) is used to estimate the 




risk of a particular outcome, and is the ratio of the odds of an event occurring in 
those with an outcome of interest, e.g. cancer patient, against those without the 
outcome, e.g. controls. For example, if A and B represent the number of cancer 
cases with the alternative or a common reference alleles, respectively, and C 
and D represent the number of controls with the alternative or a common 
reference alleles, respectively, then:   
OR = (A/B) / (C/D) 
 
An odds ratio of greater than one indicates that the event is more likely to 
happen (e.g. allele is associated with increased risk of disease). If the odds ratio 
is less than one, the event is less likely to happen and can indicate a protective 
effect. If the odds ratio equals one, then events are just as likely to occur and 
show no association. For each OR, 95% confidence intervals (CI) are also 
reported and are calculated by the formula:  
95% CI = exp (log (OR) ± 1.96 SE (log OR)) 
where 
 
SE (log OR) =     
 
is the standard error (SE) of the log odds ratio. 
 
Genotypic and allelic odds ratios together with 95% confidence intervals were 
calculated using the common homozygous genotype or common allele as the 
reference. These were determined using the formulas described above in 
Microsoft Excel.  
 
2.4.4.4 Linkage disequilibrium 
Linkage disequilibrium (LD) is the non-random association of alleles at two or 
more loci (Slatkin 2008). The level of LD depends on factors such as natural 




selection, genetic drift, non-random mating, the amount of recombination and 
the rate of mutation.  
 
LD  is  commonly  measured  using  D’  and  r2 values. Both of these derive from D, 
which is the the difference between the frequency of loci carrying the pair of 
alleles A and B at two loci (PAB) and the product of the frequencies of those 
alleles (PA and PB): 
     DAB = PAB - PAPB  
D’   is  the  ratio  of  D  to   its  maximum  possible  value,   the  smaller of PA(1-PB) and 
PB(1-PA), given the allele frequencies (Lewontin 1964). Alternatively, r2 is the 
correlation coefficient of the allele frequencies and is calculated by: 
 
r2 =   D2            .  
           PA(1-PA)PB(1-PB) 
 
Both  D’  and  r2 take values between 0 and 1 which show linkage equilibrium and 
complete/perfect linkage disequilibrium, respectively. The former implies that the 
loci are independent of each other, whereas the latter is true only if alleles have 
not been separated by recombination. An r2 of 1 also requires the SNPs to have 
the  same  allele  frequencies,  but  this  is  not  the  case  for  D’.   
 
Determination of LD between variants in the same gene was performed using 
UNPHASED v3.1.5 (Dudbridge 2008) (for COX-2, FAS, ALDH2 and CASP8) 
and Haploview (for PLCE1 variants) (Barrett et al. 2005). 
 
2.4.4.5 Haplotype analysis 
Haplotype analysis was performed using UNPHASED v3.1.5 (Dudbridge 2008) 
when multiple variants in the same gene had been genotyped. Haplotype 
frequencies were determined, followed by haplotype case-control association 
tests using the most common haplotype as the reference. A full likelihood model 




was used for analysis, testing the null hypothesis that all the haplotype odds 
ratios are equal. 
 
2.4.4.6 Gene-environment interactions 
SNPs that showed a suggestive allelic association with OSCC (P<0.05) were 
further investigated for the effect of alcohol and tobacco by stratifying cases and 
controls by smoking and alcohol drinking status and performing three 
association tests. An example of these tests is shown here for alcohol use: a 
case-only analysis (drinkers vs. non-drinkers), a case-control analysis for 
drinkers only, and a case-control analysis for non-drinkers only. In addition, 
tests of gene-environment interaction were performed using logistic regression 
in PLINK, adjusting for age, gender, alcohol and tobacco consumption. An 
example for gene-alcohol interactions is shown below: 
 
Y = β0 + β1ADD + β2Alcohol + β3Tobacco + β4Age +  
β5Gender + β6ADDAlcohol 
 
Where Y=log(p/1-p)   is   the   logit   of   the   probability   (p)   of   being   a   case,   β0 is a 
constant, β1- β5 are the SNP effects adjusted for each of the covariates and β6 is 
the interaction term to be tested with the null hypothesis H0: β6=0. 
 
In Chapter 3, demographic data for controls only became available after the 
study was published (Bye et al. 2011), and therefore, the gene-environment 
analyses are included as a supplementary analysis here.  
 
2.4.4.7 Power 
The power of a study, that is the probability that a specific magnitude of odds 
ratios can be detected given allele frequency and sample size, was determined 
using Quanto (http://hydra.usc.edu/gxe/) (Gauderman 2002).  




2.5 Case-control association study using the Immunochip 
2.5.1 Samples 
A subset of samples from the South African Black and Mixed Ancestry 
populations were chosen for genotyping on the Immunochip. Samples with the 
highest DNA yield were selected as well as ensuring a spread across the 
recruitment period to ensure all collection phases were represented. Sample 
numbers were determined by funding available. From the Black population, 300 
cases and 300 controls were genotyped for a case-control association study 
and additionally, 50 cases and 50 controls from the Mixed Ancestry population 
were selected to provide insight into their population structure.  
 
2.5.2 Genotyping 
Genotyping was carried out at the Genomics core facility, part of the NIHR 
Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust 
and King's College London.  
 
Samples were genotyped using the Infinium® HD Assay Ultra Protocol (Catalog 
# WG-901-4005;;   Part   #   11328095   Rev.   B),   following   manufacturer’s  
instructions. Briefly, 200 ng DNA per sample was denatured and neutralized 
before overnight amplification. DNA was then fragmented by an enzymatic 
reaction and precipitated using isopropanol. The DNA was resuspended and 
hybridized to the BeadChip, with non-hybridized DNA being washed away. The 
oligonucleotides on the array were then extended by a single nucleotide base 
using the sample DNA as a template. The newly incorporated bases contain a 
fluorescent label which can be excited using a laser. This process was carried 
out in the Illumina iScan machine which then detects and records the light 
emitted. 
 




2.5.3 Genotype calling and quality control 
GenomeStudio Data Analysis Software (Illumina) was used for visualizing 
genotype clusters and for the initial genotype calling and quality control (QC). At 
this stage, samples which had a genotyping call rate considerably lower than all 
other samples (<90%) were removed. 
 
Data for the remaining samples were then re-formatted for use with optiCall 
(http://www.sanger.ac.uk/resources/software/opticall/). OptiCall is a genotype 
calling software, which uses both within and across sample intensity information 
to identify intensity regions that have a high probability to contain each of the 
three genotypes (Shah et al. 2012). Using this approach, rare variants can be 
called if their intensity is in a high probability region. This work was carried out 
by Dr. Sarah L. Spain. 
 
2.5.3.1 Population stratification 
The ethnicity of study participants is self-declared and recorded in a database. 
Principal components analysis (PCA) can be used to detect population 
stratification and, hence, identify individuals who are outliers from the self-
declared population. For this analysis, only SNPs that were independent of each 
other were used, which was based on those with a pairwise LD of r2<0.2 and a 
minor allele frequency of greater than 5%. This amounted to a total of 27,132 
variants. Altogether, 661 samples were included in the analysis from both South 
African populations. 
 
Dr. Sarah Spain performed PCA using EIGENSTRAT. Samples which clustered 
with a different population (e.g. those self-declared as from the Black population 
but who clustered with the Mixed Ancestry population in the PCA) were 
reassigned to the population determined by the PCA. Population outliers, 
samples which did not cluster with individuals from either the Black or Mixed 
Ancestry populations, were also present (see Chapter 5, section 5.3.1.1 for the 




thresholds used based on the PCA plots). Sample relatedness between outliers 
was determined (see below), and one from each pair of highly related samples 
was removed from the analysis. 
 
2.5.3.2 Further quality control 
PLINK (http://pngu.mgh.harvard.edu/~purcell/plink/) was used for QC with the 
majority of steps performed by Dr. Sarah Spain (indicated below). The following 
QC steps were performed: 
x The percentage of SNPs that were successfully assigned a genotype for 
each individual (sample genotype call rates) was determined, and those 
samples with a call rate of <95% were removed. This was determined 
using  the  PLINK  command  “-- missing”  (Dr  Spain). 
x Related samples were identified based on PI-Hat scores of >0.5 (using 
the  PLINK  command  ‘-- genome’),  and  one  from  each  pair  (the  one  with  
the highest level of missing data) was removed (Dr Spain). 
x The percentage of samples successfully assigned a genotype for each 
SNP   (the  SNP  call   rate)  was  calculated   (using   the  PLINK  command   “--
missing”)  and  SNPs  with  a  call  rate  of  <95%  were  removed  (Dr  Spain). 
 
Additionally, cases and controls were mainly genotyped on separate plates and 
hence, to determine if plate effects were present, minor allele frequencies for 
SNPs with P<0.05 in the association test, were compared for each plate 
individually against all other plates using Q-Q plots. This allows plates with an 
unusual distribution of minor allele frequencies to be identified. 
 
2.5.4 Case-control genetic association study 
After the QC described above, 278 cases and 257 controls (see Table 2.4) with 
genotype data for 139,793 SNPs were available for the case-control analysis in 
the South African Black population. SNPs which had a significant deviation (P< 




1 x 10-6) from HWE in controls were excluded (based on the Bonferroni 
correction, see below). Allele frequencies in cases and controls were compared 
using  the  ‘- -assoc’  function  in  PLINK,  which  is  an  allelic  chi-square test with 1-
degree-of-freedom, with odds ratios and P-values calculated. The Bonferroni 
correction was used to account for the multiple testing of SNPs. This was based 
on 27,132 independent SNPs present (pairwise LD of r2<0.2 and MAF >0.05), 
which gave a significance threshold of P<1.84 x 10-6 (0.05/27,132).  
 
Table 2.4: Demographic information for South African Black population samples used in 
Immunochip analysis 
 Cases Controls 
Total 278 257 
Age, mean years (SD) 60.3 (11.5) 48.1 (17.5) 
Sex, n (%):   
Male 134 (48.2%) 91 (35.4%) 
Female 144 (51.8%) 164 (63.8%) 
Unknown 0 2 (0.8%) 
Smoking status, n (%):   
Smoker 159 (57.2%) 96 (37.4%) 
Non-smoker 119 (42.8%) 158 (61.5%) 
Unknown 0 3 (1.2%) 
Alcohol consumption, n (%):   
Drinker 176 (63.3% 128 (49.8%) 
Non-drinker 100 (36.0%) 128 (49.8%) 
Unknown 2 (0.7%) 1 (0.4%) 
 
2.5.4.1 Association plots 
For SNPs with an association with OSCC of P<1 x 10-5, the p-value for this and 
variants in the surrounding region (~1000kb) were visualized using SNAP (SNP 
annotation and proxy search) regional association plots 
(http://www.broadinstitute.org/mpg/snap/ldplot.php). In addition, pairwise LD (r2) 
for the index SNP compared to all other variants, as determined using PLINK, 
were also visualized on this plot. 
 




2.5.4.2 Extension study  
SNPs with an association with OSCC of PImmunochip < 1 x 10-4 were considered for 
this larger case-control extension study, with variants selected based on the 
SNAP association plots (SNPs were prioritized if the association was supported 
by nearby variants with p-values of similar magnitude) and LD levels (pairs of 
SNPs in high LD were not both genotyped). Seven variants were chosen for 
TaqMan genotyping in the South African Black population (see Table 2.5), with 
the SNPs genotyped in all available cases and controls.  
 
Table 2.5: Variants genotyped in Immunochip extension study 
Variant Chr Position (b37) Gene Location 
rs9887787 1 92222143 TGFBR3 Intronic 
rs2810893 1 92144970 TGFBR3 Downstream 
rs2182833 1 55500429 PCSK9 Upstream 
rs13390918 2 199564895 Intergenic - 
rs13147507 4 115334709 Intergenic - 
rs7714035 5 102644627 Intergenic - 
rs36590 22 30328070 MTMR3 Intronic 
 
A well-powered replication using an independent sample set was not possible 
due to inadequate numbers of OSCC cases, and hence the samples genotyped 
by Immunochip were also included in the TaqMan genotyping assay. In total, an 
additional 126 cases and 577 controls were available, giving a total of 404 
OSCC cases and 834 controls for genotyping in this extension study (see Table 
2.6). Samples identified in the PCA analysis as not being from the Black 
population (7 cases and 16 controls) were not genotyped, and the self-declared 
Mixed Ancestry samples which were shown to cluster with the Black population 
in the PCA plot were included (6 cases and 2 controls). The SNPs were 









Table 2.6: Demographic information for samples used in the Immunochip extension study 
  Cases Controls 
Total, n 404 834 
Age, mean years (SD) 59.8 (11.2) 48.7 (16.8) 
Sex, n (%): 
  Male 199 329 
Female 205 502 
Unknown 0 3 
Smoking status, n (%): 
  Smoker 240 327 
Non-smoker 163 496 
Unknown 1 11 
Alcohol consumption, n (%): 
  Drinker 252 444 
Non-drinker 149 386 
Unknown 3 4 
 
2.5.4.3 Gene-environmental interactions 
Alcohol and tobacco effects were investigated as described on page 81. 
Additionally, an Immunochip-wide gene-environment interaction analysis was 
performed, based on the genome-wide gene-environment analysis by Wu et al. 
(2012.a). In this method, the interaction between each variant on the 
Immunochip and drinking or smoking status was tested using logistic regression 
with age, gender and alcohol and smoking status as covariates using PLINK, as 
described on page 81. 




2.6 Somatic mutation identification using whole-exome 
sequencing 
Matching blood and tumour DNA were whole-exome sequenced in 8 OSCC 
patients to identify somatic mutations. This project was in collaboration with Dr 
Iwanka Kozarewa and colleagues at the Institute of Cancer Research (ICR), 
London, who had developed a protocol to sequence low quantities of input DNA 
(>50 ng), compared to the standard Agilent protocol of 3 µg DNA. Six tumour 
samples had a low DNA yield (500 ng) and, hence, were sequenced at the ICR 
using this adapted method. The matching blood DNA was also sequenced at 
the ICR using the standard protocol. Table 2.7 shows the protocol used and the 
location of sample preparation and sequencing. 
 






preparation  Sequencing 
KCL ICR  KCL ICR 
Illumina, 
USA 
P662 A 9    
 
9
232T A 9    
 
9
P1282  B 9   9
  386T B 9   9
  P1377  B 9   9
  T437 B 9   9
  P1354 B  9   9
 T416 C  9   9
 P1408 B  9   9
 T443 C  9   9
 P1400 B  9   9
 T438 C  9   9
 P1406 B  9   9
 T442 C  9   9
 P1116 B  9   9
 T441 C  9   9
 Protocol A: SureSelect Target Enrichment System for Illumina Paired-End Sequencing Library 
SureSelect Human All Exon and Human All Exon Plus Protocol Version 2.0.1, May 2010; 
Protocol B: SureSelectXT Target Enrichment System for Illumina Paired-End Sequencing 
Library. SureSelectXT Target Enrichment for Illumina Multiplexed Sequencing Version 1.2, May 
2011;  
Protocol C: ICR adapted protocol for low-input DNA.  
KCL: King’s  College  London;;  ICR: Institute of Cancer Research 




2.6.1 Sample preparation 
2.6.1.1 Standard protocol 
The standard   sample   preparation   used   Agilent’s   “SureSelectXT   Target  
Enrichment System for Illumina Paired-End Sequencing Library (SureSelectXT 
Target Enrichment for Illumina Multiplexed Sequencing), Version 1.2, May 
2011”.  Two  samples  used  an  older  version  of   this  protocol,  “SureSelect  Target  
Enrichment System for Illumina Paired-End Sequencing Library (SureSelect 
Human  All  Exon  and  Human  All  Exon  Plus),  Version  2.0.1,  May  2010”,  which  
mainly differed in the ability to add index tags. Therefore, the latest method will 
briefly be described, which is also summarized in Figure 2.1.  
 
 
Figure 2.1: Agilent’s sample preparation for whole-exome sequencing  
   (taken  from  Agilent’s  protocol) 




DNA (3 µg) was initially sheared to 150-200 nucleotides in length using the 
Covaris system. The ends of the DNA were repaired to produce blunt ended 
fragments,  with  ‘A’  bases  added  to  the  3’  end.  Adaptors  were  then  ligated  to  the  
DNA and the resulting DNA library amplified using PCR. Between each of these 
steps, samples were purified using Agencourt AMPure XP beads to remove 
non-specific DNA. Next, the prepped DNA library was hybridised to the whole-
exome capture library. Hybridised DNA was selected using streptavidin coated 
magnetic beads, which bind the biotinylated capture library baits, with unbound 
DNA discarded. The hybridised library was then amplified with index tags 
added. Samples were then prepared for cluster amplification and run on the 
Illumina   HiSeq   2000.   For   samples   sequenced   at   King’s   College   London,   this  
final step was performed by staff at the Genomics Core facility. 
 
2.6.1.2 ICR low-input DNA protocol 
For samples with  a   low   yield  of  DNA   (<3  µg),   the  standard  protocol   (Agilent’s  
“SureSelectXT  Target  Enrichment  System   for   Illumina  Paired-End Sequencing 
Library (SureSelectXT Target Enrichment for Illumina Multiplexed Sequencing), 
Version   1.2,  May   2011”)   was   adapted   by   Iwanka Kozarewa et al. at the ICR 
(personal communication). For each tumour sample, 500 ng starting DNA was 
used, although further adaptations of the protocol could be performed in order to 
sequence DNA from as little as 50ng. The method used to sequence 500 ng 
starting DNA is briefly compared to the standard protocol in Figure 2.2. The full 
low-input DNA protocol is described following this, although where long steps 











     Standard Agilent protocol                               Low-input (500 ng) protocol 
3 µg DNA in 130 µl 1. Shear DNA 500 ng DNA in 120 µl  
 
Agencourt AMPure XP beads purification 
 





Bioanalyzer DNA 1000 chip 
100 µl reaction 2. Repair the ends 
DNA samples dried from 120 µl to 83.2 µl. 
100 µl reaction 
 





Zymo column purification 
50 µl reaction.  
Incubated at 37°C for 30 mins. 3. A-tailing 
50 µl reaction. 
 Incubated at 37°C for 45 mins 
 




Zymo column purification 
50 µl reaction including 10 µl SureSelect 
Adaptor Oligo Mix. 
Incubated at 20°C for 15 mins. 
 
4. Ligation 
50 µl reaction including 2 µl SureSelect 
Adaptor Oligo Mix. 
Incubated at 20°C for 45 mins. 
Agencourt AMPure XP beads purification 
 
 
Agencourt AMPure XP beads purification 





Three 10 µl reactions for each sample. Six 
PCR cycles used. Following PCR, all 
reactions combined. 
Agencourt AMPure XP beads purification 
 
Bioanalyzer DNA 1000 
  
Agencourt AMPure XP beads purification 
 
Bioanalyzer DNA 1000 






Capture exonic regions 7. Capture selection Capture exonic regions 
Agencourt AMPure XP beads purification 
 
 Agencourt AMPure XP beads purification 




Amplify library to add index tags 
 
Agencourt AMPure XP beads purification 
 




Agencourt AMPure XP beads purification 
 
Bioanalyzer DNA High Sensitivity 
10 nM stock used 
9. Flowcell 
preparation Variable amount of stock used 
Figure 2.2: Comparison of exome sequencing sample preparation using Agilent’s  
protocol vs. low-input protocol  
The low input protocol used 500 ng starting DNA. Differences in the protocols are highlighted in 
red. (Adapted from Kozarewa et al. 2012) 




1. Shear DNA 
x 500 ng DNA was diluted with 1x TE buffer to a total volume of 120 µl in a 
1.5 ml microcentrifuge tube. 
x DNA was transferred to a Covaris microTube and samples sheared using 
a Covaris instrument using the following conditions: 
Duty Cycle:  10% 
Intensity:  5 
Cycles per Burst: 200 
Time:   6 cycles of 60 seconds each 
Set Mode:  Frequency sweeping 
Temperature: 4 – 7°C 
 
x Sheared DNA was transferred into a clean 1.5 ml microcentrifuge tube. 
x DNA quality was assessed with a Bioanalyzer DNA 1000 chip with 
fragments expected to be 150-200 nucleotides. 
 
2. Repair the ends 
x DNA was dried down to 83.2 µl or below. If less, nuclease-free water was 
added to make up the volume. 
x For each sample, the end repair reaction contained the following 
reagents and were mixed well by pipetting: 
  
DNA + nuclease-free water: 83.2 µl 
10X End repair Buffer:  10 µl 
dNTP mix: 1.6 µl 
T4 DNA polymerase: 1 µl 
Klenow DNA polymerase: 2 µl 
T4 polynucleotide kinase: 2.2 µl 
Total: 100 µl 
 




x Samples were incubated in a thermal cycler for 30 minutes at 20°C (with 
no heated lid). 
x End-repaired DNA was purified using a Zymo DNA Clean & 
ConcentratorTM-5   column   following   manufacturer’s   instructions,   except  
that 5 volumes of DNA Binding Buffer was added to each volume of DNA 
(500 µl DNA Binding Buffer to 100 µl DNA). After the washing step, DNA 
was eluted in 20 µl EB buffer (Qiagen) pre-warmed to 50°C.  
 
3. A-tailing 
x After elution, ~15 µl DNA remained.  
x The A-tailing reaction contained the following reagents for each sample 
and were mixed well by pipetting: 
 
DNA + nuclease-free water: 41 µl 
10X Klenow polymerase buffer: 5 µl 
dATP: 1 µl 
Exo(-) Klenow: 3 µl 
Total: 50 µl 
 
x Samples were incubated in a thermal cycler for 45 minutes at 37°C (with 
heated lid not exceeding 50°C). 
x A-tailed DNA was purified using a Zymo DNA Clean & ConcentratorTM-5 
column   following   manufacturer’s   instructions,   except   that   5   volumes   of  
DNA Binding Buffer was added to each volume of DNA (250 µl DNA 
Binding Buffer to 50 µl DNA). After the washing step, DNA was eluted in 
15 µl EB buffer (Qiagen) pre-warmed to 50°C.  
 
4. Ligation 
x After elution, ~11.5 µl DNA remained.  
x For each sample, the ligation reaction contained the following reagents 
and were mixed well by pipetting: 




DNA + nuclease-free water: 36.5 µl 
5X T4 DNA ligase Buffer: 10 µl 
SureSelect Adaptor Oligo Mix: 2 µl 
T4 DNA Ligase: 1.5 µl 
Total: 50 µl 
 
x Samples were incubated in a thermal cycler for 45 minutes at 20°C (no 
heated lid). 
x Samples were purified using Agencourt AMPure XP beads, according to 
the standard protocol. 
x A sub set of samples were run on Bioanalyzer High Sensitivity chip to 
confirm that DNA was present. 
 
5. Pre-hybridisation PCR 
x After purification, ~32 µl DNA remained. From this, three pre-
hybridisation PCR reactions were performed for each sample, each 
containing 10 µl DNA. Each reaction contained the following reagents 
and were mixed well by pipetting: 
 
Indexing adaptor-ligated library (DNA): 10 µl 
Nuclease-free water: 26 µl 
SureSelect primer: 1.25 µl 
SureSelect ILM indexing pre capture 
PCR reverse primer: 1.25 µl 
5X Herculase II Rxn buffer: 10 µl 
100 mM dNTP mix: 0.5 µl 
Herculase II fusion DNA polymerase: 1 µl 








x Reactions were performed using the following thermocycler conditions: 
2 mins at 98°C 
30 sec at 98°C 
30 sec at 65°C 6 cycles 
1 min at 72°C 
10 min at 72°C 
Hold at 4°C 
 
x Following PCR, the three reactions for each sample were pooled (a total 
of 150 µl). 
x Samples were purified using Agencourt AMPure XP beads, according to 
the standard protocol, except that 270 µl beads were added to DNA due 
to the increased volume of DNA (150 µl). An increased volume of ethanol 
was also used during the wash steps, if needed, to ensure beads were 
covered.  
x DNA quality was assessed using a Bioanalyzer DNA 1000 chip and the 
concentration measured. Peak size should be approximately 250-275 bp.  
 
6. Hybridization 
x After purification, ~30 µl DNA remained. The hybridization reaction 
required 250 ng DNA in a 3.4 µl volume so the samples were 
concentrated to achieve this. 
x The hybridization reaction was performed according to the standard 
protocol. 
 
7. Capture selection 
x This step was performed according to the standard protocol, followed by 








8. Addition of index tags by post-hybridization amplification 
x The  reaction  was  performed  according  to  Agilent’s   instructions,  followed  
by purification using Agencourt AMPure XP beads as per instructions.  
x DNA quality was assessed using a Bioanalyzer High Sensitivity DNA chip 
and the concentration determined using qPCR, according to the standard 
protocol.  
 
9. Pool samples for multiplexed sequencing 
x Four samples were pooled into one lane for sequencing. 
x The standard Agilent protocol used a final concentration of 10 nM for all 
DNA in the pool. For this adapted protocol, the final concentration was 
based on the lowest concentration of the samples in the pool. For 
example, if one sample had a concentration of 5 nM, then this 
concentration was used.  
x Four DNA libraries were combined so each sample was present at an 
equal amount to make a final concentration of 10 nM (or lower, see 
above). Elution buffer was added so the final volume was 19 µl. 
 
10.  Preparation for cluster amplification 
x To the 19 µl of DNA library, 1 µl 0.5N NaOH was added and then libraries 
were denatured by incubating for 5 minutes at room temperature. 
x The remaining preparation steps and the cluster generation followed the 
standard protocol. 
 
2.6.2 Analysis pipeline 
For samples prepared at KCL, sequences were aligned to the reference 
genome using Novoalign (novocraft.com) and PCR duplicates removed. 
Variants were called using SamTools (Li et al. 2009.b), and annotated using 
Annovar (Wang et al. 2010.b). These steps were performed by Dr Michael 
Simpson, KCL. 





For samples sequenced at ICR, BWA (http://bio-
bwa.sourceforge.net/bwa.shtml) was used to align sequences to the reference 
genome and PCR duplicates removed. Variants were called using GATK Broad 
Best pipeline (http://www.broadinstitute.org/gatk/index.php) with standard 
settings, and annotated using the Ensembl variation database (v61) 
(http://www.ensembl.org/index.html). Common variants (MAF of >5% in dbSNP) 
were removed. These steps were performed by Dr James Campbell, ICR. 
 
The data for all variants that differed between blood and tumour DNA was then 
exported into a Microsoft Excel format where further thresholds could be set to 
identify mutations that were likely to be somatic. 
 
2.6.3 Somatic mutation calling 
A somatic mutation was called when the alternative allele was supported by 
≥15%  of  reads  in  the  tumour  DNA  but  was  absent  in  blood  DNA  (<2%  to  allow  
for sequencing errors). This threshold allows for ~33% of the tissue to be 
derived from tumour DNA, with the rest being normal tissue DNA. For example, 
if a heterozygous mutation arose in tumour DNA, the alternative allele would be 
expected to be present ~50% if the sample was pure tumour. If the tissue was 
derived from equal amounts of tumour and normal DNA, heterozygous somatic 
mutations would now appear to be 75% reference allele and 25% alternative 
allele. 
 
If a very low number of somatic mutations were called using this threshold, it 
might indicate a high level of normal tissue contamination (>67%) in the tumour 
sample, and not simply a lack of mutations. Therefore, in these instances, the 
threshold  was   lowered   to   ≥10%  of   reads   in   tumour  DNA.  This  was  applied   to  
two blood-tumour pairs (232T-P662 and T416-P1354).  
 




In addition, the total number of reads (both reference and alternative alleles) 
required  was  ≥8  for  blood  DNA  and  ≥14  for  tumour  DNA.  These  thresholds  were  
selected based on other published exome sequencing studies (Stransky et al. 
2011; Dulak et al. 2013). 
 
2.6.4 Sanger sequencing to confirm somatic mutations 
Somatic mutations which were potentially functional (stop/gain, frameshifts and 
essential splice-site variants) or were non-synonymous mutations present in 
genes which were known to be mutated in cancer (according to the Cancer 
Gene Census - http://cancer.sanger.ac.uk/cancergenome/projects/census/) 
were prioritized for further work. Also prioritised were non-synonymous 
mutations in genes that were recurrently mutated. All of these mutations were 
visualised on Integrative Genomics Viewer (IGV) to confirm that they appeared 
to be valid (mutations present in the tumour with high confidence, but absent in 
the blood). Mutations which did not look convincing either contained variants in 
the normal DNA, or the region contained many SNPs or insertions/deletions 
called with varying degree of confidence, usually both in the tumour and normal 
DNA. Those that were valid mutations were then Sanger sequenced in the 
blood and tumour DNA to confirm the presence of the mutations using the 
standard method described on p.76, apart from a mutation in JUNB, which used 
the alternative mastermix with 10% DMSO. The primers and PCR conditions are 
shown in the Appendix, Table A.4 and Table A.5. 
 
2.6.5 TP53 exon amplification and sequencing 
The exons of TP53 were sequenced in 10 blood-tumour pairs, the total number 
of samples available (see Table 2.8). The TP53 exons selected for Sanger 
sequencing were based on the IARC TP53 database 
(http://p53.iarc.fr/Default.aspx - database version R16, November 2012) 
(Petitjean et al. 2007). As exon 1 and the majority of exon 11 are non-coding, 
the IARC sequencing protocol does not sequence these regions 




(http://p53.iarc.fr/ProtocolsAndTools.aspx), and hence, were not sequenced in 
the blood-tumour pairs. Exons 2-11 were sequenced using the standard PCR 
protocol, see p.70. Primers and PCR conditions are shown in the Appendix, 
Table A.6. Exons were then sequenced according to the method previously 
described (see p.76), using the primers used for PCR. 
 













2.6.6 PPM1D exon amplification and sequencing 
The seven exons of PPM1D (transcript ENST00000305921) were sequenced in 
11 blood-tumour pairs, the total number of samples available (see Table 2.8, 
plus 288T-P920 pair). PCR was carried out in 10 µl reactions. Exons 1, 3 and 4 
contained 10 ng DNA, 1x reaction buffer, 1.5m MgCl2, 0.2 mM dNTP, 0.4 µM 
forward primer, 0.4 µM reverse primer, 10% DMSO and 0.625 U Taq 
polymerase. Exon 2 mastermix contained 10 ng DNA, 1x reaction buffer, 1.5 
mM MgCl2, 0.2 mM dNTP, 0.4 µM forward primer, 0.4 µM reverse primer and 
0.625 U Taq polymerase. Exon 5+6, and the four amplicons of exon 7 used the 
standard PCR mastermix as described on p.70. Primers and PCR conditions 
are shown in the Appendix, Table A.7. PPM1D exons were then sequenced 
according to the method previously described (see p.76), using the primers 
used for PCR. 




3 Population-specific genetic associations with 
oesophageal squamous cell carcinoma in South 
Africa  
 
The work described in this chapter was published in 2011 in Carcinogenesis  
(Bye et al. 2011). The published paper is inserted into the thesis on pages 112-
121. A more detailed background to the work will first be given. 
 
The main aim of this chapter was to investigate genes and variants that had 
previously been reported to be associated with OSCC, and to determine 
whether they were also risk factors in South African populations. Genes and 
variants with robust evidence of association in multiple studies were prioritised 
for these case-control genetic association studies.     
 
3.1 Candidate genes and OSCC 
Before the advent of genome-wide association studies, one way of identifying 
disease susceptibility loci was through candidate gene association studies. In 
oesophageal cancer studies, genes involved in apoptosis, cell proliferation and 
DNA repair are good candidates as deregulation of these processes can cause 
uncontrolled growth leading to cancer development. Additionally, alcohol and 
tobacco smoking are known risk factors for OSCC and, therefore, genes 
involved in alcohol metabolism and tobacco detoxification are potentially 
important in OSCC development. These genes, together with evidence of their 
association with OSCC susceptibility, will now be discussed. 
 
3.1.1 Alcohol metabolism 
Upon consumption, alcohol is metabolized to acetaldehyde within the liver by 
alcohol dehydrogenase (ADH) enzymes, primarily ADH1B and ADH1C, where it 
is then oxidised to harmless acetate mainly by aldehyde dehydrogenase 2 
(ALDH2). This is summarized in below: 




      ADH1B/ADH1C      ALDH2 
Ethanol   Acetaldehyde  Acetate 
 
3.1.1.1 Aldehyde dehyrogenases 
Variants in aldehyde dehydrogenase 2 (ALDH2) are well known genetic risk 
factors for OSCC. In particular, the ALDH2 Glu504Lys (rs671) SNP has been 
associated with an increased susceptibility to OSCC in a number of studies in 
Japanese and Chinese populations (Yokoyama et al. 2002; Cui et al. 2009; 
Tanaka et al. 2010). The functional effect of ALDH2 Glu504Lys has been 
characterised, with lysine at this position shown to result in a catalytically 
inactive ALDH2 subunit which is unable to oxidise acetaldehyde (Yoshida et al. 
1984). Hence, lys/lys homozygotes have no enzyme activity and heterozygotes 
only have ~6% of the normal ALDH2 activity (Crabb et al. 1989; Yoshida et al. 
1991). This large enzymatic reduction observed in heterozygotes is due to 
ALDH2 being a tetrameric protein and the presence of lysine even in a 
heterozygous form affects the stability of the tetramer structure (Oota et al. 
2004). The ALDH2 lysine residue, therefore, acts in a dominant manner (Crabb 
et al. 1989).   
 
The Glu504Lys polymorphism is almost unique to Asian populations (Li et al. 
2009.a), with allele frequencies varying from 16-26% for the HapMap Chinese 
and Japanese populations (http://hapmap.ncbi.nlm.nih.gov/index.html.en). It is 
this  variant  that  is  responsible  for  the  alcohol  flushing  response  (“Asian  flush”),  
whereby facial reddening and nausea occurs after alcohol consumption. This 
reaction, therefore, should potentially protect against alcohol-related diseases 
as Lys/Lys carriers will avoid alcohol. Indeed, this has been shown to be the 
case in oesophageal cancer studies; the odds ratio for developing this cancer is 
0.36 (95% CI = 0.16 – 0.80) for ALDH2 Lys/Lys individuals compared to Glu/Glu 
individuals who have normal enzymes activity (Lewis and Smith 2005; Cui et al. 
2009). Heterozygous individuals are the group most at risk of developing OSCC 
as they have a less severe flushing reaction than Lys/Lys homozygotes, to 




which they may develop tolerance, but may consume large amounts of alcohol 
(Brooks et al. 2009.a).  
 
The ALDH2 504Lys allele is thought to have originated in the Han Chinese 
population of Central China but the reason for the high allele frequency there  is 
unknown (Li et al. 2009.a). It is possible that ALDH2 is involved in other cellular 
pathways in which the 504Lys allele is beneficial, thus outweighing the 
disadvantage of acetaldehyde accumulation after alcohol consumption (Oota et 
al. 2004). Alternatively, Oota et al. propose that higher acetaldehyde 
concentrations may inhibit growth of parasites and hence, provide resistance to 
diseases.   
 
In addition to acetaldehyde levels being increased in the liver, it has been 
observed that the levels of this compound are also greatly increased in saliva 
due to the ability of oral bacteria to oxidise ethanol to form acetaldehyde but 
with limited capability to form acetate (Toh et al. 2010). Acetaldehyde levels can 
be 10-100 times greater in the saliva than in blood and the direct contact of 
acetaldehyde in the saliva with the oesophagus may be another risk factor for 
the development of OSCC (Toh et al. 2010).  
 
Other ALDH2 variants have also been associated with an altered susceptibility 
to OSCC, including in European populations in whom the ALDH2 504Lys allele 
is absent. These polymorphisms include ALDH2 +82A>G, +348 C>T and -261 
C>T (Hashibe et al. 2006). The functional significance of these polymorphisms 
is not clear, although if they affect the stability of the ALDH2 protein, it may lead 
to abnormally high levels of acetaldehyde after drinking alcohol. 
 
3.1.1.2 Alcohol dehydrogenases 
Several alcohol dehydrogenase (ADH) genes have been associated with OSCC 
and other upper aerodigestive cancers, including ADH1B, ADH1C and ADH7 




(Hashibe et al. 2006; Hashibe et al. 2008; Akbari et al. 2009; Cui et al. 2009; 
Ding et al. 2009; Wu et al. 2012.a).   
 
The histidine residue at ADH1B Arg48His (rs1229984) is associated with a 
decreased risk of OSCC in several populations, including Central European, 
Iranian and Japanese (Hashibe et al. 2006; Hashibe et al. 2008; Akbari et al. 
2009; Cui et al. 2009).   This   polymorphism   results   in   the   “fast”   oxidization   of  
ethanol to acetaldehyde, which can be 100 times quicker than ADH1B Arg/Arg 
homozygotes (Hashibe et al. 2008). These results suggest that fast clearance of 
ethanol leads to a decreased risk of cancer. This would result in an increased 
rate of acetaldehyde production, which is perhaps counter-intuitive when ALDH2 
studies suggest that the build up of acetaldehyde increases risk of cancer, as 
discussed previously. However, normal activity of ALDH2 (Glu504Glu) may be 
sufficient to metabolize the resulting high levels of acetaldehyde. Indeed, the 
presence of the high-risk variants in both ALDH2 and ADH1B, where ethanol is  
metabolized slowly and the resulting acetaldehyde cannot be oxidised, results in 
synergistic effects (Cui et al. 2009). These variants, together with smoking and 
alcohol consumption, have been shown in one study to result in a nearly 190 
times increased risk of OSCC compared to individuals with low-risk ALDH2 and 
ADH1B genetic variants and who abstain from drinking and smoking (Cui et al. 
2009).    
 
In individuals who process ethanol slowly (ADH1B Arg/Arg homozygotes), it is 
proposed that other mechanisms may come into effect to metabolize the 
compound. For example, ethanol may induce cytochrome P450 2E1 (CYP2E1) 
activation, which is another enzyme that converts ethanol into acetaldehyde, in 
ADH1B Arg48 homozygotes (Brooks et al. 2009.b). However, this reaction is 
also known to produce genotoxic oxygen radicals and lipid peroxidation 
products which may result in DNA damage, perhaps further contributing to 
cancer development (Brooks et al. 2009.b).   
 




Variants in other alcohol dehydrogenase genes have also been associated with 
OSCC. The  ADH7 Gly92Ala (rs1573496) variant has been associated with a 
decreased risk of disease in European and Latin American populations, with a 
greater effect seen in drinkers, but the functional relevance of this polymorphism 
in unclear (Hashibe et al. 2008).  ADH1C 350Val and 272Gln alleles have also 
been associated with an increased risk of upper aerodigestive tract cancers in 
Central Europeans but this is not consistent in other populations (Hashibe et al. 
2006). 
 
3.1.2 Apoptosis pathway 
Apoptosis can be activated via three pathways; extrinsic, intrinsic or the 
granzyme B pathway. All three lead to activation of caspase-3 and/or-7, 
showing that caspases are essential in the apoptotic process. The extrinsic and 
intrinsic pathways are pictured below in Figure 3.1. 
 
Figure 3.1: Apoptosis pathways  
Includes the extrinsic, intrinsic and the caspase-independent apoptosis pathways (Ghavami et 
al. 2009). 





The extrinsic pathway is initiated through the activation of cell surface death 
receptors including Fas (fibroblast associated antigen, also known as CD95) 
and TNF-R (tumour necrosis factor receptor) which contain a cytosolic death 
domain (DD) (reviewed in Ghavami et al. 2009). Following the binding of ligands 
(e.g. FASL) to these receptors, adaptor proteins such as FADD (Fas-associated 
protein with death domain) bind via their death domains to those of the receptor 
to form a death inducing signalling complex (DISC). Pro-caspase 8 is then 
recruited to the DISC and becomes activated through the cleavage of the pro-
domain. Caspase-8 is able to activate downstream targets such as caspase-3 
which leads to chromatin condensation, nuclear fragmentation, membrane 
blebbing and cytoskeletal rearrangement – the process of apoptosis.  
 
3.1.2.1 Caspase-8 
Several studies have found an association between caspase-8 mutations and 
cancer. Sun et al. (2007) identified a six-nucleotide deletion (-652 6Ndel) in the 
promoter region of CASP8 which was associated with decreased risk of several 
cancers, including lung, oesophageal and breast cancers, in a Chinese 
population. Comparing 1,018 OSCC cases and 937 cancer-free controls, both 
the ins/del heterozygote and del/del homozygote were significantly associated 
with a decreased risk of OSCC with P=0.0278 (OR = 0.81; 95% CI = 0.67-0.98) 
and P=0.0082 (OR=0.57; 95% CI = 0.36-0.88), respectively.  
 
Sun et al. proposed that the -652 deletion removes a stimulatory protein 1 
(Sp1), a transcriptional activator, binding site, and showed that the deletion led 
to reduced CASP8 transcription. As T lymphocytes are important in the 
management of cancer cells in the body, the effect of the CASP-8 deletion in T 
cells was also studied. The deletion was shown to reduce activation-induced cell 
death (AICD) of T lymphocytes after cancer cell antigen stimulation. This implies 
that the immune surveillance would be more effective and, therefore, individuals 
with the deletion might be less susceptible to the development of cancer. The 




authors also acknowledged that the deletion could be associated with an 
increased risk of cancer if the deletion occurred in cancer cells as they would be 
able to avoid apoptosis. However, Sun et al. pointed out that the majority of 
tumour cells are able to avoid apoptosis stimuli and that the extrinsic pathway of 
apoptosis is aberrant in malignant cells. 
 
Conflicting results have been obtained for this polymorphism in other 
association studies both in OSCC and different cancer subtypes. In OSCC, a 
meta-analysis of two genome-wide association studies (2,961 cases and 3,400 
controls) in a Han Chinese population did not find an association with a SNP in 
high LD (r2 = 0.8) with the -652 6N deletion (Abnet et al. 2012). Additionally, the 
variant was not associated with OSCC in an northern Indian population (Umar et 
al. 2011). In other cancers, the deletion was associated with a decreased risk of 
squamous cell carcinoma of the head and neck in a non-Hispanic white 
population (Li et al. 2010.b) and also of  bladder cancer in a Chinese population 
(Wang et al. 2009). No associations were identified in breast, colorectal and 
prostate cancer in an American multi-ethnic cohort study (Haiman et al. 2008) or 
in breast cancer in a European population (Frank et al. 2008). Two meta-
analyses of all studies to date both found that the deletion was associated with a 
decreased overall risk of cancer (Yin et al. 2010; Zhang et al. 2012). However, 
even in these meta-analyses, results differed within cancer subtypes, with Yin et 
al. identifying an association with breast cancer whilst Zhang et al. did not. 
These results suggest that population and subtype-specific effects may exist. 
 
Another CASP8 polymorphism, D302H has also been associated with multiple 
cancers, including breast cancer (MacPherson et al. 2004; Cox et al. 2007). A 
meta-analysis showed that the variant  affected susceptibility to the overall risk 
of cancers (Yin et al. 2010). No studies have analyzed the effect in OSCC, 
perhaps due the variant being non-polymorphic in Asian populations, in which 
the majority of these candidate gene case-control studies were done (Sun et al. 
2007). The functional effect of this variant has yet to be determined, although 




has been hypothesized to affect the autoprocessing of the procaspase-8 
molecules or protein interactions with other molecules such as CFLAR (CASP8 
and FADD-like apoptosis regulator) due to its location on the protein surface 
(MacPherson et al. 2004).  
 
Interestingly, the meta-analysis of two Chinese OSCC GWAS, as discussed 
previously, did identify significant associations with variants at 2q33, a region 
containing CASP8, ALS2CR12 and TRAK2 (Abnet et al. 2012). The functional 
effects of these variants are unknown. The most significant association was 
observed for rs13016963, in the intron of ALS2CR12, (P=7.63 x 10-10), which 
was also in high LD with rs10931936 (P=4.74 x 10-9) located in an intron of 
CASP8. The identification of significant associations in the CASP8 region in a 
hypothesis-free GWAS does provide extra support that this gene is involved in 
OSCC susceptibility, at least in a Chinese population. The inability to detect the 
association in each of the GWAS alone suggests that the effect size may be 
small, and thus, large sample numbers are needed. 
 
In addition to the role of caspase-8 in the regulation of apoptosis, the protein is 
also involved in non-apoptotic pathways including monocyte differentiation, T 
cell activation, NF-κB   activation   and   embryonic   development   (reviewed by 
Maelfait and Beyaert 2008). These functions may have a role in cancer 
development, but have not yet been explored.  
 
3.1.2.2 FAS and FASL 
Polymorphisms in FAS and its ligand, FASL, have been tested for association 
with cancer susceptibility, including OSCC. The two most studied variants are 
FAS -1377 G/A (rs2234767) and -670A/G (rs1800682). In a Han Chinese 
population, FAS -1377 AA genotype was associated with an increased risk of 
OSCC compared with GG genotypes (OR = 1.62, 95% CI = 1.14-2.30), as was 
FAS -670 GG compared to AA genotypes (OR = 1.57, 95% CI = 1.12-2.20) (Sun 
et al. 2004). Two meta-analyses of -1377   also   suggest   that   the   ‘A’   allele  




increased overall cancer risk (Qiu et al. 2009; Zhang et al. 2009.a), although 
meaningful p-values were lacking from both studies. No association was 
observed for the -670 FAS variant in a cancer meta-analysis (Zhang et al. 
2009.a).  
 
Sun et al. (2004) also found FASL -844T/C (rs763110) variant to be associated 
with OSCC in the Han Chinese population, with the CC genotype increasing risk 
of disease compared to CT and TT genotypes (OR= 2.06, 95% CI = 1.64-2.59; 
P<0.001). This association was replicated in a meta-analysis of 19 studies from 
different types of cancers (Zhang et al. 2009.b). The presence of both FASL -
844CC and FAS -1377AA genotypes was associated with an even higher risk 
for OSCC (OR = 4.55, 95% CI = 2.75 – 7.78) (Sun et al. 2004). 
 
All three of the FAS and FASL variants are located in potentially functional 
regions. The FAS -1377 A allele and the -670 G allele disrupt Sp1 and STAT1 
transcription factor binding sites, respectively, which both lead to a decreased 
expression of FAS (Sun et al. 2004). FASL -844T/C is located in the promoter 
region within a C/EBP-β  (CAAT/enhancer-binding  protein  β)  transcription  factor  
binding site, and the presence of the C allele at this position led to higher 
expression of FASL compared to the T allele (Wu et al. 2003).  
 
In OSCC tissue compared to normal tissue, FAS expression is reduced, 
perhaps enabling tumour cells to evade apoptosis (Sun et al. 2004). In contrast, 
FASL expression is increased, which may increase the ability of tumour cells to 
counterattack the immune system by killing FAS-sensitive lymphocytes (Sun et 
al. 2004). However, more recently the role of FAS and FASL in cancer 
development has become more complex, with Chen et al. (2010) reporting that 
cancer cells require a constitutive activity of FAS for optimal growth. Here, 
independent knockdown of both FAS and FASL resulted in reduced tumour 
growth, implying that expression of both proteins is required in tumourigenesis. 
This growth-promoting role of FAS is in contrast to the traditional view that FAS 




promotes cell death through its role as a death receptor. Therefore, FAS is 
proposed to have a secondary non-apoptotic role through activation of the JNK 
pathway which affects expression of Egr1 and Fos, both of which are growth-
promoting transcription factors. 
 
3.1.3 Cyclooxygenase-2 (COX-2) 
Cyclooxygenases are enzymes responsible for the rate-limiting step of the 
conversion of arachidonic acid to prostaglandins (PGs). Prostaglandins have a 
variety of roles, including in vasodilation, pain sensitivity, inflammation and cell 
proliferation (reviewed in Sobolewski et al. 2010).  
 
COX-2 is an inducible isoform and can be activated by growth factors and 
inflammatory cytokines (reviewed in Cao and Prescott 2002 and Sobolewski et 
al. 2010). Over-expression of COX-2 has been observed in several tumours 
including oesophageal squamous cell carcinoma (Ratnasinghe et al. 1999; 
Shamma et al. 2000). This is thought to lead to several processes in cancer 
development such as enhancing proliferation and survival of tumour cells, 
inhibiting apoptosis, tumour invasion and metastasis and angiogenesis 
(reviewed in Cao and Prescott 2002 and Sobolewski et al. 2010). Inhibition of 
COX-2 expression in oesophageal cancer cell lines was shown to inhibit cell 
growth and induce apoptosis (Zimmermann et al. 1999). COX-2 inhibition has, 
therefore, been a target for cancer therapies with non-specific COX inhibitors 
such as non-steroidal anti-inflammatory drugs (NSAIDs), and COX-2 specific 
inhibitors being developed for treatment and prevention of cancer.   
 
Several studies have attempted to identify the functional variants of COX-2 
which affect the susceptibility to cancer. The polymorphism -765G>C (rs20417) 
has been association with an increased risk to OSCC in both northern Indian 
and Han Chinese populations (Zhang et al. 2005; Upadhyay et al. 2009). This 
mutation is located within the COX-2 promoter  and  the  ‘C’  allele  is  proposed  to  
disrupt a binding site for the transcriptional activator SP1 (stimulatory protein 1) 




and to create an E2F transcription factor binding site (Papafili et al. 2002; Zhang 
et al. 2005). Functional analyses of the effect of different alleles at this variant 
have produced conflicting results with the -765C allele resulting in a decreased 
expression of COX-2 in human lung fibroblasts (Papafili et al. 2002), but 
producing a >10-fold increase in prostaglandin levels in a monocyte culture (for -
765CC genotype compared to GG) (Szczeklik et al. 2004). Zhang et al. (2005) 
suggest that this is plausible due to the creation of the E2F transcription factor 
binding site. 
 
The variant -1195G>A (rs689466) in the COX-2 promoter has also been 
associated with an increased risk to OSCC in a Han Chinese population (Zhang 
et al. 2005) but not in a northern Indian population (Upadhyay et al. 2009). The 
‘A’  allele  creates  a  c-MYB (a transcription factor) binding site which results in an 
increased expression of COX-2 (Zhang et al. 2005). c-MYB is involved in the 
regulation of cell division, differentiation and cell survival and is known to 
activate COX-2 (Ramsay et al. 2003), which supports the role of the -1195G>A 
polymorphism in the susceptibility to cancer.  
 
3.1.4 O6-methylguanine-DNA methyltransferase (MGMT) 
O6-methylguanine-DNA methyltransferase (MGMT) is involved in DNA repair 
and catalyzes the irreversible transfer of the methyl group from O6-
methylguanine (O6-MeG) adducts to its own cysteine molecule (reviewed in 
Kaina et al. 2007). O6-MeG is formed due to the alkylation of DNA by alkylating 
agents, which may be present in the environment, such as in tobacco smoke or 
food, or as a product of cellular metabolic processes. This alkylation causes a 
transition mutation from G to A, resulting in a A:T pairing instead of G:C. If this 
point mutation occurs in genes involved in the regulation of cell proliferation, 
such as TP53 or KRAS, then this may initiate cancer development (reviewed in 
Esteller and Herman 2004). Mismatch repair mechanisms can repair the 
thymine residue, but unless O6-MeG is repaired by MGMT, thymine continues to 
be inserted on the opposite DNA strand (reviewed in Kaina et al. 2007). If 




MGMT is not present, DNA-double strand breaks accumulate due to the 
collapse of replication forks, leading to apoptosis (reviewed in Kaina et al. 
2007). Therefore, the presence of MGMT is essential to convert O6-MeG to its 
non-mutagenic form, to allow the normal functioning of the cell.  
 
Several polymorphisms in MGMT have been associated with susceptibility to 
cancer, although studies have produced conflicting results. Phenylalanine at 
MGMT Leu84Phe (rs12917) is associated with increased risk for upper 
aerodigestive tract (UADT) cancers in Central and Eastern European countries 
(Hall et al. 2007). However, the same SNP was associated with a decreased 
risk of head and neck cancer in an American Caucasian population (Huang et 
al. 2005). A meta-analysis of all cancer studies published found MGMT 84Phe 
to be associated with an increased risk of cancer (Zhong et al. 2010). The 
functional significance of Leu84Phe is unclear. One suggestion if that the 
polymorphism might affect the ability of MGMT to inhibit endoplasmic reticulum-
mediated cell proliferation (Zhong et al. 2010). 
 
3.2 Candidate gene association studies in the South African 
populations 
As discussed, variants in genes involved in apoptosis, DNA repair and alcohol 
metabolism have been associated with OSCC and other cancers. However, 
results across populations and in different cancer sub-types are not always 
consistent. These variants were  investigated to determine whether they were 
associated with the susceptibility to OSCC in South African populations in my 
paper   entitled   “Population-specific genetic associations with oesophageal 
squamous  cell  carcinoma   in  South  Africa”  which   is  presented   in   journal  format  
overleaf. Details of the Materials and Methods are given in Chapter 2. My 
contribution to this paper has been to perform all of the genotyping and the 
statistical analysis. I also wrote the paper, together with C. Mathew. 
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Genetic variants in multiple cellular pathways have been associ-
ated with an altered risk of oesophageal cancer. In this study, eight
genes previously associated with an altered risk of oesophageal
squamous cell carcinoma (OSCC) in European or Asian popula-
tions were investigated in two South African populations. We
genotyped 12 single-nucleotide polymorphisms and one inser-
tion/deletion variant in 1463 individuals from the Black and
Mixed Ancestry populations. No polymorphisms were associated
with OSCC in the Black population. In the Mixed Ancestry pop-
ulation, ALDH2 182 G > A (rs886205) was significantly associ-
ated with a reduced risk of OSCC (odds ratio 5 0.70, 95%
confidence interval 5 0.55–0.89; P 5 0.0038). Several other poly-
morphisms showed a suggestive association (P < 0.05), including
ADH1B Arg48His (rs1229984), COX-2 21195G > A (rs689466),
CASP8 Asp302His (rs1045485) and MGMT Leu84Phe (rs12917).
Haplotype analysis indicated that the FAS polymorphisms 2670
A > G (rs1800682) and 21377 G > A (rs2234767) were both
associated with OSCC in the Mixed Ancestry population (P 5
0.006 and P 5 0.004, respectively), as well as the CASP8 (2652
6Ndel:302His) haplotype (P 5 0.0013). This study indicates sev-
eral instances of population-specific differences in the genetic eti-
ology of OSCC between these two South African populations and
between them and other high-risk populations, which may reflect
differences in their ancestry and environmental exposures.
Introduction
Oesophageal cancer is the eighth most common cancer in the world and
is responsible for .300 000 deaths a year (1). The disease has a very
poor prognosis with a 5 years survival rate of ,10% (2). Two main
subtypes exist, squamous cell carcinoma and adenocarcinoma, which
are etiologically unrelated. Oesophageal squamous cell carcinoma
(OSCC) is the predominant form in developing countries (3). High-risk
regions have been identified in China, Japan, Iran and southern Africa.
In the Eastern Cape Province of South Africa, oesophageal cancer is the
most common malignancy in Black males and the second most com-
mon in Black females, with an incidence of 32.7 and 20.2 cases per
100 000 people, respectively (4). Alcohol and tobacco are implicated in
the majority of cases in the western world (1). In South Africa, addi-
tional risk factors include nutritional deficiencies, consumption of
maize contaminated with the Fusarium fungus and human papilloma
virus infection [reviewed in Hendricks et al. (2)].
Most genetic studies in OSCC have focused on candidate genes in-
volved in alcohol metabolism, detoxification of carcinogens, DNA
repair, apoptosis and cell proliferation [reviewed in Lao-Sirieix et al.
(5)]. However, the results have not always been consistent, particularly
across different populations. This may reflect differences in the prev-
alence of susceptibility variants between populations, differences in
environmental exposures or technical issues such as small sample
sizes which are not well powered to detect modest genetic effects.
Genome-wide association studies (GWAS) in Japanese and Chinese
populations have detected association of genetic variants in ADH1B,
ALDH2, PLCE1 and C20orf54 with OSCC (6–8). Recently, a GWAS
in upper aerodigestive cancers including OSCC in European popula-
tions reported associations in ADH7, the ALDH2 locus and a novel
association in the DNA repair gene HEL308 (9). Our previous studies
in the South African population have detected association of genetic
variants in several genes with OSCC, including GSTP1 (10), CYP2E1
(11), SULT1A1 and CYP3A5 (12). In this study, we have sought to
obtain a clearer understanding of genetic and environmental factors
contributing to the pathogenesis of OSCC in an expanded cohort from
the Black and Mixed Ancestry populations of South Africa by in-
vestigation of 12 single-nucleotide polymorphisms (SNPs) and one
insertion/deletion variant from eight genes with previous robust
evidence of association with OSCC in other populations.
Materials and methods
Study subjects
A total of 1463 individuals were recruited from the Black and Mixed Ancestry
populations of South Africa. The Black subjects were mainly Xhosa-speakers
from the Eastern or Western Cape of South Africa, who are one of the major
populations originating from the Bantu-speaking peoples of Southern Africa.
TheMixed Ancestry subjects were from theWestern Cape. This population (also
referred to in the literature and self-reported as the ‘coloured’ population of
South Africa) is an admixed population with major ancestral components from
the indigenous Khoisan, Bantu-speaking Africans, Europeans and Asians (13).
The study consisted of 358 OSCC patients and 477 controls from the Black
population and 201 OSCC patients and 427 controls from the Mixed Ancestry
population. All patients were recruited betweenMarch 2000 and September 2010
at Groote Schuur Hospital (GSH), Cape Town, South Africa, with histologically
confirmed primary invasive OSCC. Control samples were recruited from the
same populations as the patients and from the same geographical area, age group,
gender and ethnic group. Data on alcohol and tobacco use were available for
OSCC cases. Smoking status was subdivided into those who were current smok-
ers, former smokers or never-smokers. Drinkers were defined as subjects who
consumed alcohol at least once in every week. Demographic and exposure data
are given in Table I. Whole blood samples were collected with informed consent
from all subjects and DNAwas extracted at the University of Cape Town. Ethical
approval for the study was obtained from the joint University of Cape Town/GSH
Research Ethics Committee.
Candidate genes
Polymorphisms were selected for genotyping following a literature review of
published genetic association studies involving OSCC and other head-and-
neck squamous cell carcinomas (Table II). A total of 12 SNPs and one in-
sertion/deletion variant were genotyped in cases and controls: ADH1B Ar-
g48His (rs1229984); ADH7 Gly92Ala (rs1573496); ALDH2 Glu504Lys
(rs671), þ82 A . G (rs886205) and #261 C . T (rs441); FAS #670 G .
A (rs1800682) and#1377 G. A (rs2234767); FASL#844 T. C (rs763110);
COX-2 #765 G. C (rs20417) and #1195 A.G (rs689466);MGMT Leu84-
Phe (rs12917); CASP8 Asp302His (rs1045485) and CASP8 #652 6N ins/del
(rs3834129). It is important to note that the nomenclature for these variants is
based on older versions of the human genome and nucleotide annotation.
However, for simplicity and to allow consistency with previous literature in
the field, we have maintained this ‘common nomenclature’ throughout.
A summary of the updated nomenclature for these variants using the more
recent genome annotation (NCBI36) adopted by the Human Genome Variation
Society (www.HGVS.org) is provided in Supplementary Table I, available at
Carcinogenesis Online.
SNP genotyping
All samples were genotyped using the TaqMan 5# exonuclease assay with primers
and probes designed and synthesized by Applied Biosystems (Carlsbad, CA) (19).
Abbreviations: CI, confidence interval; OR, odds ratio; GWAS, genome-wide
association study; LD, linkage disequilibrium; OR, odds ratio; OSCC, oeso-
phageal squamous cell carcinoma; PCR, polymerase chain reaction.
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SNPs in the alcohol and aldehyde dehydrogenase genes (with the exception of
ALDH2 !261 T. C) were genotyped using validated TaqMan drug metabolism
genotyping assays (Applied Biosystems). SNPs in MGMT, FAS and COX-2
!1195 A . G were genotyped using validated TaqMan SNP-genotyping assays
(Applied Biosystems). Custom TaqMan assays were designed for COX-2!765G
. C [forward primer, CCCCCTCCTTGTTTCTTGGAA; reverse primer,
TGCTTAG GACCAGTATTATGAGGAGAA; reporter ACCTTTCCC(G/
C)CCTCTC], CASP8 Asp302His [forward primer, ACCACGACCTTTGAA-
GAGCTT; reverse primer, TCCATGAGTTGGTAGATTTTCAAAATCTCA; re-
porter CCCCAC(G/C)]ATGACTG] and ALDH2 !261 G . C (forward primer,
AGCCTGGGTGCCAGAGAGA; reverse primer, CCTGACAGCATTCACTTA-
GAACAAC; reporter 1, CTCGGCCTCAAAA; reporter 2, ACTCGGTCT-
CAAAAA). Reactions were carried out in 2.5 ll volumes in 96-well plates.
Each reaction contained 20 ng DNA, Absolute QPCRROXmix (Abgene, Epsom,
UK) and SNP assay mix (Applied Biosystems) according to assay instructions and
were performed on a PTC-0225 DNA Engine (MJ Research, Waltham, MA).
Fluorescent levels at the polymerase chain reaction (PCR) end-point were de-
termined using a 7900HT Fast Real-Time PCR system (Applied Biosystems) and
genotypes assigned using SDS 2.2.2 software (Applied Biosystems).
Insertion/deletion genotyping
Primers for the CASP8!652 6N ins/del were previously designed by Sun et al.
(25). Briefly, the 5 ll PCR reaction contained 1" PCR mastermix (Promega,
Madison, WI), 0.4 lM of each primer (Sigma, Dorset, UK), 10 ng of DNA and
was performed on a thermocycler as above. The PCR products were separated
by capillary electrophoresis on an ABI3730xl DNA Analyzer (Applied
Biosystems) and sized using GeneMapper software (Applied Biosystems).
Statistical analysis
Pearson’s chi-squared (v2) test was used to determine deviations from the
Hardy–Weinberg equilibrium; all genotype frequencies were in Hardy–Wein-
berg equilibrium in both populations, with the exception of FAS -670 G. A in
OSCC cases from the Black population (P 5 0.027). Genotype and allele
frequencies were calculated for cases and controls and compared using the
Pearson’s chi-squared (v2) test to test for association with OSCC. A P-value of
,0.0042 (0.05/12) was used as a significance threshold for the association test
to allow for multiple testing of the 12 variants present in these populations
based on the Bonferroni principle. No additional correction was applied for the
two populations tested. Genotypic and allelic odds ratios (ORs) with 95%
confidence intervals (CIs) were calculated using the common homozygous
genotype or common allele as the reference. Haplotype analysis and determi-
nation of linkage disequilibrium (LD) between variants in the same gene were
performed using UNPHASED (26). SNPs that were suggestive of an allelic
association (uncorrected P , 0.05) were further investigated for the effect of
alcohol and tobacco by stratifying cases based on smoking and drinking status.
Results
Case–control analysis
The results for the case–control analysis in the two South African
populations are shown in Table III and full genotype counts in Sup-
plementary Table II, available at Carcinogenesis Online. None of the
13 variants tested were associated with OSCC in the Black South
African population. The ADH1B 48His and ALDH2 504Lys alleles
were absent in this population, and the ADH7 92Ala allele was
extremely rare (only one allele observed).
In the Mixed Ancestry population, the SNP ALDH2 þ82G . A
(rs886205) showed association with OSCC (P 5 0.0038), which re-
mained significant after accounting for multiple testing. The þ82A
allele had a frequency of 40.2% in cases and 48.9% in controls giving
an allelic OR of 0.70 (95% CI 5 0.55–0.89) and was thus associated
with a reduced risk of OSCC. Suggestive associations were observed
in the Mixed Ancestry population for several other polymorphisms
(P , 0.05): ADH1B Arg48His (P 5 0.009), COX-2 !1195 A . G
(P 5 0.014), CASP8 Asp302His (P 5 0.040) and MGMT Leu84Phe
(P 5 0.023). However, these associations did not meet the required
threshold for multiple testing. Variants not showing significant associa-
tions wereCOX-2!765G.C,ALDH2!261 T. C,FAS!670G.A,
Table I. Characteristics of OSCC cases in the South African Black and
Mixed Ancestry patients
Black population Mixed Ancestry
population
Controls n 5 477 n 5 427
Cases n 5 358 n 5 201
Summary statistics—cases
Age, mean years (SD) 59.8 (11.3) 60.5 (10.6)
Sex, n (%)
Male 182 (50.8) 131 (65.2)
Female 176 (49.2) 70 (34.8)
Smoking status, n (%)
Current smoker 100 (27.9) 131 (65.2)
Former smoker 128 (35.8) 58 (28.9)
Never smoker 130 (36.3) 10 (5.0)
Unknown 0 2 (1)
Alcohol consumption, n (%)
Drinker 228 (63.7) 163 (81.1)
Non-drinker 128 (35.8) 37 (18.4)
Unknown 2 (0.6) 1 (0.5)
Table II. Summary of association results in published studies
Gene Common variant namea dbSNP ID Genetic model OR (95% CI) P-value Cancer site Population Ref
ALDH2 Glu504Lys (G . A) rs671 A versus G 1.67 (1.58–1.76) 3.27 " 10!24 OSCC Japanese (7)
ALDH2 þ82 A . G rs886205 GG versus AA 4.14 (2.03–8.46) ,0.0001 OSCC European (14)
ALDH2 !261 C . T rs441 CC versus TT 3.85 (1.78–8.36) ,0.0001 OSCC European (14)
ADH1B Arg48His (G . A) rs1229984 A versus G 1.79 (1.69–1.88) 7.75 " 10!24 OSCC Japanese (7)
GG þ GA versus AA 0.34 (0.20–0.56) — OSCC European and Latin American (15)
ADH7 Gly92Ala rs1573496 C versus G 0.45 (0.32–0.64) — OSCC European and Latin American (15)
GG versus CC 0.32 (0.13–0.82) — Head and neck SCC American Caucasian (16)
FAS !670 A . G rs1800682 GG versus AA 1.57 (1.12–2.20) ,0.001 OSCC Chinese (17)
FAS !1377 G . A rs2234767 AA versus GG 1.62 (1.14–2.30) ,0.001 OSCC Chinese (17)
FASL !844 T . C rs763110 CC versus TT 1.72 (1.12–2.64) ,0.001 OSCC Chinese (17)
CASP8 Asp302His (G . C) rs1045485 CC versus GG 0.81 (0.71–0.93) — Cancer meta-analysis — (18)
CASP8 !652 6N ins/del rs3834129 del/del versus ins/ins 0.57 (0.36–0.88) 0.0082 Oesophageal cancer Chinese (19)
COX-2 !765 G . C rs20417 GC versus GG 2.24 (1.59–3.16) ,0.0001 OSCC Chinese (20)
C versus G 1.32 (0.92–1.88) — OSCC Indian (21)
COX-2 !1195 G . A rs689466 A versus G 1.34 (1.08–1.68) 0.008 OSCC Chinese (20)
A versus G 1.23 (0.80–1.87) — OSCC Indian (21)
MGMT Leu84Phe rs12917 FF versus LL 3.27 (1.43–7.52) — OSCC European (22)
LF þ FF versus LL 0.71 (0.51–0.98) — Head and neck SCC American (23)
TT versus CC 1.24 (1.02–1.51) 0.035 Cancer meta-analysis — (24)
aVariant names correspond to common names used in majority of previous publications. Updated variant names based on more recent annotations of the human
genome are provided in Supplementary Table I, available at Carcinogenesis Online.
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FAS!1377 G. A, FASL!844T. C andCASP8!652 6N ins/del. The
ALDH2 504Lys allele was absent in Mixed Ancestry subjects, as in
the Black population.
Haplotype analysis
Multiple polymorphisms were genotyped in COX-2, ALDH2, FAS and
CASP8 genes, enabling haplotype analysis to be performed and LD to
be determined (Table IV). A low level of LD was observed between
variants in the different genes in both the Black and Mixed Ancestry
population. The LD coefficients (r2) for pairs of SNPs in COX-2,
ALDH2, FAS and CASP8 were 0.058, 0.058, 0.023 and 0.021 in the
Black population controls and 0.087, 0.228 and 0.153 and 0.001 in the
Mixed Ancestry population controls, respectively. Similar values
were observed in OSCC cases.
In the Black population, there were no significant haplotype effects.
In the Mixed Ancestry population, statistically significant haplotype
associations were observed for variants in ALDH2 (P 5 0.0028), FAS
(P5 0.0031) and CASP8 (P5 0.004). However, the haplotype result
observed for ALDH2 is entirely due to the association of the ALDH2
þ82 allele observed in the single SNP analysis, with no increase in
significance achieved by inclusion of the !261 variant. Haplotypes at
the FAS gene locus were significantly associated with a reduced risk of
OSCC in the Mixed Ancestry population (overall P 5 0.003), with
both !1377A and !670A alleles contributing independently to dis-
ease risk, consistent with the low level of LD between them. For
CASP8, the haplotype !652 6Ndel:302His was significantly associ-
ated with an increased risk of OSCC (P5 0.001, OR5 2.37; 95% CI
5 1.39–4.04), whereas the individual variants were not.
Alcohol and smoking analysis
Polymorphisms that showed a statistically significant (P, 0.0042) or
suggestive (P , 0.05) association with OSCC in the case–control
analysis were investigated further for gene–environment interactions.
These were ADH1B Arg48His, COX-2 !1195 A . G, CASP8 As-
p302His, ALDH2 þ82 G . A and MGMT Leu84Phe in the Mixed
Ancestry population only. In this population, current, former and
never-smokers account for 65.2% (n 5 131), 28.9% (58) and 5%
(10) of OSCC patients, respectively (Table I). In view of the low
numbers of never-smokers, analyses were carried out only for current
and former smokers, with each group being compared with controls
(Table V). All SNPs analyzed showed nominal evidence of associa-
tion with OSCC in current smokers (P , 0.05) and no associations in
the smaller group of former smokers. The most significant association
in current smokers compared with controls was forMGMT Leu84Phe
(P 5 0.003) and was more significant than the association seen in the
initial case–control test for all cases combined (P 5 0.023), with
a concomitant increase in the disease risk (OR all cases 1.41 and
OR current smokers 1.65).
Alcohol drinkers represent 81.1% of the Mixed Ancestry patients
(Table II). Comparing drinkers to controls, all SNPs analyzed showed
at least nominal evidence of association (P, 0.05), with the two most
significant findings at ALDH2 þ82 G . A and COX-2 !1195 A. G
(P5 0.003 and P5 0.004, respectively) (Table VI), achieving greater
significance in this stratified analysis compared with the initial anal-
ysis of all cases combined. Analysis of drinkers versus non-drinkers
showed no significant differences between the groups as did non-
drinkers versus controls, but the number of non-drinkers was small.
Discussion
In this study, we tested 13 sequence variants for association with
OSCC in eight genes involved in several candidate molecular path-
ways, including alcohol metabolism, apoptosis, cell proliferation
and DNA repair. No associations were observed in the Black South
African population, whereas several significant or suggestive associ-
ations were detected in the Mixed Ancestry population. Possible
explanations for the differences between these two South African
populations are discussed below.
In the Mixed Ancestry population, one SNP, ALDH2 þ82 A . G
(rs886205), was significantly associated with OSCC after accounting
for multiple testing. Another SNP upstream of ALDH2, !261C . T,
was not associated with OSCC in this population and the 504Lys
allele was absent. ALDH2 metabolizes acetaldehyde into acetate
and substitution of glutamic acid by lysine at amino acid position
504 results in a catalytically inactive subunit (27). The 504Lys allele
is thought to be almost unique to Asian populations (14), and this
study confirms its absence in two South African populations. The
þ82A allele was associated with a reduced risk of OSCC (OR 5
0.70) in the Mixed Ancestry population, thus replicating the associa-
tion of this SNP with OSCC previously observed in Central European
populations. It should be noted that in Europeans, the þ82G is the
minor allele, which has an increased frequency in OSCC patients and
is therefore reported as increasing cancer risk (28). Despite the dif-
ference in allele frequency between these two populations, these two
observations are consistent in that the same allele (G) is increased in
frequency in both OSCC populations. This SNP, located 360 bp up-
stream of the ATG initiation codon for ALDH2, is within or adjacent
to known or predicted binding sites for multiple transcription factors
(17,29,30). Analysis of the effect of this variant on transcriptional
activity has produced conflicting results; the þ82G allele has been
shown to be more active than the A allele in hepatoma cells (29), but
the opposite was observed in human peripheral blood leukocytes
when analyzing the basal level of transcription (17). However, the
latter study showed that higher levels of expression from the G allele
Table III. Association of polymorphisms with OSCC in the South African Black and Mixed Ancestry populations
Gene SNP Alleles (major
þ reference/minor)
Black population Mixed Ancestry population
MAF OR (95% CI) P-value MAF OR (95% CI) P-value#
Cases Controls Cases Controls
ADH1B Arg48His G/A 0 0.000 — — 0.054 0.098 0.52 (0.32–0.86) 0.009
ADH7 Gly92Ala C/G 0 0.001 — — 0.014 0.02 0.67 (0.22–2.01) 0.471
ALDH2 þ82 G . A G/A 0.247 0.252 0.98 (0.78–1.23) 0.835 0.402 0.489 0.70 (0.55–0.89) 0.004
ALDH2 !261 T . C T/C 0.154 0.145 1.07 (0.81–1.42) 0.611 0.18 0.194 0.92 (0.67–1.25) 0.587
COX-2 !765 G . C G/C 0.471 0.513 0.85 (0.69–1.03) 0.096 0.376 0.321 1.28 (0.99–1.64) 0.059
COX-2 !1195 A . G A/G 0.064 0.053 1.22 (0.80–1.86) 0.343 0.103 0.155 0.63 (0.43–0.91) 0.014
MGMT Leu84Phe C/T 0.189 0.195 0.96 (0.75–1.24) 0.770 0.222 0.168 1.41 (1.05–1.91) 0.023
CASP8 Asp302His G/C 0.154 0.152 1.02 (0.77–1.34) 1.000 0.169 0.126 1.42 (1.01–1.98) 0.040
CASP8 !652 6N ins/del Ins/Del 0.518 0.502 1.06 (0.87–1.30) 0.530 0.385 0.386 0.99 (0.77–1.27) 1.000
FAS !670 G . A G/A 0.219 0.225 0.96 (0.76–1.22) 0.750 0.356 0.406 0.81 (0.63–1.04) 0.097
FAS !1377 G . A G/A 0.096 0.072 1.36 (0.95–1.94) 0.092 0.139 0.183 0.72 (0.52–1.01) 0.058
FASL !844 T . C T/C 0.192 0.189 1.02 (0.79–1.31) 1.000 0.416 0.386 1.13 (0.89–1.45) 0.323
#P-value corrected to three decimal places.
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could be induced by acetaldehyde or ethanol, suggesting that this
SNP may contribute to interindividual or allelic differences in acet-
aldehyde elimination (17). The association of ALDH2 þ82A . G in
the South African Mixed Ancestry population is consistent with
many other studies which have found associations of other variants
at this gene with oesophageal cancer, including patients of European,
Chinese and Japanese descent (8,9, 28,31–33). Interestingly, this is
a region of extended LD in European populations, which contains
other plausible candidate genes (9).
The SNPs ADH1B Arg48His, COX-2 "1195A . G, CASP8 As-
p302His andMGMT Leu84Phe showed some evidence of association
with OSCC in the Mixed Ancestry population with P ,0.05 but did
not survive the Bonferroni threshold which was set for multiple
testing. However, given that this threshold is somewhat conservative
and that there is prior evidence for the association of these variants
with OSCC or head and neck squamous cell carcinoma in other
populations, we have referred to these as suggestive associations with
OSCC which require future follow-up in an expanded sample.
The associations of haplotypes at the FAS gene locus which con-
tained either the "1377A or "670A alleles with a reduced risk of
OSCC in the Mixed Ancestry population are only partially consistent
with data from the Han Chinese population, in which "670A was
associated with a reduced risk of OSCC but "1377A had the opposite
effect (34). The FAS protein and its ligand, FASL, play a key role in the
induction of apoptosis, and FAS expression is found to be reduced in
OSCC tissues (35,36). However, a recent study by Chen et al. (37)
showed that constitutive expression of FAS is required for optimal
growth of tumors and complete loss of FAS is rarely observed. Func-
tional studies have shown that FAS "1377A and "670G disrupt the
Sp1 and STAT1 transcription factor-binding sites, respectively, which
both lead to reduced expression of FAS (15,38,39). Taken together,
these data suggest that the FAS "1377A and "670G alleles would
both be associated with an increased risk of cancer, provided that
FAS is constitutively expressed, but population-specific effects may
occur.
In our study, neither of the CASP8 variants, Asp302His and -652
6N ins/del, were significantly associated with OSCC. However, in the
haplotype analysis, the CASP8 "652 6Ndel:302His haplotype was
significantly associated with an increased risk OSCC. Previous in-
dependent association studies of CASP8 variants with cancer have
produced somewhat conflicting results. The "652 6N deletion allele
has been associated with reduced susceptibility to multiple cancers,
including oesophageal cancer, in the Chinese population (25), but
this was not replicated for breast, colorectal and prostate cancer in
several other populations (40). A meta-analysis of 55 studies reported
a reduced overall risk of cancer for the"652 6N deletion and 302His
alleles, although stratified analysis suggested a reduced risk for es-
trogen-related cancers but an increased risk for brain tumors (18). It
is possible that population-specific or cancer subtype-specific effects
may occur, and results may also be influenced by differing environ-
mental triggers.
Gene–environment interactions are known to exist in susceptibility
to OSCC, particularly those involving an interaction between alcohol
metabolism genes and alcohol intake or smoking status. The risk of
disease conferred by the ALDH2 504Lys allele, for example, is re-
lated to the amount of alcohol consumed (8, 41), but association
studies in non-drinkers have reported conflicting results (8, 32, 41).
Smoking status also appears to interact with this variant, with smok-
ers having a greater risk of disease than non-smokers (8). The asso-
ciation observed in this study for ALDH2 þ82A . G in the South
African Mixed Ancestry population was somewhat stronger when the
data were stratified to include only those cases that drink. This fol-
lows a similar trend to that observed by Hashibe et al. (28), who
found an increased disease risk for A/G heterozygotes and G/G ho-
mozygotes in both light and medium/heavy drinkers in a European
population. Gene–environmental interactions involving ADH1B Hi-
s48Arg have also been conflicting. Cui et al. (8) found no interaction
of this SNP with drinking and smoking status in the Japanese pop-
































































































































































































































































































































































































































































































































































































































































































































































































































including OSCC, in Central European countries where only drinkers
and smokers showed an altered susceptibility to disease for this ge-
notype (42). In a study in the Chinese population, ADH1B His48Arg
was not associated with oesophageal cancer in drinkers or non-
drinkers (32). Despite this lack of consistency, one study has shown
that the combination of risk SNPs for ALDH2 Glu504Lys and ADH1B
His48Arg, together with drinking alcohol and smoking, increases the
risk of OSCC synergistically compared with individuals with no risk
genotypes who refrain from alcohol consumption and smoking [OR5
189.26 (95% CI 5 95.11–376.63)] (8).
In our study, all the significant or suggestive associations detected in
cases from the Mixed Ancestry population were also observed in alco-
hol drinkers but not in non-drinkers. However, the proportion of non-
drinkers in this population was very small, with low power to detect any
association. Interestingly, the protective effect of the COX-2 !1195
A . G SNP (P 5 0.004) was strengthened in the drinkers subgroup
relative to the whole case sample (P 5 0.014), again suggestive of
a possible gene–environmental interaction, but this requires confirma-
tion by analysis of a larger sample of non-drinking OSCC cases. In
relation to smoking status, again all associations observed in the full
sample of OSCC cases were also detected in smokers but not in former
smokers or non-smokers (those who have never smoked). However,
former smokers and non-smokers were a minority in this population,
so there was low power to detect associations in these subgroups. The
stronger association observed for MGMT Leu84Phe with OSCC in
smoking cases versus controls (P 5 0.003) compared with all cases
versus controls (P 5 0.023) suggests a possible interaction between
smoking and theMGMTDNA repair pathway but requires confirmation
by analysis of a larger sample of non-smoking cases.
The differences in the results of the genetic association tests between
the Black and Mixed Ancestry populations in this study are striking. A
number of associations reported previously in European and Asian
populations were also detected in the Mixed Ancestry population, albeit
with varying levels of support. However, none of the variants tested
showed any evidence of association in the Black population. There are
several possible explanations for these differences. One is the absence
or extreme rarity of the risk SNP in this population, such as was the case
for ADH1B 48His, ALDH2 504Lys and ADH7 92Ala. Another is a lack
of statistical power to detect modest genetic effects in the samples
available. The sample size was larger in the Black population than in
the Mixed Ancestry (N 5 835 and 628, respectively), and, in several
instances, there was high power to detect the same effect seen in the
Mixed Ancestry population. However, power in the Black population
sample varied substantially, depending on the size of the effect (OR)
and the minor allele frequency. Thus, for an SNP with a MAF of 25%
and an allelic OR of 1.5, we had 96% power to detect association (at
significance level 0.05). However, for COX-2!1195A. G (OR 1.34),
for example, the MAF was 5% and power was only 30%, whereas for
ALDH2þ82G. A (MAF5 25%, OR5 1.43), the power to detect the
same effect seen in theMixed Ancestry population was.90%. Another
possibility is that the SNPs associated with OSCC in other populations
may not be the true causal variants and may be merely tagging SNPs,
which are in high LD with the causal variant. There is generally a lower
level of LD in African populations, and hence, associations may not be
detected if the causal variant is not genotyped (43).
A further and potentially important explanation for these results is
differences in environmental exposures between these two popula-
tions. The significant or suggestive association with OSCC of variants
in genes involved in alcohol and acetaldehyde metabolism (ALDH2
and ADH1B) and DNA repair of alkylation-induced mutagenesis
(MGMT) in the Mixed Ancestry population is consistent with the high
rates of smoking and alcohol use in this cohort. However, the pro-
portion of smokers and drinkers was lower in the Black OSCC pa-
tients, thus a genetic interaction between, for example, a genetic
variant in an aldehyde dehydrogenase gene and alcohol consumption
or smoking might be weaker or absent in this population and the
genetic association would not be observed. Epidemiological studies
in Black South Africans have investigated the contribution of alcohol
consumption and smoking to oesophageal cancer risk (44–46), the
most recent of which suggests that while alcohol use in itself does
Table V. Analysis of the effect of smoking for polymorphisms that show a significant or suggestive association with OSCC in the Mixed Ancestry population
Gene Current smokers (n 5 131) versus controls (n 5 427) Former smokers (n 5 58) versus controls (n 5 427)
MAF: controls/
current smokers
OR (95% CI) P-value MAF: controls/
former smokers
OR (95% CI) P-value
ADH1B Arg48His 0.098/0.047 0.45 (0.24–0.84) 0.011 0.098/0.096 0.98 (0.51–1.91) 1.000
COX-2 !1195 A . G 0.155/0.100 0.61 (0.38–0.95) 0.029 0.155/0.129 0.81 (0.46–1.44) 0.468
CASP8 Asp302His 0.126/0.180 1.53 (1.04–2.24) 0.028 0.126/0.179 1.51 (0.90–2.56) 0.119
ALDH2 þ82 G . A 0.489/0.418 0.75 (0.56–0.99) 0.045 0.489/0.407 0.72 (0.48–1.06) 0.092
MGMT Leu84Phe 0.168/0.250 1.65 (1.18–2.32) 0.003 0.168/0.186 1.14 (0.69–1.87) 0.615
Table VI. Analysis of the effect of alcohol consumption for polymorphisms that show a significant or suggestive association with OSCC in the Mixed Ancestry
population
Gene Case-only analysis:
drinkers (n 5 163) versus
non-drinkers (n 5 37)
Drinkers (n 5 163)
versus control (n 5 427)
Non-drinkers (n 5 37)
















ADH1B Arg48His 0.042/0.057 1.38 (0.40–4.82) 0.612 0.098/0.057 0.55 (0.33–0.94) 0.026 0.098/0.042 0.40 (0.12–1.30) 0.116
COX-2 !1195 A . G 0.162/0.090 0.51 (0.25–1.06) 0.066 0.155/0.090 0.54 (0.35–0.83) 0.004 0.155/0.162 1.05 (0.55–2.01) 0.873
CASP8 Asp302His 0.111/0.184 1.80 (0.82–3.97) 0.139 0.126/0.184 1.57 (1.10–2.23) 0.012 0.126/0.111 0.87 (0.41–1.87) 0.721
ALDH2 þ82 G . A 0.432/0.394 0.85 (0.51–1.42) 0.541 0.489/0.394 0.68 (0.52–0.88) 0.003 0.489/0.432 0.79 (0.49–1.28) 0.347
MGMT Leu84Phe 0.176/0.234 1.43 (0.75–2.76) 0.277 0.168/0.234 1.52 (1.10–2.08) 0.010 0.168/0.176 1.06 (0.57–1.97) 0.863
OSCC in South Africa
1859




not increase risk (OR 0.9), smoking does (OR 1.9) and the combina-
tion of smoking and drinking increases risk further (OR 4.4) (46).
However, a major risk factor in this population is residence in the
Transkei region of the Eastern Cape Province (47,48), with long-term
residence of 35 years or more associated with high risk (OR 14.7) in
females (46). Nutritional factors such as deficiency in micronutrients
(49,50), and the consumption of maze contaminated with Fusarium
species, which produce mycotoxins (51) have been proposed as risk
factors. Taken together, these studies suggest that dietary factors are
likely to be an important component of risk for OSCC in this popu-
lation. If so, the nature of interacting genetic factors may be substan-
tially different to those found in the Mixed Ancestry and other
populations. In view of the success of genome-wide association scans
in defining the genetic components of complex disease, this approach
is likely to be the most effective means of identifying the relevant
genetic pathways involved in the pathogenesis of OSCC in these two
populations once sufficient sample sizes for genome-wide studies are
available. The identification of such pathways may shed further light
on the role of dietary factors in OSCC.
In conclusion, this study provides evidence that several genetic
variants in genes involved in alcohol metabolism and DNA repair
contribute to genetic susceptibility to OSCC in the Mixed Ancestry
but not in the Black population of South Africa. This may be ex-
plained both by differences in the genetic history and architecture
of these populations and by different environmental exposures.
Supplementary material
Supplementary Tables I and II can be found at http://carcin.oxford-
journals.org/
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Supplementary Table I: HGVS nomenclature for the OSCC variants tested 
in this study 






























































Supplementary Table II: Association of polymorphisms with OSCC in the 
South African Black and Mixed Ancestry populations  
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 Black population Mixed Ancestry population 
 Cases (%) Controls (%) OR (95% CI) P-value Cases (%) 
Controls 
(%) OR (95% CI) P-value 
ADH1B, Arg48His         
G/G - -   176 (89.8) 344 (81.1)  Ref 
G/A - - - - 19 (9.7) 77 (18.2) 0.48 (0.28 - 0.82) 0.007 
A/A - - - - 1 (0.5) 3 (0.7) 0.65 (0.07 - 6.31) 0.709 
G     371 (94.6) 765 (90.2)  Ref 
A - - - - 21 (5.4) 83 (9.8) 0.52 (0.32 - 0.86) 0.009 
ADH7, Gly92Ala         
C/C 272 (100.0) 414 (99.8)   143 (97.3) 404 (96.0)  Ref 
C/G 0 (0.0) 1 (0.2)   4 (2.7) 17 (4.0) 0.66 (0.22 - 2.01) 0.466 
G/G 0 (0.0) 0 (0.0)   0 (0.0) 0 (0.0)   
C 544 829 (99.9)   290 (98.6) 825 (98.0)  Ref 
G 0 1 (0.1)   4 (1.4) 17 (2.0) 0.70 (0.22 - 2.01) 0.471 
ALDH2,+82 G>A         
G/G 191 (55.8) 258 (56.0) Ref Ref 73 (36.9) 120 (28.2) Ref Ref 
G/A 133 (38.9) 174 (37.7) 1.03 (0.77 - 1.38) 0.831 91 (46.0) 194 (45.6) 0.77 (0.53 - 1.13) 0.183 
A/A 18 (5.3) 29 (6.3) 0.84 (0.45 - 1.55) 0.575 34 (17.2) 111 (26.1) 0.50 (0.31 - 0.82) 0.005 
G 515 (75.3) 690 (74.8) Ref Ref 237 (59.8) 434 (51.1) Ref Ref 
A 169 (24.7) 232 (25.2) 0.98 (0.78 - 1.23) 0.835 159 (40.2) 416 (48.9) 0.70 (0.55 - 0.89) 0.004 
ALDH2, -261 T>C         
T/T 243 (71.3) 340 (73.0) Ref Ref 128 (66.0) 275 (66.1) Ref Ref 
T/C 91 (26.7) 117 (25.1) 1.09 (0.79 - 1.50) 0.604 62 (32.0) 121 (29.1) 1.10 (0.76 - 1.60) 0.612 
C/C 7 (2.1) 9 (1.9) 1.09 (0.40 - 2.96) 0.868 4 (2.1) 20 (4.8) 0.43 (0.14 - 1.28) 0.120 
T 577 (84.6) 797 (85.5) Ref Ref 318 (82.0) 671 (80.6) Ref Ref 
C 105 (15.4) 135 (14.5) 1.07 (0.81 - 1.42) 0.611 70 (18.0) 161 (19.4) 0.92 (0.67 - 1.25) 0.587 
COX-2, -765 G>C         
G/G 100 (28.8) 110 (23.8) Ref  81 (42.6) 195 (46.2) Ref Ref 
G/C 167 (48.1) 230 (49.8) 0.80 (0.57 - 1.12) 0.190 75 (39.5) 183 (43.4) 0.99 (0.68 - 1.43) 1.000 
C/C 80 (23.1) 122 (26.4) 0.72 (0.49 - 1.07) 0.101 34 (17.9) 44 (10.4) 1.86 (1.11 - 3.12) 0.018 
G 367 (52.9) 450 (48.7) Ref Ref 237 (62.4) 573 (67.9) Ref Ref 
C 327 (47.1) 474 (51.3) 0.85 (0.69 - 1.03) 0.096 143 (37.6) 271 (32.1) 1.28 (0.99 - 1.64) 0.059 
COX-2,-1195 A>G         
A/A 301 (87.2) 417 (89.7)   154 (79.4) 298 (71.1) Ref Ref 
A/G 44 (12.8) 47 (10.1) 1.30 (0.84 - 2.01) 0.243 40 (20.6) 112 (26.7) 0.69 (0.46 - 1.04) 0.077 
G/G 0 (0.0) 1 (0.2) -  0 (0.0) 9 (2.1) -  
A 646 (93.6) 881 (94.7) Ref Ref 348 (89.7) 708 (84.5) Ref Ref 
G 44 (6.4) 49 (5.3) 1.22 (0.80 - 1.86) 0.343 40 (10.3) 130 (15.5) 0.63 (0.43 - 0.91) 0.014 
MGMT, Leu84Phe         
C/C 225 (65.0) 300 (64.0) Ref Ref 120 (61.2) 294 (69.5) Ref Ref 
C/T 111 (32.1) 155 (33.0) 0.95 (0.71 - 1.29) 0.762 65 (33.2) 116 (27.4) 1.37 (0.95 - 1.99) 0.093 
T/T 10 (2.9) 14 (3.0) 0.95 (0.42 - 2.18) 1.000 11 (5.6) 13 (3.1) 2.07 (0.90 - 4.76) 0.080 
C 561 (81.1) 755 (80.5) Ref Ref 305 (77.8) 704 (83.2) Ref Ref 
T 131 (18.9) 183 (19.5) 0.96 (0.75 - 1.24) 0.770 87 (22.2) 142 (16.8) 1.41 (1.05 - 1.90) 0.023 
CASP8,Asp302His         
G/G 247 (71.8) 332 (71.6) Ref Ref 135 (70.3) 326 (77.3) Ref Ref 
G/C 88 (25.6) 123 (26.5) 0.96 (0.70 - 1.32) 0.810 49 (25.5) 86 (20.4) 1.38 (0.92 - 2.06) 0.121 
C/C 9 (2.6) 9 (1.9) 1.34 (0.53 - 3.44) 0.535 8 (4.2) 10 (2.4) 1.93 (0.75 - 5.00) 0.168 
G 582 (84.6) 787 (84.8) Ref Ref 319 (83.1) 738 (87.4) Ref Ref 
C 106 (15.4) 141 (15.2) 1.02 (0.77 - 1.34) 1.000 65 (16.9) 106 (12.6) 1.42 (1.01 - 1.98) 0.040 
CASP8, -652 6N 
ins/del         
Ins / Ins 82 (24.9) 112 (24.5) Ref Ref 76 (39.8) 160 (38.6) Ref Ref 
Del / Ins 153 (46.5) 232 (50.7) 0.90 (0.63 - 1.27) 0.559 83 (43.5) 188 (45.4) 0.92 (0.63 - 1.35) 0.703 
Del / Del 94 (28.6) 114 (24.9) 1.12 (0.75 - 1.67) 0.555 32 (16.8) 66 (15.9) 1.02 (0.61 - 1.68) 1.000 
Ins 317 (48.2) 456 (49.8) Ref Ref 235 (61.5) 508 (61.4) Ref Ref 
Del 341 (51.8) 460 (50.2) 1.06 (0.87 - 1.30) 0.530 147 (38.5) 320 (38.6) 0.99 (0.77 - 1.27) 1.000 
FAS, -670 G>A         
G/G 210 (61.2) 288 (61.8) Ref Ref 87 (44.6) 155 (36.9) Ref Ref 
G/A 116 (33.8) 146 (31.3) 1.09 (0.81 - 1.47) 0.577 77 (39.5) 189 (45.0) 0.73 (0.50 - 1.05) 0.092 
A/A 17 (5.0) 32 (6.9) 0.73 (0.39 - 1.35) 0.311 31 (15.9) 76 (18.1) 0.73 (0.44 - 1.19) 0.204 
G 536 (78.1) 722 (77.5) Ref Ref 251 (64.4) 499 (59.4) Ref Ref 
A 150 (21.9) 210 (22.5) 0.96 (0.76 - 1.22) 0.750 139 (35.6) 341 (40.6) 0.81 (0.63 - 1.04) 0.097 
FAS, -1377G>A         
G/G 276 (81.4) 393 (86.2) Ref Ref 144 (74.2) 278 (67.3) Ref Ref 
G/A 61 (18.0) 60 (13.2) 1.45 (0.98 - 2.13) 0.061 46 (23.7) 119 (28.8) 0.75 (0.50 - 1.11) 0.146 
A/A 2 (0.6) 3 (0.7) 0.95 (0.16 - 5.72) 1.000 4 (2.1) 16 (3.9) 0.48 (0.16 - 1.47) 0.191 
G 613 (90.4) 846 (92.8) Ref Ref 334 (86.1) 675 (81.7) Ref  
A 65 (9.6) 66 (7.2) 1.36 (0.95 - 1.94) 0.092 54 (13.9) 151 (18.3) 0.72 (0.52 - 1.01) 0.058 
FASL, -844 T>C         
T/T 216 (64.7) 297 (64.6) Ref Ref 63 (33.0) 159 (38.0) Ref Ref 
C/T 108 (32.3) 152 (33.0) 0.98 (0.72 - 1.32) 0.880 97 (50.8) 195 (46.7) 1.26 (0.86 - 1.84) 0.240 
C/C 10 (3.0) 11 (2.4) 1.25 (0.52 - 3.00) 0.616 31 (16.2) 64 (15.3) 1.22 (0.73 - 2.05) 0.448 
T 540 (80.8) 746 (81.1) Ref Ref 223 (58.4) 513 (61.4) Ref Ref 
C 128 (19.2) 174 (18.9) 1.02 (0.79 - 1.31) 1.000 159 (41.6) 323 (38.6) 1.13 (0.89 - 1.45) 0.323 
Chapter 3: Association studies – candidate genes 
 
122 
3.3.1 Additional analysis: Gene-environment interactions 
Since publication of the paper, demographic information for the South African 
Black and Mixed ancestry controls became available, as shown in Table 3.1.  
 
Table 3.1: Demographic information for cases and controls 
 Black population  
Mixed Ancestry 
population 
  Cases Controls   Cases Controls 
Total 358 477 
 
201 427 
Age, mean years (SD) 59.8 (11.3) 56.9 (14.7) 
 
60.5 (10.6) 57.7 (14.4) 
Sex, n (%): 
     Male 182 (50.8) 183 (38.4) 
 
131 (65.2) 122 (28.6) 
Female 176 (49.2) 293 (61.4) 
 
70 (34.8) 300 (70.3) 
Unknown 0 1 (0.2) 
 
0 5 (1.2) 
Smoking status, n (%): 
     Smoker 228 (63.7) 177 (37.1) 
 
189 (94.0) 269 (63.0) 
Non-smoker 130 (36.3) 294 (61.6) 
 
10 (5.0) 158 (37.0) 
Unknown 0 6 (1.3) 
 
2 (1.0) 0 
Alcohol consumption, n (%): 
     Drinker 228 (63.7) 262 (54.9) 
 
164 (81.6) 184 (43.1) 
Non-drinker 128 (35.8) 214 (44.9) 
 
37 (18.4) 242 (56.7) 
Unknown 2 (0.6) 1 (0.2)   0 1 (0.2) 
 
Therefore, we have used this information to carry out further analysis of 
possible gene-environment interactions for those variants with a significant or 
suggested association with OSCC (P<0.05). Due to the low number of non-
smokers in the Mixed Ancestry population, only alcohol analysis was carried 




Table 3.2: Gene-alcohol interaction tests  
Tests are for the variants which showed evidence of association (P<0.05) with OSCC in the South African Mixed Ancestry population.  
Includes stratified analysis of alcohol consumption, a case-only analysis, and a gene-environment (G x E) interaction test using logistic  
regression controlling for age, sex, tobacco use and alcohol consumption.  
 
  Case-control: Drinkers only  Case-control: Non-drinkers only 








Controls OR (95% CI) P-value 
ADH1B Arg48His T 0.056 0.086 0.63 (0.35 - 1.15) 0.1328  0.042 0.104 0.38 (0.11 - 1.24) 0.0949 COX-2 -1195 A>G G 0.089 0.157 0.52 (0.32 - 0.85) 0.0079  0.162 0.153 1.07 (0.55 - 2.09) 0.8341 CASP8 Asp302His C 0.183 0.108 1.84 (1.19 - 2.85) 0.0060  0.111 0.138 0.78 (0.36 - 1.71) 0.5400 ALDH2 +82 G>A A 0.394 0.503 0.64 (0.48 - 0.87) 0.0045  0.432 0.481 0.82 (0.50 - 1.34) 0.4320 MGMT Leu84Phe T 0.233 0.175 1.43 (0.98 - 2.08) 0.0619  0.176 0.162 1.10 (0.58 - 2.11) 0.7643 
 
  Case-only  G x E 




drinkers OR (95% CI) P-value  OR (95% CI) P-value 
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The case-control interaction analysis suggested that several variants are 
associated with OSCC in drinkers but not in non-drinkers. The association in 
drinkers became more significant than the overall association for two 
variants: COX-2 -1195 A>G (drinkers P=0.0079; overall P=0.014) and 
CASP8 Asp302His (drinkers P=0.006; overall P=0.040). However, the case-
only analysis does not identify significant differences between drinkers and 
non-drinkers for any of the variants, and nor does the interaction test using 
logistic regression. This is perhaps due to the low number of non-drinkers in 
this population (n= 37, 18.4% of samples), and would probably require a 
much larger sample size to determine whether any gene-environmental 
interactions exist.  
 
In summary, the revised interaction analysis using smoking and drinking data 
from controls is consistent with the analysis reported in our paper. 
 
3.4 Summary 
This chapter investigated genetic susceptibility to OSCC in the South African 
Black and Mixed Ancestry populations, focusing on 13 variants in 8 genes 
with robust evidence of association in other populations. A SNP in the 
promoter region of ALDH2 (+82 G>A, rs886205) was associated with a 
reduced risk of OSCC in the Mixed Ancestry population. None of the variants 
were associated with the disease in the Black population. This study 
suggests differences in the genetic contribution to OSCC both between the 
Black and Mixed Ancestry populations, and between the South Africans and 
other high risk populations.   
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4 Distinct genetic association at the PLCE1 locus 
with oesophageal squamous cell carcinoma in the 
South African population 
The work in this chapter was published in Carcinogenesis in 2012 (Bye et al. 
2012). The paper is included as published on pages 132-146. A brief 
introduction to the area of work is given below. 
 
4.1 Genome-wide association studies for OSCC in the 
Chinese population 
Three independent OSCC genome-wide association studies were published 
during 2010 and 2011 (Abnet et al. 2010; Wang et al. 2010.a; Wu et al. 
2011.c). All studies consisted of over 1,000 cases and 1,000 controls in the 
original GWAS, with replication phases ranging from ~2,100 to ~7,600 cases 
and ~3,300 to ~11,000 controls. In total, eight variants in six loci were 
associated with OSCC at genome-wide significance (P<5 x 10-8). Of these, 
five were novel loci, with the known loci located on chromosome 12q24, a 
region containing ALDH2. This region has been investigated in many 
candidate gene association studies including in the South African Black and 
Mixed Ancestry populations, see Chapter 3. The novel susceptibility loci are 





Table 4.1: Summary of OSCC genome-wide association results in Chinese populations 
 







Controls OR (95% CI) P-value 
PLCE1 rs2274223 Exonic 
Wang et al. 2010.a  0.27 0.2 1.43 (1.37 - 1.49) 7.46 x 10
-56 
Abnet et al. 2010 A, G 0.259 0.209 1.34 (1.22 - 1.48) 3.85 x 10-9 
Wu et al. 2011.c  0.26 0.21 1.34 (1.26 - 1.42) 3.73 x 10
-20 
         
C20orf54/SLC52A3 rs13042395 Upstream Wang et al. 2010.a C, T 0.24 0.32 0.66 (0.58 - 0.74) 1.21 x 10-11 
         
near UNC5CL rs10484761 Downstream Wu et al. 2011.c A, G 0.12 0.09 1.33 (1.23 - 1.45) 7.48 x 10-12 
         
PDE4D rs10052657 Intronic Wu et al. 2011.c C, A 0.08 0.12 0.67 (0.62 - 0.73) 1.97 x 10-19 
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PLCE1 rs2274223 was the only variant to be associated in more than one 
GWAS, being identified in all three studies, thus providing strong evidence that it 
is a true susceptibility locus in this population. This was also the only associated 
variant to be located in an exon, producing an amino acid change from histidine 
to arginine at position 1927. PLCE1 encodes phospholipase C epsilon 1, which 
converts phosphatidyl-inositol 4,5-biphosphate to form diacylglycerol and 
inositol 1,4,5-triphosphate, which leads to the activation of protein kinase C. 
Further insight into the functions of the protein is explored in the discussion 
section of the published paper. Before the identification of PLCE1 variants as 
susceptibility loci for OSCC, PLCE1 mRNA expression was known to be 
reduced in certain tumour tissue compared to normal tissue, for example, in 
colorectal cancer (Sorli et al. 2005; Wang et al. 2008; Danielsen et al. 2011; 
Wang et al. 2012). In addition, the corresponding PLCE1 protein level was also 
found to be decreased in tumour tissue (Wang et al. 2012). Together with the 
observation that overexpression of PLCE1 inhibited proliferation of colon cancer 
cells, PLCE1 was suggested to have a suppressive role in the development of 
this cancer (Wang et al. 2012). In OSCC, PLCE1 mRNA was also reduced in 
tumour tissue compared to normal tissue (Hu et al. 2012), but levels of protein 
production were conflicting with one study showing increased levels (Wang et 
al. 2010.a) and another having no significant changes compared to normal 
tissue (Hu et al. 2012). This is in contrast to the colorectal cancer study (Wang 
et al. 2012).  
 
Several studies have attempted to replicate the association of PLCE1 
rs2274223 with OSCC. In two additional Chinese populations, one from a high-
risk disease region and one from a lower-risk region, the variant was associated 
with an increased risk of OSCC in a recessive model for GG vs. AA genotypes 
(OR = 1.95, 95% CI = 1.05 – 3.59, P=0.034; and OR = 1.49, 95% CI = 1.03-
2.17; P=0.037, for each population respectively) (Gu et al. 2012; Hu et al. 2012). 
Neither of these studies report the allelic association result which is the analysis 
model used in GWAS. Calculating this from the number of each genotype stated 
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in the papers leads to allelic associations of P=0.0055 (OR =1.40, 95% CI = 
1.10-1.78) and P=0.0018 (OR=1.25; 95% CI =1.08-1.43) for the high and low-
risk regions of China, respectively. In a Caucasian USA study of 52 OSCC 
cases and 211 controls, the rs2274223 GG genotype was reported as being 
protective against the disease in a dominant model (OR = 0.5, 95% CI = 0.3 – 
1.0 for GG vs. AA genotype), which is the opposite effect observed in the 
Chinese populations (Palmer et al. 2012). However, the authors did not report p-
values and they did not account for multiple testing. Calculating the allelic 
association using genotype numbers reported, no significant association with 
disease was identified (P=0.352; OR = 0.82, 95% CI = 0.53-1.25). Whether this 
variant has an opposite effect on OSCC susceptibility in Caucasians compared 
to Chinese populations needs to be further explored using a much larger sample 
size since the published study would have very low power to detect the effect 
sizes reported in the Chinese studies.  
 
RUNX1 (Runt-related transcription factor 1) encodes for a transcription factor 
which, when part of a protein complex, is able to regulate the transcription of 
proteins involved in growth, survival and differentiation pathways (reviewed in 
Blyth et al. 2005). The protein is known to be essential for haematopoiesis 
(Okuda et al. 1996), and is frequently reported to be involved in the 
development of a variety of leukaemias through chromosomal translocations 
and point mutations. For example, the RUNX1-ETO chromosome 
rearrangement is present in 10-20% of acute myeloid leukaemias (Blyth et al. 
2005). The fusion proteins produced from chromosomal translocations are 
thought to act as dominant negative inhibitors of expression of the normal 
RUNX1 gene and may also acquire novel functions (Blyth et al. 2005). RUNX1 
is also downregulated in solid cancers, including gastric cancer (Sakakura et al. 
2005). In addition to this tumour suppressive role, RUNX1, like other RUNX 
genes, is proposed to also act as an oncogene in a context-dependent manner 
(reviewed in Blyth et al. 2005). This is supported by the amplification or 
increased expression of RUNX1 in several cancers, including childhood acute 
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lymphoblastic leukemia (reviewed in Roumier et al. 2003) and endometrial 
carcinoma (Planaguma et al. 2004). In a small study of OSCC patients, RUNX1 
expression was found not to be statistically different between tumour and 
normal tissue (Tonomoto et al. 2007).   
 
This complex role of RUNX1 in cancer development is probably due to its ability 
to both activate and repress transcription of genes involved in key pathways of 
growth and differentiation, and hence the function of downstream targets needs 
to be explored (reviewed in Blyth et al. 2005). In addition to regulating genes in 
the haematopoiesis pathway, RUNX1 may   also   be   involved   in   the   TGFβ   and  
p53 signalling pathways in myeloid cells (reviewed in Blyth et al. 2005). If this is 
also the case in other cell types, this may provide a potential link between 
RUNX1 and solid cancer. More recently, RUNX1 has also been implicated in 
immune response pathways, such as regulating interleukin 17-producing helper 
T cell differentiation (Lazarevic et al. 2011), which may also be relevant to 
tumour formation. 
 
The RUNX1 rs2014300 variant associated with OSCC is located within an intron 
and has an unknown function. No studies have attempted to replicate the 
original GWAS finding in OSCC or other cancers.  
 
Another variant associated with OSCC in one of these GWAS was rs13042395 
which is located downstream of C20orf54, also known as SLC52A3, a riboflavin 
transporter (Wang et al. 2010.a). Riboflavin, or vitamin B2, is essential in cellular 
homeostasis for normal growth and development, and also plays a role in 
carbohydrate, lipid and amino acid metabolism (Subramanian et al. 2011). 
Riboflavin deficiency has been associated with an increased risk of OSCC in 
some studies (Siassi and Ghadirian 2005) but not others (Siassi et al. 2000), 
with riboflavin supplementation possibly leading to a reduced incidence of 
OSCC (Blot et al. 1993; He et al. 2009). The function of the associated 
rs13042395 variant is unknown. Candidate gene association studies have 
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attempted to replicate the GWAS finding without success: the variant was not 
associated with OSCC in another Chinese population or a Caucasian population 
from USA (Gu et al. 2012; Palmer et al. 2012). In the latter study particularly, 
this may be due to an under-powered study as sample sizes were very small 
with only 52 OSCC cases and 211 controls (Palmer et al. 2012). Other variants 
in C20orf54 have also been tested for association with OSCC, with Ji et al. 
(2011) identifying two functional variants in this gene associated with the 
disease.  
 
PDE4D is a c-AMP phosphodiesterase, responsible for the hydrolysis of cAMP 
to   form   5’AMP.   cAMP   is   involved   in   several cellular signalling pathways 
including proliferation and apoptosis (Savai et al. 2010). PDE4D is proposed to 
be a tumour suppressor gene based on deletions observed in oesophageal 
adenocarcinoma and lung cancer (Weir et al. 2007; Nancarrow et al. 2008; Gu 
et al. 2010). However, overexpression of PDE4D in lung tumours resulted in 
increased cell proliferation, with decreased proliferation observed when PDE4D 
was inhibited (Pullamsetti et al. 2012). These conflicting reports may be due to 
cAMP having both pro-apoptotic and anti-apoptotic roles (reviewed in Insel et al. 
2012). The PDE4D rs10052657 variant associated with OSCC in the study by 
Wu et al. (2011) has not been tested for association in any other populations or 
with different cancer subtypes. It is located within an intron, with an unknown 
functional effect. 
 
Finally, a variant on chromosome 6p21 was found to be associated with OSCC 
in a region which contains no known genes. The nearest gene, which is located 
about 200 Kb away, is UNC5CL, which inhibits activation of the NF-kB 
transcription factor and hence, may regulate downstream pathways of NF-kB 
including cell proliferation. The variant was not associated with head and neck 
cancer in a Chinese population (Yuan et al. 2013), and has not been further 
investigated in OSCC.  
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4.2 Association studies in South African populations 
The aim of this chapter was to investigate the novel loci associated with OSCC 
in the Chinese GWAS studies with genetic susceptibility to OSCC in the South 
African Black and Mixed Ancestry populations. Although not all of the loci 
currently have a known role which would indicate an involvement in cancer 
development, future functional work may establish this. This work is published in 
my   paper   entitled   “Distinct genetic association at the PLCE1 locus with 
oesophageal squamous cell carcinoma in the South African  population”, which 
is presented in journal format overleaf. Details of the Materials and Methods are 
given in Chapter 2. 
 
My contribution to this paper has been to perform all the lab work, including the 
genotyping and Sanger sequencing, and the analysis of results, as well as 
writing the paper, together with C. Mathew. 
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Oesophageal squamous cell carcinoma (OSCC) has a high 
prevalence in the Black and Mixed Ancestry populations of 
South Africa. Recently, three genome-wide association studies 
in Chinese populations identified five new OSCC susceptibility 
loci, including variants at PLCE1, C20orf54, PDE4D, RUNX1 and 
UNC5CL, but their contribution to disease risk in other popula-
tions is unknown. In this study, we report testing variants from 
these five loci for association with OSCC in the South African 
Black (407 cases and 849 controls) and Mixed Ancestry (257 cases 
and 860 controls) populations. The RUNX1 variant rs2014300, 
which reduced risk in the Chinese population, was associated 
with an increased risk of OSCC in the Mixed Ancestry population 
[odds ratio (OR) = 1.33, 95% confidence interval (CI) = 1.09–1.63, 
P = 0.0055], and none of the five loci were associated in the Black 
population. Since PLCE1 variants increased the risk of OSCC in 
all three Chinese studies, this gene was investigated further by 
sequencing in 46 Black South Africans. This revealed 48 vari-
ants, 10 of which resulted in amino acid substitutions, and much 
lower linkage disequilibrium across the PLCE1 locus than in the 
Chinese population. We genotyped five PLCE1 variants in cases 
and controls, and found association of Arg548Leu (rs17417407) 
with a reduced risk of OSCC (OR = 0.74, 95% CI = 0.60–0.93, 
P = 0.008) in the Black population. These findings indicate sev-
eral differences in the genetic contribution to OSCC between the 
South African and Chinese populations that may be related to dif-
ferences in their genetic architecture.
Introduction
Oesophageal cancer is the eighth most common cancer worldwide 
and the sixth most common form of death from cancer (1). The pre-
dominant subtype in developing countries is oesophageal squamous 
cell carcinoma (OSCC), whereas oesophageal adenocarcinoma is 
more common in the western world where its incidence is increas-
ing. High-risk regions for OSCC include southern Africa, Japan, 
China and northern Iran. In southern Africa, oesophageal cancer is 
the third most common cancer in both males and females with age-
adjusted incidence rates of 22.3 and 11.7 per 100 000, respectively 
(2); higher rates are observed in certain regions such as the Eastern 
Cape Province of South Africa (3). Environmental risk factors for 
the development of OSCC in South Africa include alcohol intake 
and tobacco use, nutritional deficiencies, consumption of Fusarium-
(fungi) contaminated maize and infection with human papilloma 
virus (reviewed in ref. 4).
Candidate gene studies have analysed multiple genetic variants for 
association with OSCC in two indigenous South African populations, 
the Mixed Ancestry and the Black populations, with a high prevalence 
of this disease. Single nucleotide polymorphisms (SNPs) in GSTM1, 
GSTP1 (5), CYP3A5 (6) and CYP2E1 (7) showed some evidence of 
association, although sample sizes were small and data from the two 
populations were pooled in some analyses. In view of the differences 
in population structure between these two South African populations 
(8), recent studies by our group have analysed the Black and Mixed 
Ancestry populations separately, and increased the power to detect 
association by expansion of the sample sizes. We reported signifi-
cant association of a 37 kb deletion in GSTT2B (9) and of the variant 
ALDH2 + 82 G>A (rs886205) (10) with OSCC in the Mixed Ancestry 
population. However, none of the variants tested in these studies were 
associated with OSCC in the Black South African population, which 
may be related to differences in their ancestry or environmental expo-
sures (10), or to chance.
The development of genome-wide association scans (GWAS) has 
had a major impact on the discovery of susceptibility genes for com-
plex disease. The first GWAS for OSCC was published in 2009 and 
identified significant associations with ALDH2 Glu504Lys (rs671) on 
chromosome 12q24 and ADH1B Arg48His (rs1229984) on chromo-
some 4q23 in the Japanese population (11). These SNPs were tested 
for association in the South African Black and Mixed Ancestry popu-
lations; the ALDH2 Glu504Lys variant was non-polymorphic in both 
populations, and ADH1B Arg48His showed a suggestive association 
in the Mixed Ancestry population but was non-polymorphic in the 
Black population (10). Recently, three independent OSCC GWAS in 
Chinese populations have identified a total of eight SNPs in six suscep-
tibility loci, including PLCE1 His1927Arg (rs2274223) on chromo-
some 10q23, which was the only locus significantly associated in all 
three studies (12–14). Other loci identified were C20orf54/SLC52A3 
(rs13042395) on chromosome 20p13 (13), PDE4D (rs10052657) on 
chromosome 5q12 (14), RUNX1 (rs2014300) on chromosome 21q22.3 
(14), a variant near UNC5CL (rs10484761) on chromosome 6p21.1 
(14), and three SNPs at a locus on 12q24—ACAD10 (rs11066015), 
C12orf51 (rs2074356) and rs11066280 (14). The contribution of the 
new loci to the risk of OSCC in other populations is unknown.
The aim of this study was to determine whether the new loci identi-
fied in the Chinese GWAS were associated with OSCC in the South 
African Black and Mixed Ancestry populations, and to investigate 
genetic variation and the genetic architecture of the PLCE1 gene in 
the South African population.
Materials and methods
Study subjects
This study consisted of 407 OSCC patients and 849 controls from the South 
African Black population, and 257 OSCC patients and 860 controls from the 
South African Mixed Ancestry population. The Black patients were mainly 
Xhosa-speakers (98.8%) from the Eastern or Western Cape of South Africa. 
The Black controls were recruited from factories and outpatient clinics in the 
Western Cape. The proportion of Xhosa-speakers was 98.2%; they had no his-
tory of any cancer, lived in the same residential areas, and had a similar socio-
economic status to the patients. The Mixed Ancestry cases and controls were 
all recruited from the Western Cape. This is an admixed population with major 
ancestral components from the indigenous Khoisan, Bantu-speaking Africans, 
Europeans and Asians (8). Patients with histologically confirmed primary inva-
sive OSCC were recruited between March 2000 and August 2011 at Groote 
Schuur and Tygerberg Hospitals in Cape Town. Data on alcohol consumption 
and tobacco use were available for both cases and controls. Smoking status 
Abbreviations: CI, confidence interval; GWAS, genome-wide association 
scans; LD, linkage disequilibrium; MAF, minor allele frequency; OR, odds 
ratio; OSCC, oesophageal squamous cell carcinoma; SNP, single nucleotide 
polymorphisms; UTR, untranslated region.
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was subdivided into ever-smokers (those who had smoked at some point in 
their lives) or never-smokers. Drinkers were defined as subjects who consumed 
alcohol at least once every week. Demographic and exposure data are given 
in Table I. Whole blood samples were collected with informed consent from 
all subjects and DNA was extracted at the University of Cape Town. Ethical 
approval for the study was obtained from the joint University of Cape Town/
Groote Schuur Hospital Research Ethics Committee and the University of 
Stellenbosch/Tygerberg Hospital Ethics Committee.
SNP selection and genotyping
Index SNPs (those with the strongest evidence for association with OSCC in 
the Chinese GWAS studies) from five of the six loci were polymorphic in the 
Yoruban (Nigerian) and Masai in Kinyawa (Kenyan) HapMap populations, 
suggesting that they were likely to be informative in the Black South African 
population. These five SNPs, PLCE1 His1927Arg (rs2274223), C20orf54/
SLC52A3 (rs13042395), PDE4D (rs10052657), RUNX1 (rs2014300) and a 
variant near UNC5CL (rs10484761), were selected for genotyping. Two of 
the SNPs at the 12q24 locus (rs2074356 and rs11066280) were non-poly-
morphic in African HapMap populations. No HapMap data was available for 
rs11066015, but this SNP is in strong linkage disequilibrium (LD) with rs671 
in the Chinese population, which we found to be absent in both the Black and 
Mixed Ancestry South African populations (10). Thus, these three SNPs are 
likely to be rare or absent in our South African populations, and we would 
have limited power to detect association with OSCC. The five prioritized 
SNPs were genotyped in 407 cases and 849 controls from the South African 
Black population and 257 OSCC cases and 860 controls from the Mixed 
Ancestry population using validated TaqMan 5′ exonuclease SNP genotyping 
assays (Applied Biosystems). Reactions were carried out in 2.5 µl volumes 
in 96-well plates. Each reaction contained 20 ng DNA, Absolute QPCR ROX 
mix (ABgene) and TaqMan SNP assay mix (Applied Biosystems) according 
to assay instructions and were performed on a PTC-0225 DNA Engine (MJ 
Research). Fluorescent levels at the PCR endpoint were determined using a 
7900HT Fast Real-Time PCR system (Applied Biosystems) and genotypes 
assigned using SDS 2.2.2 software (Applied Biosystems).
Sequencing of PLCE1
The 34 exons of PLCE1 were sequenced by Sanger sequencing in 46 cancer 
patients (38 OSCC and 8 other cancers) from the Black South African popu-
lation. Exons were amplified by PCR with primers designed using Primer3 
(15) and synthesized by Integrated DNA Technologies. PCR was carried out 
in a 10 µl reaction containing 10 ng DNA, 5 µl 2× PCR mix (Promega), 0.4 
pmoles of each forward and reverse primer for all exons apart from exon 
1. For this exon, the reaction contained 1× Flexi reaction buffer (Promega), 
1.5 mM MgCl2, 0.4 pmoles of each forward and reverse primer, 1 U Flexi Taq 
polymerase (Promega), 0.2mM dNTP and 10% dimethyl sulfoxide. All reac-
tions were carried out on a PTC-0225 DNA Engine (MJ Research) using the 
following conditions: 2 min at 92°C; then 30 cycles of 20 s at 92°C, 30 s at 
the optimized annealing temperature, and between 30 s and 3 min at 72°C 
(depending on amplimer length); with a final 5 min at 72°C. Primer sequences 
and PCR conditions for each amplicon are shown in Supplementary Table 1, 
available at Carcinogenesis Online. Subsequent ExoSAP-IT clean up (USB 
Europe, Staufen, Germany) followed by forward and/or reverse cycle sequenc-
ing was performed for each exon using 8 pmoles of sequencing primer (see 
Supplementary Table 2, available at Carcinogenesis Online) and 0.25 μl of 
BigDye Terminator v3.1 (Applied Biosystems) in a 5.25  μl reaction vol-
ume under recommended reaction conditions. Products were analysed on an 
ABI3730xl DNA sequencer (Sequence Analysis, Applied Biosystems) and 
aligned to the human reference genome using Staden software package (16).
Genotyping of PLCE1 SNPs
Three non-synonymous SNPs in PLCE1, Arg548Leu (rs17417407), 
Pro1890Leu (rs58539480), and the novel variant Gly1199Ser were selected for 
genotyping in the Black South African population on the basis of strong evolu-
tionary conservation of the amino acid residue, a predicted damaging effect in 
at least one of the two programs, Polyphen 2 (17) and SIFT (Sorting Intolerant 
From Tolerant) (18), and a minor allele frequency (MAF) of >0.05 in this 
population. The variant Ile1777Thr (rs3765524) was also selected since it was 
very strongly associated with OSCC in the Chinese population and common 
in the Black South African population. A common insertion/deletion (indel) in 
the 5′-untranslated region (UTR) was also selected. These five variants were 
genotyped in an initial sample of 323 cases and 459 controls that was avail-
able from the Black South African population. If a suggestive association with 
OSCC was observed (P < 0.05) then further samples that subsequently became 
available were genotyped in an expanded sample set from this population (a 
total of 407 cases and 849 controls), and in the Mixed Ancestry population 
(257 cases and 860 controls). The SNPs were genotyped using custom KASP 
By-Design assays (KBioscience) following manufacturer’s instructions. The 
14 bp indel (CCCGGGCTCTGCCT) in the 5′UTR of exon 1 was PCR ampli-
fied and genotyped by size separation of PCR products using 3% agarose gel 
electrophoresis and visualized with ethidium bromide/UV light. Primers used 
for amplification were as follows: forward GGGAGCGGACTGTGAACG and 
reverse GTGTCCCCGCTACTGTGTGT. The 10 µl PCR reaction contained 
1× Flexi reaction buffer (Promega), 1.5 mM MgCl2, 0.4 pmoles of each for-
ward and reverse primer, 1 U Flexi Taq polymerase (Promega), 0.2 mM dNTP 
and 10% DMSO. Reaction conditions were as described previously, with 63°C 
annealing temperature and 30 s extension time.
Statistical analysis
Pearson’s chi-squared (χ2) test was used to determine whether the propor-
tions of genotypes were consistent with Hardy–Weinberg equilibrium, using 
a cut-off of P < 0.05. P values were >0.05 for all SNPs tested. Genotype and 
allele frequencies were calculated for cases and controls and the allele frequen-
cies compared using the Pearson’s chi-squared (χ2) test to test for associa-
tion with OSCC. For the association tests of the five Chinese GWAS SNPs, 
a Bonferroni-corrected P value of <0.01 (0.05/5) was used as a significance 
threshold to account for multiple testing. This threshold was also applied to 
the association tests of the five PLCE1 variants genotyped after identification 
by sequencing. No additional correction was applied for the two populations 
tested. Allelic odds ratios (OR) and 95% confidence intervals (CI) were cal-
culated using the common allele as the reference. As a secondary analysis, 
logistic regression was carried out adjusting for age, sex, smoking and alcohol 
consumption to determine whether these covariates influenced the association 
results determined using the Pearson’s (χ2) test; these results are reported as 
P(adjusted). For SNPs with suggestive evidence of allelic association (P < 0.05), 
the effect of alcohol and tobacco was investigated by testing for association 
in cases and controls stratified by smoking and drinking status. We tested for 
interactions by performing a case-only analysis of alleles based on smoking 
and drinking status, and by carrying out a gene–environment interaction test 
using logistic regression in a case–control analysis. The power of the study 
was determined using Quanto (http://hydra.usc.edu/gxe/). LD between PLCE1 
variants in the South African Black population was assessed using Haploview 
(19). PLCE1 haplotype analysis was performed using UNPHASED (20).
Table I. Characteristics of OSCC cases and controls in the South African Black and Mixed Ancestry populations
Black population Mixed Ancestry population
Cases Controls Cases Controls
n 407 849 257 860
*Age, mean years (SD) 59.8 (11.3) 48.8 (16.7) 60.6 (10.6) 46.7 (16.8)
Male 199 (48.9%) 335 (39.5%) 165 (64.2%) 309 (35.9%)
Female 208 (51.1%) 511 (60.2%) 91 (35.4%) 551 (64.1%)
Unknown 0 (0.0%) 3 (0.4%) 1 (0.4%) 0 (0.0%)
*Smoking status, n (%) Ever-smoker 242 (59.5%) 333 (39.2%) 240 (93.4%) 597 (69.4%)
Never-smoker 164 (40.3%) 505 (59.5%) 15 (5.8%) 258 (30.0%)
Unknown 1 (0.2%) 11 (1.3%) 2 (0.8%) 5 (0.6%)
*Alcohol consumption, n (%) Drinker 253 (62.2%) 452 (53.2%) 212 (82.5%) 419 (48.7%)
Non-drinker 151 (37.1%) 393 (46.3%) 45 (17.5%) 436 (50.7%)
Unknown 3 (0.7%) 4 (0.5%) 0 (0.0%) 5 (0.6%)
*Age, sex, smoking status and alcohol consumption were significantly different between cases and controls in both populations (P < 0.01).
*Sex, n (%) 
H.Bye et al.
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Five SNPs (PLCE1 rs2274223, RUNX1 rs2014300, C20orf54 
rs13042395, PDE4D rs10052657 and a variant near UNC5CL 
rs10484761) were tested for association in the South African Black 
and Mixed Ancestry populations (Table II). In the South African 
Mixed Ancestry population, the minor ‘A’ allele of rs2014300 
in RUNX1 was significantly associated with an increased risk of 
OSCC (OR = 1.33, 95% CI = 1.09–1.63, P = 0.0055), with minor 
allele frequencies of 43.8% and 37.0% in cases and controls, 
respectively. However, this effect is in the opposite direction to 
that found in the Chinese population, where the minor ‘A’ allele 
confers a reduced risk of OSCC (OR  =  0.70) (14). The other 
four SNPs were not associated with OSCC in this population. 
In the Black South African population there was no evidence 
of association with OSCC for any of the variants tested. In 
both populations, adjusting for covariates in logistic regression 
produced very similar results. None of the five loci was associated 
with OSCC in the Black population, and ORs were similar to the 
unadjusted analysis. In the Mixed Ancestry population, the four 
loci not associated with the unadjusted analysis were also not 
associated with the adjusted analysis, and the RUNX1 variant 
rs201400 remained associated with a moderately increased effect 
(ORadjusted = 1.51, 95% CI = 1.19–1.92; P(adjusted) = 0.0007). There 
were substantial differences in allele frequencies for three of the 
five SNPs in the two South African populations; for rs2014300 
and rs10484761, the minor allele in the Black population was 
the common allele in the Mixed Ancestry population, and the ‘T’ 
allele of rs13042395 was very rare (0.5%) in the Black population 
compared with the Mixed Ancestry population (6.8%) (Table II).
The association tests in the South African populations had good 
power to detect the ORs reported in the Chinese GWAS studies for 
four out of the five loci tested, if it is assumed that the associated vari-
ant and the causal variant are either the same or are in complete LD. 
The ORs reported in the Chinese studies were 1.34–1.43 (PLCE1), 
1.33 (UNC5CL), 0.67 (PDE4D), 0.70 (RUNX1) and 0.66 (C20orf54) 
(12–14). Using the allele frequencies determined in the Black con-
trols, power in the Black population was >80% to detect the effects 
seen in PLCE1, UNC5CL, PDE4D and RUNX1, and there was 80% 
power to detect ORs of 1.27, 1.28, 1.49 and 1.28 for these four loci, 
respectively. In the Mixed Ancestry population, power was somewhat 
lower but still adequate at >75% for these four SNPs, with 80% power 
to detect ORs of 1.33, 1.35, 1.54 and 1.35, respectively. The low fre-
quency of the C20orf54 SNP rs13042395 in both populations (0.5% 
and 6.8% in Black and Mixed Ancestry controls, respectively) did 
not provide sufficient power to detect the association reported in the 
Chinese population.
Sequencing and genotyping of PLCE1
The strong association of the SNP rs2274223 (His1927Arg) in 
PLCE1 with OSCC in the Chinese population (12–14) was not 
replicated in either of the South African populations tested. Since 
genetic variability is highest in African populations and LD is gen-
erally much lower, we investigated the PLCE1 locus in the Black 
South African population by sequencing all 34 exons of PLCE1 and 
adjacent splice sites in 46 individuals from this population to exam-
ine LD and to identify potential functional sequence variants. A total 
of 48 polymorphic variants were detected, including 26 known 
SNPs, 11 novel variants and one known 14 bp insertion/deletion in 
the 5′-UTR. Ten of these 48 variants produce amino acid substitu-
tions in the encoded PLCE1 protein and could therefore be consid-
ered as candidate OSCC causal variants; their locations relative to 
the putative protein domains of PLCE1 are shown in Figure 1. The 
potential functional consequences of these variants were assessed 
by examination of evolutionary conservation across multiple spe-
cies and use of the predictive programs Polyphen2 and SIFT (see 
Materials and methods). Six of the ten SNPs were predicted to have 
probable or possible damaging effects by one or more of these meth-
ods (Table III).
Pair-wise analysis of all 48 variants detected by sequencing in the 
46 Black South African individuals showed that there is very low LD 
across the PLCE1 gene in this population (Supplementary Figure 1, 
available at Carcinogenesis Online). Sixteen of these variants have 
also been genotyped in the HapMap project, allowing a comparison 
of the LD structure between the South African Black population and 
HapMap populations such as the Han Chinese from Beijing (CHB) and 
Yoruba in Ibadan, Nigeria (YRI) (Figure 2; Supplementary Figure 2, 
Table II. Case–control analysis of five loci from Chinese GWAS in South African Black and Mixed Ancestry OSCC
Black population Mixed Ancestry population
Cases Controls OR (95% CI) P value Cases Controls OR (95% CI) P value
PLCE1 
rs2274223
His/His 140 (33.5%) 302 (35.5%) His/His 78 (30.7%) 310 (36.2%)
His/Arg 208 (49.8%) 411 (48.4%) His/Arg 130 (51.2%) 408 (47.6%)
Arg/Arg 70 (16.7%) 137 (16.1%) Arg/Arg 46 (18.1%) 139 (16.2%)
His 488 (58.4%) 1015 (59.7%) Reference — His 286 (56.3%) 1028 (60.0%) Reference —
Arg 348 (41.6%) 685 (40.3%) 1.06 (0.89–1.25) 0.5208 Arg 222 (43.7%) 686 (40.0%) 1.16 (0.95–1.42) 0.1386
C20orf54 
rs13042395
C/C 402 (99.5%) 837 (98.9%) C / C 221 (87.0%) 742 (87.2%)
C/T 2 (0.5%) 9 (1.1%) C / T 32 (12.6%) 103 (12.1%)
T/T 0 (0.0%) 0 (0.0%) T / T 1 (0.4%) 6 (0.7%)
C 806 (99.8%) 1683 (99.5%) Reference — C 474 (93.3%) 1587 (93.2%) Reference —
T 2 (0.2%) 9 (0.5%) 0.46 (0.10–2.15) 0.3150 T 34 (6.7%) 115 (6.8%) 0.99 (0.67–1.47) 1.0000
near UNC5CL 
rs10484761
G/G 107 (26.9%) 225 (26.6%) A / A 105 (41.5%) 398 (47.2%)
G/A 210 (52.8%) 435 (51.4%) G / A 117 (46.2%) 362 (42.9%)
A/A 81 (20.4%) 186 (22.0%) G / G 31 (12.3%) 84 (10.0%)
G 424 (53.3%) 885 (52.3%) Reference — A 327 (64.6%) 1158 (68.6%) Reference —
A 372 (46.7%) 807 (47.7%) 0.96 (0.81–1.14) 0.6542 G 179 (35.4%) 530 (31.4%) 1.20 (0.97–1.47) 0.0933
PDE4D 
rs10052657
C/C 300 (74.6%) 642 (76.0%) C / C 171 (67.1%) 613 (71.6%)
C/A 94 (23.4%) 190 (22.5%) C / A 79 (31.0%) 220 (25.7%)
A/A 8 (2.0%) 13 (1.5%) A / A 5 (2.0%) 23 (2.7%)
C 694 (86.3%) 1474 (87.2%) Reference — C 421 (82.5%) 1446 (84.5%) Reference —
A 110 (13.7%) 216 (12.8%) 1.08 (0.85–1.38) 0.5329 A 89 (17.5%) 266 (15.5%) 1.15 (0.88–1.50) 0.3005
RUNX1 
rs2014300
A/A 152 (37.7%) 311 (37.1%) G / G 81 (32.1%) 346 (40.9%)
A/G 197 (48.9%) 378 (45.1%) A / G 121 (48.0%) 374 (44.2%)
G/G 54 (13.4%) 149 (17.8%) A / A 50 (19.8%) 126 (14.9%)
A 501 (62.2%) 1000 (59.7%) Reference — G 283 (56.2%) 1066 (63.0%) Reference —
G 305 (37.8%) 676 (40.3%) 0.90 (0.76–1.07) 0.2342 A 221 (43.8%) 626 (37.0%) 1.33 (1.09–1.63) 0.0055
OSCC susceptibility in South African populations
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available at Carcinogenesis Online). This shows that the South African 
Black population has the lowest level of LD across PLCE1 among 
these three populations. The index SNP rs2274223 is in very strong 
LD with multiple other SNPs in the CHB population, but is in low 
to moderate LD with other SNPs in the South Africans. The variants 
Arg548Leu (rs17417407), Ile1777Thr (rs3765524), Pro1890Leu 
(rs58539480) and the novel Gly1199Ser SNP, together with the 
5′-UTR 14 bp indel, were selected for genotyping (see Materials and 
methods) and tested for association with OSCC in the Black South 
African population. Results for allelic association tests are shown in 
Table IV. Only one variant, PLCE1 Arg548Leu (rs17417407), showed 
suggestive evidence for association with OSCC (P  =  0.035) and 
was therefore genotyped in an additional set of cases and controls. 
Combined analysis of 407 cases and 849 controls revealed a MAF (T, 
548Leu) of 16.6% in cases and 21.1% in controls, giving an OR = 0.74 
(95% CI = 0.60–0.93, P = 0.008). Similar results were obtained for 
these five PLCE1 variants when adjusting for age, sex, smoking and 
drinking status, except that the rs1741707 association was slightly less 
significant (ORadjusted = 0.75, 95% CI = 0.59–0.95, P(adjusted) = 0.019). 
Haplotype analysis of the five SNPs and indel of PLCE1 show that 
none of the haplotypes were associated with OSCC in the Black South 
African population (P = 0.977 for overall association, data not shown). 
The Arg548Leu SNP (rs17417407) was also genotyped in the Mixed 
Ancestry population, but no evidence of association was detected, with 
MAF for the Leu allele of 17.4% and 18.0% in cases and controls, 
respectively (OR = 0.96, 95% CI = 0.74–1.25, P = 0.764).
Alcohol and smoking analysis
Gene–environment interactions between OSCC and smoking and 
alcohol drinking habits were tested for variants that showed an asso-
ciation with OSCC (P < 0.05). In the Mixed Ancestry population, 
RUNX1 rs2014300 showed no significant associations in case–control 
analysis for either drinkers or non-drinkers, or for a case-only analysis 
of drinkers versus non-drinkers (see Supplementary Table 3, available 
at Carcinogenesis Online). The low number of non-smokers (n = 15) 
in the Mixed Ancestry population prevented analysis by smoking sta-
tus. The PLCE1 Arg548Leu SNP (rs17417407) showed no interac-
tion with alcohol use in the Black population. When stratifying by 
smoking status in cases and controls, an association was observed in 
a case–control analysis of ever-smokers, OR = 0.64 (P = 0.005), with 
weakened association in never-smokers (OR = 0.87). However, the 
case-only analysis of ever- versus never-smokers was not significant 
(P = 0.16). Logistic regression analysis showed no evidence for an 
interaction with smoking or alcohol with either RUNX1 rs2014300 or 
PLCE1 Arg548Leu (rs17417407).
Discussion
The aim of this study was to determine whether five new loci reported 
to be associated with susceptibility to OSCC in the Chinese population 
(12–14) also contribute to susceptibility in two South African popu-
lations. In the South African Mixed Ancestry population, only one 
SNP, RUNX1 rs2014300, was associated with OSCC, with the minor 
Fig. 1. Potential functional variants detected in the PLCE1 gene. Top shows exon/intron structure with vertical lines representing exons for NM_016341.3 
(dotted vertical line reflects exon present only in NM_001165979.1). Locations of non-synonymous SNPs and 5′-UTR insertion/deletion identified by sequencing 
in the South African Black population are indicated with vertical arrows (* indicates novel variants). Bottom shows the predicted functional domains of the 
PLCE1 protein and the position of variants which are located within a domain.
Table III. PLCE1 non-synonymous SNPs in the South African Black population
SNP identifier Chr location (build 37), 
major > minor allele
Amino acid  
change
MAFa Amino acid conservationb Polyphen 2 (score) SIFT (score)
rs115135156 10:95848924, T>C Phe25Leu 0.043 Rhc, Moc, Doc, Elc, Opc Benign (0.013) Damaging (0)d
rs17417407 10:95931087, G>T Arg548Leu 0.178 Rh, Mo, Do, El, Op, Ch, X_t, Ze Probably damaging (0.981) Tolerated (0.12)
Novel 10:96014026, G>A Gly1120Asp 0.011 Rh, Mo, Do, El, Op, Ch, X_t Probably damaging (0.968) Damaging (0.04)
Novel 10:96018597, G>A Gly1199Ser 0.058 Rh, Mo, Do, El, Op, Ch, X_t Probably damaging (0.984) Tolerated (0.12)
rs2274224 10:96039597, C>G Pro1575Arg 0.318 Not conserved Benign (0) Tolerated (0.53)
rs61732525 10:96039606, A>G Asn1578Ser 0.045 Rh, Do, El, X_t, Ze Benign (0.002) Tolerated (0.42)
rs3765524 10:96058298, T>C Ile1777Thr 0.386 Not conserved Benign (0.002) Tolerated (0.85)
rs58539480 10:96066230, C>T Pro1890Leu 0.087 Rh, Mo, Do, El, Op, X_t, Ze Probably damaging (0.999) Tolerated (0.33)
rs2274223 10:96066341, A>G His1927Arg 0.489 Ze Benign (0) Tolerated (0.83)
rs3203713 10:96087728, A>G Lys2304Glu 0.141 Rhc, Doc, Elc Unknown Damaging (0.01) d
aMAF calculated from the number of individuals genotyped successfully (n = 43–46).
bAmino acid conservation is shown for Rhesus Macaque (Rh), Mouse (Mo), Dog (Do), Elephant (El), Opossum (Op), Chicken (Ch), Xenopus Tropicalis (X_t) 
and Zebrafish (Ze).
cConservation only available for nucleotide sequence.








‘A’ allele conferring an increased risk of disease (OR = 1.33, 95% 
CI = 1.09–1.63). However, the association is in the opposite direction 
to that found in the Chinese population, where allele ‘A’ is also the 
minor allele but is protective (OR = 0.70) (14). Since it is unlikely that 
the same allele of this SNP would have opposite effects on suscepti-
bility to the same disease in these two populations, the finding in the 
Mixed Ancestry population may be a false positive, despite remain-
ing significant after correction for multiple testing. Further analysis 
of this SNP in other populations would help to establish whether this 
association is specific to OSCC in the Chinese population.
In the South African Black population, none of the five SNPs 
showed evidence of association with OSCC. This is consistent with 
our previous study, in which none of the 13 variants associated with 
OSCC in other populations was associated in South African Black 
OSCC (10). There are several possible reasons for the lack of associa-
tion of the five SNPs in the South African populations. One is that the 
GWAS findings are false positives. This is very unlikely for PLCE1 
since the association has been observed in three independent studies 
(12–14). The associations at PDE4D and RUNX1 were convincingly 
replicated in the original study (14), with combined P values of 10–19 
and 10–21, respectively, so these are also probably to be robust find-
ings. Replication of the UNC5CL locus was less convincing (14), and 
the C20orf54 association was only observed in one of the three GWAS 
(13). A  meta-analysis of all three Chinese GWAS would help to 
resolve the status of some of these loci. An alternative explanation for 
the lack of association in South African OSCC is insufficient power. 
We had high power to detect the effect observed in the Chinese studies 
for four of the five SNPs, with the other SNP (C20orf54 rs13042395) 
being very rare in the Black population. However, if the effect size 
at these loci is much smaller in South Africans than in Chinese, the 
power of this study would be reduced. A  further possible reason is 
that the SNPs genotyped in the Chinese GWAS studies may not be the 
actual causal SNPs that are driving the association, but merely mark-
ers that tag them with high LD. Since LD is generally lower in African 
populations (21), our studies may not be able to detect an association 
if the causal SNP is not genotyped directly.
The importance of the PLCE1 locus in OSCC susceptibility in the 
Chinese population prompted us to investigate sequence variation 
in this gene and its genetic architecture in the South African Black 
population in more detail, since substantial differences in sequence 
variation and LD structure could exist between these two populations. 
Sequencing of the entire coding region in 46 individuals revealed 
that LD across PLCE1 was much weaker in the South African Black 
population compared with the Chinese. This suggests that very high 
density SNP analysis across its entire genomic structure would be 
required for a complete interrogation of the contribution of PLCE1 
to OSCC in this population. We tested five coding sequence changes 
that were conserved and/or predicted to alter protein function and 
an insertion/deletion polymorphism in the 5′-UTR as these were 
sufficiently common to allow detection of association with OSCC 
in the South African Black population. Only the Arg548Leu variant 
(rs17417407) was associated with OSCC. The Arg548 allele is 
conserved across species (Rhesus, Mouse, Dog, Elephant, Opossum, 
Chicken, Xenopus Tropicalis and Zebrafish) and is predicted to 
Fig. 2. HapMap LD structure for 16 SNPs across PLCE1 gene region. 
Plots show r2 values for pairwise LD between variants in the South African 
Black population and two HapMap populations, Yoruban from Nigeria and 
Han Chinese from Beijing. Colour schemes and labelling are according to 
Haploview as follows: white (r2 = 0), black (r2 = 1) or shades of grey (0 < r2 
< 1); numbers indicate r2 values (×100).
Table IV. Case–control analysis of five potential functional PLCE1 variants 
for OSCC in the South African Black population
Cases Controls OR (95% 
CI)
P value
5′-UTR 14 bp  
indel
Ins/Ins 185 (57.6%) 260 (57.0%)
Ins/Del 122 (38.0) 171 (37.5%)
Del/Del 14 (4.4%) 25 (5.5%)
Ins 492 (76.6%) 691 (75.8%) Reference —





Arg/Arg 226 (70.4%) 271 (61.5%)
Arg/Leu 81 (25.2%) 152 (34.5%)
Leu/Leu 14 (4.4) 18 (4.1%)
Arg 533 (83.0%) 694 (78.7%) Reference —





Gly/Gly 289 (90.0%) 410 (91.3%)
Gly/Ser 30 (9.3%) 38 (8.5%)
Ser/Ser 2 (0.6%) 1 (0.2%)
Gly 608 (94.7%) 858 (95.5%) Reference —





Ile/Ile 86 (27.2%) 126 (27.9%)
Ile/Thr 162 (51.3%) 233 (51.5%)
Thr/Thr 68 (21.5%) 93 (20.6%)
Ile 334 (52.8%) 485 (53.7%) Reference —





Pro/Pro 262 (85.3%) 375 (87.4%)
Pro/Leu 45 (14.7%) 53 (12.4%)
Leu/Leu 0 (0.0%) 1 (0.2%)
Pro 569 (92.7%) 803 (93.6%) Reference —
Leu 45 (7.3%) 55 (6.4%) 1.15 
(0.77–1.74)
0.490
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be ‘probably damaging’ by Polyphen2 but tolerated by SIFT. This 
SNP was not included in the GWAS SNP micorarrays used by 
the three Chinese studies. However, it is in complete LD (r2 =  1) 
with rs2689700 in the combined Chinese/Japanese (CHB/JPT) 
HapMap population, which is an intronic SNP that was present on 
the GWAS chips used in all three GWAS studies and is not listed 
as associated with OSCC. In both the Chinese/Japanese and South 
African Black populations, Arg548Leu rs17417407 is in very low LD 
with His1927Arg rs2274223 (r2 = 0.023 and 0.03, respectively), the 
Chinese OSCC index risk variant. This suggests that two independent 
variants in PLCE1 may contribute to OSCC susceptibility loci in the 
Chinese and South African Black populations.
An important question regarding the association at the PLCE1 locus 
is whether variants within PLCE1 itself are driving this association, 
since the GWAS signal appears to include at least one other adjacent 
gene, NOC3L (12–14). The protein encoded by PLCE1, phospholipase 
C epsilon 1, is responsible for the hydrolysis of phosphatidyl-inositol 
4,5-biphosphate to generate diacylglycerol and inositol 1,4,5-triphos-
phate, which causes the release of calcium and activation of protein 
kinase C. PLCE1 can also act as a guanine-exchange factor, activat-
ing Ras, which is unique to this class of phospholipase C enzymes; 
PLCE1 is itself activated by Ras and Rho family GTPases, and thus 
could be affected by the oncogenic properties of Ras in cancer cells, 
although this has not yet been shown (reviewed in ref. 22). Studies of 
PLCE1 expression and protein levels in tumours have produced con-
flicting results, with mRNA shown to be reduced in OSCC tissue (23), 
but with unchanged (23) or increased levels (13) of the protein being 
reported in tumour tissues compared with normal tissue. Activation 
of PLCE1 has also been linked to tumour cell migration in head and 
neck squamous cell carcinoma (24). However, sequence variation in 
PLCE1 has also been associated with non-cancer phenotypes. The 
Ile1777Thr variant (rs3765524), which is strongly associated with 
OSCC (12), is also associated with dengue shock syndrome (25), and 
biallelic mutations in PLCE1 are an important cause of nephrotic syn-
drome (26). The adjacent gene, NOC3L (also known as FAD24) has 
been shown to regulate DNA replication during adipogenesis (27). It 
has also been reported to have a role in repression of NF-κB activity 
and H-Ras-mediated transformation (28), and silencing of the gene 
produces sensitivity to Tamoxifen, a drug that inhibits estrogen recep-
tor α signalling in breast cancer (29). Fine mapping of the region of 
association with a dense panel of SNPs in parallel with functional are 
needed to confirm the identity of the causal gene.
Two of the SNPs showing the strongest association at the PLCE1 
locus in the Chinese population are the non-synonymous variants 
Ile1777Thr (rs3765524) and His1927Arg (rs2274223), which raises 
the question of whether one or other of them might be the causal vari-
ant at this locus. His1927Arg is located within the protein calcium-
dependent lipid-binding C2 domain of PLCE1, but our bioinformatic 
analysis of this variant (Table III) shows that it is not conserved and 
is scored as benign or tolerated by the functional prediction pro-
grams PolyPhen and SIFT. Ile1777Thr is located in the PI-PLC Y-box 
domain that is important for catalytic activity, but is not evolutionary 
conserved and is also scored as benign or tolerated by the prediction 
programs. Thus, neither variant has strong credentials as the causal 
variant. Interestingly, the Arg548Leu variant rs17417407, which 
showed modest association with OSCC in the South African Black 
population, is located in a Ras-guanine-exchange factor domain, and 
may therefore affects its capacity to activate the Ras protein. It does 
show strong evolutionary conservation and is predicted to be damag-
ing by one of the two prediction programs. It should also be noted that 
non-coding variants and synonymous SNPs may have important func-
tional effects (30,31), and multiple associations with complex disease 
have been detected in gene deserts, which do not contain any known 
coding genes (32). These classes of variants will need to be taken 
into account when attempting to define causal variants at complex 
disease loci.
In conclusion, this study has examined a series of new genetic 
associations with OSCC, which have emerged from GWAS in the 
Chinese population, in two indigenous populations from South 
Africa. None of these associations was replicated in either of the two 
indigenous South African populations studied. However, although 
none of the variants in PLCE1 that conferred an increased risk of 
OSCC in Chinese populations were associated in the South African 
populations, we found that the Arg548Leu variant rs17417407 is 
associated with a reduced risk of OSCC in the Black South African 
population. As discussed previously (10), the reasons for variation 
in genetic associations between populations may include differences 
in both genetic architecture and in environmental risk factors that 
interact with genetic factors to promote development of the disease. 
The emerging differences that we have observed between the genetic 
factors contributing to the development of OSCC in African versus 
Asian populations (9,10) suggest that well-powered GWAS in non-
Asian populations are needed to define the genetic basis of this cancer 
in Africa and elsewhere.
Supplementary material
Supplementary Tables 1–3 and Figures 1 and 2 can be found at http://
carcin.oxfordjournals.org/
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Supplementary Table I.  PCR primers for amplification of PLCE1 exons   







1 GGGAGCGGACTGTGAACG GAGCGCGAGGACACTTTTC 63 30 sec 444 
2 TTTTGGCTGGAAGCAGAAGT GCTATCAATTGGAGTATCTGTTTTCA 57 2 min 1922 
NM_001165979.1 
Exon 1 CCTCCCTCGATTCTGGGTAT AACAGTCCCCAGGATTCCAT 58 30 sec 472 
3 TTTGCACTTGGAGCATCTGA TTCTCTTAAAGAAGCGACTTTTACTT 55 30 sec 543 
4 CAGAACTCTTCACTAAGCAGAGGA CATGGAAGTGGCAAGACAGA 60 30 sec 568 
5 CCCAGCCAGGACCTACAG GCCTTTGGTGCTGAAAGAAG 60 30 sec 437 
6 GGAATTTAGGCTCCTTGCTG TCCAAGGATCTATGTGCTACCC 57 30 sec 482 
7 TCCTGGAGGCTCTTGTTTTC TTGGAATTGGTAAGGTTTGAAGA 57 30 sec 506 
8 CACCTGGCCTCGGTTATTAG TAAAAGCTGCCCAAGGTCAC 57 1 min 977 
9, 10, 11 TGGGTGGCCAGATCATTATT TTTGGAGAATCATGGCTTAGG 57 3 min 3108 
12+13 AGCTTCAATCTTAAATAACTTGCAC TTTCCCTACACAGCAGTAATAGC 55 30 sec 599 
14 TCCTATCACTATGTGAAGCCAGAA AGCCTGGCCACAGAGTAAGA 61 30 sec 591 
15, 16 CAGCCTTCTTTTCTCATTCTCTTC AGCCAGTTTTCCCACACATC 57 30 sec 722 
17 CCATTTGCCCTTCTGCTTTA GCTTGATGGTATGGGCTTGT 55 30 sec 459 
18 TGGCCTTATCCTCATGCTTC GTTGCAGTGAGCCAAGACTG 55 30 sec 425 
19 GCTTCTTTCCTAGTTCCTCTTCC TCTTGGGTGAGTGAGATGAGAG 57 30 sec 491 
20 CATTGCATTTCGAGGGAATC TGAATTCAGAAACTCCTGGACA 57 30 sec 433 
21, 22 TGCTTCAAGCCATCATTTTG TTCATGAGCATCAAGGCAAA 57 2 min 1506 
23 GCATGCAGTTCTTGTTGCAT CCAGCCTGAAATGCTGTTTT 58 30 sec 541 
24 TCCAAGAGGTATTCTGATGTGG AAACATCGGAGGCACAATTC 58 30 sec 592 
25 TGGGACGAATGGGTGATTAT TTCTGGGAACTAAATCTGTATGACC 58 30 sec 439 
26 TCATTCACTTTGTCCATTCCAG TGTGCTTCAAAAGTGCTCCA 58 30 sec 543 
27 CTGTTGGTTGCATGCCTGT GTGCCAAGTGTCAGCCATTA 58 30 sec 396 
28 CAAATGGACTCTCATCTTTTGC TCATCCACATGGACTTTTGC 57 30 sec 385 
29 TGAATAAGTTGTGCCGTTGC TGTGCAGAAGAATAAAACTGTTCA 57 30 sec 574 
30 GCACAGTAGTTTCCTCCTCTCA CACACACTCCCCTTTGAGGT 57 30 sec 484 
31 TCTGGAAGATCCCCTTCATC GACTGCTTAACCGCAAGCTC 57 30 sec 529 
32 GAGCTTGCGGTTAAGCAGTC CCATAGAGCCCTTGAAGAATG 57 1 min 1062 
33 CATTGTGAGTACAGAGGAAACAGTC TCTAGCCTGCCACCTGTTTT 57 1 min 692 
Exon numbers are based on GenBank accession number NM_016341.3, apart from NM_001165979.1 exon 1, as indicated.
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Supplementary Table II.  Primers for Sanger sequencing of PLCE1 
exons  
Exon  Forward primer Reverse primer 




CACATACTGTCAGACGAAGTGG   
CTGGAACTAGACAGACCTTCCA   
TGCTTTGAAGGCTCTTGTGA   
 
NM_001165979.1 
Exon 1 CCTCCCTCGATTCTGGGTAT AACAGTCCCCAGGATTCCAT 
3 TTTGCACTTGGAGCATCTGA   
4 CAGAACTCTTCACTAAGCAGAGGA   
5 CCCAGCCAGGACCTACAG   
6 GGAATTTAGGCTCCTTGCTG TCCAAGGATCTATGTGCTACCC 
7 TCCTGGAGGCTCTTGTTTTC   
8 
CACCTGGCCTCGGTTATTAG   
GACGGAGCTCATCCCTTG   
TGCTGGATTAAGTAGCCTGAC   
9 TGGGTGGCCAGATCATTATT   
10 CGGTCAGCCTTAATGTAGGTC   
11 CCACCAGATTAGCCCATTCA   
12+13 AGCTTCAATCTTAAATAACTTGCAC TTTCCCTACACAGCAGTAATAGC 
14 TCCTATCACTATGTGAAGCCAGAA   
15 CAGCCTTCTTTTCTCATTCTCTTC ATGGCCCGTGAGGTAGGTAT 
16 ATCCCTTGCAGAAGTTCGAG AGCCAGTTTTCCCACACATC 
17 CCATTTGCCCTTCTGCTTTA   
18 TGGCCTTATCCTCATGCTTC   
19 GCTTCTTTCCTAGTTCCTCTTCC   
20 CATTGCATTTCGAGGGAATC   
21 TGCTTCAAGCCATCATTTTG   
22 TCTAGGAAAGCTGTTGGGACA   
23 GCATGCAGTTCTTGTTGCAT   
24 TCCAAGAGGTATTCTGATGTGG AAACATCGGAGGCACAATTC 
25 TGGGACGAATGGGTGATTAT   
26 TCATTCACTTTGTCCATTCCAG   
27 CTGTTGGTTGCATGCCTGT   
28 CAAATGGACTCTCATCTTTTGC   
29 TGAATAAGTTGTGCCGTTGC   
30 GCACAGTAGTTTCCTCCTCTCA   
31 TCTGGAAGATCCCCTTCATC   
32 
GAGCTTGCGGTTAAGCAGTC   
AAAGTATCCAAACCAAGGAGGA   
ATGCTATTGAACACCGCCTA   
33 
CATTGTGAGTACAGAGGAAACAGTC   
TTGATGATTTCTGAACTGAAGC   




Supplementary Table III. Stratified analysis of smoking and alcohol use for variants associated with OSCC  
 
Smoking analysis could not be performed in the Mixed Ancestry population due to the low number of non-smokers (n=15)  
  
   Case-control: Drinkers only Case-control: Non- drinkers only Case-only: Drinkers vs. non-drinkers 

















Ancestry A 0.454/0.403 
1.23 
(0.97 - 1.57) 0.0563 0.367/0.336 
1.14 
(0.73 - 1.79) 0.5642 0.454/0.367 
1.44 
(0.90 - 2.30) 0.1297 
PLCE1 
Arg548Leu Black T 0.174/0.220 
0.73 
(0.55 - 0.97) 0.0288 0.160/0.203 
0.75 
(0.53 - 1.07) 0.1111 0.171/0.160 
1.09 
(0.74 - 1.60) 0.6777 
 
   Case-control: Ever smokers Case-control: Never smokers Case-only: Ever vs. never 





(95% CI) P-value 
MAF: cases/ 





(95% CI) P-value 
PLCE1 
Arg548Leu Black T 0.150/0.216 
0.64 
(0.47 - 0.88) 0.0052 0.187/0.209 
0.87 (0.63 - 
1.20) 0.4003 0.150/0.187 
0.77 
(0.53 - 1.11) 0.1635 
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Supplementary Fig. 1.  Linkage disequilibrium (LD) between all 48 polymorphic variants in 
PLCE1 identified by sequencing 46 individuals from the South African Black population; a) = 
r2,  b)  =  D’.  Colour  schemes  and  labelling  are  according  to  Haploview.  For  r2 plots: white (r2 = 
0), black (r2 = 1) or shades of grey (0 < r2 < 1), and numbers indicate r2 values (x 100).  For 
D’:  white  (D’  <  1;;  LOD  <  2),  shades  of  pink/red  (D’  <  1;;  LOD  ≥  2),  blue  (D’  =  1;;  LOD  <  2)  or  
bright  red  (D’  =  1;;  LOD  ≥  2).  Numbers   indicate  D’  values  (x  100).  Where numbers are not 
shown,  D’  =  1. 
  












































Supplementary Fig. 2. HapMap LD structure for 16 SNPs across PLCE1 gene region. Plots 
show  D’  values  for  pairwise  LD  between  variants  in  the  South  African  Black  population  and  two  
HapMap populations from Yoruban, Ibadan Nigeria and Han Chinese from Beijing. Colour 
schemes and labelling are according to Haploview: white (D’< 1; LOD < 2), shades of pink/red 
(D’< 1; LOD ≥ 2), blue (D’= 1; LOD < 2) or bright red (D’= 1; LOD ≥ 2). Numbers indicate 











This chapter investigated genetic susceptibility to OSCC in the South African 
Black and Mixed Ancestry populations, focusing on 5 loci that were associated 
with the disease in several GWAS in the Chinese population. The RUNX1 SNP 
rs2014300 was associated with an increased risk of OSCC in the South African 
Mixed Ancestry population, but this effect was the opposite of that reported in 
the Chinese and thus is not a replication. None of the index SNPs at the 5 loci 
was associated with the disease in the Black population.  
 
Since one of these variants, PLCE1 His1927Arg (rs2274223), was associated 
with OSCC in all three independent Chinese GWAS, it provided strong evidence 
for the involvement of this gene in disease susceptibility in the Chinese 
population. Therefore, PLCE1 was further investigated in the South African 
Black population by sequencing all exons to identify potential functional variants. 
Five potentially functional variants were selected for case-control association 
studies, and one of these, Arg548Leu (rs17417407), was found to be 
significantly associated with OSCC in the South African Black population. 
 
Although the incidence of OSCC is high in both South African and Chinese 
populations, this work suggests that the genetic contribution to the disease 
differs between these populations. 
 




5 Investigation of the genetic susceptibility to 
oesophageal cancer using the Immunochip 
5.1 Involvement of the immune system in cancer development 
A link between cancer and inflammation was first noted around 150 years ago, 
in 1863, when Rudolf Virchow observed that cancers originate at the site of 
chronic inflammation (reviewed in Balkwill and Mantovani 2001). Since that 
time, inflammation has been implicated in a number of different types of 
cancers, although the process is far from understood. Inflammation results in 
the recruitment of immune cells to a specific area which is controlled by a 
network of signalling molecules including cytokines, growth factors and 
chemokines. This inflammation may be caused by a number of factors, including 
chronic infections, chemical irritation and wound healing, which cause tissue 
damage.  
 
A variety of cancers are thought to involve inflammation. For example, in lung 
cancer, inflammation is caused by tobacco smoke, a chemical irritant which also 
causes DNA mutations, enabling cells to survive in this environment. 
Oesophageal adenocarcinoma develops in some individuals who suffer from 
gastroesophageal reflux disease, which causes inflammation in the oesophagus 
(Barrett’s  oesophagus).  World-wide, around 16% of cancers are thought to be 
attributable to infectious agents, with this figure rising to 32.7% in sub-Saharan 
Africa (de Martel et al. 2012). This includes cervical cancer (human papilloma 
virus),   Burkitt’s   lymphoma   (Epstein-Barr virus) and liver cancer (hepatitus 
viruses).  
 
The mechanism by which inflammation is involved in cancer development is not 
fully understood. It is thought that the increased epithelial cell turnover needed 
to repair tissue damage brought about by inflammation may result in mutations 
in the replacement cells to allow them to survive in the harsh conditions (Moss 
and Blaser 2005). These cells have an abnormal growth, leading to metaplasia 




and dysplasia, which is thought to be the precursor of cancer (Lu et al. 2006). 
Chronic activation of immune cells around these regions of pre-malignant 
tissues may promote tumour development by a number of mechanisms 
(reviewed in de Visser et al. 2006). This includes blocking CD8+ cytotoxic T 
lymphocyte responses to prevent the killing of tumour cells, and by promoting 
pro-tumour processes, including angiogenesis and proliferation, by the induction 
of signalling molecules such as growth factors and cytokines.  
  
It is suggested that polymorphisms in immune-related genes may determine an 
individual’s  response  to  inflammation,  and  hence  risk  of  cancer,  at  certain  sites  
(Savage et al. 2004). Indeed, genetic variants have been shown to be 
associated with cancer susceptibility. For example, polymorphisms in cytokines 
TNF-α, IL4, IL6, IL8 and IL10 are reported to be associated with an increased 
risk of oral cancer (reviewed in Serefoglou et al. 2008). In oesophageal 
squamous cell carcinoma, variants in TNF-α, TNF-β, IL23R, IL12A, IL12B, 
IL12Rβ1 and HLA-G  have reported to be associated with the disease in 
Chinese populations (Guo et al. 2005; Chu et al. 2012; Tao et al. 2012; Chen et 
al. 2012.a), as well as a polymorphism in IL6 in an Indian population (Upadhyay 
et al. 2008).  
 
5.2 The Immunochip 
The Immunochip is a custom genotyping array manufactured by Illumina which 
contains 196,524 variants that were chosen by groups researching 12 different 
immune-mediated inflammatory diseases (Trynka et al. 2011). These SNPs 
were either in regions of known associations in an attempt to fine-map the 
region, or had previously showed evidence of association but failed to meet the 
genome-wide significance threshold. The fine-mapping focused on 186 regions, 
with SNPs within 0.2 cM on either side of the top GWAS SNPs selected for 
inclusion on the Immunochip. These SNPs were selected from sequencing data 
obtained from individuals with European ancestry who were sequenced as part 
of the 1000 Genomes Project low-coverage pilot project, or from sequencing 




data by groups involved in the chip design. Additionally, SNPs were included 
which showed evidence of association in non-immunological diseases, including 
Barrett’s  oesophagus  and  oesophageal  adenocarcinoma,  Parkinson’s  Disease,  
and reading and mathematical abilities, studied in the Wellcome Trust Case-
Control Consortium 2 project 
(http://www.wtccc.org.uk/ccc2/wtccc2_studies.html). Due to the collaboration of 
researches in different fields, specifically in immune-related diseases, the 
demand for the Immunochip was high enabling the price per chip to be 
considerably lower than other genome-wide chips.  
 
The large number of SNPs on the Immunochip enables the degree of population 
structure of sample collections to be assessed. This had not yet been 
investigated in the South African oesophageal cancer cases and controls, and 
hence, the Immunochip provides a good opportunity to do so. This, together 
with evidence of the involvement of inflammation in cancer development and the 
low-cost of the Immunochip, provided the justification for genotyping these 
samples on this platform. 
 
 
5.3 Genotyping of South African oesophageal squamous cell 
carcinoma cases and controls using the Immunochip 
To explore the role of immune-related genes in susceptibility to oesophageal 
squamous cell carcinoma in the South African Black population, 300 cases and 
300 controls were genotyped on the Immunochip. This was the first large-scale 
genotyping study to be carried out in this population and, hence, was the first 
substantial investigation of population structure. A total of 300 cases and 300 
controls from the South African Black population were genotyped. In addition, 
50 cases and 50 controls from the South African Mixed Ancestry population 
were genotyped to examine population structure in this sample collection.  
 




5.3.1 Immunochip data quality control 
Several quality control (QC) steps were performed to ensure the data was of the 
highest quality before association tests were carried out. An initial QC step was 
first performed using GenomeStudio Data Analysis Software (see Methods). 
This removed six samples which had a genotyping call rate considerably lower 
than all other samples (<87% compared to >97%, respectively). Normalized 
intensities were then exported for the remaining 694 samples into optiCall 
(http://www.sanger.ac.uk/resources/software/opticall/), where the genotypes 
were re-called as the software is better for rare variant calling. QC steps were 
performed using the genotypes assigned using optiCall.  
 
These QC measures were as follows: 1) Principal component analysis (PCA) for 
removal of population outliers and to reassign samples which clustered with a 
different population; 2) PCA to remove duplicated and highly related samples; 3) 
Determination of sample call rates (for each sample, this was the percentage of 
polymorphic variants that were assigned a genotype), and removal of samples 
with <95% call rate; 4) Determination of SNP call rates (for each variant, this 
was the percentage of samples that were assigned a genotype), and removal of 
those SNPs with <95% call rate. 
 
5.3.1.1 Population stratification 
Principal component analysis (PCA) was used to examine population 
stratification (see Methods for details). PCA infers continuous axes of genetic 
variation, with each axis (or eigenvector) in turn accounting for as much 
variation as possible (Price et al. 2006). As such, populations with different 
geographical and ethnic origins separate into clusters, enabling outliers to be 
identified. A total of 27,132 independent SNPs were used in the analysis. The 
initial PCA plot is shown in Figure 5.1. 
 




















Figure 5.1: Immunochip PCA plots  








Figure 5.1(a) separates the South African Black and Mixed Ancestry populations 
along the eigenvector 1 axis, with the Black population tightly clustered and the 
Mixed Ancestry population showing varying Eigenvector 1 values. The majority 
of samples were clustered together in the Eigenvector 2 vs. 3 plot (Figure 
5.1(b)), which shows that the majority of the variation between samples has 
already been explained by eigenvector 1 (Figure 5.1(a)). Outliers were present 
in both plots which were defined by thresholds of eigenvector 3 <-0.5 or 
eigenvector 2 >0.3, based on the eigenvector 2 vs. eigenvector 3 PCA plot 
(Figure 5.1(b)). Outliers may indicate a distinct population or duplicated/related 
samples. The level of sample relatedness for the outliers was determined (see 
p.158), which showed that highly related samples were present. Only one of the 
related samples was kept in the analysis, and the PCA was repeated, as shown 
in Figure 5.2. Again, outliers were present, using a threshold of eigenvector 2 
values of >0.07 or <-0.06 based on the eigenvector 1 vs. eigenvector 2 PCA plot 
(Figure 5.2(a)). One of each highly related samples were removed.  





Figure 5.2: Immunochip PCA plots with outliers removed 








It was evident that some samples did not cluster with the population group that 
was self-declared by the individuals, with several Black individuals clustered 
with the Mixed Ancestry population, and vice versa. In total, 30 individuals 
clustered with a different population group using eigenvector 1=0 as a threshold 
(based on values in Figure 5.2(a)). For the self-declared Black population, 22 
individuals clustered with the Mixed Ancestry population (7 cases and 15 
controls), and 8 individuals from the Mixed Ancestry population clustered with 
the Black population (6 cases and 2 controls). These samples were kept in the 
analysis but reassigned to the population that was best described by the PCA 
analysis. 
 
The South African samples were also analyzed together with several HapMap 
populations in a PCA to determine how they cluster with known populations 
(Figure 5.3). The HapMap populations were: CEU (Utah residents with Northern 
and Western European ancestry from the CEPH collection), ASW (African 
ancestry in Southwest USA), JPT (Japanese in Tokyo, Japan) and YRI (Yoruba 
in Ibadan, Nigeria). The South African Black population clustered tightly near the 
YRI population, whereas the Mixed Ancestry population showed more genetic 
heterogeneity than any other population in the analysis.    
 


















Figure 5.3: Immunochip PCA plot of the South African samples together with HapMap 
populations 
Eigenvector 1 vs. eigenvector 2 (a), and eigenvector 2 vs. eigenvector 3 (b).  
HapMap populations: CEU = Utah residents with Northern and Western European ancestry from 
the CEPH collection; ASW = African ancestry in Southwest USA; JPT = Japanese in Tokyo, 








5.3.1.2 Sample genotype call rates 
Sample genotype call rates (the percentage of SNPs successfully assigned a 
genotype for each individual) are shown in Figure 5.4 for the Black and Mixed 
Ancestry populations. The threshold for acceptable call rates was set at 95% for 
both populations. As a result of this, 30 samples were removed from the Black 





Figure 5.4: Immunochip sample genotyping call rates  
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5.3.1.3 Removal of duplicated/related samples 
To test if duplicated or highly related samples were present, relatedness was 
estimated by pairwise identity-by-descent (IBD) probabilities in PLINK using the 
Pi-hat score. Pi-hat is an estimate of the proportion of the genomic variation that 
is shared, with identical samples (e.g. monozygotic twins or duplicated samples) 
having a Pi-hat score of 1, first-degree relatives a Pi-hat of 0.5, and second-
degree relatives 0.25.  
 
In total, 22 pairs of individuals (21 from Black population and 1 from Mixed 
Ancestry population) showed a high degree of relatedness (Pi-Hat>0.5), see 
Table 5.1. Included in this, are four individuals who have a high degree of 
relatedness with more than one individual. Only one sample from each set of 
highly related individuals (Pi-Hat>0.5) was retained in the analysis, with the 
others being removed based on the sample with the lowest SNP call rates. In 
total, 19 individuals (18 from Black population, 1 from Mixed Ancestry 




















Table 5.1: Highly related samples from the South African populations  
Highly related samples are those with Pi-hat>0.5. 
Sample 1 Sample 2 Pi_Hat 
Sample 1 – 
missing 
genotypes 





BN0468 BN0704 1 0.0020 0.0023 BN0704 
BN0535 BN0536 0.5975 0.0035 0.0024 BN0535 
BN0535 BN0770 0.6015 0.0035 0.0018 BN0535 
BN0535 BN0931 1 0.0035 0.0036 BN0931 
BN0536 BN0770 1 0.0024 0.0018 BN0536 
BN0536 BN0931 0.589 0.0024 0.0036 BN0931 
BN0580 BN0738 1 0.0037 0.0038 BN0738 
BN0709 BN0810 0.6017 0.0025 0.0021 BN0709 
BN0766 BN0787 0.5753 0.0028 0.0022 BN0766 
BN0770 BN0931 0.5838 0.0018 0.0036 BN0931 
BN0778 BN0839 0.5781 0.0020 0.0019 BN0778 
BN0789 BN0863 1 0.0021 0.0019 BN0789 
BN0814 BN0823 1 0.0019 0.0024 BN0823 
BN0820 BN0834 0.5934 0.0024 0.0020 BN0820 
BN0871 BN0875 0.5684 0.0021 0.0025 BN0875 
BN0886 BN0967 1 0.0039 0.0044 BN0967 
BN0913 BN0964 1 0.00174 0.002551 BN0964 
BN0932 BN0937 0.6061 0.002464 0.001833 BN0932 
P1394 P1397 1 0.002408 0.002125 P1394 
P520 P550 1 0.002105 0.001807 P520 
P549 P562 1 0.002274 0.002002 P549 
P135 P195 1 0.00403 0.004585 P195 
  
5.3.1.4 Summary of sample selection  
The number of samples that were removed or added to each population is 
shown in Table 5.2 and Table 5.3. In the Black population, 600 samples were 
genotyped (300 of each cases and controls), with 535 (278 cases and 257 
controls) remaining after QC. The Mixed Ancestry population began with 100 
genotyped samples (50 of each cases and controls), with 106 (48 cases and 60 








Table 5.2: Summary of sample selection in the South African Black population 










Samples genotyped: - 300  - 300 
Removed in GenomeStudio: -5 295  0 300 
Black samples clustering with 
Mixed Ancestry population: -7 288 
 
-15 285 
Mixed Ancestry samples 





Related or duplicated samples: -3 291  -15 272 
<95% call rate: -13 278  -15 257 
 
Table 5.3: Summary of sample selection in the South African Mixed Ancestry population 










Samples genotyped: - 50  - 50 
Removed in GenomeStudio: -1 49  0 50 
Mixed Ancestry samples 
clustering with Black population: -6 43 
 
-2 48 
Black samples clustering with 
Mixed Ancestry population: +7 50 
 
+15 63 
Related or duplicated samples: 0 49  -1 62 
<95% call rate: -3 46  -2 60 
 
5.3.1.5 SNP removal 
The SNP call rates (the percentage of samples successfully assigned a 
genotype for each SNP) for the South African Black population is shown in  
Figure 5.5. The call rate threshold for inclusion in the analysis was set at 95%, 
and 2,559 SNPs failed to meet this threshold. A further 2,656 SNPs were 
removed from analysis in this population due to failure to meet the HWE 
threshold of P<1x10-6, and an additional 47,301 variants were monomorphic. 
Therefore, a total of 139,793 SNPs were available for the case-control analysis 
in the Black population. A case-control association analysis was not performed 
in the Mixed Ancestry population, so SNP call rates are not shown. 






Figure 5.5: Immunochip SNP call rates 
Cumulative distribution of SNP call rates in the South African Black population 
 
5.3.1.6 Plate effects 
Cases and controls were genotyped mainly on separate plates (see Table 5.4). 
Therefore, any differences in allele frequencies observed between cases and 
controls may be due to plate effects and represent false positives.  
 
Table 5.4: Number of samples on each Immunochip genotyping plate 
Plate number Cases Controls 
5 64 25 
6 0 36 
7 0 83 
8 0 79 
9 47 32 
10 89 0 
11 72 0 
12 2 6 
 
To determine if plate effects were present, minor allele frequencies for SNPs 
with P<0.05, were compared for each plate individually against all other plates 
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allele frequencies of plate 5 against that in all the other plates (plates 6-12). No 
plate effects were observed, with the minor allele frequencies for each plate not 
deviating from that of all the other plates. 
 
 
Figure 5.6: Comparison of minor allele frequencies between genotyping plates  
As cases and controls were mainly genotyped on different plates, the minor allele frequencies 
(MAF) of SNPs with P<0.05 were plotted for each plate (plate 5 shown above) against all other 
plates. Plates showing different minor allele frequencies may indicate genotyping errors.   
 
5.3.2 Case-control genetic association analysis 
A case-control analysis was performed for the 139,793 SNPs in 278 cases and 
257 controls from the South African Black population. After testing each SNP for 
association with OSCC, 221 SNPs showed at least nominal evidence of 
association (P<1 x 10-3). Genotype plots were checked for these SNPs to 
ensure genotypes clustered into 2 or 3 distinct groups. Based on this, the 
genotypes of 74 variants were found to be incorrectly clustered and, hence, 
were removed at this point.  
 
A Q-Q plot showing –log(p-value) for observed results vs. expected values for 
all SNPs is shown in Figure 5.7. Points show a good fit for the expected line 
across a wide range of p-values  and  there  is  no  evidence  of  inflation  (λ  =  1.000),  
indicating that there was no problem with population stratification in the study. At 




high values of –log(p-value), several SNPs deviate from the expected P-values 
under the null hypothesis of no association, suggesting that there are variants 
associated with oesophageal cancer. 
 
 
Figure 5.7: Q-Q plot of Immunochip OSCC association results 
Q-Q plot showing -log of observed vs. expected p-values for all SNPs genotyped on the 
Immunochip (genomic  control  λ  =  1.00). 
 
The results of the case-control analysis for SNPs with PImmunochip<1 x 10-4 (20 
SNPs) are shown in Table 5.5. Results for SNPs with PImmunochip<1 x 10-3 (147 















Table 5.5: Immunochip case-control association results  
SNPs with P<1 x 10-4. 




MAF: Cases / 
controls P-value OR (95% CI) 
rs9887787 1 92222143 G / A 0.0596 / 0.1516 8.86 x 10-7 0.35 (0.23-0.54) 
rs10493860 1 92212703 G / A 0.0612 / 0.1529 1.05 x 10-6 0.36 (0.24-0.55) 
rs2810893 1 92144970 G / A 0.2392 / 0.3765 1.16 x 10-6 0.52 (0.40-0.68) 
rs2182833 1 55500429 A / G 0.4245 / 0.2843 1.85 x 10-6 1.86 (1.44-2.40) 
rs11165441 1 92224347 G / A 0.0594 / 0.1431 4.96 x 10-6 0.38 (0.25-0.58) 
rs36590 22 30328070 G / A 0.0216 / 0.0807 9.51 x 10-6 0.25 (0.13-0.48) 
rs36596 22 30335269 G / A 0.0216 / 0.0807 9.51 x 10-6 0.25 (0.13-0.48) 
rs36600 22 30337586 G / A 0.0216 / 0.0807 9.51 x 10-6 0.25 (0.13-0.48) 
rs5763634 22 30350532 G / A 0.0216 / 0.0807 9.51 x 10-6 0.25 (0.13-0.48) 
rs4239932 22 30368384 C / A 0.0216 / 0.0807 9.51 x 10-6 0.25 (0.13-0.48) 
rs5763674 22 30386358 A / G 0.0216 / 0.0807 9.51 x 10-6 0.25 (0.13-0.48) 
rs5752993 22 30387160 A / G 0.0217 / 0.0807 1.01 x 10-5 0.25 (0.13-0.49) 
rs13147507 4 115334709 A / G 0.2464 / 0.1431 2.29 x 10-5 1.96 (1.43-2.68) 
rs13390918 2 199564895 G / A 0.4802 / 0.3529 2.59 x 10-5 1.69 (1.32-2.17) 
rs1400978 2 199565298 G / A 0.5090 / 0.3824 3.28 x 10-5 1.68 (1.31-2.14) 
rs12052337 2 181045431 A / G 0.1817 / 0.2882 3.89 x 10-5 0.55 (0.41-0.73) 
rs1001434 19 30205448 G / A 0.3435 / 0.4667 4.21 x 10-5 0.60 (0.47-0.77) 
rs228125 14 81338068 G / A 0.1637 / 0.0824 5.99 x 10-5 2.18 (1.48-3.21) 
rs1547354 21 26946709 G / A 0.0162 / 0.0635 6.64 x 10-5 0.24 (0.11-0.51) 
rs7714035 5 102644627 A / T 0.5036 / 0.3824 6.94 x 10-5 1.64 (1.28-2.09) 
 
Using the Bonferroni correction, a significance threshold of P<1.84 x 10-6 was 
applied to account for the multiple testing of 27,132 independent SNPs (those 
with r2<0.2 and MAF >0.05). Only three SNPs were significantly associated with 
OSCC (as shown in bold in Table 5.5), with an additional SNP having a 
borderline p-value (PImmunochip<1.85 x 10-6). These variants are all located on 
chromosome 1, with the top three SNPs and one other within the TGFBR3 
gene. Additional clusters of associated SNPs were located on chromosome 2 (3 
SNPs), and chromosome 22 (7 SNPs). The chromosomal region for each SNP 
with P<1 x 10-4 was visualised using association plots on the SNAP website 
which plots the association p-values together with LD between the SNP of 
choice and other variants. The association plots for chromosomal regions that 
contain multiple SNPs with P<1 x 10-4 are shown for rs9887787 (chr 1), 




rs13390918 (chr 2) and rs5752993 (chr 22) in Figure 5.8, Figure 5.9 and Figure 
5.10, respectively. The regional association plots for all SNPs with P<1 x 10-4 
are included in the Appendix, Figure A.1. 
 
 
Figure 5.8: Association plot of chromosome 1 TGFBR3 region 
Shown in the diagram are the observed p-values (-logP), LD (r2) between rs9887787 and other 
variants (with the colour of the square indicating the level of LD), recombination hotspots (in light 
blue), and known annotated genes (green).  
 
rs11165441 
rs10493860 rs2810893 rs9887787 P=8.86 x 10-7 





Figure 5.9: Association plot of chromosome 2 rs13390918 region  




Figure 5.10: Association plot of chromosome 22 MTMR3 rs4239932 region  
This region contains 7 variants associated with OSCC that are in complete LD   




The plots above all show that the association at the key SNP is supported by 
other SNPs in the region which have p-values of similar magnitude, as expected 
by the LD structure within the region, and indicating that the results are not due 
to genotyping errors. However, some SNPs with PImmunochip<1 x 10-4 are in 
regions with few genotyped SNPs, for example rs12052337 (PImmunochip=3.89 x 
10-5) on chromosome 2, which is shown in Figure 5.11. 
 
 
Figure 5.11: Association plot of chromosome 2 rs12052337 region  
 
LD (r2) was calculated between all SNPs with P<1 x 10-3 for the chromosomes 
which had multiple SNPs with PImmunochip<1 x 10-4. LD plots are shown in 





















Figure 5.12: LD (r2) between SNPs with P<0.001 on chromosome 1 















Figure 5.13: LD (r2) between SNPs with P<0.001 on chromosome 2 





Figure 5.14: LD (r2) between SNPs with P<0.001 on chromosome 22 









On chromosome 1, three of the four SNPs at the TGFBR3 locus with 
PImmunochip<1 x 10-4 (rs9887787, rs10493860 and rs11165441) are in high LD 
(r2>0.7). The other SNP, rs2810893, is not in LD with these (r2 = 0.08-0.1), 
which suggests that it may be an independent signal. However, using logistic 
regression and conditioning on the top SNP rs9887787, rs2810893 had an 
association of P=1.0 x 10-3 which is less significant than the non-conditioned 
result (P=1.16 x 10-6) suggesting that it is not independent. The associations for 
rs10493860 and rs11165441 disappear when conditioned on rs9887787. The 
other SNP on chromosome 1 showing nominal evidence of disease association, 
rs2182833, is located 37 Mb away from the TGFBR3 locus so is likely to be an 
independent association.  
 
On chromosome 22, the majority of the 28 variants are in a high level of LD, 
including the 7 SNPs with P<1 x 10-4 which are in complete LD (r2=1). These 7 
SNPs are also in high LD (r2>0.87) in the Yoruban population (using the 1000 
Genomes dataset).  
 
5.3.3 Extension association study for selected variants 
Seven variants were chosen for genotyping in an extension study in the South 
African Black population. An independent replication was not possible due to 
insufficient sample sizes to perform a well-powered study. Therefore, all 
available samples (404 OSCC cases and 834 controls) were genotyped to 
maximize the power to detect associations. These included the 278 cases and 
257 controls that were analyzed in the Immunochip assay, although the samples 
were genotyped again using TaqMan assays.  
 
SNPs with an association with OSCC of PImmunochip < 1 x 10-4 were considered for 
this extension study, with variants selected based on: (1) having the lowest p-
values; (2) the SNAP association plots (SNPs were prioritized if the association 
was supported by nearby variants with p-values of similar magnitude); (3) LD 




between associated SNPs (with one SNP selected from variants in high LD). 
The selected SNPs are shown in Table 5.6. 
 
Table 5.6: Genotyped SNPs for Immunochip extension study 
Variant Chr Position (build 37) Gene Location 
rs9887787 1 92222143 TGFBR3 Intronic 
rs2810893 1 92144970 TGFBR3 Downstream 
rs2182833 1 55500429 PCSK9 Upstream 
rs13390918 2 199564895 Intergenic - 
rs13147507 4 115334709 Intergenic - 
rs7714035 5 102644627 Intergenic - 
rs36590 22 30328070 MTMR3 Intronic 
 
The TaqMan genotyping call rate was >97.8% for all SNPs. Genotypes for all 
SNPs were in HWE in controls (P>0.5), and as well as in cases (P>0.1) except 
for rs9887787 (P=0.0091). Genotypic and allelic association results are shown 





















Table 5.7: Genotypic and allelic association results for the Immunochip extension study 
in the South African Black population 
Variant Genotype or allele Cases Controls OR (95% CI) P-value 
rs9887787 
G/G 350 0.879 624 0.759 Ref Ref 
G/A 43 0.108 185 0.225 0.41 (0.29 - 0.59) 1.0 x 10-6 
A/A 5 0.013 13 0.016 0.69 (0.24 - 1.94) 0.155 
G 743 0.933 1433 0.872 Ref Ref 
A 53 0.067 211 0.128 0.48 (0.35 - 0.66) 4.0 x 10-6 
rs2810893 
G/G 234 0.584 380 0.461 Ref Ref 
G/A 137 0.342 355 0.430 0.63 (0.49 - 0.81) 3.3 x 10-4 
A/A 30 0.075 90 0.109 0.54 (0.35 - 0.84) 6.2 x 10-3 
G 605 0.754 1115 0.676 Ref Ref 
A 197 0.246 535 0.324 0.68 (0.56 - 0.82) 6.6 x 10-5 
rs2182833 
A/A 135 0.338 370 0.447 Ref Ref 
A/G 200 0.500 360 0.435 1.52 (1.17 - 1.98) 1.6 x 10-3 
G/G 65 0.163 97 0.117 1.84 (1.27 - 2.66) 1.2 x 10-3 
A 470 0.588 1100 0.665 Ref Ref 
G 330 0.413 554 0.335 1.39 (1.17 - 1.66) 1.8 x 10-4 
rs13390918 
G/G 120 0.304 306 0.373 Ref Ref 
A/G 193 0.489 391 0.476 1.26 (0.96 - 1.65) 0.098 
A/A 82 0.208 124 0.151 1.69 (1.19 - 2.39) 3.3 x 10-3 
G 433 0.548 1003 0.611 Ref Ref 
A 357 0.452 639 0.389 1.29 (1.09 - 1.54) 3.2 x 10-3 
rs13147507 
A/A 235 0.595 548 0.672 Ref Ref 
A/G 132 0.334 241 0.296 1.28 (0.98 - 1.66) 0.066 
G/G 28 0.071 26 0.032 2.51 (1.44 - 4.38) 8.3 x 10-4 
A 602 0.762 1337 0.820 Ref Ref 
G 188 0.238 293 0.180 1.43 (1.16 - 1.75) 7.7 x 10-4 
rs7714035 
A/A 110 0.277 304 0.370 Ref Ref 
A/T 191 0.481 391 0.476 1.35 (1.02 - 1.78) 0.034 
T/T 96 0.242 126 0.153 2.11 (1.49 - 2.97) 1.8 x 10-5 
A 411 0.518 999 0.608 Ref Ref 
T 383 0.482 643 0.392 1.45 (1.22 - 1.72) 2.1 x 10-5 
rs36590 
G/G 380 0.948 729 0.880 Ref Ref 
G/A 21 0.052 96 0.116 0.42 (0.26 - 0.68) 3.5 x 10-4 
A/A 0 0.000 3 0.004 - - 
G 781 0.974 1554 0.938 Ref Ref 
A 21 0.026 102 0.062 0.41 (0.25 - 0.66) 1.6 x 10-4 




A summary of the allelic association results together with the corresponding 
data from the Immunochip for comparison is shown in Table 5.8. The disease 
association was less significant in the extension study as compared to the 
Immunochip data for six of the seven SNPs. One SNP, rs7714035, had 
strengthened evidence of association from PImmunochip = 6.94 x 10-5 to PExtension = 
2.1 x 10-5. The SNP with the strongest evidence of association is rs9887787, 
with PExtension = 4.0 x 10-6. However, if the Bonferroni correction is applied for all 
independent SNPs tested on the Immunochip (P < 1.84 x 10-6), none of the 
variants were significantly associated with OSCC. The less significant results in 
the extension study are mainly a result of changes in the allele frequencies in 
the expanded panel of controls. Nonetheless, the direction of the effects 





Table 5.8: Summary of allelic association results for the Immunochip extension study and Immunochip data 
 
   Extension study Immunochip study 




cases/controls OR (95% CI) P-value 
MAF: 
cases/controls OR (95% CI) P-value 
rs9887787 G A 0.067 / 0.128 0.48 (0.35 - 0.66) 4.0 x 10-6 0.060 / 0.152 0.35 (0.23 - 0.54) 8.86 x 10-7 
rs2810893 G A 0.246 / 0.324 0.68 (0.56 - 0.82) 6.6 x 10-5 0.239 / 0.377 0.52 (0.40 - 0.68) 1.16 x 10-6 
rs2182833 A G 0.413 / 0.335 1.39 (1.17 - 1.66) 1.8 x 10-4 0.425 / 0.284 1.86 (1.44 - 2.40) 1.85 x 10-6 
rs13390918 G A 0.452 / 0.389 1.29 (1.09 - 1.54) 3.2 x 10-3 0.480 / 0.353 1.69 (1.32 - 2.17) 2.59 x 10-5 
rs13147507 A G 0.238 / 0.180 1.43 (1.16 - 1.75) 7.7 x 10-4 0.246 / 0.143 1.96 (1.43-2.68) 2.29 x 10-5 
rs7714035 A T 0.482 / 0.392 1.45 (1.22 - 1.72) 2.1 x 10-5 0.504 / 0.382 1.64 (1.28 - 2.09) 6.94 x 10-5 












5.3.4 Comparison of TaqMan and Immunochip genotypes 
Genotyping the same samples and variants on two independent platforms 
allows comparison between the methods. Overall, 3745 genotypes were tested 
(535 samples for each of the seven variants). Of these, 37 genotypes could not 
be called in the TaqMan SNP assays, and 3 were not called on the Immunochip 
(0.99% and 0.08%, respectively). Only one genotype that was called on both 
platforms produced a conflicting result; sample P332 for rs13390918 had an AA 
genotype using Immunochip but GG genotype using the TaqMan assay.  
 
5.3.5 Gene-environment interactions 
Cases and controls from the extension study were stratified by smoking status 
and alcohol consumption to test for gene-environment interactions for all seven 
SNPs genotyped in the extension study. Four tests were carried out for each 
risk factor. For example, for gene-alcohol interactions the tests were: drinkers 
case-control, non-drinkers case-control, case-only (drinker vs. non-drinker), and 
a gene-alcohol interaction test using logistic regression controlling for age, sex, 
smoking, alcohol, the genetic effect and the gene-alcohol interaction effect. 
Results are shown in Table 5.9 and Table 5.10. The Bonferroni correction used 
for the original case-control analysis was used as the significance threshold 
(P<1.84 x 10-6), except for the gene-environment interaction test, which used a 










Table 5.9: Gene-alcohol interaction tests for SNPs genotyped in the Immunochip extension study  
Stratified analysis of alcohol consumption, a case-only analysis, and a gene-environment (G x E) interaction test using logistic 
regression. Cases: drinkers = 252, non-drinkers = 149; Controls: drinkers = 444, non-drinkers = 386.  
 
  Case-control: Drinkers only  Case-control: Non-drinkers only 








Controls OR (95% CI) P-value 
rs36590 T 0.024 0.061 0.38 (0.20 - 0.71) 0.0018  0.03 0.063 0.47 (0.23 - 0.97) 0.0365 
rs2182833 G 0.41 0.312 1.53 (1.22 - 1.92) 0.0003  0.419 0.362 1.27 (0.97 - 1.67) 0.0861 
rs2810893 T 0.244 0.317 0.69 (0.54 - 0.89) 0.0040  0.243 0.329 0.66 (0.48 - 0.89) 0.0065 
rs7714035 T 0.478 0.389 1.44 (1.15 - 1.80) 0.0013  0.493 0.395 1.49 (1.13 - 1.95) 0.0040 
rs9887787 T 0.071 0.12 0.56 (0.37 - 0.83) 0.0040  0.058 0.137 0.39 (0.23 - 0.66) 0.0003 
rs13390918 T 0.467 0.386 1.40 (1.12 - 1.75) 0.0034  0.418 0.395 1.10 (0.84 - 1.45) 0.4783 
rs13147507 G 0.227 0.179 1.35 (1.02 - 1.77) 0.0328  0.253 0.179 1.55 (1.13 - 2.14) 0.0070 
 
  Case-only  G x E 






OR (95% CI) P-value  OR (95% CI) P-value 
rs36590 T 0.024 0.03 0.78 (0.33 - 1.88) 0.5858  0.74 (0.27 - 2.03) 0.5562 
rs2182833 G 0.41 0.419 0.96 (0.72 - 1.29) 0.7973  1.38 (0.94 - 2.02) 0.0989 
rs2810893 T 0.244 0.243 1.00 (0.72 - 1.40) 1.000  1.04 ( 0.70 - 1.55) 0.8506 
rs7714035 T 0.478 0.493 0.94 (0.70 - 1.26) 0.6775  1.03 (0.71 - 1.49) 0.8772 
rs9887787 T 0.071 0.058 1.24 (0.68 - 2.25) 0.4851  1.20 (0.62 - 2.32) 0.5859 
rs13390918 T 0.467 0.418 1.22 (0.91 - 1.63) 0.1819  1.02 ( 0.71 - 1.47) 0.9230 











Table 5.10: Gene-smoking interaction tests for SNPs genotyped in the Immunochip extension study  
Stratified analysis of tobacco smoking status, a case-only analysis, and a gene-environment (G x E) interaction test using  
logistic regression. Cases: smokers = 240, non-smokers = 163; Controls: smokers = 327, non-smokers = 496. 
 
  Case-control: Smokers only  Case-control: Non-smokers only 








Controls OR (95% CI) P-value 
rs36590 T 0.025 0.064 0.38  (0.20 - 0.72) 0.0023  0.028 0.061 0.44 (0.22 - 0.89) 0.0201 
rs2182833 G 0.418 0.289 1.77 (1.38 - 2.27) 7.0 x 10-6  0.401 0.368 1.15 (0.89 - 1.49) 0.2825 
rs2810893 T 0.235 0.323 0.65 (0.49 - 0.85) 0.0014  0.262 0.326 0.74 (0.56 - 0.98) 0.033 
rs7714035 T 0.460 0.394 1.31 (1.03 - 1.66) 0.0283  0.513 0.388 1.66 (1.29 - 2.14) 8.4 x 10
-5 
rs9887787 T 0.078 0.136 0.54 (0.36 - 0.81) 0.0026  0.050 0.121 0.38 (0.22 - 0.65) 2.6 x 10
-4 
rs13390918 T 0.459 0.399 1.28 (1.02 - 1.60) 0.0300  0.441 0.375 1.31 (1.00 - 1.73) 0.0484 
rs13147507 G 0.231 0.186 1.31 (0.98 - 1.76) 0.0694  0.250 0.177 1.55 (1.15 - 2.10) 0.0039 
 
  Case-only  G x E 






OR (95% CI) P-value  OR (95% CI) P-value 
rs36590 T 0.025 0.028 0.91 (0.38 - 2.17) 0.8235  0.99 (0.36 - 2.74) 0.9835 
rs2182833 G 0.418 0.401 1.07 (0.80 - 1.43) 0.642  1.74 ( 1.20 - 2.53) 0.0037 
rs2810893 T 0.235 0.262 0.87 (0.62 - 1.20) 0.3833  1.11 (0.74 - 1.66) 0.6095 
rs7714035 T 0.460 0.513 0.81 (0.61 - 1.08) 0.1448  0.81 (0.56 - 1.16) 0.2442 
rs9887787 T 0.078 0.050 1.63 (0.89 - 2.98) 0.1116  1.44 (0.72 - 2.88) 0.3058 
rs13390918 T 0.459 0.441 1.08 (0.81 - 1.43) 0.6132  1.14 (0.79 - 1.64) 0.4827 
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No variants were significantly associated with drinking status, with the gene-
alcohol interaction test and the case-only analysis showing no evidence of 
interaction.  
 
One variant, rs2182833, appeared to interact with smoking status. The minor 
allele frequencies for cases who are smokers and non-smokers are similar 
(0.418 and 0.401, respectively), but the frequencies in controls for these 
groups differ (0.289 and 0.368, respectively). Evidence for association of this 
variant with OSCC was strengthened in smokers (P = 7.0 x 10-6; OR = 1.77), 
compared to the non-stratified analysis (P = 1.8 x 10-4; OR = 1.39), see 
Table 5.7. The gene-smoking interaction test for this variant gives P = 
0.0037, which is significant when using the Bonferroni correction for the 
smoking interactions only (P<0.0071). 
 
Additionally, an Immunochip-wide gene-environment interaction analysis 
(using 278 cases and 257 controls) was performed for alcohol consumption 
and smoking (see Table 5.11 and Table 5.12, respectively, for the 10 SNPs 
with the strongest evidence for interaction). No variants showed an 
association with OSCC which would survive the Bonferroni correction for 
multiple testing (P< 1.84 x 10-6).  
 
Table 5.11: Immunochip-wide gene-alcohol interaction test 
Chr SNP ID Position (b37) OR (95% CI) P-value 
1 rs10493941 101445821 3.22 (1.74 - 5.93) 1.83 x 10-4 
1 rs12726628 101446276 3.22(1.74 - 5.93) 1.83 x 10-4 
2 rs17025022 40291538 0.33 (0.18 - 0.59) 2.13x 10-4 
1 rs17123572 101442211 3.17 (1.72 - 5.84) 2.21 x 10-4 
1 rs2494287 203207520 8.38 (2.51 - 27.96) 5.45 x 10-4 
1 rs1400986 207038686 2.60 (1.51 - 4.49) 6.14 x 10-4 
1 rs4908109 101453655 0.31 (0.16 - 0.61) 6.93 x 10-4 
1 rs1188734 101457021 0.31 (0.16 - 0.61) 6.93 x 10-4 
1 rs67858127 17678599 0.35 (0.19 - 0.65) 9.05 x 10-4 
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Table 5.12: Immunochip-wide gene-smoking interaction test 
Chr SNP ID Position (b37) OR (95% CI) P-value 
1 rs1052240 198634814 3.49 (1.98 - 6.16) 1.66 x 10-5 
7 rs10085839 131570695 0.25 (0.13 - 0.48) 4.26 x 10-5 
11 rs11215001 114338079 3.02 (1.73 - 5.26) 1.02 x 10-4  
11 rs7124064 114344225 3.02 (1.73 - 5.26) 1.02 x 10-4 
10 rs4934742 35559191 0.31 (0.17 - 0.57) 1.23 x 10-4   
11 rs10750052 114342631 0.34 (0.20 - 0.59) 1.24 x 10-4   
8 1kg_8_11087411* 11050001 4.71 (2.12 - 10.46) 1.41 x 10-4   
16 rs16961198 59591652 0.24 (0.11 - 0.50) 1.41 x 10-4   
1 rs7515488 1163804 3.17 (1.74 - 5.77) 1.61 x 10-4   
2 rs759844 207428868 2.69 (1.60 - 4.53) 2.00 x 10-3 
*Immunochip  ID  number  shown  as  an  ‘rs’  number  was  not  available 
 
5.4 Replication of OSCC GWAS associated SNPs in the South 
African Black population using Immunochip 
To date, three independent OSCC GWAS have been completed in the 
Chinese population (Abnet et al. 2010; Wang et al. 2010.a; Wu et al. 2011.c). 
A meta-analysis has also been performed for two of these (Abnet et al. 2012) 
and additionally, a more thorough replication of the Wu et al. GWAS has 
been published, whereby variants with 10-7 < P < 10-4 were studied (Wu et al. 
2012.a). Based on these five studies, 38 SNPs were significantly associated 
with  OSCC,   although   not   all   were   independent   loci.   A  GWAS   for   Barrett’s  
oesophagus in a European population has also identified two variants 
associated with the disease (Su et al. 2012).  
 
The degree of association with OSCC in the South African Black population 
of these 40 variants was examined using the Immunochip data. In addition to 
the index SNPs identified in the published studies, tagging variants (or 
proxies) were also explored. To identify variants in high LD with the index 
SNPs (r2>0.8 and within 500kb) that were present on the Immunochip, a 
SNAP proxy search was used 
(http://www.broadinstitute.org/mpg/snap/ldsearch.php). This was performed 
in the Chinese/Japanese (CHB/JPT) or European (CEU) HapMap 3 and 
1000  Genomes  populations,   for  OSCC  studies  or   the  Barrett’s  oesophagus  
Chapter 5: Immunochip 
 
180 
GWAS, respectively. A proxy search was also performed in the Yoruban 
(YRI) population for both the index SNPs and proxies identified in the 
CHB/JPT and CEU populations. This was to identify variants that were in 
high LD with the index SNP in the YRI population, and to determine if the 
proxies identified in the CHB/JPT and CEU populations also tag additional 
variants in the YRI population. However, for the latter, no additional proxies 
were identified. The 40 index SNPs, together with any proxies present on the 
Immunochip are shown in Table 5.13.  
 
 
Table 5.13:  Summary  of  OSCC  and  Barrett’s  oesophagus  GWAS  associations,  and  the  
presence of these index SNPs or proxies on the Immunochip  
Study Chr location 
Gene or 






SNPs on Immunochip that are in 
high LD (r2>0.8) with index SNP in 
1000 Genomes or HapMap 3 
populations  
CHB/JPT or 






rs2274223 No - - 
rs3765524 No - - 
rs3781264 No - - 
rs11187842 No - - 
rs753724 No - - 





rs12263737 No - - 
rs2274223 No - - 




10q23 PLCE1 rs2274223 No - - 
5q11 PDE4D rs10052657 No - - 
21q22 RUNX1 rs2014300 No - - 
6p21 near UNC5CL rs10484761 No - - 





rs11066280 No - - 














rs9288316 (1.00) - 
rs9288318 Proxies rs13016963 (0.83) rs9288316 (0.82) - 
rs10201587 Proxies rs13016963 (0.83) rs9288316 (0.82) - 
rs7578456 No - - 







rs4785204 Proxies rs12445755 (0.96) rs7204293 (0.89) - 
rs7206735 Proxies rs6500291 (1.00) - 
17q21 HAP1 rs6503659 No - - 





3q27 ST6GAL1 rs2239612 No - - 
17p13 SMG6 rs17761864 No - - 
18p11 PTPN2 rs2847281 Index SNP - - 
22q12 CHEK2 
rs4822983 No - - 
rs1033667 No - - 
4q23 
ADH1A rs1229977 No - - 
ADH1B 
rs1042026 Proxies rs1229984 (0.89) - 
rs17033 No - - 
ADH1C 
rs1614972 Index SNP - - 
rs1789903 No - - 
ADH4 rs3805322 No - - 
ADH7 rs17028973 No - - 
ADH6 rs1893883 No - - 
2q22 IGFB2 rs9288520 No - - 
































Only 6 variants were present on the Immunochip, with association results 
only available for four SNPs; rs13016963 in the region on chromosome 2q 
containing CASP8/ALS2CR12/TRAK2, rs2847281 in PTPN2, rs1614972 in 
ADH1C and rs9936833 near FOX1. The other 2 variants were monomorphic 
in controls and/or cases. In total, ten index SNPs had proxies that were 
present on the Immunochip. The association results for the index SNPs and 
proxies are shown in Table 5.14. None of the variants were associated with 
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OSCC in the South African Black population (P > 0.0.5), with several SNPs 
being monomorphic in this population.  
 
Table 5.14: Immunochip OSCC association results for the South African Black 
population for SNPs previously associated with OSCC and Barrett's oesophagus in 
GWAS 
Index SNP Tagging SNP 




controls OR (95% CI) P-value 
rs2074356 - 0.0000 0.0000 NA NA 
rs13016963 - 0.3309 0.3333 0.99 (0.77-1.28) 0.9338 
rs10931936, rs13016963, 
rs9288318, rs10201587 rs9288316 0.4694 0.4725 0.99 (0.78-1.26) 0.9187 
rs4785204 rs12445755 0.1960 0.1961 1.00 (0.74-1.35) 0.9988 
rs4785204 rs7204293 0.4802 0.4980 0.93 (0.73-1.18) 0.5609 
rs7206735 rs6500291 0.2968 0.3137 0.92 (0.71-1.20) 0.5479 
rs2239815 rs2097461 0.3849 0.3406 1.21 (0.94-1.56) 0.1332 
rs2239815 rs5762788 0.3849 0.3406 1.21 (0.94-1.56) 0.1332 
rs2239815 rs5762795 0.2248 0.1772 1.35 (0.99-1.82) 0.0531 
rs2847281 - 0.0809 0.0824 0.98 (0.63-1.52) 0.9327 
rs1042026 rs1229984 0.0324 0.0333 0.97 (0.49-1.90) 0.9300 
rs1614972 - 0.3849 0.4216 0.86 (0.67-1.10) 0.2225 
rs9257809 - 0.0054 0.0000 NA 0.0967 
rs9257809 rs429479 0.0000 0.0000 NA NA 
rs9257809 rs406511 0.0054 0.0000 NA NA 
rs9257809 rs1233480 0.2428 0.2314 1.07 (0.80 - 1.41) 0.6612 
rs9257809 rs442694 0.0000 0.0000 NA NA 
rs9257809 rs1535039 0.0000 0.0000 NA NA 
rs9257809 rs2746149 0.0755 0.0824 0.91 (0.58 - 1.42) 0.6800 
rs9257809 rs2746150 0.0000 0.0000 NA NA 
rs9257809 rs1233491 0.0000 0.0000 NA NA 
rs9257809 rs2523443 0.0000 0.0000 NA NA 
rs9257809 rs404240 0.0000 0.0000 NA NA 
rs9257809 rs3749971 0.0018 0.0020 0.92 (0.06 - 14.70) 0.9512 
rs9257809 rs3117427 0.0216 0.0235 0.92 (0.41 - 2.06) 0.8305 
rs9257809 rs3117439 0.0324 0.0412 0.78 (0.41 - 1.48) 0.4445 
rs9257809 rs3117425 0.0324 0.0412 0.78 (0.41 - 1.48) 0.4445 
rs9936833 - 0.2356 0.2216 1.08 (0.81-1.44) 0.5856 
rs9936833 rs1532167 0.2626 0.2627 1.00 (0.76-1.31) 0.9954 








5.5.1 Case-control association analysis 
After completing the case-control association study using the Immunochip, 
three SNPs in TGFBR3 were significantly associated with OSCC using the 
Bonferroni correction to account for multiple testing (P < 1.84 x 10-6). Since 
this correction is conservative, additional variants with PImmunochip < 1 x 10-4 
were also selected for follow up. A well-powered independent replication 
study was not possible due to insufficient sample sizes. However, an 
extension study using an additional 126 cases and 577 controls provided 
improved power to investigate whether these variants were significantly 
associated with OSCC. 
 
Seven variants were genotyped in this extension study, most of which were 
in regions with a high density of SNPs on the Immunochip. Several SNPs 
adjacent to the index variants also showed some evidence of association. 
These variants were prioritized over regions where only a single SNP 
showed association, as the latter were more likely to be genotyping artifacts. 
It should be noted that such regions may yet represent true associations. 
However, due to limited funds, not all SNPs that showed evidence of 
association could be genotyped in the extension study. 
 
A case-control analysis of the extension study showed that the associations 
became less significant for six out of the seven SNPs, with one variant 
becoming more significant. However, none of the variants now showed a 
significant association using the Bonferroni correction as, although the 
sample sizes were larger, the observed effect sizes were reduced. More 
samples are needed to increase the power to establish whether these alleles 
affect OSCC susceptibility in the South African Black population. However, to 
achieve 80% power at a significance threshold of P < 1.84 x 10-6 and to 
detect the odds ratios that were observed in the extension study, the number 
of cases that would be needed ranges from ~500 to ~1,400 for the different 
variants with a larger number of controls also required. Sample collection is 
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continuing and additional recruitment centres are being established in other 
regions of South Africa.  
 
Promisingly, some of the variants which showed evidence of association in 
the Immunochip study, and, thus included in the extension study, are located 




Four of the five SNPs most strongly associated with OSCC in the 
Immunochip analysis were all located in TGFBR3, transforming growth factor 
beta receptor 3. Three of these SNPs were the only variants to remain 
significant after correction for multiple testing. TGFBR3 is located on 
chromosome  1p32  and  encodes  TβRIII (also known as betaglycan). TβRIII  is  
a co-receptor, binding TGF-β   superfamily   ligands   including   TGF-β1-3, and 
bone morphogenetic proteins (BMPs) 2, 4 and 7, and facilitates their binding 
to TGF-β  superfamily   receptors  (initially   to   type  II   receptors  and then type I 
receptors) (reviewed in Gordon and Blobe 2008). Downstream, this leads to 
phosphorylation of the Smad family of transcription factors that regulate gene 















Figure 5.15: TGF-β  signalling pathway  
The ligand, TGF-β,  binds  to  the  TGF-β  receptors  (TGFBR1  and  TGFBR2),  facilitated  by  the  
co-receptor TGFBR3. This leads to phosphorylation and activation of Smad transcription 
factors which regulate gene expression. (Adapted from Glick 2012) 
 
Defects in the TGF-β  superfamily  signaling  pathways  have  been   implicated  
in numerous diseases spanning a range of phenotypes including skeletal and 
muscular disorders, developmental disorders, cardiovascular diseases, as 
well as cancer development (reviewed in Gordon and Blobe 2008).  
 
The TGF-β   cytokine   is   involved   in   regulating   a   number   of   processes  
including differentiation, proliferation, angiogenesis, apoptosis as well as 
immune responses and embryonic development, and has a complex role in 
carcinogenesis (reviewed in Gatza et al. 2010). Early on in cancer formation, 
TGF-β   acts   as   a   tumour   suppressor,   inhibiting   growth   and   inducing  
apoptosis. However, in later stages, the protein supports tumour progression 
by promoting processes such as angiogenesis, cell growth and survival, and 
invasion (Gordon and Blobe 2008; Bernabeu et al. 2009). This misregulation 
is caused by either the inactivation of critical components in the TGF-β  
signaling pathway such as the receptors and co-receptors, or by the loss of 
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process is due to the misregulation of other genes downstream in the 
cytostatic pathway which prevents the tumour-suppressor functions of TGF-β  
from acting but take advantage of its other regulatory functions to allow 
cancer cells to invade other regions and to evade immune responses 
(Massague 2008).  
 
The chromosome arm containing TGFBR3 frequently shows loss of 
heterozygosity (LOH) in several tumour types, including oesophageal, 
stomach, colon and rectum, and breast cancers (Ragnarsson et al. 1999). 
TGFBR3 expression is also frequently downregulated in a number of cancers 
and correlates with a worsening disease progression including in breast, 
prostate, pancreatic adenocarcinoma and non-small cell lung cancer (Dong 
et al. 2007; Turley et al. 2007; Finger et al. 2008; Gordon et al. 2008). 
Increasing gene expression back to normal levels in both breast and prostate 
cancer cells inhibits some tumour-promoting activities (Dong et al. 2007; 
Turley et al. 2007). All of this evidence suggests that TGFBR3 is a tumour 
suppressor gene and may be a good drug target in human cancers (Gatza et 
al. 2010).  
 
Although expression of TGFBR3 has not been investigated in OSCC, the 
TGFBR2 receptor has been shown to play a role in the disease (Achyut et al. 
2013). Achyut et al. first studied knock-out mice that harboured a TGFBR2 
deletion in stromal fibroblasts and found that inflammation and DNA damage 
was induced in adjacent epithelial cells, which led to the development of 
SCC of the mouse forestomach. The lining of the mouse forestomach is 
reported to be similar to that in the human oesophagus, which led to the 
authors to investigate TGFBR2 in human OSCC. In stromal cells of OSCCs, 
reduced expression of TGBFBRII was observed, together with increased 
expression of inflammatory and DNA damaging mediators, which was 
suggested to drive human OSCC tumourigenesis (Achyut et al. 2013). This, 
therefore, shows that a functional TGF-β   pathway   is   needed   to   prevent  
OSCC, and suggests that deregulation of other components of the pathway, 
including TGRBR3, may also result in the disease. 
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Polymorphisms in genes in the TGF-β   pathway   are   associated   with  
susceptibility to several cancers. For example, variants in TGFBR1 are 
associated with overall cancer risk in a meta-analysis, which also includes 
significant associations with breast and ovarian cancer (Kaklamani et al. 
2003). There have been no candidate gene association studies testing 
polymorphisms in TGFBR3 with cancer susceptibility, and no associations 
have been identified in genome-wide association studies. Variants in 
TGFBR3 have, however, been associated with a variety of other traits 
including bone mineral density (Xiong et al. 2009) and optic disc area (Khor 
et al. 2011). The function of TGFBR3 makes it a plausible susceptibility gene 
in cancer development, and hence it is promising that four of the five top 
variants associated with OSCC in the Immunochip study are located in this 
gene. 
 
Three of the four variants in TGFBR3 that show evidence of association with 
OSCC are located in introns, with the fourth being downstream of the gene. 
None of these variants have previously been associated with any diseases or 
traits. However, several variants are predicted to be in regulatory regions. 
This was determined using RegulomeDB (http://regulome.stanford.edu/) 
(Boyle et al. 2012) and HaploReg 
(http://www.broadinstitute.org/mammals/haploreg/haploreg.php) (Ward and 
Kellis 2012) which combine functional studies, such as ENCODE data 
(ENCODE Project Consortium 2011), and computational predictions into 
easy-to-use browsers. The SNP rs2810893 is predicted to be in a motif for 
the binding of the REST transcription factor. REST is suggested to be a 
tumour suppressor gene in colorectal cancer (Westbrook et al. 2005). The 
variant rs10493860 is predicted to be in a binding site for TRIM28 (KAP1) 
and SETDB1 which regulate transcription. TRIM28 is suggested to be a 
tumour suppressor in lung cancer (Chen et al. 2012.b), and the histone 
methyltransferase, SETDB1, is upregulated in a number of cancers, 
including lung, breast, ovarian and melanoma (Ceol et al. 2011). The 
variants rs9887787 and rs11165441 are not predicted to be in any regulatory 
regions. However, these variants may be in high LD with other SNPs which 
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are located in regulatory regions. Functional work may establish if any of 
these variants are involved in cancer development. 
 
5.5.1.2 PCSK9 
In the Immunochip analysis, rs2182833 is on the borderline of a significant 
association (PImmunochip = 1.85 x 10-6) and is located upstream of PCSK9, 
proprotein convertase subtilisin/kexin type 9. The protein is involved in 
cholesterol metabolism and is able to regulate the number of low-density 
lipoprotein (LDL) receptors on the cell surface, hence controlling intracellular 
LDL levels (reviewed in Lopez 2008). Gain-of-function and loss-of-function 
mutations in PCSK9 are associated with hypercholesterolemia and 
hypocholesterolemia, respectively. Some studies have suggested a modest 
association between low concentrations of LDL cholesterol in the plasma and 
an increased risk of cancer, although results are not convincing and have 
been conflicting (Law and Thompson 1991; Folsom et al. 2007; Strasak et al. 
2009; Benn et al. 2011). The method by which LDL concentrations and 
cancer may be linked is unclear. It may be that low cholesterol levels 
contribute to cancer susceptibility, or cholesterol is lowered as an effect of 
cancer, or a confounder may effect both processes (Kritchevsky et al. 1991; 
Law and Thompson 1991). Nevertheless, this has led to the hypothesis that 
low levels of plasma LDL due to specific genotypes in PCSK9 may also be 
associated with cancer susceptibility. However, two studies have not found 
any associations (Folsom et al. 2007; Benn et al. 2011).  
 
This evidence does not support a role for PCSK9 in cancer susceptibility 
and, hence, the association observed in the Immunochip study between 
rs2182833 and OSCC cannot be easily explained. In addition, the SNP is not 
predicted to be in any regulatory regions using HaploReg and RegulomeDB. 
Other genes in the vicinity of the variant include BSND (Bartter syndrome, 
infantile, with sensorineural deafness (Barttin), TMEM61 (transmembrane 
protein 61) and USP24 (ubiquitin specific peptidase 24). Only the latter has 
been linked to a potential role in carcinogenesis. USP24 is a deubiquitinating 
enzyme,   with   polymorphisms   in   this   gene   associated   with   Parkinson’s  
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disease (Li et al. 2006; Wu et al. 2010). Although no associations have been 
identified with USP24 variants and cancer susceptibility, several other 
deubiquitinating enzymes are thought to play an important role in cancer 
development (Song et al. 2008; Pereg et al. 2010; Schwickart et al. 2010). 
This includes USP9X which is able to regulate protein levels of MCL1 by 
removing ubiquitin chains that would normally target the protein for 
degradation (Schwickart et al. 2010). MCL1 is a member of the Bcl-2 protein 
family and promotes cell survival (Adams and Cory 1998), and 
overexpression of MCL1 is observed in a variety of lymphomas and solid 
cancers (Kitada et al. 1998; Warr and Shore 2008). Other deubiquitinating 




Another gene of interest is MTMR3, myotubularin related protein 3, where 
seven SNPs in complete LD showed a suggestive association with OSCC in 
the Immunochip analysis (PImmunochip = 9.51 x 10-6). All of the variants are 
located in introns, over a region of 60kb. MTMR3 is a phosphoinositide 3-
phosphate (PtdIns3P) phosphatase and is involved in the regulation of 
autophagy and in cell migration (Taguchi-Atarashi et al. 2010; Oppelt et al. 
2012). 
 
Autophagy is a mechanism to degrade and recycle or eradicate cellular 
components or pathogens in a response to stress or starvation (reviewed in 
Mathew et al. 2007). It is mainly controlled by the PI3 kinase pathway and its 
downstream  protein   ‘mammalian  target  of  rapamycin’  (mTOR).  The  process  
has been shown to have a role in cancer development (reviewed in Mathew 
et al. 2007 and White et al. 2010). Under metabolic stress conditions, cells 
with defects in apoptosis (such as in tumour cells) had a sustained period of 
autophagy, which allowed the cells nutrient supply to be restored, enabling 
continued proliferation and growth. This is maintained until cells are unable 
to restore enough nutrients, when cell death eventually occurs.  
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The involvement of MTMR3 in autophagy is supported by evidence that the 
overexpression of MTMR3 leads to the formation of small abnormal 
autophagsomes and a reduction in autophagic activity (Taguchi-Atarashi et 
al. 2010). In addition, MTMR3 expression was downregulated in gastric 
cancer, which  resulted in increased levels of autophagy (Lin et al. 2012). 
MTMR3 expression was shown to be inhibited by a micro RNA, miR-181a, 
which itself was upregulated in gastric cancer tissue. MTMR3 is predicted to 
contain two binding sites for miR-181a   in   the  3’  UTR,  one  of  which   is  only  
present when MTMR3 rs12537   ‘C’   allele   is   present.  Hence,   Lin   et al. also 
performed a case-control association study for this variant in gastric cancer, 
and showed that individuals with CT genotypes at rs12537 had an increased 
risk of disease compared to those with CC genotypes (P = 7.78 x 10-6; OR = 
1.86 (95% CI =1.42-2.45)). The variant rs12537 is included on the 
Immunochip but was not found to be associated with OSCC in the Black 
South African population, with minor allele frequencies of 46% and 49.4% in 
cases and controls, respectively (P = 0.327).  
 
MTMR3, together with PIKfyve, a phosphoinositide 5-kinase, act on PtdIns3P 
to produce PtdIns5P (phosphatidylinositol 5-phosphate) which stimulates cell 
migration (Oppelt et al. 2012). MTMR3 has a key role in this, with depletion 
of MTMR3 protein decreasing cell migration (Oppelt et al. 2012). Cell 
migration is thought to be essential in cancer development, enabling cells to 
invade surrounding tissue (Yamaguchi et al. 2005), and hence, based on the 
findings of the Oppelt et al. study, higher MTMR3 levels would perhaps be 
expected in cancer development to lead to increased cell migration. This is 
not consistent with the studies described above where MTMR3 levels were 
decreased in gastric cancer cells (Lin et al. 2012). However, MTMR3 
depleted cells are less successful at migrating towards a wound, due to 
being  unable to orientate their Golgi and cytoskeleton (Oppelt et al. 2012), 
which may prevent wound healing. This was discussed earlier as being a 
cause of inflammation which may lead to cancer development.  
 
In addition to gastric cancer, variants in MTMR3 have also been associated 
with childhood-onset inflammatory bowel disease (Henderson et al. 2011) 
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and lung cancer (Hu et al. 2011). In a lung cancer GWAS in a Han Chinese 
population, rs36600 was associated with the disease (Hu et al. 2011). The 
minor  ‘A’  allele  had  frequencies  of  11.9%  in  cases  and  9.4%  in  controls,  with  
an OR of 1.29 (95% CI = 1.20-1.38) and P = 6.2 x 10-13 in the combined 
GWAS and replication phases. This SNP showed a suggestive association 
(PImmunochip = 9.51 x 10-6) with OSCC in our South African study, and a SNP in 
complete LD with it, rs36590, was genotyped in the extension study. The 
variant showed opposite effects in our study compared to the Chinese study, 
with the minor   ‘A’   allele   having   a   protective   effect   with   minor   allele  
frequencies of 2.6% and 6.2% in cases and controls, respectively (OR=0.41, 
95% CI = 0.25 - 0.66; P = 1.6 x 10-4). It is not unusual for variants to show 
opposing effects in different diseases or populations (this will be further 
explored in the Discussion, section 7.2). Hu et al. (2011) also note that their 
MTMR3 region of association also extends to the neighboring HORMAD2, an 
open reading frame protein which may be involved in mitotic checkpoints and 
DNA repair. However, in our study, the region of association does appear to 
peak over the MTMR3 gene (see Figure 5.10, p.166). 
 
Apart from rs36600 which is associated with lung cancer, as described 
above, none of the SNPs in MTMR3 showing evidence of association with 
OSCC in the South African population have been implicated in susceptibility 
to other diseases. Using RegulomeDB and HaploReg, some of the variants 
are predicted to be in regulatory regions. The variant rs36590 is predicted to 
alter the binding motif for POU2F1 (OCT-1) and AREB6 transcription factors; 
rs36600 is in a DNase hypersensitive site in several cell types; rs36596 and 
rs5752993 are in regulatory motifs for the CDX2 transcription factor binding 
site; rs5763634 is in a binding site for GATA1 and CEBPB transcription 
factors. The SNPs rs5763674 and rs4239932 are not predicted to be in any 
regulatory regions. All of these SNPs may also be in high LD with other 
variants that are predicted to be in regulatory regions.  
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5.5.1.4 Intergenic regions 
The three other SNPs (rs13147507, rs13390918 and rs771403) that were 
genotyped in the extension study were all in intergenic regions. The nearest 
genes to rs13147507 are ARSJ, UGT8 and NDST4. Of these genes, only 
UGT8 (UDP glycosyltransferase 8) has been implicated in cancer, with high 
expression levels observed in metastatic prostate cancer cells compared to 
non-metaststic cells (Oudes et al. 2005). In addition, increased gene 
expression levels are associated with an increased risk of lung metastases in 
breast cancer patients (Landemaine et al. 2008). The variant is predicted to 
be located in binding sites for the transcription factors FOXA2 and CDP 
using RegulomeDB and HaploReg. 
 
For rs13390918, the closest genes are PLCL1 and SATB2. PLCL1 is 
phospholipase C-like 1, and variants in PLCL1 have previously been 
associated  with  Crohn’s  disease  (Franke et al. 2010) and hip bone size (Liu 
et al. 2008) but its function remains unknown. Interestingly, variants in 
PLCE1, phospholipase C epsilon 1, have been associated with OSCC in 
Chinese populations (Abnet et al. 2010; Wang et al. 2010.a; Wu et al. 
2011.c) and in our South African Black population (see Chapter 4). SATB2, 
special AT-rich-binding protein 2, is a transcription factor involved in several 
processes including the regulation of osteoblast differentiation and skeletal 
development (Dobreva et al. 2006). In addition, it may have a role in cancer 
development, with high expression levels observed in colorectal tumours 
(Magnusson et al. 2011; Eberhard et al. 2012). The variant is predicted to be 
in the binding motif for NANOG transcription factor using RegulomeDB. 
 
The other intergenic variant is rs7714035, which is predicted (by 
RegulomeDB and HaploReg) to be in a regulatory region that binds several 
regulatory proteins including FOSL2, FOXA1, FOXA2, HNF4A, MAFF and 
MAFK. In addition, it is predicted to alter the POU1F1 transcription factor 
binding site. The variant is closest to C5orf30, GIN1 (gypsy retrotransposon 
integrase 1), NUDT12 (nudix (nucleoside diphosphate linked moiety X)-type 
motif 12) and PAM (peptidylglycine alpha-amidating monooxygenase), none 
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of which have a known function that is likely to contribute to cancer 
development. PPIP5K2 (diphosphoinositol pentakisphosphate kinase 2) is 
also in the region, and is involved in cell signaling, although the exact 
function of the gene is yet to be determined. It is known that PPIP5K2 (and 
PPIP5K1) binds PtdIns(3,4,5)P3 with a high affinity which may prevent other 
ligands from binding or displace weaker-bound ligands (Gokhale et al. 2011). 
PtdIns(3,4,5)P3 is involved in the phosphatidylinositol 3-kinase (PI3K) 
pathway, and phosphorylation of PtdIns(3,4,5)P3 by PI3K leads to the 
activation of the kinase AKT which regulates processes including cell growth, 
proliferation and apoptosis (Vivanco and Sawyers 2002). Mutations in 
several genes in the PI3K pathway have been identified in a variety of 
cancers (reviewed in Vivanco and Sawyers 2002). Therefore, the potential 
ability of PPIP5K2 to regulate PtdIns(3,4,5)P3 levels through its binding may 
be important in carcinogenesis.  
 
Taken together, there is limited evidence that these three intergenic variants 
are involved with cancer development. All SNPs are near genes that may be 
involved in tumourigenesis, including UGT8, SATB2 and PPIP5K2, but there 
is no evidence that the variants affect the expression of these genes. 
However, all three variants are in regulatory regions, which will require 
functional studies to establish whether they have a role in cancer 
development. 
  
5.5.1.5 Gene-environment interactions 
Only one variant, rs2182833, in the extension study showed evidence of 
gene-environment interactions. Unusually, the frequency of this SNP in 
controls differed between smokers and non-smokers (0.289 and 0.368, 
respectively) but had similar frequencies in smoker and non-smoker cases 
(0.418 and 0.401, respectively). This resulted in a significant association of 
the variant in smokers (P = 7.0 x 10-6) but not in non-smokers (P = 0.2825). 
The difference in minor allele frequencies between non-smoking cases and 
controls is difficult to interpret. Our expectation for gene-environmental 
interactions is that the minor allele frequency will differ in cases, showing 
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that, for example, a higher frequency of the risk allele in smokers compared 
to non-smokers increases the risk of disease in smokers. The number of 
smokers and non-smokers in controls in this study is 327 and 496, 
respectively, and the SNP is common, indicating that the results observed 
are not due to a lack of rare homozygotes or heterozygotes. Additionally, this 
SNP has not been associated with smoking behavior in GWAS so there is no 
prior expectation for frequencies to differ in controls. Expansion of sample 
sizes for both cases and controls would help to establish whether this is a 
robust finding. The lack of interactions with alcohol drinking is not surprising 
considering none of the variants have a known role in alcohol metabolism. 
 
In addition to this work, an Immunochip-wide gene-environmental interaction 
test was performed, which used logistic regression adjusted for age, gender, 
alcohol consumption and tobacco smoking. This approach was based on a 
study by Wu et al. (2012.a) who performed a genome-wide gene-
environmental interaction test and were the first to analyze OSCC GWAS 
data in this manner. This led to the identification of 15 variants located at the 
ALDH2 locus on chromosome 12q24, which were associated with OSCC in 
the Chinese population. SNPs at this locus had previously been found to 
interact with alcohol to affect disease susceptibility (Wu et al. 2011.c). Two 
novel susceptibility loci, rs9288520 and rs17450420 on chromosome 2q22 
and 13q33, respectively, were also associated with OSCC. A stratified 
analysis, whereby case-control studies for drinkers and non-drinkers were 
performed separately, showed that the minor alleles of both variants were 
associated with a decreased disease risk in non-drinkers but an increased 
risk in drinkers (Wu et al. 2012.a). These SNPs were not associated in the 
GWAS alone, without an interaction test. This, therefore, suggests the 
importance of considering environmental risk factors at an early stage of 
analysis rather than stratifying only significant case-control associations by 
these factors, as is the standard approach to analysis.  
 
Analysis of the South African Immunochip-wide gene-environmental 
interaction test did not identify any variants associated with OSCC that would 
survive the Bonferroni correction (P<1.84 x 10-6). In the gene-alcohol 
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interaction test, the most strongly associated SNPs were rs10493941 and 
rs12726628 (both with P=1.83 x 10-4) in SLC30A7 (solute family carrier 30 
(zinc transporter), member 7). An additional four of the top 10 variants were 
also in this region, which also included DPH5 downstream of SLC30A7. 
SLC30A7 is a zinc transporter and does not have any known roles in alcohol 
metabolism, although another solute family carrier (SLC10A2) was 
associated with OSCC in the gene-alcohol interaction test by Wu et al. 
(2012.a). In the gene-smoking interaction test, rs1052240 in the intron of 
PTPRC was the most strongly associated SNP (P = 1.66 x 10-5). PTPRC 
(protein tyrosine phosphatase, receptor type, C), also known as CD45, is 
involved in the regulation of immune cell signaling (Hermiston et al. 2003; 
Saunders and Johnson 2010). It is also involved in cancer development, 
acting as a tumour suppressor in T-cell acute lymphoblastic leukemia (Porcu 
et al. 2012). As none of these variants had a significant association with 
OSCC, a stratified analysis was not performed. 
 
None of the 20 variants identified through the Immunochip-wide gene-
environmental interaction tests were associated with OSCC in the case-
control study (P>0.2). Since these variants do not show evidence of 
involvement in alcohol or smoking pathways, and fail to meet the Bonferroni 
correction for a significant association, it is unlikely they play a role in OSCC 
susceptibility in the South African Black population.  
 
5.5.2 Population structure 
Principal components analysis was used to investigate population structure 
in the South African samples. The Mixed Ancestry population showed a large 
degree of heterogeneity, which is consistent with historical knowledge of the 
population being formed from indigenous Khoi, Europeans, Asians and other 
African populations. A previous large-scale analysis of the Mixed Ancestry 
population by de Wit et al. (2010) estimated that the main ancestral groups 
were Khoesan (32%-43%), Bantu-speaking Africans (20-36%), Europeans 
(21-28%) and Asians (9-11%). 
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In contrast to the Mixed Ancestry population, the South African Black cases 
and controls are tightly clustered in the PCA plots, forming a distinct group 
indicative of a relatively homogeneous genetic architecture. This is 
consistent with the fact that almost all patients and controls are Xhosa-
speakers, originating from a single linguistic ancestral population. 
Interestingly, the Black individuals clustered adjacent to the HapMap 
Yoruban subjects, consistent with a common sub-Saharan Bantu-speaking 
ancestry (Tishkoff et al. 2009). The only other study of an extensive panel of 
genetic markers in the Xhosa population (also known as isiXhosa) is from 
Patterson et al. (2010)  who genotyped 20 individuals on an Affymetrix 900K 
SNP array. This also showed tight clustering of the Xhosa in the PCA plots, 
closely adjacent to the Yoruban population.  
 
5.5.3 Replication of Chinese GWAS hits using the South African 
Immunochip data 
The use of the Immunochip containing ~200,000 variants also allowed other 
SNPs of interest to be investigated, such as those associated with OSCC in 
other populations. For the 40 variants identified through Chinese GWAS and 
the   European   Barrett’s   oesophagus GWAS, only 6 were present on the 
Immunochip, with an additional 7 covered by proxies. This low number is 
probably due to the majority of the SNPs not having a known role in immune-
related diseases, for which the Immunochip array was designed. None of the 
index SNPs or proxies were associated with OSCC in the Black population, 
all with P>0.05. These loci may represent population-specific disease 
associations. Alternatively, different variants in the region may be associated 
in the South African population but the effect could not detected by 
genotyping of the index SNP. This will be discussed in the following section. 
Additionally, our study had low power to detect modest genetic effect sizes, 
with only 278 cases and 257 controls tested for disease association. This 
compares to the thousands of samples included in the GWAS studies (Abnet 
et al. 2010; Wang et al. 2010.a; Wu et al. 2012.a). A larger sample set would 
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help to determine whether the Chinese GWAS hits also contribute to OSCC 
susceptibility in the South African Black population.  
 
5.5.4 Summary of case-control study 
This study found three variants that were significantly associated with OSCC 
in the South African Black population using the Immunochip. These SNPs 
were all located in TGFBR3, which is a strong candidate gene for cancer 
development due to its involvement in the regulation of processes such as 
proliferation, angiogenesis, apoptosis and immune responses. Other variants 
with a suggestive association were also in regions that have previously been 
associated with carcinogenesis, including MTMR3.  
 
Following an extension study which genotyped 7 variants in an expanded set 
of cases and controls, no variants were significantly associated with OSCC. 
The significance threshold (P<1.84 x 10-6) was determined using the 
Bonferroni correction for the number of independent SNPs tested on the 
Immunochip. However, this is a conservative correction, which the top SNP 
in TGFBR3 just failed to meet (P= 4.0 x 10-6). In addition, sample numbers 
were relatively small with 407 cases and 834 controls.  
 
It is possible that these loci are associated with OSCC in the South African 
population but a significant association could not be detected. This may be 
due to several factors. Firstly, and perhaps most importantly, the chip was 
designed for European populations. Therefore, if an index SNP was merely a 
tagging SNP in a high level of LD with the causal variant in a European 
population, then an association may not be observed in African populations. 
This is due to Africans having a lower level of LD than Asian and European 
populations (Teo et al. 2010). If the index SNP was in moderate LD with the 
causal variant in an African population, then a significant disease association 
may still not be observed due to a loss of power to detect a weaker effect 
size (Teo et al. 2010). Additionally, an array designed for Europeans results 
in the absence of SNPs (both common and rare) which are only present in 
African populations. Thus, the variants in regions which show evidence of 
Chapter 5: Immunochip 
 
198 
association with OSCC in the South African Black population may not have 
been fully explored. The Immunochip was also designed several years ago 
and more variants in these loci are likely to have been identified which were 
not included. Further follow up of the results from the Immunochip scan 
should be carried out when a larger number of cases and controls from this 
population are available to increase the power of the study.  
 
Alternatively, the results may indicate that none of the regions are 
significantly associated with OSCC in the South African Black population. 
Several SNPs on the Immunochip have previously been associated with 
OSCC in Chinese populations (either directly or as tagging SNPs) (Wu et al. 
2011.c; Abnet et al. 2012; Wu et al. 2012.a), suggesting that these regions 
may be important in disease susceptibility. Therefore, these loci may 
represent population-specific disease associations, with the risk loci absent 
in the South African population, but a much larger sample size would be 
required to exclude them. Alternatively, gene-environment interactions may 
be important, with environmental risk factors being population-specific.   
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6 Identification of somatic mutations in oesophageal 
squamous cell carcinoma 
6.1 Known somatic mutations in OSCC 
Somatic mutations that occur in OSCC have been explored for over 20 
years. In 1990, the first mutations to be discovered were in TP53, which were 
found using a candidate gene sequencing approach (Hollstein et al. 1990). In 
that study, TP53 mutations were identified in 2/4 (50%) of OSCC cell lines 
and 5/14 (36%) of OSCC tumours. In the years since, TP53 has been 
investigated in OSCC patients in different in populations, with mutation rates 
ranging from 17-84% (reviewed in Egashira et al. 2007). The candidate gene 
approach has also been successful in identifying somatic mutations in 
several other genes including MTS1/CDH4I (52% of tumours) (Mori et al. 
1994), PIK3CA (12%) (Phillips et al. 2006; Maeng et al. 2012), p16/CDKN2 
(28%) (Gamieldien et al. 1998) and MLH1 (8%) (Maeng et al. 2012).  
 
In more recent years, technologies have been developed enabling genome-
wide mutation analysis to investigate all somatic mutations present in a 
tumour. The first and only study to perform this in OSCC was by Agrawal et 
al. (2012), who sequenced the exome of 12 OSCC tumours and matched 
normal tissue from patients in the USA. The tumours contained an average 
of 83 somatic mutations, with the most frequently mutated gene being TP53, 
present  in  92%  of  tumours.  Other  frequently  mutated  genes  (≥3/12  tumours)  
were NOTCH1, NOTCH3, FBXW7, KIF16B, KIF21B and MYCBP2. These 
genes, together with NOTCH2, were sequenced in an additional 41 tumours 
and normal tissues and resulted in the following mutation frequencies: TP53 
(62% of tumours), NOTCH1 (21%), NOTCH2 (6%), NOTCH3 (8%), FBXW7 
(6%), with no mutations found in KIF16B, KIF21B and MYCBP2. Agrawal et 
al. also sequenced these five frequently mutated genes in 48 OSCC samples 
and matched controls from a Chinese population. Of these, 71% harboured a 
mutation in TP53 but NOTCH mutations were rare, occurring in 3 tumours 
(one mutation in each NOTCH1, NOTCH2 and NOTCH3). The authors 
conclude that the mechanisms of tumourigenesis may vary between different 
populations which could have implications for the success of drug treatments 
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in populations where the mutational landscape is not known. Interestingly, 
TP53, NOTCH1, NOTCH2, NOTCH3, FBXW7 are also mutated in head and 
neck squamous cell carcinoma (Agrawal et al. 2011; Stransky et al. 2011). 
 
A summary of somatic mutations occurring in OSCC is shown in Table 6.1, 
the majority of which were identified using candidate gene studies. As many 
TP53 studies have been performed, a review article has been included which 
summarizes these studies (Egashira et al. 2007).  
 
Table 6.1: Summary of somatic mutations in OSCC 






Agrawal et al. 2012  
Exome sequencing 
- discovery phase 
TP53 11/12 92% 
NOTCH1 4/12 33% 
NOTCH3 3/12 25% 
FBXW7 2/12 17% 
Exome sequencing 
- follow-up 
TP53 - 62% 
NOTCH1 - 21% 
NOTCH2 - 6% 
NOTCH3 - 8% 
FBXW7 - 6% 
Maeng et al. 2012  Candidate gene 
PIK3CA 10/80 11.5% 
MLH1 7/80 8.0% 
TP53 3/80 3.5% 
BRAF 1/80 1.2% 
CTNNB1 1/80 1.2% 
EGFR 1/80 1.2% 




Review of TP53 
mutation studies - 17% - 84% 
Phillips et al. 2006  Candidate gene 
PIK3CA 4/35 11.8% 
PIK3CB 0/35 0.0% 
Hu et al. 2004  Candidate gene 
CDKN2A 14/56 25% 
CDKN2B 1/56 1.8% 
Li et al. 2003  Candidate gene DICE 3/56 5.4% 
Lo et al. 2002  Candidate gene RNF6 3/24 12.5% 
Giroux et al. 2002 Candidate gene CDKN2A 6/100 6.0% 
Gamieldien et al. 1998  Candidate gene 
CDKN2A 21/76 28% 
TP53 13/76 17% 
Esteve et al. 1996  Candidate gene CDKN2A 2/21 9.5% 
Suzaki et al. 1995  Candidate gene 
CDKN2A 5/35 14% 
CDKN2B 1/39 3% 
Mori et al. 1994  Candidate gene MTS1/CDH4I 14/27 51.9% 
Chapter 6: Somatic mutations 
 
201 
6.2 Somatic mutations in OSCC from South African 
populations 
Only one study has analyzed OSCC somatic mutations in South African 
patients (Gamieldien et al. 1998). This used a candidate gene approach and 
focused on TP53 exons 5-8 and p16/CDKN2 exons 1-2, and found that these 
genes were mutated in 17% and 28% of tumours, respectively.  
 
The aim of this chapter is to further explore the somatic changes occurring in 
OSCC patients from the South African population using a whole-exome 
sequencing approach. This will be achieved by initially sequencing matched 
blood and tumour DNA from 8 OSCC patients in order to identify driver 
mutations.
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6.3 Exome sequencing of OSCC blood-tumour pairs 
6.3.1 Exome sequencing metrics 
Eight blood-tumour pairs were whole-exome sequenced and the summary 
statistics are shown in Table 6.2. The median sequencing depth ranged from 
52-283x. The samples sequenced by Illumina (232T and P662) had the 
highest median depths (283 and 244, respectively), with those sequenced at 
KCL having higher values than ICR (71-129 vs. 52-66, respectively). The 
percentage of targeted regions covered at 40x ranged from 63-93%. 
 
Table 6.2: Summary statistics for whole-exome sequencing  





Percentage of targeted 
regions covered at: Median depth 10x 20x 40x 
T416 ICR 94061126 72 93 87 71 63 
P1354 ICR 98554907 70 93 87 71 64 
T438 ICR 96023847 74 94 87 72 66 
P1400 ICR 82668200 67 93 85 64 52 
T441 ICR 90426864 74 94 87 71 62 
P1116 ICR 83906875 68 92 84 63 52 
T442 ICR 97546354 72 93 87 72 65 
P1406 ICR 78138522 70 93 86 64 52 
T443 ICR 94027141 71 93 86 69 61 
P1408 ICR 90488711 71 93 86 69 60 
386T KCL 110579550 78 95 92 85 125 
P1282 KCL 114420987 77 96 92 86 129 
T437 KCL 61513647 78 93 87 74 71 
P1377 KCL 108294987 80 96 92 86 128 
232T KCL 270262199 70 98 96 93 283 
P662 KCL 240263017 68 98 95 91 244 
 
 
6.3.2 Somatic mutations identified 
Several thresholds were applied for a somatic mutation to be called. Firstly, 
the  total  number  of  sequencing  reads  required  was  ≥8  and  ≥14  for  blood  and  
tumour sample, respectively. In addition, the threshold for the frequency of 
the mutant alternative allele  was  set  at  ≥15%  in  the  tumour  and  <2%  in  the  
normal blood DNA. However, the alternative allele frequency was lowered to 
≥10%  in   two  tumours   in  which  very   few  mutations  were   identified  using   the  
≥15%  threshold.     
 
The number of potential somatic mutations in each of the blood-tumour pairs 
is summarized in Table 6.3, with the results visualised in Figure 6.1. 
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Table 6.3: Summary of potential somatic mutations  
Mutations are present in ≥15%  of  sequencing reads in the tumour and absent (<2%) in the blood DNA (a). The threshold was  

















site mutations and non-
synonymous mutations in 
cancer gene census genes 
T386-P1282 301 14 185 102 8 
T438-P1400 215 13 103 102 8 
T437-P1377 171 4 109 58 7 
T441-P1116 111 3 39 69 2 
T443-P1408 48 8 16 24 0 
T442-P1406 23 3 5 15 0 
232T-P662 6 1 2 3 0 




x = Stop-gain/loss, frameshift, non-synonymous, splice sites, synonymous, intergenic, intronic, UTR 
y = Stop-gain/loss, frameshift, essential splice sites 


















site mutations and non-
synonymous mutations in 
cancer gene census genes 
232T-P662 55 10 16 29 0 
T416-P1354 10 1 3 6 0 
a) 












Figure 6.1: Summary of potential somatic mutations 
The number (a) and percentage (b) of each type of somatic mutation present in the blood-
tumour pairs. The minor allele frequency  (MAF)  for  each  variant  was  ≥15%  in  the  tumours,  
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The total number of potential somatic mutations was variable between 
tumours, ranging from 10 to 301. The number of protein truncating/splice-site 
mutations (stop-gain/loss, frameshift insertions or deletions, and essential 
splice sites) ranged from 1 to 14 in each tumour. However, not all mutations 
appeared to be real when the sequencing data was visualised using 
Integrated Genomics Viewer (IGV). IGV was used to view stop-gain/loss, 
frameshift and essential splice sites mutations, together with non-
synonymous mutations that were in genes present in the Cancer Gene 
Census, in all blood-tumour pairs. These mutations were considered more 
likely to be involved in cancer development, and hence were prioritised over 
silent mutations. Table 6.4 shows the potentially functional somatic mutations 
identified, together with a prediction of whether they appear to be valid 
mutations on IGV. 
 
Table 6.4: Somatic mutations identified by whole-exome sequencing  
The reference (ref) and alternative (alt) alleles are shown, together with the minor allele 
frequency (MAF) for the alternative allele in the tumour. All tumours used a threshold of 
≥15%   of reads supporting the alternative allele, apart from 232T-P662 and T416-P1354 
which   used   a   ≥10%   threshold. Each mutation was visualised using Integrated Genomics 
Viewer (IGV) to determine whether they appeared to be valid mutations. 










C9orf142 9:139887697 T G 0.17 Essential splice site No 
CRHBP 5:76249852 A C 0.26 Essential splice site No 
DPP6 7:154681166 G A 0.16 Essential splice site No 
ERCC5 13:103498666 T G 0.22 Non-synonymous No 
FANCA 16:89805074 C G 0.17 Non-synonymous No 
GNAS 20:57429620 G C 0.17 Non-synonymous No 
GNAS 20:57429907 A C 0.21 Non-synonymous No 
IQCH 15:67547287 T G 0.16 Essential splice site No 
KNSTRN 15:40675525 T G 0.16 Essential splice site No 
MEF2C 5:88026048 C A 0.16 Stopgain Yes 
MKL1 22:40815208 C A 0.16 Non-synonymous Yes 
MN1 22:28194178 T G 0.17 Non-synonymous No 
NOXO1 16:2030366 A C 0.15 Essential  splice site No 
PPM1D 17:58740836 C T 0.23 Stopgain Yes 
PPP2R1A 19:52723071 T G 0.18 Non-synonymous No 
PRELID1 5:176733533 G C 0.22 Stoploss No 
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RBM26 13:79940771 - T 0.21 Frameshift Yes 
TP53 17:7579389 G A 0.31 Stopgain Yes 
TSC22D2 3:150127930 - C 0.15 Frameshift No 
TTC22 1:55251654 A C 0.15 Essential splice site No 
ZZEF1 17:4045834 A C 0.17 Essential  splice site No 
T438-
P1400 
APC 5:112173713 G C 0.30 Non-synonymous Yes 
APC 5:112174228 G A 0.27 Non-synonymous Yes 
APC 5:112174347 G C 0.21 Non-synonymous Yes 
ARHGAP21 10:24884912 T TA 0.19 Frameshift Yes 
ATAD5 17:29214214 AT A 0.30 Frameshift Yes 
CARS 11:3059285 C G 0.24 Non-synonymous Yes 
CNGB1 16:57996877 C T 0.45 Essential  splice site Yes 
CORO2B 15:68937546 C A 0.27 Stopgain Yes 
FCRL3 1:157667452 G A 0.23 Stopgain Yes 
KRT27 17:38937523 C G 0.35 Essential  splice site Yes 
MLL2 12:49448371 C T 0.26 Non-synonymous Yes 
NLRC5 16:57111288 TAG T 0.32 Frameshift Yes 
NOTCH2 1:120512275 C CA 0.17 Frameshift Yes 
OR52A5 11:5153238 AACCCT A 0.17 Frameshift Yes 
OVGP1 1:111957563 C CT 0.22 Frameshift No 
PMS1 2:190738302 G C 0.24 Non-synonymous Yes 
SP1 12:53777373 C T 0.33 Stopgain Yes 
TP53 17:7578466 G A 0.36 Non-synonymous Yes 
TP53 17:7578458 G GGA 0.30 Frameshift Yes 
ZNF521 18:22804986 C G 0.19 Non-synonymous Yes 
ZNF750 17:80789692 G GA 0.28 Frameshift Yes 
T437-
P1377 
DGKI 7:137282649 C A 0.17 Stopgain No 
FCGR2B 1:161642797 T G 0.18 Non-synonymous No 
HOXA11 7:27224414 T G 0.15 Non-synonymous No 
MLL2 12:49426251 T G 0.19 Non-synonymous No 
MLLT6 17:36861953 T G 0.18 Non-synonymous No 
RECQL4 8:145737856 G T 0.16 Non-synonymous Yes 
RECQL4 8:145738086 A G 0.19 Non-synonymous No 
SCARB1 12:125299662 T G 0.16 Essential  splice site No 
SCN8A 12:52115555 - A 0.17 Frameshift No 
TAF15 17:34171676 A G 0.18 Non-synonymous No 
TARBP1 1:234601455 C A 0.20 Essential  splice site No 
T441-
P1116 ARHGEF2 1:155931616 
TGATAAA T 0.16 Frameshift Yes TACCC 




Examples of mutations that appear to be valid and those that are 
unconvincing using IGV are shown in Figure 6.2 and Figure 6.3, respectively. 
The former shows the mutation to be absent in the blood and present in a 
number of reads in the tumour. The latter places the identified mutation in a 
COX6C 8:100899805 G C 0.20 Non-synonymous Yes 
FLT3 13:28611364 C G 0.17 Non-synonymous Yes 
FZD6 8:104340628 C T 0.15 Stopgain Yes 
IL21R 16:27459982 C T 0.23 Non-synonymous Yes 
LARGE 22:33780177 C T 0.32 Essential  splice site Yes 
PAX7 1:18961022 G A 0.16 Non-synonymous Yes 
TET2 4:106156540 C T 0.32 Stopgain Yes 
TMPRSS2 21:42843880 C T 0.32 Non-synonymous Yes 
T443-
P1408 
DNAH10 12:124285943 AG A 0.18 Frameshift Yes 
JUNB 19:12902663 C CCT 0.33 Frameshift Yes 
KL 13:33628178 AC A 0.34 Frameshift Yes 
OSBPL3 7:24901235 T A 0.32 Stopgain Yes 
RORA 15:60789688 G T 0.16 Stopgain Yes 
RTL1 14:101348698 G A 0.17 Stopgain Yes 
SRPX X:38080687 CAA C 0.33 Frameshift Yes 
VAMP4 1:171678834 G A 0.21 Stopgain Yes 
T442-
P1406 
GPRASP2 X:101970164 A T 0.15 Stopgain Yes 
HPX 11:6458700 G A 0.18 Stopgain Yes 
WDR17 4:177083305 CT C 0.18 Frameshift Yes 
232T-
P662 
BBC3 19:47729819 A C 0.10 Essential  splice site No 
DPP7 9:140007195 A C 0.11 Essential  splice site No 
DPY19L1 7:34979763 A C 0.13 Essential  splice site No 
FAM131C 1:16384994 C - 0.10 Frameshift Yes 
MTR 1:237038025 G A 0.11 Essential  splice site No 
MYH14 19:50789941 C - 0.10 Frameshift Yes 
NFIA 1:61872232 A C 0.13 Essential  splice site No 
NFIA 1:61872233 G C 0.17 Essential  splice site No 
SREBF1 17:17716680 A C 0.11 Essential  splice site No 
TOPAZ1 / 
C3orf77 3:44283603 C T 0.10 Stopgain Yes 
T416-
P1354 CXorf30 X:36324916 AT A 0.13 Frameshift Yes 
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region containing many variants, both in the blood and tumour. The degree 
of confidence in calling these variants is varied, with the lighter coloured 
letters indicating a lower confidence.  This may represent mis-alignment or 





Figure 6.2: Sequencing reads for a valid somatic mutation 
This mutation was identified by whole-exome sequencing and visualised using IGV. The 





Figure 6.3: Sequencing reads for an unconvincing somatic mutation  
This mutation was identified by whole-exome sequencing but by visualising the region on 














Site of identified mutation 
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The number of mutations that were confirmed on IGV is summarized in Table 
6.5 for each blood-tumour pair. 
 
Table 6.5: Number of somatic mutations confirmed on IGV 
Sample Mutations confirmed on IGV (%) 
T386-P1282 5/21 (24%) 
T438-P1400 20/21 (95%) 
T437-P1377 1/11 (9%) 
T441-P1116 9/9 (100%) 
T443-P1408 8/8 (100%) 
T442-P1406 3/3 (100%) 
232T-P662 3/10 (30%) 
T416-P1354 1/1 (100%) 
 
Five blood-tumour pairs had a high confirmation rate (>95%). However, three 
pairs had low rates (<30%), which were the samples where the mutation 
calling was carried out at KCL, whereas the others were analysed at the ICR. 
To ensure that these results did not reflect a poor performing calling 
algorithm, all other blood-tumour pairs were run through the KCL analysis 
pipeline, with results shown in Table 6.6.  
 
Table 6.6: Comparison of mutations confirmed on IGV using the ICR and KCL analysis 
pipelines 
Sample 
Mutations confirmed  
on IGV (%) 
ICR KCL 
T438-P1400 20/21 (95%) 16/17 (94%) 
T441-P1116 9/9 (100%) 9/14 (64%) 
T443-P1408 8/8 (100%) 8/10 (80%) 
T442-P1406 3/3 (100%) 6/9 (67%) 
T416-P1354 1/1 (100%) 9/23 (39%) 
 
The percent of mutations confirmed using the KCL calling algorithm is lower 
than that for the ICR method (39-94% versus 95-100%, respectively). This 
suggests that the KCL algorithm could be further optimized. However, in 4 
out of 5 tumours, the KCL method identified more mutations than ICR, with a 
similar number of mutations confirmed (apart from T416-P1354), although 
they were not always the same mutations. Therefore, the KCL method may 
introduce more false positives but is still be able to identify true positives. 
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Hence, the specificity of the KCL method is lower, but the sensitivity is 
higher. 
 
Mutations which appeared to be valid on IGV were selected for Sanger 
sequencing to confirm their presence using an independent technique. 
 
6.3.3 Sanger sequencing to confirm somatic mutations 
Protein truncating/splice-site mutations and non-synonymous mutations that 
were in genes present in the Cancer Gene Census were prioritized for 
confirmation by Sanger sequencing. The variants selected for Sanger 
sequencing are shown in Table 6.7, together with the results. 
 
Table 6.7: Confirmation of somatic mutations using Sanger sequencing 







MEF2C Stopgain 5:88026048 C A 0.16 No 
MKL1 Non-synonymous 22:40815208 C A 0.16 No 
PPM1D Stopgain 17:58740836 C T 0.23 Yes 
RBM26 Frameshift 13:79940771 - T 0.21 Yes 
TP53 Stopgain 17:7579389 G A 0.31 Yes 
T438-
P1400 
APC Non-synonymous 5:112173713 G C 0.30 Yes 
APC Non-synonymous 5:112174228 G A 0.27 Yes 
APC Non-synonymous 5:112174347 G C 0.21 Yes 
ARHGAP21 Frameshift 10:24884912 T TA 0.19 Yes 
ATAD5 Frameshift 17:29214214 AT A 0.30 Yes 
CARS Non-synonymous 11:3059285 C G 0.24 Yes 
CNGB1 Essential  splice site 16:57996877 C T 0.45 Yes 
CORO2B Stopgain 15:68937546 C A 0.27 Yes 
FCRL3 Stopgain 1:157667452 G A 0.23 Yes 
KRT27 Essential  splice site 17:38937523 C G 0.35 Yes 
MLL2 Non-synonymous 12:49448371 C T 0.26 Yes 
NLRC5 Frameshift 16:57111288 TAG T 0.32 Yes 
NOTCH2 Frameshift 1:120512275 C CA 0.17 No 
OR52A5 Frameshift 11:5153238 AACCCT A 0.17 Yes 
PMS1 Non-synonymous 2:190738302 G C 0.24 Yes 
SP1 Stopgain 12:53777373 C T 0.33 Yes 
TP53 Frameshift 17:7578458 G GGA 0.30 Yes 
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TP53 Non-synonymous 17:7578466 G A 0.36 Yes 
ZNF521 Non-synonymous 18:22804986 C G 0.19 Yes 




synonymous 8:145737856 G T 0.16 No 
T441-
P1116 
ARHGEF2 Frameshift 1:155931616 TGATAAA TACCC T 0.16 Yes 
COX6C Non-synonymous 8:100899805 G C 0.20 Yes 
FLT3 Non-synonymous 13:28611364 C G 0.17 Yes 
FZD6 Stopgain 8:104340628 C T 0.15 Yes 
IL21R Non-synonymous 16:27459982 C T 0.23 Yes 
LARGE Essential  splice site 22:33780177 C T 0.32 Yes 
PAX7 Non-synonymous 1:18961022 G A 0.16 No 
TET2 Stopgain 4:106156540 C T 0.32 Yes 
TMPRSS2 Non-synonymous 21:42843880 C T 0.32 No 
T443-
P1408 
DNAH10 Frameshift 12:124285943 AG A 0.18 Yes 
JUNB Frameshift 19:12902663 C CCT 0.33 Yes 
KL Frameshift 13:33628178 AC A 0.34 Yes 
OSBPL3 Stopgain 7:24901235 T A 0.32 Yes 
RORA Stopgain 15:60789688 G T 0.16 Yes 
RTL1 Stopgain 14:101348698 G A 0.17 Yes 
SRPX Frameshift X:38080687 CAA C 0.33 Yes 
VAMP4 Stopgain 1:171678834 G A 0.21 Yes 
T442-
P1406 
GPRASP2 Stopgain X:101970164 A T 0.15 Yes 
HPX Stopgain 11:6458700 G A 0.18 Yes 
WDR17 Frameshift 4:177083305 CT C 0.18 Yes 
232T-
P662 
FAM131C Frameshift 1:16384994 C - 0.10 * 
MYH14 Frameshift 19:50789941 C - 0.10 No 
TOPAZ1 / 
C3orf77 Stopgain 3:44283603 C T 0.10 No 
T416-
P1354 CXorf30 Frameshift X:36324916 AT A 0.13 Yes 
* Specific primers could not be designed due to similarity with another region 



























Figure 6.4: Examples of Sanger sequencing chromatograms showing somatic 
mutations  
 
The mutations that were confirmed are summarized in Table 6.8. Two 
tumours (T232 and T437) were found not to harbour any somatic mutations 
that resulted in stop codons, frameshifts or were potential functional variants 




















- -  - -  -  -  -  - -  - - -  -  
Chapter 6: Somatic mutations 
 
213 
Table 6.8: Somatic mutations confirmed by Sanger sequencing 
Sample Gene Position Effect Protein 
386T-P1282 
PPM1D 17:58740836 Stopgain R581X 
RBM26 13:79940771 Frameshift T378fs 
TP53 17:7579389 Stopgain Q100X 
T438-P1400 
APC 5:112173713 Non-synonymous D808H 
APC 5:112174228 Non-synonymous M979I 
APC 5:112174347 Non-synonymous G1019A 
ARHGAP21 10:24884912 Frameshift Y20fs 
ATAD5 17:29214214 Frameshift N1361fs 
CARS 11:3059285 Non-synonymous V183L 
CNGB1 16:57996877 Essential splice site - 
CORO2B 15:68937546 Stopgain Y16X 
FCRL3 1:157667452 Stopgain Q186X 
KRT27 17:38937523 Essential splice site - 
MLL2 12:49448371 Non-synonymous D114N 
NLRC5 16:57111288 Frameshift I1611 
OR52A5 11:5153238 Frameshift L210fs 
PMS1 2:190738302 Non-synonymous E852Q 
SP1 12:53777373 Stopgain Q541X 
TP53 17:7578458 Frameshift V157fs 
TP53 17:7578466 Non-synonymous T155I 
ZNF521 18:22804986 Non-synonymous E966Q 
ZNF750 17:80789692 Frameshift P213fs 
T441-P1116 
ARHGEF2 1:155931616 Frameshift E431fs 
COX6C 8:100899805 Non-synonymous F52L 
FLT3 13:28611364 Non-synonymous D423H 
FZD6 8:104340628 Stopgain R509X 
IL21R 16:27459982 Non-synonymous T332M 
LARGE 22:33780177 Essential splice site - 
TET2 4:106156540 Stopgain Q481X 
T443-P1408 
DNAH10 12:124285943 Frameshift R742fs 
JUNB 19:12902663 Frameshift L26fs 
KL 13:33628178 Frameshift D58fs 
OSBPL3 7:24901235 Stopgain K311X 
RORA 15:60789688 Stopgain S513X 
RTL1 14:101348698 Stopgain R810X 
SRPX X:38080687 Frameshift D4fs 
VAMP4 1:171678834 Stopgain R106X 
T442-P1406 
GPRASP2 X:101970164 Stopgain K123X 
HPX 11:6458700 Stopgain R225X 
WDR17 4:177083305 Frameshift L951fs 
T416-P1354 CXorf30 X:36324916 Frameshift L151fs 
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6.3.4 Function of genes with somatic mutations 
The genes found to harbour somatic mutations are shown in Figure 6.9 with 
a brief description of their function according to the NCBI Gene resource 
(http://www.ncbi.nlm.nih.gov/gene), unless otherwise stated. Several genes 
are involved in processes that may contribute to cancer development, 
including the known tumour suppressors TP53, APC and KL. The last 
column in Figure 6.9 shows whether the genes may have a potential role in 
OSCC development, given the known function. 
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Table 6.9: Function of somatically mutated genes 









PPM1D Protein phosphatase, Mg2+/Mn2+ dependent, 1D Regulates, and is itself regulated by, TP53 No Stopgain Yes 
RBM26 RNA binding motif protein 26 No known function No Frameshift No 
TP53 Tumour protein p53 Cell cycle, apoptosis, DNA repair. A tumour suppressor. Yes Stopgain Yes 
T438-
P1400 
APC Adenomatous polyposis coli Cell migration and adhesion, transcriptional activation, and apoptosis. A tumour suppressor. Yes 
Non-
synonymous Yes 
ARHGAP21 Rho GTPase activating protein 21 Cell proliferation and cytoskeleton organization in prostate adenocarcinoma (a) No Frameshift Yes 
ATAD5 ATPase family, AAA domain containing 5 DNA damage response, apoptosis, DNA replication (b,c) No Frameshift Yes 
CARS Cysteinyl-tRNA synthetase An aminoacyl-tRNA synthetase, located in a tumour-suppressor gene region (11p15.5) Yes 
Non-
synonymous Yes 
CNGB1 Cyclic nucleotide gated channel beta 1 Rod photoreceptor No Essential splice site No 
CORO2B Coronin, actin binding protein, 2B Reorganization of the neuronal actin cytoskeleton, and potentially neuronal cell migration (d) No Stopgain No 
FCRL3 Fc receptor-like 3 Regulation of immune system No Stopgain No 
KRT27 Keratin 27 Forms the cytoskeleton of epithelial cells No Essential splice site No 
MLL2 Myeloid/lymphoid or mixed-lineage leukemia 2 
A histone methyltransferase involved in the regulation of 
several pathways, including p53. (e) Yes 
Non-
synonymous Yes 
NLRC5 NLR family, CARD domain containing 5 Regulation of immune system No Splice site, frameshift No 
OR52A5 Olfactory receptor, family 52, subfamily A, member 5 Response to smell No Frameshift No 
PMS1 PMS1 postmeiotic segregation increased 1 (S. cerevisiae) DNA repair Yes 
Non-
synonymous Yes 
SP1 Sp1 transcription factor 
Cell differentiation, cell growth, apoptosis, immune 
responses, response to DNA damage, and chromatin 
remodeling 
No Stopgain Yes 















ZNF521 Zinc finger protein 521 Regulates B cell development (f) Yes Non-synonymous No 
ZNF750 Zinc finger protein 750 Epidermal differentiation (g) No Frameshift No 
T441-
P1116 
ARHGEF2 Rho/Rac guanine nucleotide exchange factor (GEF) 2 Cell migration (h) No Frameshift Yes 
COX6C Cytochrome c oxidase subunit Vic 
Catalyzes the electron transfer from reduced cytochrome c 
to oxygen. Upregulated or involved in gene-fusion events 
in some tumours (i, j) 
Yes Non-synonymous Yes 
FLT3 fms-related tyrosine kinase 3 Regulates apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow Yes 
Non-
synonymous Yes 
FZD6 Frizzled family receptor 6 Cell proliferation and apoptosis No Stopgain Yes 
IL21R Interleukin 21 receptor Proliferation and differentiation of T cells, B cells, and natural killer (NK) cells Yes 
Non-
synonymous Yes 
LARGE Like-glycosyltransferase Glycosylation of alpha-dystroglycan No Essential splice site No 




DNAH10 Dynein, axonemal, heavy chain 10 Microtubule motor involved in cell division and migration No Frameshift Yes 
JUNB Jun B proto-oncogene Involved in regulating cell division and tumour invasion (k) No Frameshift Yes 
KL Klotho Tumour suppressor (l) No Frameshift Yes 
OSBPL3 Oxysterol binding protein-like 3 Intracellular lipid receptor No Stopgain No 
RORA RAR-related orphan receptor A Cellular stress response (m) No Stopgain Yes 
RTL1 Retrotransposon-like 1 Maintenance of the fetal capillaries No Stopgain No 
SPRX Trypsin-like serine protease No information No Frameshift No 
VAMP4 Vesicle-associated membrane protein 4 Trafficking synaptic vesicles to the presynaptic membrane No Stopgain No 
T442-
P1406 
GPRASP2 G protein-coupled receptor associated sorting protein 2 
Regulates G protein-coupled receptors. In HNSCC, gene 
is overexpressed in patients who develop metastases (n) No Stopgain Yes 
HPX Hemopexin Transports heme No Stopgain No 
WDR17 WD repeat domain 17 Unknown function. Expressed in retina. No Frameshift No 
T416-
P1354 CXorf30 Chromosome X open reading frame 30 No known function No Frameshift No 
(a) = Lazarini et al. 2013; (b) = Lee et al. 2013; (c) = Bell et al. 2011; (d) = Nakamiyra et al. 1999; (e) = Guo et al. 2012; (f) = Mega et al. 2011; (g) = Sen et al. 2012; (h) =Nalbant et al. 
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6.3.5 Recurrently mutated genes 
Genes that are mutated in multiple tumours of the same type are potentially 
important in the development of OSCC, with the mutations driving the 
disease. Analysis of protein truncating/splice-site mutations (stopgain, 
frameshift and essential splice sites) and non-synonymous mutations in 
genes known to be mutated in cancer (from the Cancer Gene Census) in our 
data identified only one gene, TP53, that was mutated in several tumours. 
One tumour (T386) contained a TP53 stop gain mutation, with a second 
tumour (T438) harbouring both a frameshift insertion and a non-synonymous 
mutation. If all non-synonymous mutations were included, two additional 
genes, GPR98 and SRRM2, were found to be mutated in two tumours (and 
confirmed by Sanger sequencing), as shown in Table 6.10.  
 
Table 6.10: Recurrently mutated genes 
Sample Location (Hg19) Gene 
Protein 
change SIFT (score) Polyphen (score) 
T438-P1400 17:578458 TP53 GA insertion - - 
T438-P1400 17:7578466 TP53 T155I Deleterious (0) Probably damaging (0.938) 
T386-P1282 17:7579389 TP53 Q100X - - 
T443-P1408 5:89953731 GPR98 I1463T Tolerated (0.95) Benign (0.003) 
T441-P1116 5:90046431 GPR98 R3680C Deleterious (0) Probably damaging (1) 
T438-P1400 16:2815904 SRRM2 G1044E Tolerated (0.47) Probably damaging (1) 
T441-P1116 16:2809653 SRRM2 S275C Deleterious (0) Probably damaging (0.999) 
 
The   power   to   detect   frequently  mutated   genes   (≥2/8   tumours)   is   shown   in  
Table 6.11, given different gene mutation rates. For example, if the mutation 
rate  of  a  gene  is  20%,  then  the  probability  to  detect  recurrent  mutations  (≥2/8  
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Probability  of  ≥2  of  8  










In order to identify more potential driver mutations, the genes which 
contained confirmed somatic mutations in our study were reviewed for 
evidence that they were mutated in other published studies in related 
cancers (Table 6.12). These studies all used a whole-exome sequencing 
approach to sequence OSCC, oesophageal adenocarcinoma (OAC) and 
head and neck squamous cell carcinoma (HNSCC). Numbers of tumours in 
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n = 12 n = 11 n = 145 n = 32 n =74 
T386-P1282 
PPM1D Yes No Yes Yes Yes 
TP53 Yes Yes Yes Yes Yes 
RBM26 No No Yes No Yes 
T438-P1400 
APC No Yes Yes No Yes 
ARHGAP21 No No Yes No No 
ATAD5 No No Yes No No 
CARS No No Yes No No 
CNGB1 No No Yes No Yes 
CORO2B No No Yes No Yes 
FCRL3 No No Yes No Yes 
KRT27 No No No No No 
MLL2 Yes No Yes No Yes 
NLRC5 No No No No Yes 
OR52A5 No No Yes No No 
PMS1 No No Yes No Yes 
SP1 No No Yes No No 
TP53 Yes Yes Yes Yes Yes 
ZNF521 No No Yes No Yes 
ZNF750 Yes No Yes No Yes 
T441-P1116 
ARHGEF2 No No Yes No Yes 
COX6C No No No No No 
FLT3 No No Yes No Yes 
FZD6 No No Yes No No 
IL21R No No Yes No No 
LARGE No No No No Yes 
TET2 No No No No Yes 
T443-P1408 
DNAH10 No No Yes No Yes 
JUNB No No Yes No No 
KL No No Yes No No 
OSBPL3 No No Yes No No 
RORA No No Yes No Yes 
RTL1 No No Yes No No 
SPRX No No No No No 
VAMP4 No No No No No 
T442-P1406 
GPRASP2 Yes No Yes No Yes 
HPX No No No No Yes 
WDR17 No No Yes No Yes 
T416-P1354 CXorf30 No No No No No 
* Data only available for genes that were mutated in >1 tumour  
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Five of the 6 blood-tumour pairs (excluding the 2 tumours where no 
mutations were identified) contained mutations in genes that are mutated in 
either OSCC, OAC or HNSCC, thereby providing support that driver 
mutations are present in the South African OSCC samples. Interestingly, 28 
of the 37 mutated genes (75.7%) were also mutated in more than one OAC 
tumour in the study by Dulak et al. (2013). This study whole-exome 
sequenced 149 patients, showing that a large number of samples are 
needed to identify recurrent mutations. In the OSCC study by Agrawal et al. 
(2012), mutations were present in 5 of the 37 (13.5%) genes that were 
mutated in South African OSCC patients. This lower number is probably due 
to the relatively small number of samples sequenced in the Agrawal et al. 
study (n=12).  
 
GPR98 and SRRM2 are also mutated in other OSCC, OAC and HNSCC 
exome sequencing studies, as shown in Table 6.13. 
 















n = 12 n = 11 n = 145 n = 32 n =74 
GPR98 Yes  No Yes No Yes 
SRRM2 Yes  No Yes No Yes 
* Data only available for genes that were mutated in >1 tumour  
 
6.3.6 TP53 sequencing 
As TP53 is the most commonly mutated gene in cancer (Efeyan and Serrano 
2007), this gene was further investigated by Sanger sequencing the coding 
regions of the gene in all of the 10 blood-tumour pairs that were available. 
Eight of these had been whole-exome sequenced, but Sanger sequencing 
could potentially identify mutations that were missed. In total, 8 somatic 
mutations were identified in 6 tumours, giving a TP53 mutation rate of 60%. 
The mutations are summarized in Table 6.14, with the sequencing 
chromatograms shown in Figure 6.5. Of these eight mutations, two were 
frameshifts, four were non-synonymous, one was a stop mutation and one 
was in a splice site.   
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SNP ID Mutation ID (a) Location 
Genotypes Triplet code 
mRNA Protein Blood   Tumour (blood --> tumour) 
T386-
P1282 4 7579389 - COSM44032 Stop C/C C/T CAG --> TAG 298C>T Gln100X 
           
T443-
P1408 4 7579358 rs11540654 COSM10716 Non-synonymous G/G G/T CGT --> CTT 329G>T Arg110Leu 
           
T438-
P1400 5 7578466 - COSM44033 Non-synonymous C/C C/T ACC --> ATC 464 C>T Thr155Ile 
           
T438-
P1400 5 7578458 - - Frameshift WT 
TC ins / 
WT  471-472 Val157fs 
           
GSH-
P1508 5 7578407 rs138729528 COSM10870 Non-synonymous C/C G/C CGC --> GGC 523C>G Arg175Gly 
           
T441-
P1116 6 7578177 - COSM44014 
Splice site/ 
synonymous G/G G/A GAG -- GAA 672G>A Glu224Glu 




7577572 (b) - - Frameshift WT 






           
T442-
P1406 8 7577100 - COSM11123 Non-synonymous A/A A/G AGA --> GGA 838A>G Arg280Gly 
(a) Mutation ID from COSMIC database (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) 
(b) Exact position could not be determined due to poor sequence quality in the forward direction  
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Three of the four non-synonymous mutations are predicted to be probably 
damaging by Polyphen and deleterious by SIFT (Table 6.15). The fourth 
mutation, Arg110Leu, is predicted to be possibly damaging and tolerated by 
each program, respectively, but this does vary depending on the TP53 
transcript. For example, in the ENST00000503591 transcript the mutation is 
predicted to be deleterious in SIFT (score = 0.02). 
 
Table 6.15: Functional predictions of TP53 non-synonymous mutations  
Based on TP53 ENST00000269305 transcript. 
Sample Mutation Polyphen (score) SIFT (score) 
T443-P1408 Arg110Leu Possibly damaging (0.46) * Tolerated (0.06) * 
T438-P1400 Thr155Ile Probably damaging (0.938) Deleterious (0) 
GSH-P1508 Arg175Gly Probably damaging (0.98) Deleterious (0) 
T442-P1406 Arg280Gly Probably damaging (0.982) Deleterious (0) 
        * Prediction varies depending on TP53 transcript  
 
Seven of the eight somatic mutations were located in tumours that had been 
whole-exome sequenced. Of these, 4 had been detected by this method but 
3 mutations were not, which may be due to the sequence reads not meeting 
the thresholds to call a mutation. The exome sequencing data was reviewed 
in IGV for these mutations, with screen shots of these mutations shown 
below.  
 
Figure 6.6 shows the Arg110Leu mutation present in T443-P1408, where 
leucine (A allele) was present in 34% of reads in the tumour and absent in 
the blood. The total number of reads at this position was 90 and 80 for blood 
and tumour DNA, respectively. The mutation was not identified by the ICR 
exome sequencing analysis pipeline as it was mis-identified as a common 
SNP and removed from the analysis. 
 






Figure 6.6: Exome sequencing reads of TP53 Arg110Leu mutation 
The somatic mutation was identified in the blood-tumour pair T443-P1408. Exome 
sequencing data was visualised on IGV. 
 
Figure 6.7 shows the Arg280Gly mutation present in T442-P1406, where 
glycine (C allele) was present in 12% of reads in the tumour (below the 15% 
threshold) and absent in the blood  The total number of reads at this position 





Figure 6.7: Exome sequencing reads of TP53 Arg280Gly mutation 
The somatic mutation was identified in the blood-tumour pair T442-P1406. Exome 
















Figure 6.8 shows the frameshift insertion in exon 7 present in T441-P1116, 
where the insertion was present in 6% of reads in the tumour (below the 15% 
threshold) and absent in the blood. The total number of reads at this position 






Figure 6.8: Exome sequencing reads of TP53 exon 7 frameshift insertion  
The insertion was identified in the blood-tumour pair T441-P1116. Exome sequencing data 
was visualised on IGV. 
 
 
6.3.7 PPM1D sequencing 
A stopgain mutation was identified in PPM1D by whole-exome sequencing. 
As this gene is involved in the TP53 pathway, the exons of PPM1D were 
Sanger sequenced in all available 11 blood-tumour pairs. Sequencing was 
incomplete for one tumour (288T) which had a low yield. In total, six somatic 
mutations  were  identified:  one  in  the  5’  UTR,  two  synonymous,  two  identical  
non-synonymous mutations, and one resulting in a stop-codon. These were 
present in four of the blood-tumour pairs, with seven tumours not containing 
a somatic mutation in PPM1D. The results are summarized in Table 6.16, 






Mutation – insertion 















SNP ID Location Genotypes Blood   Tumour 
Mutation/ 
variant mRNA Protein 
T386-P1282 1 58677580 rs116268471 5' UTR T / C T / - - - - 
          
T386-P1282 1 58677865 rs16944543 Synonymous G / A G / - GAG --> GAA 90G>A Glu30Glu 
          
T386-P1282 6 58740836 Novel Stop mutation C / C C / T CGA --> TGA 1741 C>T Arg581X (tumour) 
          
288T-P920 5 58734091 rs111239559 Synonymous A / C A / - GGA --> GGC 1149 A>C Gly383Gly 
          
GSHT-P1508 6 58740785 Novel Non-synonymous G / C G / - GCA --> CCA 1690 G>C Ala564Pro (blood) 
          
TBHT-TB62 6 58740785 Novel Non-synonymous G / C G / - GCA --> CCA 1690 G>C Ala564Pro (blood) 






































Figure 6.9: Sanger sequencing chromatograms of PPM1D somatic mutations 
 
The stop codon (Arg581X) is a novel mutation located in exon 6 of PPM1D. The 
germline DNA was homozygous for the wildtype allele (Arg/Arg) whilst the 
tumour was heterozygous (Arg/X). The non-synonymous mutation found in both 
GSHT-P1508 and TBHT-TB62 was a novel variant resulting in a alanine to 
proline substitution at position 564. The variant was heterozygous (Ala/Pro) in 
the blood, but showed loss of heterozygosity (LOH) in the tumour (Ala/Ala or 
Ala/-). The change from alanine to proline is predicted to be possibly damaging 
by Polyphen but tolerated by SIFT. The two synonymous mutations, Glu30Glu 
and  Gly383Gly,   and   the  5’  UTR  mutations  are   all   known   variants,   and  all   are  
heterozygous in the blood and show LOH in the tumour. A total of 4 of 11 
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tumours showed LOH at the PPM1D locus, and one of these also harboured a 













Whole-exome sequencing was performed in 8 matching blood-tumour pairs 
from South African OSCC patients. The median depth of sequencing reads 
ranged from 52 to 283, with >84% of targeted regions covered at >20X and 
>63% covered at >40X. The samples sequenced by Illumina achieved the 
highest coverage (median depth of >244) due to only one sample being 
sequenced per lane of the flow cell, compared to multiple samples for those 
sequenced at KCL and ICR.   
 
The number of potential somatic mutations in the tumours ranged between 10 
and 301, with an average of 117 per tumour. The thresholds which were used to 
identify a somatic mutation are discussed below. 
 
6.4.1 Thresholds used in somatic mutation identification 
The initial criteria for calling a somatic mutation was based on the variant being 
essentially absent in the blood (<2% to allow for sequencing errors) and present 
in  ≥15%  of  sequencing  reads  in  the  tumour.  However,  in  two  blood-tumour pairs 
(232T-P662 and T416-P1354), a low number of somatic mutations were 
identified in each tumour using this threshold (6 and 3 mutations, respectively). 
This lack of mutations was likely the result of a high level of normal tissue 
contamination in the tumour sample. An alternative explanation could be that 
only a small number of mutations are needed to cause cancer development. 
However, in one blood-tumour pair (T416-P1354), no protein truncating/splice-
site mutations (stopgain, frameshift or essential splice site) somatic mutations 
were identified, suggesting that no driver mutations were present. The other 
blood-tumour pair (232T-P662) only contained one protein altering mutation. As 
a result, the threshold for the percentage of sequencing reads supporting the 
alternative allele in the tumour was lowered to  ≥10%  for  these  two  samples,  to  
compensate for a higher level of normal tissue contamination.  
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Decreasing the threshold resulted in a modest increase in potential somatic 
mutations, with 55 and 10 mutations identified in the two tumour pairs (232T-
P662 and T416-P1354, respectively), which is at the lower end of the number of 
somatic mutations detected in all tumours. The number of protein 
truncating/splice-site mutations present increased to 10 and 1 for the tumour 
pairs, respectively. It may be very difficult to identify valid somatic mutations in 
tumour T416 particularly, as false-positives would become more common if the 
threshold was lowered any further. Alternatively, there may in fact be very few 
point mutations in these particular tumours (see section 6.4.4) 
 
There is no consensus for what the threshold in the tumour should be. Several 
other  cancer  studies  have  used  ≥15%  (see  Table 6.17), which allows for ~33% 
of the tissue sample to be derived from tumour DNA. Other published studies 
use  a  ≥10%  threshold  or  do  not  state  a  value.  A  recent  study has used varying 
thresholds depending on cross-contamination estimates for each sample (Dulak 
et al. 2013). 
 
Table 6.17: Thresholds used for somatic mutation calling in published exome sequencing 
studies 
Study % reads containing mutation in tumour 
Minimum total reads 
required in: 
Blood Tumour 
Agrawal et al. 2012 15% - - 
Dulak et al. 2013 Per-sample basis 8 14 
Stransky et al. 2011 - 8 14 
Agrawal et al. 2011 10% or 15% 9 - 
Le Gallo et al. 2012 - 5 5 
Liu et al. 2012 15% 8 15 
“-“  =  No  information  available 
 
Another threshold imposed stipulates the number of sequencing reads that must 
be   present.   In   this   analysis,   ≥8   and   ≥14   total   reads   in   the   blood  and   tumour,  
respectively, were required to call a somatic mutation. This threshold was 
chosen based on published studies, for example, those by Dulak et al. (2013) 
and Stransky et al. (2011), see Table 6.17.  
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6.4.2 Confirmation of somatic mutations 
The first step to confirm potential mutations identified by exome sequencing was 
to visualise the sequencing data using the Integrative Genomics Viewer (IGV). 
Mutations were confirmed to be accurately called as somatic mutations if they 
were absent in the normal DNA and clearly present in the tumour. However, 
some variants did not appear to be somatic mutations, mainly as they were 
located in a region with many other variants, both in blood and tumour, 
suggesting that it might represent mis-alignment or sequencing errors. 
Alternatively, some variants were also present in the normal DNA. Visualising all 
protein truncating/splice-site mutations and non-synonymous mutations in 
genes in the Cancer Gene Census produced varying results, with some tumours 
having a large proportion of mutations called correctly (100%), and others with a 
high degree of false-positives (9% confirmed). The rate of mutation confirmation 
using IGV was much higher for the exomes analysed by the ICR than those at 
KCL (95-100% vs. 9-30%, respectively). However, using the KCL calling 
algorithm on the samples that were originally called by the ICR, a similar 
number of mutations were confirmed by IGV, although there were more false 
positives, suggesting the specificity of the KCL method is lower but the 
sensitivity is higher compared to the ICR pipeline. Therefore, the low percentage 
confirmed for the 3 samples only analyzed by KCL is unlikely to be due to a sub-
optimal mutation calling pipeline.  
  
The large number of synonymous and intronic mutations detected were not 
analysed by IGV due to time constraints and the low probability that they 
represent driver mutations in these tumours.  
 
The mutations that appeared to be valid using IGV were then analysed by 
Sanger sequencing. In four of the tumours, all somatic mutations were 
confirmed. In the other four tumours, confirmation rates were 95% (20/21 
mutations), 30% (3/10), 24% (5/21) and 9% (1/11). The reasons for the lack of 
somatic mutations in some tumours are discussed in 6.4.4. 




6.4.3 Genes with somatic mutations 
Protein truncating/splice-site mutations were identified in several genes that 
have functions including regulation of the cell cycle and apoptosis. This 
suggests that, if mutated, they may be involved in tumourigenesis, and hence, 
are plausible driver mutations. For example, stop mutations were identified in 
SP1, PPM1D and FZD6, which are all involved in cell proliferation and growth, 
and in apoptosis. However, whether these mutations actually are driver 
mutations is difficult to determine from our data as, apart from TP53, none of the 
genes were found to be recurrently mutated, as discussed below. 
 
6.4.3.1 Recurrently mutated genes 
For mutations likely to cause protein truncation, are in essential splice-sites or 
are non-synonymous mutations in genes that are present in the Cancer Gene 
Census, only one gene contained mutations in more than one tumour. This 
gene, TP53, was mutated in 2/8 tumours (25%) based on the exome 
sequencing data.  When all non-synonymous mutations are considered, not just 
those in the Cancer Gene Census, two additional genes are found to be 
recurrently mutated in the South African OSCC patients. Both GPR98 and 
SRRM2 contain non-synonymous mutations in two tumours each (25% mutation 
rate), which were confirmed by Sanger sequencing. 
 
GPR98 (G protein-coupled receptor 98) has been found to be involved in 
several processes and diseases, including the regulation of bone mineral 
density (Urano et al. 2012) and Usher syndrome which causes deafness and 
blindness (Weston et al. 2004; Ebermann et al. 2009). The role of GPR98 in 
cancer development is not clear, although it is frequently mutated in melanoma 
(27.5% of tumours) (Prickett et al. 2011), and is mutated   in   Barrett’s  
oesophagus (Streppel et al. 2013). G protein-coupled receptors are known to 
regulate functions including cell proliferation and survival (reviewed in Dorsam 
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and Gutkind 2007), and so mutations in GPR98 may be shown to alter key 
pathways leading to cancer formation.  
 
SRRM2 (serine/arginine repetitive matrix 2) is an RNA splicing factor that has 
been  shown  to  be  differentially  expressed  in  Parkinson’s  disease   (Shehadeh et 
al. 2010). The RNA binding protein is also involved in cell migration in ovarian 
cancer cell lines (Mukherji et al. 2006), and is deregulated in colorectal cancer 
patients (Wu et al. 2012.b).  
 
GPR98 and SRRM2 are both mutated in other OSCC, OAC and HNSCC exome 
sequencing studies (Stransky et al. 2011; Agrawal et al. 2012; Dulak et al. 
2013). However, although mutated in up to 12% of samples (9/74) (Stransky et 
al. 2011), neither gene is reported to be significantly mutated in the studies by 
Dulak et al. (2013) and Stransky et al. (2011). Significant mutations were 
identified by comparing the observed number of mutations in each gene to the 
number expected by chance given the background mutation rate. The non-
significant mutations are suggested more likely to be passenger mutations, 
rather than driver mutations (Stransky et al. 2011). 
 
Only 3 genes (TP53, GPR98 and SRRM2) were recurrently mutated in the 
South African OSCC tumours, and the significance of the GPR98 and SRRM2 
mutations is not yet clear. Our pilot study lacked power to detect other relatively 
frequently mutated genes, with only a 50% probability to detect recurrent 
mutations  (≥2/8  tumours)  in  a  gene  with  a  20%  mutation  rate.  Therefore,  more  
tumours need to be sequenced in order to identify genes that contain driver 
mutations in OSCC in South African populations. Promisingly, of the 37 genes 
that were mutated, 28 (75.7%) were also recurrently mutated in OAC (Dulak et 
al. 2013), providing evidence that driver mutations may be present. 
 




p53 is a transcription factor that is activated in response to cellular stress, such 
as DNA damage (reviewed in Vousden and Lu 2002). Activation of p53 enables 
cells to undergo cell-cycle arrest, thereby preventing DNA replication occurring 
in these abnormal conditions, following which they may re-enter the cell cycle or 
undergo apoptosis.  
 
TP53 is one of the most commonly mutated genes in human cancers, with 
approximately 50% of tumours harbouring a mutation (Vousden and Lu 2002). 
In OSCC, mutation rates range from 17 to 84% (reviewed in Egashira et al. 
2007). In the South African OSCC patients described in this chapter, six out of 
10 tumours (60%) contained somatic mutations in TP53. Of the 8 mutations 
identified by Sanger sequencing, one was a stop-mutation, two were frameshift 
insertions, 4 were non-synonymous, and 1 was at a splice site (the last base-
pair of the exon). All of the mutations were located in the region encoding the 
DNA binding domain (residues 92-292), where the majority (97%) of missense 
mutations have previously been shown to reside (Olivier et al. 2002). The stop 
mutation and frameshifts are likely to alter the function of the protein. The four 
non-synonymous mutations are also all predicted to be deleterious and probably 
damaging by SIFT and Polyphen, respectively, in one or more TP53 gene 
transcripts, thereby also possibly affecting protein function.  
 
The exome-sequencing data called only 4 of the 7 TP53 mutations that were 
identified by Sanger sequencing (1 additional mutation was in a tumour sample 
that was not exome sequenced). Two mutations did not reach the required 
threshold for the percentage of reads supporting the mutation in the tumour 
sample   (≥15%).  These  were  Arg280Gly   in   T442-P1406 (12% of reads) and a 
frameshift insertion in T441-P1116 (6% of reads). A third mutation, Arg110Leu, 
in T443-P1408 was present in 34% of reads in the tumour and absent in the 
blood according to IGV, with a high number of sequencing reads at the position 
(>80). The variant was not identified as a somatic mutation by the ICR analysis 
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pipeline as it was mis-identified as a common SNP and removed from the 
analysis.  
 
6.4.3.3  PPM1D 
A stop-gain somatic mutation in PPM1D was identified in the blood-tumour pair 
T386-P1282. PPM1D (protein phosphatase, Mg2+/Mn2+ dependent, 1D) is a 
proto-oncogene involved in DNA damage response (Bulavin et al. 2002). 
PPM1D is involved in a negative feedback loop, both regulating the activity of 
p53 and itself being regulated by p53 (reviewed in Lu et al. 2005). Briefly, 
following DNA damage, p53 is activated through its phosphorylation by a 
number of proteins to result in cell-cycle arrest leading to the repair of DNA 
damage or apoptosis. TP53 activation also leads to an increased expression of 
PPM1D, which then causes the dephosphorylation of p53 either directly or 
indirectly, leading to decreased p53 activity (reviewed in Lu et al. 2008). This 
allows the cell to return to the cell-cycle after DNA repair.  
 
Changes in PPM1D expression may have knock-on effects on TP53 which 
could result in mis-regulation of the tumour suppressor gene. For example, 
overexpression of PPM1D may prevent the activation of TP53 resulting in cells 
that are unable to undergo apoptosis (Lu et al. 2008). Indeed, PPM1D mRNA 
overexpression has been observed in a number of cancers including breast, 
neuroblastomas, ovarian clear cell carcinomas and gastric cancer (Bulavin et al. 
2002; Li et al. 2002; Saito-Ohara et al. 2003; Fuku et al. 2007; Tan et al. 2009). 
In addition, PPM1D inactivation is shown to suppress tumourigenesis (Bulavin 
et al. 2004). Somatic mutations in PPM1D have also been identified including in 
head and neck squamous cell carcinoma (HNSCC) and OSCC (Agrawal et al. 
2011; Stransky et al. 2011; Agrawal et al. 2012). However, the mutations are not 
recurrent in each study (1/12 OSCC patients and 1/32 HNSCC cases), and 
hence, are not reported in the main text of published papers (Agrawal et al. 
2011; Agrawal et al. 2012). In addition to somatic mutations, mosaic germline 
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mutations have recently been identified in PPM1D which predispose to breast 
and ovarian cancer (Ruark et al. 2013). 
 
This evidence suggests that PPM1D is an important gene for cancer 
development, and hence, the stop-gain mutation (Arg581X) identified through 
whole-exome sequencing may play a role in OSCC tumourigenesis. This 
mutation was absent in the blood (P1282) and was heterozygous in the 
matching tumour (T386). The mutation, located in exon 6, is not located in a 
known protein domain and is downstream of the catalytic phosphatase domain 
and the nuclear localization signal, suggesting that the protein may still be 
functional. This is consistent with functional studies by Ruark et al. (2013) which 
show that truncating mutations in this C-terminal region result in enhanced 
suppression of p53 in response to ionising radiation, suggesting that the mutant 
alleles encode hyperactive PPM1D isoforms.  
 
The seven exons of PPM1D were Sanger sequenced in all available blood-
tumour pairs to further investigate somatic mutations. Although 8 of the 11 
matched pairs had been whole-exome sequenced, they were Sanger 
sequenced to ensure that no mutations had been missed. The stop mutation 
was confirmed, but no other somatic mutations were detected. However, four 
patients (36%) were heterozygous for one or more germline variants in PPM1D, 
with loss of heterozygosity occurring in their respective tumours. Only one of 
these was a non-synonymous mutation, with two synonymous mutations and a 
mutation   in   the   5’   UTR   also   identified.   This   data   suggests   that   LOH   at  
chromosome 17q23.2 may be common in these tumours. It would be important 
to determine the extent of the loss to establish whether other genes might be 
involved. One tumour showing LOH (T386) was exome sequenced, allowing 
neighbouring regions to be assessed for LOH. Using IGV to visualise the data, 
no LOH was observed in a ~2,000 kb region surrounding PPM1D. Other studies 
have analyzed LOH and copy number alterations in OSCC, with several 
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identifying LOH at chromosome 17q (Hu et al. 2006; Hu et al. 2009; 
Chattopadhyay et al. 2010), although none included the 17q23.2 PPM1D locus.  
 
The non-synonymous mutation, Ala564Pro, is located in exon 6. The variant 
was identified in two patients (GSHT-P1508 and TBHT-TB62), and was 
heterozygous in the blood but absent in the tumour, indicative of LOH. The 
variant is novel and is predicted to be possibly damaging by Polyphen but 
tolerated by SIFT. It is located just downstream of the cluster of germline 
truncating mutations in exon 6 of PPM1D (amino acids 420-546) previously 
associated with an increased risk of breast and ovarian cancers (Ruark et al. 
2013), and it is therefore possible that the Ala564Pro mutation in the germline 
DNA may represent a susceptibility variant for OSCC. This would need to be 
determined using a large case-control association study, and the potential 
functional effect of the mutation investigated.  
 
6.4.4 Samples which lack somatic mutations 
Two tumours did not contain any somatic mutations that were likely to be driver 
mutations (either protein truncating/splice-site mutations or non-synonymous 
mutations present in the Cancer Gene Census). T437 and T232 contained 1 
and 3 potential mutations, respectively, but none were confirmed by Sanger 
sequencing. The threshold for the percentage of alternative alleles in the tumour 
was  set  at  ≥15%  for  T437,  as  171  somatic  mutations  were  initially  identified  by  
exome sequencing. Therefore, lowering this threshold  to  ≥10%  may  identify  true  
somatic mutations that are possibly drivers. The tumour T232 used the lower 
threshold   of   ≥10%   sequencing   reads   supporting   the   alternative   allele.   This  
threshold  allows  the  detection  of  heterozygous  mutations  in  ‘tumour  DNA’ where 
only ~33% of the sample is derived from tumour tissue. If this were reduced 
further, false positives may be introduced.  
 
The most likely explanation for the lack of potential driver mutations is that there 
was a high degree of normal tissue contamination within the tumour samples. 
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The percentage of tumour tissue present in each sample was not known since it 
is the practice of our collaborators to take multiple biopsies from patients, and 
the biopsy used for histological diagnosis of OSCC is not the one used for DNA 
extraction. Any further exome sequencing studies should ensure that an 
estimate of the tumour tissue content is provided through histological 
examination of tissue sections taken from the same biopsy used for DNA 
extraction, and that those with the highest estimate are selected for sequencing. 
Normal tissue could also be removed from specimens using macrodissection 
(Biankin et al. 2012). However, most patients with OSCC are not resected, so 
limiting amounts of tissue are available from biopsies. 
 
Alternatively, an estimate of the amount of tumour tissue in a sample could be 
obtained by genotyping matching blood and tumour DNA on a SNP genotyping 
array (Song et al. 2012). If the tumour contains regions of LOH, the amount of 
contamination of the sample with normal tissue can be quantified from the shift 
in SNP allele frequency at regions of LOH. Software (qpure) to implement this 
method is available (Song et al. 2012). This approach has been used in a study 
of pancreatic cancers, where samples successfully whole-exome sequenced 
contained as little as 20% tumour DNA (Biankin et al. 2012). 
 
6.4.5 Summary 
The exomes of 8 OSCC blood-tumour pairs were sequenced, with five tumours 
successfully sequenced using 500 ng of starting DNA, instead of the 
recommended 3 µg. The total number of potential somatic mutations varied 
between 10 and 301, although some of these are likely to be artefacts, as 
shown by visualisation of the data using IGV. Two samples did not appear to 
contain any potential driver mutations, which was most likely due to a high 
contamination with normal tissue DNA. In the other 6 tumours, mutations were 
identified in known tumour suppressor genes including TP53, KL and APC. 
Recurrent mutations only occurred in 3 genes, TP53, GPR98 and SRRM2, 
which is probably due to the relatively low number of samples that were 
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sequenced. The latter two genes contained only non-synonymous mutations 
which may not alter protein function. However, it is promising that the majority of 
genes that were mutated have previously been mutated in either OSCC, 
oesophageal adenocarcinoma or head and neck squamous cell carcinoma. 
Sequencing additional OSCC samples may enable these mutations to be 
confirmed as recurrent, providing evidence that they may be driver mutations for 
the disease.   
 




7.1 Key findings 
7.1.1 Genetic susceptibility to OSCC 
This thesis aimed to identify genetic variants associated with OSCC in the South 
African Black and Mixed Ancestry populations. Initially, candidate gene 
association studies were performed. In Chapter 3, variants were selected based 
on their evidence of association with OSCC in candidate gene studies in other 
populations, namely Asian and European populations. Thirteen variants were 
tested for association with the disease in the South African populations, and 
only one, ALDH2 +82 A>G (rs886205) was significantly associated with OSCC 
(P=0.0038). In addition, a further four variants had a suggestive association with 
the disease (P<0.05). All of these were identified in the Mixed Ancestry 
population, with no variants showing evidence of association in the Black 
population.  
 
Following this work, three independent OSCC GWAS were published in the 
Chinese population (Abnet et al. 2010; Wang et al. 2010.a; Wu et al. 2011.c). 
These identified a total of 8 SNPs in 6 loci associated with the disease, including 
PLCE1 His1927Arg (rs2274223), which was associated in all studies. In 
Chapter 4 of this thesis, these variants were investigated in the South African 
populations using a case-control association study. Only RUNX1 rs2014300 
was associated with OSCC in the Mixed Ancestry population, with no variants 
associated in the Black population. Due to the strong evidence of the 
involvement of PLCE1 in OSCC development in the Chinese population, this 
gene was further investigated in the South African Black population by 
sequencing all of the exons in 46 individuals to identify potential functional 
variants present in this population. This led to five variants being selected for 
follow-up genotyping, based on amino acid conservation across species and 
whether the mutations were predicted to be damaging. In a case-control 
association study, one of these variants, PLCE1 Arg548Leu (rs17417407), was 
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significantly associated with OSCC in the Black population, with a minor allele 
frequency of 16.6% in cases and 21.1% in controls (P = 0.008). This was the 
first variant in any of our studies to be significantly (or suggestively) associated 
with OSCC in the Black population. Although this variant was not genotyped in 
the Chinese GWAS studies, a SNP in high LD (r2 = 1) with it, rs2689700, was 
not reported as being associated with OSCC. PLCE1 Arg548Leu was not in LD 
with His1927Arg in either the Chinese/Japanese HapMap population or the 
South African Black populations, suggesting that Arg548Leu is an independent 
risk variant.  
 
The genetic susceptibility to OSCC was further investigated using the 
Immunochip, a custom genotyping platform designed for immune related 
disorders. This array was selected due to the evidence of immune responses, 
and particularly inflammation, being involved in cancer development, and due to 
the low cost of the array. This was the first large-scale genotyping platform to be 
used in South African OSCC samples. A case-control association study was 
performed using 278 cases and 257 controls (remaining from the original 300 of 
each after QC) from the Black population. Three SNPs were significantly 
associated with OSCC, using the Bonferroni correction to account for multiple 
testing (P<1.84 x 10-6). These variants were all located in TGFBR3, a co-
receptor in the   TGFβ   signalling   pathway   which   is   involved   in   proliferation,  
apoptosis and immune responses (reviewed in Gatza et al. 2010). Due to 
insufficient sample numbers to complete an independent replication, an 
extension study was completed where an additional 126 cases and 577 controls 
were available. Seven SNPs were selected for genotyping in the extension 
study, which were genotyped in all samples available (407 OSCC cases and 
834 controls). None of the variants were significantly associated with OSCC 
when accounting for multiple testing, with all but one variant becoming less 
significant in this analysis. In addition, no SNPs were associated with the 
disease when only the additional samples, those not genotyped on the 
Immunochip, were analyzed.  




7.1.2 Somatic mutations in OSCC 
Sequencing the exomes of 8 blood-tumour pairs identified between 10 and 301 
somatic mutations in each tumour, although some of these are false positives. 
Somatic mutations were identified in several genes known to be mutated in 
cancer, including TP53 and KL. However, 2 tumours did not contain any 
confirmed functional mutations. TP53 and PPM1D were further investigated by 
Sanger sequencing the coding regions in all available blood-tumour pairs (10 
and 11 pairs, respectively). TP53 somatic mutations were identified in 60% of 
tumours. For PPM1D, only 1 tumour contained a somatic mutation (a stop 
codon), with four tumours showing evidence of loss of heterozygosity (LOH) at 
this region, suggesting that this may be an important alteration for OSCC 
development. 
 
7.2 Lack of variants significantly associated with OSCC in 
South African populations  
7.2.1 Candidate gene studies 
In this thesis, a total of 18 variants previously associated with OSCC in Asian or 
European populations were tested for association with the disease in two South 
African populations. In the Mixed Ancestry population, two variants were 
significantly associated with the disease; ALDH2 +82 A>G (rs886205) and 
RUNX1 rs2014300. No variants were significantly, or suggestively (P<0.05), 
associated in the Black population. 
 
A lack of replication for disease associated variants is fairly common, with 
several of the variants tested in this thesis previously showing inconsistent 
effects both within and between populations. This includes CASP8 -652 6N 
indel (rs3834129) and COX-2 -1195G>A (rs689466), which are both associated 
with OSCC in Chinese populations (Zhang et al. 2005; Sun et al. 2007) but not 
in a northern Indian population (Upadhyay et al. 2009; Umar et al. 2011). 
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Other studies have specifically focused on the effect of disease associated 
variants in different populations, and have found varying results. In a study of 
type 2 diabetes, 19 variants associated with the disease in a European 
population were tested for disease association in individuals from 5 other 
populations (European/American, African Americans, Latinos, Japanese 
Americans and Native Hawaiians) (Waters et al. 2010). The authors conclude 
that there were consistent associations for all risk variants across six 
populations, with the effect of the variants being in the same direction in the 
pooled analysis of all samples compared to the original European association. 
However, when observing the results for each population separately, the odds 
ratios were often in opposite directions to the pooled data, which suggests that 
some variants may have opposite effects, or have no effect, in different 
populations, which appears to contradict  the  authors’  conclusions. 
 
Ntzani et al. (2012) have compared allele frequencies and the effect sizes of 
108 risk loci identified in association studies from different populations. This 
covered any disease where variants associated in GWAS had been tested for 
association in an additional population, with data for each variant obtained from 
two distinct ancestral groups; European, Asian or African. For African versus 
European populations, and African versus Asian studies, the genetic risk 
estimate was in the opposite direction or >2-fold different in 79% and 89% of 
studies, respectively. Given this large difference in effects, the authors conclude 
that it is not possible to predict the effect size of variants in different populations. 
However, the disparities, particularly when the genetic effect is in the same 
direction but with a >2-fold difference, may be due to underpowered studies in 
African populations. Indeed, Ntzani et al. note that studies in African populations 
showed weaker genetic effects than other populations, which is probably due to 
the GWAS data being obtained from the non-African populations. The reasons 
for this, in the context of the work in this thesis, are discussed below.  
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There are several explanations for the lack of replications observed in the South 
African populations. Firstly, the variants tested for association may have been 
false positives in the original European/Asian studies. However, with five of the 
variants originally identified in large GWAS which use independent replication 
phases, these are less likely to be false positives than associations identified 
through candidate gene association studies. In addition, most variants had been 
previously investigated in a number of populations and/or with different cancer 
subtypes.  
 
Alternatively, risk loci may be population specific and may be absent in the 
South African populations. For example, the OSCC risk variant, ALDH2 
Glu504Lys (rs671), is specific to Asian populations (Li et al. 2009.a), and was 
monomorphic in the South African Black and Mixed Ancestry populations. 
However, the same gene may be associated with disease in several populations 
but be due to different risk variants. For example, ALDH2 +82 A>G (rs886205) 
was associated with OSCC in the South African Mixed Ancestry population, 
showing a common role for ALDH2 in OSCC susceptibility across populations. 
Therefore, even though a specific variant may not be associated with disease in 
a replication study, additional work may identify other variants in the same gene 
associated with disease across populations.  
 
Perhaps the most important reason for the lack of replication observed in the 
South African study is due to the fact that association studies do not necessarily 
identify causal variants. The SNPs selected for genotyping in this thesis were all 
identified as OSCC susceptibility loci in European or Asian populations. These 
SNPs may be the causal variant or merely be in a high level of LD with it, i.e. 
tagging SNPs. Africans are known to be the most genetically diverse 
populations in the world, who have smaller haplotype blocks and lower levels of 
LD between variants (reviewed in Teo et al. 2010). Therefore, tagging SNPs 
associated with disease in European/Asian populations may be in very low LD 
with the causal variant in African populations. If this is the case, a disease 
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association would not be identified. If a moderate level of LD does exist between 
the causal and tagging variant in African populations, studies may lack power to 
detect the weaker effect size that would be observed. Indeed, it is known that it 
is more difficult to achieve genome-wide significance levels in African 
populations due to this problem (Jallow et al. 2009).   
 
Lack of power may also be caused by inadequate sample sizes to detect a 
significance difference in allele frequency between cases and controls. This will 
be particularly relevant if the effect size of the risk variant is lower in the African 
populations compared to the original study, which may be due to genotyping of 
a tagging variant, as discussed above, or due to a genuine difference in effect 
size between populations. 
 
Gene-gene or gene-environment interactions may also be important in OSCC 
susceptibility which may differ between populations. The latter of these was 
investigated in the South African populations for alcohol and tobacco use, but 
other population-specific environmental risk factors may exist.  
 
7.2.2 Immunochip study 
The lack of significant associations with OSCC in the Immunochip study could 
be the result of several factors. One is the small sample size, which was driven 
by the small budget for the project. A second is that the screen was restricted to 
loci with previous evidence of association with immune diseases and some 
additional phenotypes from the WTCCC. Thirdly, variants specific to African 
populations were not included as the Immunochip design was based on GWAS 
data from European populations. Therefore, it is possible regions that show 
suggestive evidence of association with OSCC harbour additional unknown 
variants which are more significantly associated with the disease. For example, 
with 4 out of the 5 most significantly associated variants located in TGFBR3, this 
gene may harbour further variants specific to African populations that were not 
investigated by the Immunochip. Sequencing of this gene in individuals from the 
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South African Black population and performing a case-control association 
analysis may identify novel variants which have a higher degree of association 
with OSCC. This approach has been used by Jallow et al. (2009), who fine-
mapped a region associated with malaria resistance in their African GWAS. 
After imputing the data to a larger set of samples, they were able to identify a 
SNP more significantly associated with disease than any SNP on the GWAS 
panel in the same region. This variant was the known causal variant, providing 
evidence that this approach can be successful. 
 
7.3 Advantages and disadvantages of genetic association 
studies in African populations 
7.3.1 South African Black population 
As discussed in section 7.2, African populations have the lowest levels of LD 
world-wide. This has proved problematic in genetic association studies, as 
unless the causal variants are genotyped directly, genetic associations might 
not be detected. However, using African populations can be a great advantage 
over other populations, since the lower level of LD can lead to the identification 
of causal variants (reviewed in Teo et al. 2010). To achieve this, the region of 
association needs to be fine-mapped to enable all polymorphic variants to be 
tested for association with the disease. It is also important to use a large set of 
SNPs to assess population structure in any population not previously studied in 
depth, and correct for this if necessary. 
 
7.3.2 South African Mixed Ancestry population 
The substantial amount of genetic heterogeneity in the composition of the South 
African Mixed Ancestry population leads to a series of questions when using 
these samples in genetic association studies. Should this population be used for 
candidate gene association studies? Would these samples be suitable for a 
GWAS? Is there a method to correct for the population structure? 
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In the candidate gene association studies carried out in this study, cases and 
controls were both obtained from the same region of the Western Cape in South 
Africa in order to limit heterogeneity between them. However, since only a small 
number of genetic variants were genotyped in these initial studies, there was 
insufficient data to assess population structure and apply appropriate 
corrections. Other studies have performed candidate gene case-control 
association studies without making any adjustments for population structure (de 
Wit et al. 2011; Matsha et al. 2012). De Wit et al. (2011) tested for gene-gene 
interactions between tuberculosis genes and did not adjust for population 
variation due to the population being relatively homogeneous. This conclusion 
was based on an earlier study that showed cases and controls from the Mixed 
Ancestry population not to be significantly different from each other, based on 
genotyping a panel of 25 SNPs (Barreiro et al. 2006). In contrast, another study 
found the Mixed Ancestry population to be substantially heterogeneous 
(Patterson et al. 2010), which is in agreement with the genotyping of our 
samples on the Immunochip. Patterson et al. (2010) recommend that all 
association studies in this population are corrected for population stratification, 
with EIGENSTRAT, which uses principal components analysis, being a suitable 
method (Price et al. 2006). However, this method requires a large number of 
SNPs to be genotyped. Therefore, the candidate gene association results in this 
thesis may contain both false-positive and false-negative results due to 
population stratification.  
 
In future studies, large-scale genotyping platforms should be used for the South 
African Mixed Ancestry population, and it is proposed that genome-wide 
association studies can confidently be performed in this population using the 
EIGENSTRAT method for correction (Patterson et al. 2010). However, no 
studies have done so to date, although GWAS have been performed in other 
admixed populations, including African-Americans (Adeyemo et al. 2009; Lettre 
et al. 2011). Another method that has been successful in identifying disease 
susceptibility loci in admixed populations is by using admixture mapping 
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(reviewed in Winkler et al. 2010). This approach is based on the principle that 
both allele frequencies and disease incidence differ between populations. 
Individuals with a disease might have a chromosomal region that is more 
frequently inherited from the population ancestry that has a higher disease 
incidence. The strategy requires genotyping several thousand variants across 
the genome, which have different frequencies across populations. This could be 
achieved using ancestry-informative markers, a panel of SNPs known to differ in 
frequency amongst populations, or using genome-wide genotyping arrays. Most 
admixture mapping studies have been in the African-American populations, 
which are on average derived from 20% European ancestry and 80% African 
ancestry (Patterson et al. 2004; Reiner et al. 2005). No such studies have been 
performed in the South African Mixed Ancestry population, which may prove 
more complex to analyze due to the contribution of more ancestral groups. 
 
7.4 Other genetic factors involved in disease susceptibility 
This thesis investigated the association of common variants, mainly SNPs and 2 
insertions/deletions, with susceptibility to OSCC. Other variants may also be 
involved in cancer susceptibility which were not investigated. Firstly, rare 
variants may contribute to susceptibility but sample numbers are required to be 
extremely large to identify significant associations, unless the effect sizes are 
very large. In addition, genotyping of a single SNP in a case-control association 
study is unlikely to be a successful approach. One recent method to investigate 
rare variants has been to utilise next generation sequencing for a panel of 
genes involved in DNA repair (Ruark et al. 2013). Focusing on protein-
truncating variants (PTVs), PPM1D was shown to harbour more of these 
mutations in breast and ovarian cancer cases than controls. PTVs were present 
in 25 out of >7,000 cancer cases compared to 1 out of >5,000 controls, showing 
the large number of samples needed, which may be unattainable in many 
studies. The role of rare variants in OSCC has not been investigated in any 
population.  
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Copy number variants (CNVs) may also contribute to cancer susceptibility, as 
reviewed by Kuiper et al. (2010), although this has not been fully investigated 
due to more complex genotyping methods than SNP genotyping. However, it is 
unknown how much heritability CNVs will account for. A large study by the 
Wellcome Trust Case Control Consortium has shown that common CNVs make 
little contribution to common disease susceptibility (Craddock et al. 2010). 
 
7.5 Somatic mutations 
As discussed in detail in chapter 6, section 6.4, the results of the pilot whole-
exome sequencing study in OSCC blood-tumour pairs show that substantial 
numbers of somatic mutations exist in most of these tumours, but their 
importance as potential driver mutations is, with the exception of TP53,  not yet 
clear. This should be addressed by expanding exome sequencing to a larger 
number of blood-tumour pairs to look for recurrent mutation of genes, and 
following up the most promising findings by sequencing those genes in a large 
panel of tumours to determine the extent of their contribution to South African 
OSCC.        
 
7.6 Limitations 
The search for disease susceptibility genes in this thesis was largely restricted 
to the analysis of candidate-gene or GWAS-derived loci from studies in other 
populations, which is clearly a limitation. However, the negative results obtained 
are informative, since they suggest that there may be substantial differences in 
the genetic components of OSCC susceptibility particularly in the Black South 
African population. A further limitation is that this study does not rule out the 
possibility that other un-genotyped or as yet unknown variants in these genes 
are involved. However, a lack of genotyping platforms specifically designed for 
the South African populations does not permit a well-powered genome-wide 
approach for the identification of genetic susceptibility in these populations.   
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Another potential limitation for the genetic susceptibility studies was the 
available sample size. Sample sizes were increased during the course of the 
thesis, reaching 407 cases and 849 controls from the South African Black 
population, and 257 cases and 860 controls from the Mixed Ancestry 
population. Genome-wide association studies regularly use >2,000 cases and 
controls, so sample sizes will need to be increased to detect association of 
variants with moderate or small effect sizes.  
 
The relatively low number of blood-tumour pairs that were exome sequenced in 
the pilot study (8 in total) limits the detection of genes that are recurrently 
mutated in OSCC, and more should be sequenced.  Another limitation for this 
part of the project is that no potentially functional somatic mutations were 
detected in 2 OSCC tumours, suggesting that a high degree of normal tissue 
may have been present in the tumour samples. More preliminary quality control 
of tumour content is clearly required before submitting samples to exome 
sequencing.  
 
7.7 Future directions 
Directly following on from work described in this thesis, TGFBR3 could be 
further investigated as a candidate gene, as the Immunochip data suggests that 
it might be involved in OSCC susceptibility. The first step would be to attempt to 
replicate the suggestive association by genotyping the top SNP in a further set 
of Black South African cases and controls, and then carry out a meta-analysis of 
the primary and replication data. If the analysis strengthened the evidence of 
association at this locus,  ideally, the entire genomic region containing the gene 
(4550 bp) would be sequenced by targeted NGS in a panel of around 50-100 
OSCC patients from the Black South African population to identify most 
common variants in this region and their LD relationships. This mini-Hapmap 
could then be used to select a subset of variants representing common variation 
across the gene for genotyping in a well-powered case-control association 
study.   




For future OSCC association studies in the South African populations, we need 
to progress from the candidate gene approach. Given our knowledge of the 
lower levels of LD in African populations, and the inability to replicate disease 
associations throughout this thesis, it is evident that candidate gene studies 
testing one variant at a time, is not a suitable approach. 
 
GWAS arrays specific to the South African Black and Mixed Ancestry 
populations are not currently available, and there is little or no whole-genome 
sequence data available. Therefore, it would be necessary to carry out whole-
genome sequencing on a panel of individuals from these two populations and 
then design SNP arrays which provided good coverage of common variation. 
These could then be used to carry out well-powered GWAS for OSCC. An 
alternative strategy is to use low coverage whole-genome sequencing with 
imputation for the GWAS. This approach is based on the observation that even 
extremely low sequence coverage of 0.1-0.5x, when coupled with imputation to 
1000 Genomes reference panels, can deliver high accuracy and power 
comparable to high density SNP arrays, and at a comparable or cheaper price 
(Pasaniuc et al. 2012). However, this is a new approach, and pilot data would 
be required to validate it.  
 
Both of these methods are potentially powerful to identify variants associated 
with OSCC in the South African study, as they are genome-wide and would 
address the issue of the lower LD levels in African populations. Apart from the 
Immunochip study, comprehensive studies have not been performed in the 
South African population, and therefore, the variants with the largest genetic 
effects   (if   present),   the   ‘low-hanging   fruit’,   could  potentially  be  detected  with  a  
moderate sample size. However, as other association studies have shown, 
sample numbers are required to be large to have enough power to identify 
common variants of low-moderate effect. Therefore, sample sizes must continue 
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to be increased in order to perform well-powered studies. Most GWAS now 
genotype at least 2,000 cases and controls. 
 
As discussed in section 7.5, the whole exome pilot sequencing project to detect 
somatic mutations in OSCC could be followed up at relatively modest cost by 
exome sequencing a larger number of blood-tumour pairs and following up 
recurrently mutated genes in a larger panel of tumours. However, it is clear that 
many important sequence changes such as large-scale rearrangements or copy 
number changes and mutations in regulatory regions would be missed using the 
exome approach. In future, therefore, a substantial number of blood-tumour 
pairs should be whole-genome sequenced to identify all possible somatic 
variants, as recommended by the International Cancer Genome Consortium 
(www.icgc.org).   
 
7.8 Conclusions 
The aim of this thesis was to investigate genetic susceptibility to oesophageal 
squamous cell carcinoma in the Black and Mixed Ancestry populations of South 
Africa. Based on candidate-gene association studies, one SNP, PLCE1 
Arg548Leu (rs17417407), was significantly associated with OSCC in the Black 
population, and two variants, ALDH2 +82 A>G (rs886205) and RUNX1 
rs2014300 were associated in the Mixed Ancestry population. Another 15-20 
variants were found to be not associated with the disease in each population, 
which suggests that there may be substantial differences in the genetic 
architecture of OSCC in African populations. The finding in our Immunochip 
study that multiple variants in the TGFBR3 gene show suggestive association 
with  OSCC  is  promising,  as  the  TGFβ  pathway  has  been  shown  to  be  important  
in preventing OSCC (Achyut et al. 2013).  
 
These studies highlight the need for genotyping arrays that are designed for the 
populations that are to be tested, or the development of targeted next 
generation sequencing approaches. High throughput genomic infrastructure is 
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not available in most African countries at present, but collaborations and 
capacity building via, for example, the H3 Africa Genetics programme, could 
address this (h3africa.org).    
 
Finally, the pilot exome sequencing project to screen for somatic mutations in 
tumours from OSCC patients from South African populations identified 
mutations present in genes already known to be mutated in other cancers, 
including tumour suppressor genes. TP53 was the most commonly mutated 
gene, with mutations occurring in 60% of tumours. This study should be 
expanded in order to identify likely driver mutations in OSCC. This is important 
to understand the mechanisms of OSCC development, which may lead to the 
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Table A.1: Primers and PCR conditions for amplification of PLCE1 exons 







Fwd GGGAGCGGACTGTGAACG 63 30 sec 444 
Rev GAGCGCGAGGACACTTTTC    
2 
Fwd TTTTGGCTGGAAGCAGAAGT 57 2 min 1922 
Rev GCTATCAATTGGAGTATCTGTTTTCA    
1* 
Fwd CCTCCCTCGATTCTGGGTAT 58 30 sec 472 
Rev AACAGTCCCCAGGATTCCAT    
3 
Fwd TTTGCACTTGGAGCATCTGA 55 30 sec 543 
Rev TTCTCTTAAAGAAGCGACTTTTACTT    
4 
Fwd CAGAACTCTTCACTAAGCAGAGGA 60 30 sec 568 
Rev CATGGAAGTGGCAAGACAGA    
5 
Fwd CCCAGCCAGGACCTACAG 60 30 sec 437 
Rev GCCTTTGGTGCTGAAAGAAG    
6 
Fwd GGAATTTAGGCTCCTTGCTG 57 30 sec 482 
Rev TCCAAGGATCTATGTGCTACCC    
7 
Fwd TCCTGGAGGCTCTTGTTTTC 57 30 sec 506 
Rev TTGGAATTGGTAAGGTTTGAAGA    
8 
Fwd CACCTGGCCTCGGTTATTAG 57 1 min 977 
Rev TAAAAGCTGCCCAAGGTCAC    
9, 10, 
11 
Fwd TGGGTGGCCAGATCATTATT 57 3 min 3108 
Rev TTTGGAGAATCATGGCTTAGG    
12, 13 
Fwd AGCTTCAATCTTAAATAACTTGCAC 55 30 sec 599 
Rev TTTCCCTACACAGCAGTAATAGC    
14 
Fwd TCCTATCACTATGTGAAGCCAGAA 61 30 sec 591 
Rev AGCCTGGCCACAGAGTAAGA    
15, 16 
Fwd CAGCCTTCTTTTCTCATTCTCTTC 57 30 sec 722 
Rev AGCCAGTTTTCCCACACATC    
17 
Fwd CCATTTGCCCTTCTGCTTTA 55 30 sec 459 
Rev GCTTGATGGTATGGGCTTGT    
18 
Fwd TGGCCTTATCCTCATGCTTC 55 30 sec 425 
Rev GTTGCAGTGAGCCAAGACTG    
19 
Fwd GCTTCTTTCCTAGTTCCTCTTCC 57 30 sec 491 
Rev TCTTGGGTGAGTGAGATGAGAG    
20 
Fwd CATTGCATTTCGAGGGAATC 57 30 sec 433 
Rev TGAATTCAGAAACTCCTGGACA    
21, 22 
Fwd TGCTTCAAGCCATCATTTTG 57 2 min 1506 
Rev TTCATGAGCATCAAGGCAAA    




Rev CCAGCCTGAAATGCTGTTTT    
24 
Fwd TCCAAGAGGTATTCTGATGTGG 58 30 sec 592 
Rev AAACATCGGAGGCACAATTC    
25 
Fwd TGGGACGAATGGGTGATTAT 58 30 sec 439 
Rev TTCTGGGAACTAAATCTGTATGACC    
26 
Fwd TCATTCACTTTGTCCATTCCAG 58 30 sec 543 
Rev TGTGCTTCAAAAGTGCTCCA    
27 
Fwd CTGTTGGTTGCATGCCTGT 58 30 sec 396 
Rev GTGCCAAGTGTCAGCCATTA    
28 
Fwd CAAATGGACTCTCATCTTTTGC 57 30 sec 385 
Rev TCATCCACATGGACTTTTGC    
29 
Fwd TGAATAAGTTGTGCCGTTGC 57 30 sec 574 
Rev TGTGCAGAAGAATAAAACTGTTCA    
30 
Fwd GCACAGTAGTTTCCTCCTCTCA 57 30 sec 484 
Rev CACACACTCCCCTTTGAGGT    
31 
Fwd TCTGGAAGATCCCCTTCATC 57 30 sec 529 
Rev GACTGCTTAACCGCAAGCTC    
32 
Fwd GAGCTTGCGGTTAAGCAGTC 57 1 min 1062 
Rev CCATAGAGCCCTTGAAGAATG    
33 
Fwd CATTGTGAGTACAGAGGAAACAGTC 57 1 min 692 
Rev TCTAGCCTGCCACCTGTTTT    





Table A.2: Primers for Sanger sequencing of PLCE1 exons 
Exon Forward primer Reverse primer 
1 GGGAGCGGACTGTGAACG GAGCGCGAGGACACTTTTC 
2_1 TTTTGGCTGGAAGCAGAAGT CACAGGTATGAGAACAGAAGCTG 
2_2 GATCTACCACCTTAAAACCCTGA AGGAAGGCCATGCTGATG 
2_3 CACATACTGTCAGACGAAGTGG - 
2_4 CTGGAACTAGACAGACCTTCCA - 
2_5 TGCTTTGAAGGCTCTTGTGA - 
1* CCTCCCTCGATTCTGGGTAT AACAGTCCCCAGGATTCCAT 
3 TTTGCACTTGGAGCATCTGA - 
4 CAGAACTCTTCACTAAGCAGAGGA - 
5 CCCAGCCAGGACCTACAG - 
6 GGAATTTAGGCTCCTTGCTG TCCAAGGATCTATGTGCTACCC 
7 TCCTGGAGGCTCTTGTTTTC - 
8_1 CACCTGGCCTCGGTTATTAG - 
8_2 GACGGAGCTCATCCCTTG - 
8_3 TGCTGGATTAAGTAGCCTGAC - 
9 TGGGTGGCCAGATCATTATT - 
10 CGGTCAGCCTTAATGTAGGTC - 
11 CCACCAGATTAGCCCATTCA - 
12, 13 AGCTTCAATCTTAAATAACTTGCAC TTTCCCTACACAGCAGTAATAGC 
14 TCCTATCACTATGTGAAGCCAGAA - 
15 CAGCCTTCTTTTCTCATTCTCTTC ATGGCCCGTGAGGTAGGTAT 
16 ATCCCTTGCAGAAGTTCGAG AGCCAGTTTTCCCACACATC 
17 CCATTTGCCCTTCTGCTTTA - 
18 TGGCCTTATCCTCATGCTTC - 
19 GCTTCTTTCCTAGTTCCTCTTCC - 
20 CATTGCATTTCGAGGGAATC - 
21 TGCTTCAAGCCATCATTTTG - 
22 TCTAGGAAAGCTGTTGGGACA - 
23 GCATGCAGTTCTTGTTGCAT - 
24 TCCAAGAGGTATTCTGATGTGG AAACATCGGAGGCACAATTC 
25 TGGGACGAATGGGTGATTAT - 
26 TCATTCACTTTGTCCATTCCAG - 
27 CTGTTGGTTGCATGCCTGT - 
28 CAAATGGACTCTCATCTTTTGC - 
29 TGAATAAGTTGTGCCGTTGC - 
30 GCACAGTAGTTTCCTCCTCTCA - 
31 TCTGGAAGATCCCCTTCATC - 
32_1 GAGCTTGCGGTTAAGCAGTC - 




32_3 ATGCTATTGAACACCGCCTA - 
33_1 CATTGTGAGTACAGAGGAAACAGTC - 
33_2 TTGATGATTTCTGAACTGAAGC - 
* Exon 1 in NM_001165979.1 
Multiple primers were used for some exons to ensure complete coverage 
 
 
Table A.3: Primer and reporter sequences for Custom TaqMan SNP genotyping assays 




Reporter 1 ACCTTTCCCGCCTCTC 
Reporter 2 ACCTTTCCCCCCTCTC 




Reporter 1 CCCCACGATGACTG 
Reporter 2 CCCCACCATGACTG 




Reporter 1 CTCGGCCTCAAAA 
Reporter 2 ACTCGGTCTCAAAAA 
  
306 
Table A.4: Primers and PCR conditions for Sanger sequencing of somatic mutations 









MEF2C Fwd CACATTTGAGACAAACAGCTCA 58.97 54 30 sec 297 
 Rev CCAATTTTATCAAAGCTACCACCT 59.81    MKL1 Fwd CCATCTCACCAAAGGTGTCC 60.36 55 30 sec 378 
 Rev AGCTGAAGCAGGAGCTGAAG 60.04    PPM1D Fwd CCCCCTGATGAAGAAGCATA 60.03 56 30 sec 198 
 Rev CCAGATGCATTTCAGCAAAC 59.28    RBM26 Fwd CTCCTGTTGTTGAAGGACCA 58.69 54 30 sec 304 
 Rev TTGGCACAGGCTACAAAGTG 59.9    TP53 Fwd GAAGACCCAGGTCCAGATGA 60.05 56 30 sec 216 
 Rev ACTGACCGTGCAAGTCACAG 59.94    
T438-P1400 
APC Fwd GCTCAAGCTTGCCATCTCTT 59.72 54 30 sec 344 
(112173713) Rev TAGACCAATTCCGCGTTCTC 60.21    APC Fwd AAGAAGCTCTGCTGCCCATA 60.12 54 30 sec 507 
(112174228) Rev TGTGGTTGGAACTTGAGGTG 59.57    APC Fwd As above     
(112174347) Rev      ARHGAP21 Fwd TGAAGAGAGGCTCAGGGAGT 59.13 54 30 sec 403 
 Rev TGAAAGGGGCATTTTAGCTG 60.2    ATAD5 Fwd TTCATCCTCAAGAAGAGCATTT 58.07 54 30 sec 386 
 Rev CCCAGCCATAGCACAGATTT 60.1    CARS Fwd ATCCCGAGTCTCCTTCCAGT 60.07 54 30 sec 402 
 Rev GGTTGCAGCCATTTTCAGTAA 60.12    CNGB1 Fwd CATCCTGCCCCTTGTTCTTA 60.07 62 30 sec 291 
 Rev TGAGCTAGGGGAAGTTGAGG 59.42    CORO2B Fwd GCATATGAGTGTGCCCTGAA 59.68 55  412 
 Rev GCAGCTGGAGTGAAGGTAGG 60.01    FCRL3 Fwd TAGTCTCCAGGGTGGTGAGG 60.1 54 30 sec 417 
 Rev TGTCAGGGGAAAGACAACAA 59.11    KRT27 Fwd AAGGCTTGAGACAACGTCAAA 59.91 62 30 sec 369 
 Rev AGCGAGACTCGGTCTCAAAA 60.13    MLL2 Fwd ACATAGTTCTGGGCCCTCCT 59.96 64 30 sec 438 






 NLRC5 Fwd GAGTGGGGTGTGGACAAGAT 59.82 54 30 sec 342 
 Rev AGAAAGGCCCAGAGAAGAGC 60.1    OR52A5 Fwd GGTCACGAATTTGCTTGGTC 60.5 54 30 sec 461 
 Rev ACTCAGGGCTGCCATTCTTA 59.84    PMS1 Fwd GGAACAAAACTTTGTCCTGACTG 60.06 54 30 sec 375 
 Rev TGTGTGGCCTGGTTCCTAAC 60.95    SP1 Fwd GTGAATGCTGCTCAACTCTCC 60.01 58 30 sec 340 
 Rev CCAGAAGTGCTCCTTCCTCA 60.52    TP53 Fwd GAAGACCCAGGTCCAGATGA 60.05 56 30 sec 216 
 Rev ACTGACCGTGCAAGTCACAG 59.94    ZNF521 Fwd CCTCAAGTCAGGGTGCATTT 60.11 54 30 sec 368 
 Rev GGGCAGCCTACACTATGGAA 60.1    ZNF750 Fwd CCAGCAGGTAAGGCGAGTAG 60.03 54 30 sec 308 
 Rev TTCTGCATTTGTTCCAGTCG 59.84    
T437-P1377 RECQL4 Fwd CCAGCTCACTGAACTCCACA 60.02 55 30 sec 344 
 Rev GTTGGAGACGAGGTTGGAGA 60.24    
T441-P1116 
ARHGEF2 Fwd TAAGACCTGCAGGCATCTCC 60.36 57 30 sec 460 
 Rev AAGGCTCGGTATGACCACAG 60.13    COX6C Fwd GGGACAGTCACCTGTATTTGC 59.47 55 30 sec 343 
 Rev CCTCCACCCCTTAGGAAATG 60.67    FLT3 Fwd AGCCTGCGTGGTAGAGTGA 57.89 57 30 sec 399 
 Rev TGCAGCATCTCCTGTAGCAA 50    FZD6 Fwd AAGCAAAAGCTCGACCAGAA 45 57 30 sec 279 
 Rev CCAAACTTCAGTTGGCAAATC 42.86    IL21R Fwd CCCTCACCTTACCCTCATCC 60.7 55 30 sec 384 
 Rev GGTAGCCGTCATCCTCACAG 60.68    LARGE Fwd GGCAGCTGTATCAGAGCACA 55 57 30 sec 311 
 Rev GGTGTGCCTAGCTCTCCATC 60    PAX7 Fwd ACCCCTGCCTAACCACATC 59.79 55 30 sec 321 
 Rev AACAATGGGAGGACATCTGG 59.78    TET2 Fwd TTCCACAGGTTCCTCAGCTT 59.84 57 30 sec 358 
 Rev TGCTGGCAGTTGTCCTGTAG 60.05     TMPRSS2 Fwd AAGATTCTGCCAACCTGCTT 58.94 55 30 sec 348 








DNAH10 Fwd AATCTCTTGACCGCAAAAGC 59.46 63 30 sec 408 
 Rev ATCTTCATCCCAACGACAGC 60.08    JUNB Fwd AGCCTGACAGGGCTTTTG 58.96 57 30 sec 431 
 Rev GAAGAGGCGAGCTTGAGAGA 59.97    KL Fwd CACTCAGGGAGGTCAGGTGT 60.15 63 30 sec 399 
 Rev CCTGAGACAAACCAGCCATT 60.11    OSBPL3 Fwd TTGTCTCCCCCACAAGGTTA 60.34 63 30 sec 362 
 Rev AGGTCCCGAAACCTTTTTCT 59.08    RORA Fwd TCATTGTTTCCCCTCCTTTG 59.9 54 30 sec 356 
 Rev CCTGACGGTGTGTCCTTTCT 60.15    RTL1 Fwd GTTTGGTCGTCGATTTGGAT 59.8 63 30 sec 422 
 Rev CGCCATCACAACGTCTACTG 60.32    SPRX Fwd CCCCAAGTTCGCTATTACCA 59.95 57 30 sec 368 
 Rev GGTTGAGAACAACCCAGGAA 59.94    VAMP4 Fwd GCCCTGTTCTCACAGAGGTT 59.3 63 30 sec 407 
 Rev GCAAACTGATCTGCAAGCTG 59.75    
T442-P1406 
GPRASP2 Fwd GGTCCAAGTAATGGGTGGTG 60.09 54 30 sec 256 
 Rev TGATCCAGACTCAGCAGTGG 59.98    HPX Fwd GGTCTCACCAAATGCCTGTT 59.97 54 30 sec 307 
 Rev ACAAGCTCAGGGAAAGTGGA 59.84    WDR17 Fwd TTCTAGACTCCTGCACAAAGTCA 59.18 54 30 sec 220 
 Rev CGAAGACATGCAAAACCAGA 59.84    
232T-P662 
MYH14 Fwd CCATCTCCCTCAAACTGGAA 60.04 54 30 sec 334 
 Rev TGATGGCTGGTTGTTTTTCA 60.09    
TOPAZ1/ 
C3orf77 
Fwd GGGTCAGAGGGCAGTAGGTA 59.16 62 30 sec 321 
Rev CTGATGCTGCAACCGACTTA 60.01    
T416-P1354 
CXorf30 Fwd ACAAACATCGACCCTGCATA 59 57 30 sec 237 












Table A.5: Primers and PCR conditions for Sanger sequencing of somatic mutations in recurrently mutated genes 
 










T443-P1408 GPR98 5:89953731 Fwd TGCAAAAGTTTCATTTATCCAAAA 59.89 54 30 sec 307 
   Rev TTTCTCCCTGTCTGAACTCCA 59.83    
T441-P1116 GPR98 5:90046431 Fwd AGGGAACCCCTTGTGACTTT 59.83 54 30 sec 263 
   Rev CCATAAGGCAGGATTTGGTC 59.39    
T438-P1400 SRRM2 16:2815904 Fwd CCGAAAAATCGAGGTCTTCA 60.18 54 30 sec 350 
   Rev AGAACGCTTCCGACTGGTT 59.86    
T441-P1116 SRRM2 16:2809653 Fwd GAGAATCCAGGGCAGGTACA 60.07 54 30 sec 306 






Table A.6: TP53 primers and conditions for PCR 





2+3 Fwd CAGCCATTCTTTTCCTGCTC 55 30 sec 498 
 Rev GGGGACTGTAGATGGGTGAA    
4 Fwd CTGGTAAGGACAAGGGTTGG 55 30 sec 495 
 Rev GCCAAAGGGTGAAGAGGAAT    
5+6 Fwd GCCGTCTTCCAGTTGCTTTA 55 30 sec 557 
 Rev GGGAGGTCAAATAAGCAGCA    
7 Fwd CGACAGAGCGAGATTCCATC 64 30 sec 284 
 Rev GGGTCAGAGGCAAGCAGA    
8+9 Fwd CAAGGGTGGTTGGGAGTAGA 55 30 sec 545 
 Rev ACCAGGAGCCATTGTCTTTG    
10 Fwd TGCATGTTGCTTTTGTACCG 55 30 sec 300 
 Rev GAAGGCAGGATGAGAATGGA    
11 Fwd AAAGCATTGGTCAGGGAAAA 55 30 sec 349 
 Rev CCACAACAAAACACCAGTGC     
Table A.7: PPM1D primers and conditions for PCR 





1 Fwd GCTCGCTCCACTCGACTC 58 1 min 907 
 Rev ATACTTTGGTTGCGCTCTGG    
2 Fwd TTGTTGCCATTTGTATCCTGA 62 30 sec 544 
 Rev CCTTGGGGCTCACTGAAATA    
3 Fwd CCTCTCTGAACAGGAATTTTGG 54 30 sec 449 
 Rev GCATGGCTTCGATTAGGTTC    
4 Fwd TCAAATGCTTTTCTGCGTCT 54 30 sec 431 
 Rev CAGATCAAGGCAAATGCAAA    
5+6 Fwd AGCTTTGTTTGGGCCACAG 62 30 sec 674 
 Rev TTCTGGGCTACGAGATTCAAA    
7_1 Fwd TGAATGCATACCCCGTTTTT 55 30 sec 581 
 Rev TCTTTCGCTGTGAGGTTGTG    
7_2 Fwd CCAAATGAAAGCCCAAGAAA 55 30 sec 709 
 Rev CATCACTTTTCCAGTCTGCTT    
7_3 Fwd TTGTGACAATAGGGCTAAATGTT 55 30 sec 659 
 Rev CAAATTCAGCAACATGAGGAA    
7_4 Fwd TCCCAGACCAATGGCATTAT 54 30 sec 590 





Table A.8: Results of Immunochip case-control analysis showing SNPs with P<1x10-3 






MAF: Cases / 
controls P-value OR (95% CI) 
rs9887787 1 92222143 G / A 0.060 / 0.152 8.86 x 10-7 0.35 (0.23-0.54) 
rs10493860 1 92212703 G / A 0.061 / 0.153 1.05 x 10-6 0.36 (0.24-0.55) 
rs2810893 1 92144970 G / A 0.239 / 0.377 1.16 x 10-6 0.52 (0.40-0.68) 
rs2182833 1 55500429 A / G 0.425 / 0.284 1.85 x 10-6 1.86 (1.44-2.40) 
rs11165441 1 92224347 G / A 0.059 / 0.143 4.96 x 10-6 0.38 (0.25-0.58) 
rs36590 22 30328070 G / A 0.022 / 0.081 9.51 x 10-6 0.25 (0.13-0.48) 
rs36596 22 30335269 G / A 0.022 / 0.081 9.51 x 10-6 0.25 (0.13-0.48) 
rs36600 22 30337586 G / A 0.022 / 0.081 9.51 x 10-6 0.25 (0.13-0.48) 
rs5763634 22 30350532 G / A 0.022 / 0.081 9.51 x 10-6 0.25 (0.13-0.48) 
rs4239932 22 30368384 C / A 0.022 / 0.081 9.51 x 10-6 0.25 (0.13-0.48) 
rs5763674 22 30386358 A / G 0.022 / 0.081 9.51 x 10-6 0.25 (0.13-0.48) 
rs5752993 22 30387160 A / G 0.022 / 0.081 1.01 x 10-5 0.25 (0.13-0.49) 
rs13147507 4 115334709 A / G 0.246 / 0.143 2.29 x 10-5 1.96 (1.43-2.68) 
rs13390918 2 199564895 G / A 0.480 / 0.353 2.59 x 10-5 1.69 (1.32-2.17) 
rs1400978 2 199565298 G / A 0.509 / 0.382 3.28 x 10-5 1.68 (1.31-2.14) 
rs12052337 2 181045431 A / G 0.182 / 0.288 3.89 x 10-5 0.55 (0.41-0.73) 
rs1001434 19 30205448 G / A 0.344 / 0.467 4.21 x 10-5 0.60 (0.47-0.77) 
rs228125 14 81338068 G / A 0.164 / 0.082 5.99 x 10-5 2.18 (1.48-3.21) 
rs1547354 21 26946709 G / A 0.016 / 0.063 6.64 x 10-5 0.24 (0.11-0.51) 
rs7714035 5 102644627 A / T 0.504 / 0.382 6.94 x 10-5 1.64 (1.28-2.09) 
rs12257237 10 6435157 C / G 0.305 / 0.202 0.000118 1.74 (1.31-2.30) 
rs6043883 20 1683539 G / A 0.061 / 0.016 0.000138 4.09 (1.87-8.92) 
rs6962404 7 7442169 A / C 0.230 / 0.139 0.000140 1.85 (1.34-2.54) 
rs62226440 22 30590222 G / A 0.014 / 0.057 0.000146 0.24 (0.11-0.53) 
rs17728461 22 30598552 G / C 0.014 / 0.057 0.000146 0.24 (0.11-0.53) 
rs72660277 5 150181241 G / C 0.358 / 0.472 0.000150 0.62 (0.49-0.80) 
rs13419935 2 199565637 G / C 0.079 / 0.153 0.000156 0.48 (0.32-0.70) 
rs10176099 2 199566014 A / G 0.079 / 0.153 0.000156 0.48 (0.32-0.70) 
rs9809480 3 60448671 A / G 0.161 / 0.084 0.000161 2.08 (1.41-3.06) 
rs17643918 22 30273725 G / A 0.022 / 0.069 0.000176 0.30 (0.15-0.58) 
rs9620926 22 30275091 G / A 0.022 / 0.069 0.000176 0.30 (0.15-0.58) 
rs6739633 2 13028547 G / A 0.074 / 0.145 0.000176 0.47 (0.31-0.70) 
rs2643468 5 96657330 G / A 0.425 / 0.539 0.000179 0.63 (0.49-0.80) 
rs13386177 2 199566857 T / A 0.520 / 0.406 0.000196 1.58 (1.24-2.02) 
rs923396 12 29122650 G / A 0.412 / 0.526 0.000204 0.63 (0.50-0.81) 
rs41162 22 30408710 G / A 0.020 / 0.065 0.000218 0.29 (0.15-0.58) 
rs3762315 1 67772011 A / G 0.206 / 0.303 0.000263 0.60 (0.45-0.79) 
rs7816547 8 11147853 A / G 0.130 / 0.063 0.000264 2.21 (1.43-3.42) 
rs3762316 1 67772023 A / G 0.207 / 0.304 0.000272 0.60 (0.45-0.79) 
chr1:160854085 1 160854085 C / A 0.006 / 0.038 0.000289 0.14 (0.04-0.48) 




rs10139869 14 24346429 C / A 0.182 / 0.104 0.000311 1.91 (1.34-2.74) 
rs62199977 2 186055665 C / G 0.034 / 0.086 0.000314 0.37 (0.22-0.65) 
rs17103942 1 48410683 A / T 0.189 / 0.110 0.000318 1.89 (1.33-2.68) 
rs8069115 17 40469180 G / A 0.149 / 0.235 0.000353 0.57 (0.42-0.78) 
chr20:1554639 20 1554639 A / G 0.326 / 0.228 0.000359 1.64 (1.25-2.15) 
rs2335813 3 21694884 A / G 0.212 / 0.308 0.000365 0.61 (0.46-0.80) 
rs17106245 14 69206572 G / A 0.036 / 0.088 0.000368 0.39 (0.22-0.66) 
rs17689022 16 68515208 G / A 0.135 / 0.069 0.000381 2.12 (1.39-3.22) 
rs2834868 21 36632643 A / G 0.290 / 0.393 0.000387 0.63 (0.49-0.81) 
rs7164531 15 88814356 A / G 0.389 / 0.496 0.000408 0.65 (0.51-0.82) 
rs1800775 16 56995236 A / C 0.284 / 0.386 0.000410 0.63 (0.49-0.82) 
chr8:57021505 8 57021505 A / G 0.029 / 0.077 0.000413 0.36 (0.20-0.65) 
rs3130267 6 33306794 C / A 0.344 / 0.245 0.000440 1.61 (1.23-2.11) 
rs6043636 20 1647384 G / A 0.085 / 0.033 0.000440 2.68 (1.52-4.73) 
rs10818474 9 123489964 A / G 0.338 / 0.443 0.000442 0.64 (0.50-0.82) 
rs10143801 14 88321793 A / G 0.372 / 0.478 0.000459 0.65 (0.51-0.83) 
rs12338330 9 30753635 G / A 0.050 / 0.108 0.000467 0.44 (0.27-0.70) 
rs2700986 7 37389804 G / A 0.110 / 0.051 0.000467 2.29 (1.43-3.69) 
rs4134832 19 7691698 G / A 0.144 / 0.076 0.000480 2.03 (1.36-3.04) 
rs8109557 19 55211859 G / A 0.216 / 0.310 0.000481 0.61 (0.47-0.81) 
rs2760512 1 192561545 G / A 0.363 / 0.469 0.000487 0.65 (0.51-0.83) 
rs13186205 5 40289988 G / A 0.040 / 0.092 0.000490 0.41 (0.24-0.68) 
rs6864103 5 40302452 G / A 0.040 / 0.092 0.000490 0.41 (0.24-0.68) 
rs17226632 5 40311005 A / G 0.040 / 0.092 0.000490 0.41 (0.24-0.68) 
rs10462010 5 40311568 A / G 0.040 / 0.092 0.000490 0.41 (0.24-0.68) 
rs4957127 5 40316010 T / A 0.040 / 0.092 0.000490 0.41 (0.24-0.68) 
rs10858396 9 138275776 G / A 0.534 / 0.428 0.000496 1.54 (1.21-1.96) 
rs11893706 2 199583546 A / G 0.155 / 0.239 0.000503 0.58 (0.43-0.79) 
rs4747989 10 12590175 G / A 0.230 / 0.326 0.000507 0.62 (0.47-0.81) 
rs8061192 16 9437050 A / C 0.254 / 0.167 0.000523 1.70 (1.26-2.30) 
rs2491101 9 130215249 G / A 0.347 / 0.451 0.000536 0.65 (0.51-0.83) 
rs12886388 14 81273539 A / G 0.192 / 0.116 0.000555 1.82 (1.29-2.57) 
rs12259024 10 6411528 C / A 0.223 / 0.141 0.000569 1.75 (1.27-2.40) 
rs5756708 22 37903578 G / A 0.407 / 0.512 0.000570 0.65 (0.51-0.83) 
rs8128521 21 40452693 G / A 0.194 / 0.117 0.000572 1.82 (1.29-2.56) 
rs1914011 3 2717559 A / C 0.112 / 0.186 0.000580 0.55 (0.39-0.77) 
rs1885842 14 88335978 G / A 0.128 / 0.206 0.000594 0.56 (0.41-0.78) 
rs12269345 10 102005620 G / A 0.209 / 0.300 0.000602 0.62 (0.47-0.81) 
rs10105920 8 8648737 G / A 0.480 / 0.376 0.000604 1.53 (1.20-1.96) 
rs6084626 20 4086072 G / A 0.173 / 0.259 0.000610 0.60 (0.44-0.80) 
rs7636212 3 33025871 A / G 0.148 / 0.080 0.000615 1.98 (1.33-2.94) 
rs7910961 10 6077796 G / A 0.175 / 0.102 0.000650 1.86 (1.30-2.67) 
rs7305646 12 17264337 G / A 0.482 / 0.378 0.000650 1.53 (1.20-1.95) 




rs2332807 14 72710126 A / G 0.273 / 0.371 0.000676 0.64 (0.49-0.83) 
rs9625919 22 30500958 C / A 0.018 / 0.057 0.000698 0.30 (0.15-0.63) 
rs4337577 22 30512128 G / C 0.018 / 0.057 0.000698 0.30 (0.15-0.63) 
rs4239933 22 30512414 G / C 0.018 / 0.057 0.000698 0.30 (0.15-0.63) 
rs9625926 22 30539427 A / G 0.018 / 0.057 0.000698 0.30 (0.15-0.63) 
rs9625933 22 30555216 G / A 0.018 / 0.057 0.000698 0.30 (0.15-0.63) 
rs755856 8 10736552 G / C 0.142 / 0.077 0.000702 1.99 (1.33-2.98) 
rs2542184 18 12749300 G / A 0.290 / 0.200 0.000703 1.63 (1.23-2.17) 
rs12286448 11 79121342 A / C 0.281 / 0.192 0.000712 1.64 (1.23-2.19) 
rs10788994 1 55500976 G / A 0.272 / 0.184 0.000717 1.65 (1.23-2.21) 
rs11217040 11 118680648 C / A 0.272 / 0.184 0.000717 1.65 (1.23-2.21) 
rs4446396 4 115329332 G / A 0.198 / 0.122 0.000720 1.78 (1.27-2.50) 
rs10763790 10 30791355 G / C 0.095 / 0.165 0.000722 0.53 (0.37-0.77) 
rs1356487 2 199569646 A / G 0.300 / 0.210 0.000726 1.62 (1.22-2.14) 
rs1518099 2 199577125 A / G 0.300 / 0.210 0.000726 1.62 (1.22-2.14) 
rs1878665 2 199580726 A / C 0.300 / 0.210 0.000726 1.62 (1.22-2.14) 
chr15:79150671 15 79150671 A / G 0.177 / 0.263 0.000738 0.60 (0.44-0.81) 
rs8010479 14 81125280 G / A 0.115 / 0.057 0.000762 2.16 (1.37-3.41) 
rs2263657 20 1520233 C / A 0.115 / 0.057 0.000762 2.16 (1.37-3.41) 
rs2263658 20 1520272 G / A 0.115 / 0.057 0.000762 2.16 (1.37-3.41) 
rs2246154 20 1528038 C / A 0.115 / 0.057 0.000762 2.16 (1.37-3.41) 
rs2250199 20 1539350 G / A 0.115 / 0.057 0.000762 2.16 (1.37-3.41) 
rs11829361 12 9926680 A / G 0.004 / 0.029 0.000777 0.12 (0.03-0.52) 
rs3116482 2 204553757 T / A 0.317 / 0.416 0.000778 0.65 (0.51-0.84) 
rs2635357 4 118491393 G / A 0.210 / 0.300 0.000782 0.62 (0.47-0.82) 
rs73207778 4 836762 G / A 0.040 / 0.008 0.000796 5.21 (1.78-15.2) 
rs1400983 2 199605159 A / G 0.304 / 0.214 0.000803 1.61 (1.22-2.12) 
rs3777723 6 167353701 G / A 0.394 / 0.296 0.000806 1.55 (1.20-1.99) 
rs11680586 2 100746207 C / A 0.067 / 0.024 0.000807 2.96 (1.53-5.74) 
rs6713524 2 100747357 A / G 0.067 / 0.024 0.000807 2.96 (1.53-5.74) 
rs13000759 2 100753903 T / A 0.067 / 0.024 0.000807 2.96 (1.53-5.74) 
rs7911500 10 6037726 G / A 0.076 / 0.029 0.000826 2.70 (1.48-4.93) 
rs9295124 6 160570172 G / A 0.484 / 0.382 0.000845 1.51 (1.19-1.93) 
rs6427405 1 157840353 G / A 0.103 / 0.173 0.000863 0.55 (0.38-0.78) 
rs7713567 5 150430955 G / A 0.122 / 0.063 0.000864 2.08 (1.34-3.23) 
rs2243603 20 1546911 C / G 0.122 / 0.063 0.000864 2.08 (1.34-3.23) 
rs156029 5 131532634 A / G 0.259 / 0.353 0.000864 0.64 (0.49-0.83) 
rs2583523 4 115928192 G / A 0.117 / 0.059 0.000885 2.12 (1.35-3.32) 
rs718772 22 30504207 A / G 0.020 / 0.059 0.000887 0.32 (0.16-0.65) 
rs11090598 22 30521770 A / G 0.020 / 0.059 0.000887 0.32 (0.16-0.65) 
rs8135823 22 30522459 A / C 0.020 / 0.059 0.000887 0.32 (0.16-0.65) 
rs8141765 22 30562239 C / A 0.020 / 0.059 0.000887 0.32 (0.16-0.65) 
rs1978083 22 30570443 C / G 0.020 / 0.059 0.000887 0.32 (0.16-0.65) 




rs10771457 12 29127004 A / C 0.434 / 0.535 0.000887 0.66 (0.52-0.85) 
rs62198554 2 186033255 T / A 0.016 / 0.053 0.000905 0.29 (0.14-0.63) 
rs11121129 1 8268095 G / A 0.135 / 0.073 0.000913 1.99 (1.32-3.02) 
rs1928042 13 47437216 A / C 0.473 / 0.373 0.000917 1.51 (1.18-1.93) 
rs16944898 18 26124419 A / G 0.228 / 0.319 0.000919 0.63 (0.48-0.83) 
rs40512 5 59805467 A / G 0.203 / 0.128 0.000919 1.75 (1.25-2.44) 
rs4398410 3 189344011 G / A 0.353 / 0.259 0.000930 1.56 (1.2-2.030) 
rs13138121 4 115329386 A / T 0.196 / 0.122 0.000934 1.76 (1.26-2.47) 
rs4993442 22 30253256 A / C 0.011 / 0.043 0.000934 0.24 (0.10-0.60) 
rs4823063 22 30308780 G / C 0.011 / 0.043 0.000934 0.24 (0.10-0.60) 
rs36591 22 30328763 A / G 0.011 / 0.043 0.000934 0.24 (0.10-0.60) 
rs5763644 22 30355676 A / G 0.011 / 0.043 0.000934 0.24 (0.10-0.60) 
rs2117615 8 11153045 A / G 0.355 / 0.261 0.000935 1.56 (1.20-2.03) 
rs9921632 16 75220263 A / G 0.369 / 0.469 0.000947 0.66 (0.52-0.85) 
rs6985292 8 11140699 A / T 0.286 / 0.199 0.000952 1.61 (1.21-2.15) 
rs7655600 4 81841042 G / A 0.074 / 0.135 0.000967 0.51 (0.34-0.76) 
rs2237219 6 16375252 G / C 0.058 / 0.114 0.000984 0.48 (0.30-0.75) 







Figure A.1: SNAP association plots for variants with an Immunochip association of P< 
1 x 10-4  
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